WEST Search History

DATE: Wednesday, October 29, 2003

Set Name side by side	Query	Hit Count	Set Name
DB=USP7	T,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ	1	
L20	(beta-amyloid)	1767	L20
L19	L18 AND beta-amyloid	67	L19
L18	((514/2)!.CCLS.)	5449	L18
L17	L16 AND beta-amyloid	16	L17
L16	(424/130.1.CCLS.)	1159	L16
L15	L14 AND beta-amyloid	179	L15
L14	((530/300 530/350 530/387.1)!.CCLS.)	15553	L14
L13	Yednock-T.IN.	5	L13
L12	Yednock-Theodore.IN.	2	L12
L11	Yednock.IN.	33	L11
L10	Bard-Fred.IN.	0	L10
L9	Bard-F.IN.	5	L9
L8	Bard-Frederique.IN.	4	L8
L7	Bard.IN.	705	L7
L6	Schenk-D.IN.	6	L6
L5	Schenk-Dale.IN.	3	L5
L4	Schenk-D-B.IN.	16	L4
L3	Schenk-Dale-B.IN.	21	L3
L2	Schenk.IN.	2234	L2
L1	(Schenck.IN.)	468	L1

END OF SEARCH HISTORY

WEST Search History

DATE: Wednesday, October 29, 2003


Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB	,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ	1	
L6	L3 AND N-terminus	449	L6
L5	L4 AND N-terminus	425	L5
L4	L3 AND Alzheimer	1188	L4
L3	L2 AND antibody	1255	L3
L2	L1 AND beta-amyloid	1767	L2
L1	(amyloid)	6109	L1

END OF SEARCH HISTORY

Entrez-PubMed Page 1 of 39








			A	of Medici	ne Nim	
Entrez PubMed	Nucleotide	Protein	Genome	Structure PMC	Journals	860
Search PubMed	for beta-	amyloid AND hun	nan AND antibo	ody Go	Clear	
About Entrez 🦠	Limits	Preview/Inc	dex Hist	ory Clipbo	ard De	etails
Same	Display Sun	nmary	Show: 500	▼ Sort ▼	Send to Text	
Text Version	Ite	ms 1-342 of 342			On	ne page
Entrez PubMed		. Currie JR. Mehts	i PD, Potempska	A, Hwang YW, Wegi	el Related Article	s, Links
Overview Help FAQ Tutorial New/Noteworthy	Biochem	l immune respo istry: 2003 Oct 14;4 4529278 [PubMed	42(40):11682-92	r beta-amyloid pep	tide.	
E-Utilities	Г 2: Maddaler Hegi T. N	<u>ia A. Papassotirope</u> litsch RM, Hock C	oul <u>os A. Muller-'</u> 	Fillmanns B. Jung HH	Related Article	s, Links
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Malcher Clinical Queries	fluid rat Arch Net	•	lated tau prote):1202-6.	disease by measuri ein to beta-amyloid EDLINE]	•	spinal
LinkOut	T3: LeVine 1	1 3rd_			Related Article	s, Links
Cubby Related Resources Order Documents NLM Gateway TOXNET	Alzhein Arch Bio	peta(1-40) fluoro ner's beta-peptid chem Biophys. 200 2921787 [PubMed	le. 3 Sep 1;417(1):1		e in conformers	s of
Consumer Health Clinical Alerts	1 4: Torp R. (Ottersen OP, Cotma	m CW, Head E.		Related Article	s, Links
Clinical Trials gov PubMed Central Privacy Policy	Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing. Neuroscience. 2003;120(2):291-300. PMID: 12890502 [PubMed - indexed for MEDLINE]					
	5: Tang K.	Wang C. Shen C.S	heng S, Ravid R	Jing N.	Related Article	s, Links
	Identific precurse Eur J Neu		l alternative sp APP639. (1):102-8.	olicing isoform of	human amyloic	ŀ
	6: Kishore U BC, Reid	J. Gupta SK. Perdi KB	koulis MV, Kojo	uharova MS, Urban	Related Article	s, Links
	human (r organization o C1q A, B, and C ol. 2003 Jul 15;1716 2847249 [PubMed	C chains. (2):812-20.	-terminal, globular EDLINE]	head region o	f
	7: <u>Du Y. W.</u> L. Oertel	ei X, Dodel R, Som WII, Fatlow M	imer N. Hampel	H, Gao F, Ma Z, Zhao	. Related Adicle	s, Links
		anti-beta-amylo vent beta-amylo		block beta-amyloidurotoxicity.	l fibril formation	on

8: Austin L., Arendash GW, Gordon MN, Diamond DM, DiCarlo G. Related Articles, Links Dickey C, Ugen K, Morgan D.

Brain. 2003 Sep;126(Pt 9):1935-9. Epub 2003 Jun 23. PMID: 12821522 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 2 of 39



Characteristic developmental expression of amyloid beta40, 42 and 43 in


patients with Down syndrome. Brain Dev. 2003 Apr;25(3):180-5 Entrez-PubMed Page 3 of 39

PMID: 12689696 [PubMed - indexed for MEDLINE] 17: Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Related Articles, Links Memo M. Neutralization of TRAIL death pathway protects human neuronal cell line from beta-amyloid toxicity. Cell Death Differ. 2003 Jan;10(1):134-41. PMID: 12655302 [PubMed - in process] 18: Cai J. Wang S. Zhong Y. Cheng J. Ji Z. Sheng S. Zhang C. Related Articles, Lanks Screening and characterization of human single-chain Fv antibody against beta-amyloid peptide 40. Neuroreport. 2003 Feb 10;14(2):265-8. PMID: 12598743 [PubMed - indexed for MEDLINE] 19: Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Related Articles, Links Guido T. Hoenow K. Hu K. Johnson-Wood K. Khan K. Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D. Tang P. Vasquez N. Seubert P. Yednock T. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2023-8. Epub 2003 Feb 03. PMID: 12566568 [PubMed - indexed for MEDLINE] 1 20: Blasko I. Grubeck-Loebenstein B. Related Articles, Links Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging. 2003;20(2):101-13. Review. PMID: 12534311 [PubMed - indexed for MEDLINE] 1 21: Matsuoka Y. Saito M. LaFrançois J. Saito M. Gaynor K. Olm V. Related Articles, Links Wang L., Casey E. Lu Y, Shiratori C. Lemere C. Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33. PMID: 12514198 [PubMed - indexed for MEDLINE] 22: Friedland RP. Related Articles, Links Lipid metabolism, epidemiology, and the mechanisms of Alzheimer's disease. Ann N Y Acad Sci. 2002 Nov;977:387-90. Review. PMID: 12480777 [PubMed - indexed for MEDLINE] 23: Kjenzl E. Jellinger K. Janetzky B. Steindl H. Bergmann J. Related Articles, Links A broader horizon of Alzheimer pathogenesis: ALZAS--an early serum biomarker? J Neural Transm Suppl. 2002;(62):87-95. PMID: 12456054 [PubMed - indexed for MEDLINE] 1 24: Leclercq PD, Stephenson MS, Murray LS, McIntosh TK, Graham Related Articles, Links DI, Gentieman SM Simple morphometry of axonal swellings cannot be used in isolation for dating lesions after traumatic brain injury. J Neurotrauma. 2002 Oct;19(10):1183-92. PMID: 12427327 [PubMed - indexed for MEDLINE] 1 25: Tan J, Town T, Crawford F, Mori T, DelleDonne A, Crescentini R, Related Articles, Links Obregon D, Flavell RA, Mulian MJ

Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice.

Nat Neurosci. 2002 Dec;5(12):1288-93.

Entrez-PubMed Page 4 of 39



Advanced glycation end products (AGE) and their receptor (RAGE) in the

brain of patients with Creutzfeldt-Jakob disease with prion plaques.


Entrez-PubMed Page 5 of 39

Neurosci Lett. 2002 Jun 28;326(2):117-20. PMID: 12057842 [PubMed - indexed for MEDLINE] 35: Nagele RG, D'Andrea MR, Anderson WJ, Wang HY, Related Articles, Links Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 2002;110(2):199-211. PMID: 11958863 [PubMed - indexed for MEDLINE] **736:** Frenkel D. Solomon B. Related Articles, Links Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE] 737: Thal DR. Ghebremedhin E, Haass C. Schultz C. Related Articles, Links UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain. Clin Neuropathol. 2002 Jan-Feb;21(1):35-40. PMID: 11846043 [PubMed - indexed for MEDLINE] 38: Schenk D. Games D. Seubert P. Related Articles, Links Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization. J Mol Neurosci. 2001 Oct; 17(2):259-67. Review. PMID: 11816797 [PubMed - indexed for MEDLINE] 39: Cummings BJ, Mason AJ, Kirn RC, Sheu PC, Anderson AJ Related Articles, Links Optimization of techniques for the maximal detection and quantification of Alzheimer's-related neuropathology with digital imaging. Neurobiol Aging. 2002 Mar-Apr;23(2):161-70. PMID: 11804699 [PubMed - indexed for MEDLINE] 40: Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G. Related Articles, Links Dickey C. Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J. Morgan D. Number of Abeta inoculations in APP+PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol. 2001 Nov;20(11):731-6. PMID: 11788051 [PubMed - indexed for MEDLINE] 41: Solomon B. Related Articles, Links Immunotherapeutic strategies for prevention and treatment of Alzheimer's DNA Cell Biol. 2001 Nov;20(11):697-703. PMID: 11788047 [PubMed - indexed for MEDLINE] 17 42: Coraci IS, Husemann J, Berman JW, Hulette C, Dufour JH, Related Articles, Links Campanella GK, Luster AD, Silverstein SC, El-Khoury JB CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am J Pathol. 2002 Jan; 160(1):101-12. PMID: 11786404 [PubMed - indexed for MEDLINE] 43: Lambri M, Djurovic V, Kibble M, Cairns N, Al-Sarraj S. Related Articles, Links

Specificity and sensitivity of betaAPP in head injury.

Clin Neuropathol. 2001 Nov-Dec;20(6):263-71. PMID: 11758782 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 6 of 39



Science. 2001 Aug 24;293(5534):1491-5.

PMID: 11520988 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 7 of 39

53: Monsonego A, Maron R, Zota V, Selkoe DJ, Weiner HL. Related Articles, Links Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10273-8. Epub 2001 Aug 21. PMID: 11517335 [PubMed - indexed for MEDLINE] 17 54: Brayden DJ, Templeton L. McClean S, Barbour R, Huang J. Related Articles, Links Nguyen M, Ahem D, Motter R, Johnson-Wood K, Vasquez N. Schenk D. Seubert P. Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice. Vaccine. 2001 Jul 20;19(30):4185-93. PMID: 11457544 [PubMed - indexed for MEDLINE] 55: Toupalik P. Bouska I, Jezkova J. Related Articles, Links [Effect of autolysis on histochemical examinations of the central nervous Soud Lek. 2001 Apr;46(2):18-20. Czech. PMID: 11455721 [PubMed - indexed for MEDLINE] 1 56: Pluta R, Misicka A, Barcikowska M, Spisacka S, Lipkowski AW. Related Articles, Links Januszewski S Possible reverse transport of beta-amyloid peptide across the blood-brain barrier. Acta Neurochir Suppl. 2000;76:73-7. PMID: 11450095 [PubMed - indexed for MEDLINE] 57: Town T, Tan J, Sansone N, Obregon D, Klein T, Mullan M. Related Articles, Links Characterization of murine immunoglobulin G antibodies against human amyloid-beta1-42. Neurosci Lett. 2001 Jul 13;307(2):101-4. PMID: 11427310 [PubMed - indexed for MEDLINE] 58: Myagkova MA. Gavrilova Sl, Lermontova NN, Kalyn YB. Related Articles, Links Selezneva ND, Zharikov GA, Kolykhalov IV, Abramenko TV, Serkova TP, Bachurin SO. Autoantibodies to beta-amyloid and neurotransmitters in patients with Alzheimer's disease and senile dementia of the Alzheimer type. Bull Exp Biol Med. 2001 Feb; 131(2):127-9. PMID: 11391392 [PubMed - indexed for MEDLINE] 59: Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K. Related Articles, Links Yamaguchi [beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's Neuroscience. 2001;104(2):299-310. PMID: 11377835 [PubMed - indexed for MEDLINE] 60: Matsumoto A, Itoh K, Seki T, Motozaki K, Matsuvama S. Related Articles, Links Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. Eur J Neurosci. 2001 May;13(9):1653-7.

Effects of the beta-amyloid and carboxyl-terminal fragment of Alzheimer's

Related Articles, Links

PMID: 11359517 [PubMed - indexed for MEDLINE]

61: Chong YH. Sung JH. Shin SA, Chung JH, Suh YH.

Entrez-PubMed Page 8 of 39

amyloid precursor protein on the production of the tumor necrosis factoralpha and matrix metalloproteinase-9 by human monocytic THP-1. J Biol Chem. 2001 Jun 29;276(26):23511-7. Epub 2001 Apr 16. PMID: 11306564 [PubMed - indexed for MEDLINE] C 62: Englund P, Jacobsson SO, Fowler C.L. Related Articles, Links Investigation into the effects of amyloid (1-42) beta-peptide upon basal and antigen-stimulated hexosaminidase and serotonin release from rat RBL-2H3 basophilic leukemia cells. Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):657-61. PMID: 11294005 [PubMed - indexed for MEDLINE] Codazo-Minguez A, Wichager B, Winblad B, Huttinger M, Related Articles, Links Cowburn RF. Effects of apolipoprotein E (apoE) isoforms, beta-amyloid (Abeta) and apoE/Abeta complexes on protein kinase C-alpha (PKC-alpha) translocation and amyloid precursor protein (APP) processing in human SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem Int. 2001 Jun;38(7):615-25. PMID: 11290387 [PubMed - indexed for MEDLINE] 64: Frenkel D, Kariv N, Solomon B. Related Articles, Links Generation of auto-antibodies towards Alzheimer's disease vaccination. Vaccine. 2001 Mar 21;19(17-19):2615-9. PMID: 11257400 [PubMed - indexed for MEDLINE] 65: Gerlai R. Related Articles, Links Alzheimer's disease: beta-amyloid hypothesis strengthened! Trends Neurosci. 2001 Apr;24(4):199. No abstract available. PMID: 11249992 [PubMed - indexed for MEDLINE] 66: Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T. Related Articles, Links Expression of human brain carboxypeptidase B, a possible cleaving enzyme for beta-amyloid precursor protein, in peripheral fluids. Neurosci Res. 2001 Mar;39(3):313-7. PMID: 11248371 [PubMed - indexed for MEDLINE] 67: Husemann J, Silverstein SC. Related Articles, Links Expression of scavenger receptor class B, type I, by astrocytes and vascular smooth muscle cells in normal adult mouse and human brain and in Alzheimer's disease brain. Am J Pathol. 2001 Mar;158(3):825-32. PMID: 11238031 [PubMed - indexed for MEDLINE] 68: D'Andrea MR, Nagele RG, Wang HY, Peterson PA, Lee DH. Related Articles, Links Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology. 2001 Feb;38(2):120-34. PMID: 11207825 [PubMed - indexed for MEDLINE] 69: Russo C, Salis S, Dolcini V, Venezia V, Song XII, Teller JK, Related Articles, Links Schettini G. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.

Neurobiol Dis. 2001 Feb;8(1):173-80. Erratum in: Neurobiol Dis 2001 Jun;8(3):540.

PMID: 11162251 [PubMed - indexed for MEDLINE]

Kumar VB, Farr SA, Flood JF, Kamlesh V, Franko M, Banks WA,


Entrez-PubMed Page 9 of 39

70. Morley JE. Related Adicles, Links Site-directed antisense oligonucleotide decreases the expression of amyloid precursor protein and reverses deficits in learning and memory in aged SAMP8 mice. Peptides. 2000 Dec; 21(12): 1769-75. PMID: 11150636 [PubMed - indexed for MEDLINE] 71: Vanderstichele H, Van Kerschaver F, Hesse C, Davidsson P, Related Articles, Links Buyse MA, Andreasen N, Minthon L, Wallin A, Blennow K, Vanmechelen E Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid. 2000 Dec;7(4):245-58. PMID: 11132093 [PubMed - indexed for MEDLINE] 72: Seiffert D. Mitchell T. Stern AM, Roach A, Zhan Y, Grzanna R. Related Articles, Links Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing. Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26. PMID: 11113538 [PubMed - indexed for MEDLINE] 73: Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim Related Articles, Links KS, Zlokovie B. Kalra VK beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1772-81. PMID: 11078691 [PubMed - indexed for MEDLINE] 74: Frenkel D. Katz O. Solomon B. Related Articles, Links Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration. Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9. PMID: 11027345 [PubMed - indexed for MEDLINE] 75: Ogawa K. Yamada T. Tsujioka Y. Taguchi J. Takahashi M. Tsuboi Related Articles, Links Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H, Mitsui S, Yamaguchi N. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26. PMID: 10997858 [PubMed - indexed for MEDLINE] 76: Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad Related Articles, Links B. Bogdanovi nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease. Exp Neurol. 2000 Sep;165(1):12-26. PMID: 10964481 [PubMed - indexed for MEDLINE] 77: Taguchi J, Fujii A, Fujino Y, Tsujioka Y, Takahashi M, Tsuboi Y, Related Articles, Links Wada I. Yamada T. Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain. Acta Neuropathol (Berl). 2000 Aug; 100(2):153-60. PMID: 10963362 [PubMed - indexed for MEDLINE]

78: Tanabe Y, Ishizu H, Ishiguro K, Itoh N, Terada S, Haraguchi T.

Kawai K, Kuroda S.

Entrez-PubMed Page 10 of 39



1 88: Azizeh BY, Head E, Ibrahim MA, Torp R, Tenner AJ, Kim RC,

Entrez-PubMed Page 11 of 39

Lott IT, Cotman CW

Synd

Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs.

Exp Neurol. 2000 May;163(1):111-22.

PMID: 10785449 [PubMed - indexed for MEDLINE]

7 89: Capell A, Steiner H, Romig H, Keck S, Baader M, Grim MG, Baumeister R, Haass C

Related Articles, Links

Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch.

Nat Cell Biol. 2000 Apr;2(4):205-11.

PMID: 10783238 [PubMed - indexed for MEDLINE]

90: Salinero O. Moreno-Flores MT, Wandosell F.

Related Articles, Links



Increasing neurite outgrowth capacity of beta-amyloid precursor protein proteoglycan in Alzheimer's disease.

J Neurosci Res. 2000 Apr 1;60(1):87-97.

PMID: 10723071 [PubMed - indexed for MEDLINE]

1 91: Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J.

Related Articles, Links



Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein.

Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456-60.

PMID: 10677483 [PubMed - indexed for MEDLINE]

Related Articles, Links



Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis.

J Neurochem. 2000 Mar;74(3):1131-9.

92: Cescato R. Domerrouth E. Spiess M. Paganetti PA

PMID: 10693945 [PubMed - indexed for MEDLINE]

☐ 93: Matsumoto A.

Related Articles, Links



The 68K protease has beta-secretase-like activity for lymphocyte precursor protein but not for brain substrate.

Neuroreport. 2000 Feb 7;11(2):373-7.

PMID: 10674489 [PubMed - indexed for MEDLINE]

94: Yoshiyama Y, Asahina M, Hattori T.

Related Articles, Links



Selective distribution of matrix metalloproteinase-3 (MMP-3) in

Alzheimer's disease brain.

Acta Neuropathol (Berl). 2000 Feb;99(2):91-5.

PMID: 10672313 [PubMed - indexed for MEDLINE]

95: Toro F, Lopera F, Ossa J, Madrigal L, Mira A, Diaz A, Parra S.

Related Articles, Links



[Detection of antibodies to beta-amyloid in carriers of E280A mutation in the presentilin-1 gene]

Rev Neurol. 1999 Dec 16-31;29(12):1104-7. Spanish. PMID: 10652730 [PubMed - indexed for MEDLINE]

7 96: Campbell E, Pearson RC, Parkinson D.

Related Articles, Links




Methods to uncover an antibody epitope in the KPI domain of Alzheimer's amyloid precursor protein for immunohistochemistry in human brain.

J Neurosci Methods. 1999 Nov 15;93(2):133-8.


PMID: 10634498 [PubMed - indexed for MEDLINE]

97: Frederikse PH, Zigler SJ Jr, Famsworth PN, Carper DA.



PMID: 10394892 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 13 of 39



PMID: 10098861 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 14 of 39


116: Fabrizi C, Businaro R, Lauro GM, Starace G, Fumagalli L. Related Articles, Links Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells. Exp Neurol. 1999 Feb;155(2):252-9. PMID: 10072300 [PubMed - indexed for MEDLINE] 117: Winkler K, Scharnagl H, Tisljar U, Hoschutzky H, Friedrich I, Related Articles, Links Hoffmann MM, Huttinger M, Wieland H, Marz W. Competition of Abeta amyloid peptide and apolipoprotein E for receptormediated endocytosis. J Lipid Res. 1999 Mar; 40(3): 447-55. PMID: 10064733 [PubMed - indexed for MEDLINE] 118: Huber G. Thompson A. Gruninger F. Mechler H. Hochstrasser R., Related Articles, Links Hauri HP, Malherbe P. cDNA cloning and molecular characterization of human brain metalloprotease MP100: a beta-secretase candidate? J Neurochem. 1999 Mar;72(3):1215-23. PMID: 10037494 [PubMed - indexed for MEDLINE] 119: Ohara S. Tsukada M. Ikeda S. Related Articles, Links On the occurrence of neuronal sprouting in the frontal cortex of a patient with Down's syndrome. Acta Neuropathol (Berl). 1999 Jan;97(1):85-90. PMID: 9930899 [PubMed - indexed for MEDLINE] 120: Egensperger R. Weggen S. Ida N. Multhaup G. Schnabel R. Related Articles, Links Bevreuther K, Baver TA Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease. Acta Neuropathol (Berl). 1999 Feb;97(2):113-8. PMID: 9928821 [PubMed - indexed for MEDLINE] 121: Tuszynski MH, Smith DE, Roberts J, McKay H, Mufson E. Related Articles, Links Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate beta-amyloid plaque deposition. Exp Neurol. 1998 Dec; 154(2): 573-82. PMID: 9878192 [PubMed - indexed for MEDLINE] 122: Jin LW, Hearn MG, Ogburn CF, Dang N, Nochlin D, Ladiges Related Articles, Links WC, Martin GM Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis. Am J Pathol. 1998 Dec; 153(6): 1679-86. PMID: 9846957 [PubMed - indexed for MEDLINE] 123: Daly J 4th, Lahiri DK, Justus DE, Kotwal GJ Related Articles, Links Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's disease brain. Life Sci. 1998;63(23):2121-31. PMID: 9839536 [PubMed - indexed for MEDLINE]

Pitfalls in the quantitative estimation of beta-amyloid immunoreactivity in


Related Articles, Links

124: Kraszpulski M, Sommen H, Riekkinen P Sr, Alafuzoff I

Entrez-PubMed Page 15 of 39



Entrez-PubMed Page 16 of 39



isoforms of beta-amyloid precursor protein. Brain Res Brain Res Protoc. 1997 Dec 1;2(1):23-30. Entrez-PubMed Page 17 of 39

PMID: 9438067 [PubMed - indexed for MEDLINE] 143: Pluta R, Misicka A, Januszewski S, Barcikowska M, Lipkowski Related Articles, Links Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia. Acta Neurochir Suppl (Wien). 1997;70:247-9. PMID: 9416336 [PubMed - indexed for MEDLINE] 144: Gearing M. Levey AI, Mirra SS. Related Articles, Lanks Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers. J Neuropathol Exp Neurol. 1997 Dec;56(12):1363-70. PMID: 9413285 [PubMed - indexed for MEDLINE] 145: An SF, Giometto B, Groves M, Miller RF, Beckett AA, Gray F. Related Articles, Links Tavolato B, Scaravilli F. Axonal damage revealed by accumulation of beta-APP in HIV-positive individuals without AIDS. J Neuropathol Exp Neurol. 1997 Nov;56(11):1262-8. PMID: 9370237 [PubMed - indexed for MEDLINE] 146: Lahiri DK, Farlow MR, Sambamurti K, Nall C. Related Articles, Links The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. Life Sci. 1997;61(20):1985-92. PMID: 9366505 [PubMed - indexed for MEDLINE] 147: Matsumoto A, Minani M, Matsumoto R. Related Articles, Links The beta-amyloid epitope masking activity in human brain is identified as albumin. Neuroreport. 1997 Oct 20;8(15):3297-301. PMID: 9351660 [PubMed - indexed for MEDLINE] 148: Lahiri DK, Farlow MR, Numberger JI Jr, Greig NII. Related Articles, Links Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci. 1997 Sep 26;826:416-21. PMID: 9329715 [PubMed - indexed for MEDLINE] 149: Sasaki S. Iwata M. Related Articles, Links Immunocytochemical and ultrastructural study of pericapillary rosettes in amyotrophic lateral sclerosis. Acta Neuropathol (Berl). 1997 Oct;94(4):338-44. PMID: 9341934 [PubMed - indexed for MEDLINE] 150; Shea TB, Prabhakar S, Ekinci FJ. Related Articles, Links Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE] 151: Miller II), Cummings J. Maresh GA, Walker DG, Castillo GM, Related Articles, Links Ngo C, Kimata K, Kinsella MG, Wight TN, Snow AD

Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of

beta-amyloid protein into rodent hippocampus.

Entrez-PubMed Page 18 of 39

Glia. 1997 Oct;21(2):228-43.

PMID: 9336237 [PubMed - indexed for MEDLINE]

152: Little SP, Dixon EP, Norris F, Buckley W, Booker GW, Johnson Related Articles, Links M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D. Corvalan J. McClure D. Liu X, Stephenson D, Clemens J. Johnstone EM




Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain.

J Biol Chem. 1997 Oct 3;272(40):25135-42. PMID: 9312124 [PubMed - indexed for MEDLINE]

153: Yamada T, Tsuboi Y, Takahashi M.

Related Articles, Links



Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):267-72. PMID: 9298627 [PubMed - indexed for MEDLINE]

154: Dewji NN, Singer SJ.

Related Adicles, Links



Cell surface expression of the Alzheimer disease-related presenilin

Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9926-31. PMID: 9275228 [PubMed - indexed for MEDLINE]

155: Cataldo AM, Barnett JL, Pieroni C, Nixon RA

Related Articles, Links



Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

J Neurosci. 1997 Aug 15;17(16):6142-51. PMID: 9236226 [PubMed - indexed for MEDLINE]

156: Cutler P, Brown F, Camilleri P, Carpenter D, George A, Gray C. Related Articles, Links Haran M. Stewart B




The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid.

FEBS Lett. 1997 Jul 28;412(2):341-5. PMID: 9256248 [PubMed - indexed for MEDLINE]

157: Ohsawa I, Takamura C, Kohsaka S.

Related Articles, Links



The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture.

Biochem Biophys Res Commun. 1997 Jul 9;236(1):59-65. PMID: 9223426 [PubMed - indexed for MEDLINE]


158: Giometto B, An SF, Groves M, Scaravilli T, Goddes JF, Miller R., Related Articles, Links Tavolato B, Beckett AA, Scaravilli F.

Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.

Ann Neurol. 1997 Jul;42(1):34-40.

PMID: 9225683 [PubMed - indexed for MEDLINE]

Related Articles, Links 159: Haas C, Cazorla P, Miguel CD, Valdivieso F, Vazquez J.




Biochem J. 1997 Jul 1;325 (Pt 1):169-75.

PMID: 9224643 [PubMed - indexed for MEDLINE]

160: Ishizuka K. Kimura T. Igata-yi R. Katsuragi S. Takamatsu J. Miyakawa T

Entrez-PubMed Page 19 of 39



Bcl-xl-specific antibody labels activated microglia associated with

Related Articles, Links

169: Drache B, Diehl GE, Beyreuther K, Perlmutter LS, Konig G.


Entrez-PubMed Page 20 of 39

Alzheimer's disease and other pathological states. J Neurosci Res. 1997 Jan 1;47(1):98-108. PMID: 8981243 [PubMed - indexed for MEDLINE] 170: Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R Related Articles, Links Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain. Neurosci Lett. 1996 Dec 20;220(3):159-62. PMID: 8994217 [PubMed - indexed for MEDLINE] 171: Sihag RK, Cataldo AM. Related Articles, Links Brain beta-spectrin is a component of senile plaques in Alzheimer's disease. Brain Res. 1996 Dec 16;743(1-2):249-57. PMID: 9017252 [PubMed - indexed for MEDLINE] 172: Nielson KA, Cummings BJ, Cotman CW. Related Articles, Links Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Res. 1996 Nov 25;741(1-2):284-93. PMID: 9001734 [PubMed - indexed for MEDLINE] 173: Citron M, Diehl TS, Gordon G, Biere AL, Scubert P, Selkoe DJ. Related Articles, Links Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5. PMID: 8917563 [PubMed - indexed for MEDLINE] 174: Su JH, Cummings BJ, Cotman CW. Related Articles, Links Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments. Brain Res. 1996 Nov 11;739(1-2):79-87. PMID: 8955927 [PubMed - indexed for MEDLINE] 175: Dewji NN, Singer SJ. Related Articles, Links Specific transcellular binding between membrane proteins crucial to Alzheimer disease. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12575-80. PMID: 8901624 [PubMed - indexed for MEDLINE] 176: Stephens DJ, Austen BM. Related Articles, Links Metabolites of the beta-amyloid precursor protein generated by betasecretase localise to the trans-Golgi network and late endosome in 293 J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] 177: De Bleecker JL, Ertl BB, Engel AG Related Articles, Links Patterns of abnormal protein expression in target formations and unstructured cores. Neuromuscul Disord. 1996 Oct;6(5):339-49. PMID: 8938698 [PubMed - indexed for MEDLINE]

178: Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Related Articles, Links

Fujimori O, Ojika K

Entrez-PubMed Page 21 of 39



polar bear brains.

Neurobiol Aging, 1996 Mar-Apr; 17(2):249-57

Entrez-PubMed Page 22 of 39


PMID: 8744406 [PubMed - indexed for MEDLINE] 187: Liberski PP, Yanagihara R, Brown P, Kordek R, Kloszewska I. Related Articles, Links Bratosiewicz J, Gajdusek DC. Microwave treatment enhances the immunostaining of amyloid deposits in both the transmissible and non-transmissible brain amyloidoses. Neurodegeneration, 1996 Mar;5(1):95-9. PMID: 8731388 [PubMed - indexed for MEDLINE] 188: Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ. Related Articles, Links Localization and cell association of C1q in Alzheimer's disease brain. Exp Neurol. 1996 Mar;138(1):22-32. PMID: 8593893 [PubMed - indexed for MEDLINE] 189: Yasuhara O, Schwab C, Matsuo A, Kim SU, Steele JC, Akiguchi Related Articles, Links I. Kimura J. McGeer FG, McGeer PL Midkine-like immunoreactivity in extracellular neurofibrillary tangles in brains of patients with parkinsonism-dementia complex of Guam. Neurosci Lett. 1996 Feb 23;205(2):107-10. PMID: 8907328 [PubMed - indexed for MEDLINE] 190: Askanas V, McFerrin J, Baque S, Alvarez RB, Sarkozi F, Engel Related Articles, Links WK. Transfer of beta-amyloid precursor protein gene using adenovirus vector causes mitochondrial abnormalities in cultured normal human muscle. Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1314-9. PMID: 8577761 [PubMed - indexed for MEDLINE] 191: Konig G, Graham P, Bushnell A, Webster S, Wunderlich D. Related Articles, Links Perlmutter LS. Development and characterization of a monoclonal antibody 369.2B specific for the carboxyl-terminus of the beta A4 peptide. Ann N Y Acad Sci. 1996 Jan 17;777:344-55. PMID: 8624111 [PubMed - indexed for MEDLINE] 192: McGeer PL, McGeer EG. Related Articles, Links Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann N Y Acad Sci. 1996 Jan 17;777:213-20. Review. PMID: 8624086 [PubMed - indexed for MEDLINE] 193. Solomon B, Koppel R, Hanan E, Katzay T. Related Articles, Links Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5. PMID: 8552659 [PubMed - indexed for MEDLINE] 194: Lahiri DK, Farlow MR. Related Articles, Links Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci. 1996 Spring;7(1):41-9. PMID: 8835781 [PubMed - indexed for MEDLINE] 195: Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska FB, Related Articles, Links Wischik CM Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.

196: Akaaboune M, Verdiere-Sahuque M, Lachkar S, Festoff BW,

Related Articles, Links

Acta Neuropathol (Berl). 1996;91(6):633-41. PMID: 8781663 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 23 of 39



Alzheimer's disease: detection of highly mutated V regions in both heavy

and light chains.

Entrez-PubMed Page 24 of 39

Clin Immunol Immunopathol. 1995 May;75(2):159-67. PMID: 7704974 [PubMed - indexed for MEDLINE] 205: Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa Related Articles, Links T, Horiuchi S. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport. 1995 Apr 19;6(6):866-8. PMID: 7612872 [PubMed - indexed for MEDLINE] 206: Pike CJ, Cummings BJ, Cotman CW. Related Articles, Links Early association of reactive astrocytes with senile plaques in Alzheimer's disease. Exp Neurol. 1995 Apr;132(2):172-9. PMID: 7789457 [PubMed - indexed for MEDLINE] 207: Kim CS, Han YF, Etcheberrigaray R, Nelson TJ, Olds JL. Related Articles, Links Yoshioka T. Alkon DL Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4. PMID: 7708775 [PubMed - indexed for MEDLINE] Related Articles, Links 208: Walker DG, Kim SU, McGeer PL. Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res. 1995 Mar 1;40(4):478-93. PMID: 7616608 [PubMed - indexed for MEDLINE] Related Articles, Links 209: Van Gool D. De Strooper B. Van Leuven F. Dom R. Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease. Dementia, 1995 Mar-Apr;6(2):63-8. PMID: 7606281 [PubMed - indexed for MEDLINE] Related Articles, Links 210: Armstrong RA, Winsper SJ, Blair JA. Hypothesis: is Alzheimer's disease a metal-induced immune disorder? Neurodegeneration, 1995 Mar;4(1):107-11. PMID: 7600179 [PubMed - indexed for MEDLINE] 211: McRae A. Gilland E. Bona E. Hagberg H. Related Articles, Links Microglia activation after neonatal hypoxic-ischemia. Brain Res Dev Brain Res. 1995 Feb 16;84(2):245-52. PMID: 7743644 [PubMed - indexed for MEDLINE] 1212: Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y. Related Articles, Links Kawashima S Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron. 1995 Feb;14(2):457-66. PMID: 7857653 [PubMed - indexed for MEDLINE] 213: Sabo S, Lambert MP, Kessey K, Wade W, Krafft G, Klein WL. Related Articles, Links Interaction of beta-amyloid peptides with integrins in a human nerve cell


Neurosci Lett. 1995 Jan 16;184(1):25-8.

Del Valle ME. Vega JA

PMID: 7739799 [PubMed - indexed for MEDLINE]

214: Cabal A. Alonso-Cortina V. Gonzalez-Vazquez LO. Naves FJ.

Entrez-PubMed Page 25 of 39



Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies.

Entrez-PubMed Page 26 of 39

Clin Neuropathol. 1994 Nov-Dec;13(6):306-14.

PMID: 7851045 [PubMed - indexed for MEDLINE] 224: McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer EG Related Articles, Links Pathological proteins in senile plaques. Tohoku J Exp Med. 1994 Nov;174(3):269-77. PMID: 7761992 [PubMed - indexed for MEDLINE] 225: Yang F. Mak K. Vinters HV, Frautschy SA, Cole GM. Related Articles, Links Monoclonal antibody to the C-terminus of beta-amyloid. Neuroreport. 1994 Oct 27;5(16):2117-20. PMID: 7865758 [PubMed - indexed for MEDLINE] 1 226: Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN, Related Articles, Links Cataldo AM. Nixon RA Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Res. 1994 Oct 24;661(1-2):35-42. PMID: 7834382 [PubMed - indexed for MEDLINE] 1 227: Sherriff FE, Bridges LR, De Souza DS. Related Articles, Links Non-Alzheimer neurofibrillary tangles show beta-amyloid-like immunoreactivity. Neuroreport. 1994 Oct 3;5(15):1897-900. PMID: 7531003 [PubMed - indexed for MEDLINE] 1 228: Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich Related Articles, Links D. Wirak DO, Davis G. Brini CM. Buckholz TM. Konig G, et al. Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by a familial Alzheimer's disease mutation. Eur J Biochem. 1994 Sep 1;224(2):265-71. PMID: 7523115 [PubMed - indexed for MEDLINE] 229: van de Nes JA, Shuiter AA, Pool CW, Kamphorst W, Ravid R, Related Articles, Links Swaab DF. The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in Alzheimer's disease, also reacts with a large subpopulation of somatostatin neurons in the normal human hypothalamus and adjoining areas. Brain Res. 1994 Aug 29;655(1-2):97-109. PMID: 7812796 [PubMed - indexed for MEDLINE] 230: Durham HD, Minotti S, Dooley NP, Nalbantoglu J. Related Articles, Links Expression of the intermediate filament-associated protein related to betaamyloid precursor protein is developmentally regulated in cultured cells. J Neurosci Res. 1994 Aug 15;38(6):629-39. PMID: 7807580 [PubMed - indexed for MEDLINE] 1 231: Hemonen O. Soininen H. Syrjanen S. Neittaanmaki H. Paljarvi L. Related Articles, Links Kosunen O, Syrjanen K, Riekkinen P Sr beta-Amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study. Arch Neurol. 1994 Aug;51(8):799-804. PMID: 8042928 [PubMed - indexed for MEDLINE] 232: Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA. Related Articles, Links

Development of an anti-A beta monoclonal antibody for in vivo imaging

of amyloid angiopathy in Alzheimer's disease.

Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13.

Entrez-PubMed Page 27 of 39

PMID: 7888086 [PubMed - indexed for MEDLINE]

Related Articles, Links 233: Singh VK Studies of neuroimmune markers in Alzheimer's disease. Mol Neurobiol. 1994 Aug-Dec;9(1-3):73-81. PMID: 7534089 [PubMed - indexed for MEDLINE] 234: Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM. Related Articles, Links Krafft GA, Holzman RB, Holzman TF. Complement C1q does not bind monomeric beta-amyloid. Exp Neurol. 1994 Jul; 128(1):136-42. PMID: 8070518 [PubMed - indexed for MEDLINE] 1 235: Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Related Articles, Links Visualization of A beta 42(43) and A beta 40 in senile plaques with endspecific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994 Jul; 13(1):45-53. PMID: 8043280 [PubMed - indexed for MEDLINE] 1 236: Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E. Related Articles, Links Ihara Y, Kawashima S Spatial resolution of the primary beta-amyloidogenic process induced in postischemic hippocampus. J Biol Chem. 1994 May 27;269(21):15253-7. PMID: 8195161 [PubMed - indexed for MEDLINE] 237: Schmidt ML, DiDario AG, Lec VM, Trojanowski JQ. Related Articles, Links An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plaques in Alzheimer disease. FEBS Lett. 1994 May 9;344(1):69-73. PMID: 8181568 [PubMed - indexed for MEDLINE] 238: Murphy GM Jr, Forno LS, Higgins L, Scardina JM, Eng LF, Related Articles, Links Cordell B. Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am J Pathol. 1994 May; 144(5): 1082-8. PMID: 8178931 [PubMed - indexed for MEDLINE] 1239: Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak Related Articles, Links DR, Nelson SJ, Griffin WS. Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol. 1994 May;53(3):231-8. PMID: 8176406 [PubMed - indexed for MEDLINE] 240: Akaabounc M, Ma J, Festoff BW, Greenberg BD, Hantai D. Related Articles, Links Neurotrophic regulation of mouse muscle beta-amyloid protein precursor and alpha 1-antichymotrypsin as revealed by axotomy. J Neurobiol. 1994 May;25(5):503-14. PMID: 8071658 [PubMed - indexed for MEDLINE] 241: Beeson JG, Shelton ER, Chan HW, Gage FH. Related Articles, Links

Differential distribution of amyloid protein precursor immunoreactivity in

the rat brain studied by using five different antibodies.

Entrez-PubMed Page 28 of 39


J Comp Neurol. 1994 Apr 1;342(1):78-96. PMID: 8207129 [PubMed - indexed for MEDLINE] 7 242: Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Related Articles, Links Graham DL Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):419-25. PMID: 8163989 [PubMed - indexed for MEDLINE] 243: Bilak M. Askanas V. Engel WK. Related Articles, Links Alpha 1-antichymotrypsin is strongly immunolocalized at normal human and rat neuromuscular junctions. Synapse, 1994 Apr;16(4):280-3. PMID: 8059338 [PubMed - indexed for MEDLINE] 244: Bickel U. Lee VM. Trojanowski JQ. Pardridge WM. Related Articles, Links Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease. Bioconjug Chem. 1994 Mar-Apr;5(2):119-25. PMID: 8031874 [PubMed - indexed for MEDLINE] 245: Loftler J. Langui D. Probst A. Huber G. Related Articles, Links Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex. Neurochem Int. 1994 Mar;24(3):281-8. PMID: 8025536 [PubMed - indexed for MEDLINE] 246: Snow AD, Schignchi RT, Nochlin D, Kalaria RN, Kimata K. Related Articles, Links Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain. Am J Pathol. 1994 Feb;144(2):337-47. PMID: 8311117 [PubMed - indexed for MEDLINE] 247: Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Bruckner G. Related Articles, Links Digoxigenin-tagged anti-GFAP and multiple labelling of human glia, vessels and beta-amyloid. Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1994 Apr 14;5 (8):following 1014. PMID: 8025246 [PubMed - indexed for MEDLINE] 248: Snow AD, Schiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani Related Articles, Links A, Arai M, Schreier WA, Morgan DG. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron. 1994 Jan;12(1):219-34. PMID: 8292358 [PubMed - indexed for MEDLINE] 1 249: Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ. Related Articles, Links Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau. Am J Pathol. 1994 Jan; 144(1): 177-87.

PMID: 8291607 [PubMed - indexed for MEDLINE]

250: Westarp ME. Foring B, Rasmussen H, Schraff S, Mertens T.

Kornhuber HH

Entrez-PubMed Page 29 of 39



PMID: 8264949 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 30 of 39

□ 260:	Holmes C, Webster MT, Procter AW, Francis PT, Bowen DM	Related Articles, Links
	Relationship between beta-amyloid precursor protein, and astrocytes in human neocortex. Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract av PMID: 8224394 [PubMed - indexed for MEDLINE]	•
261 :	Miklossy J.	Related Articles, Links
	Alzheimer's diseasea spirochetosis? Neuroreport. 1993 Jul;4(7):841-8. PMID: 8369471 [PubMed - indexed for MEDLINE]	
□ 262:	Leelere A, Tome FM, Fardeau M.	Related Articles, Links
	Ubiquitin and beta-amyloid-protein in inclusion body of familial IBM-like disorder and oculopharyngeal muscu immunocytochemical study. Neuromuscul Disord. 1993 Jul;3(4):283-91. PMID: 8268725 [PubMed - indexed for MEDLINE]	
□ 263:	Singhrao SK, Neal JW, Newman GR.	Related Articles, Links
	Corpora amylacea could be an indicator of neurodegen Neuropathol Appl Neurobiol. 1993 Jun;19(3):269-76. PMID: 8355813 [PubMed - indexed for MEDLINE]	eration.
□ 264	Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor F Jr.	Related Articles, Links
	The cellular pathology associated with Alzheimer beta in non-demented aged individuals. Neuropathol Appl Neurobiol. 1993 Jun;19(3):261-8. PMID: 8355812 [PubMed - indexed for MEDLINE]	-amyloid deposits
□ 265	DeWitt DA, Silver J, Canning DR, Perry G.	Related Articles, Links
	Chondroitin sulfate proteoglycans are associated with Alzheimer's disease. Exp Neurol. 1993 Jun;121(2):149-52. PMID: 8339766 [PubMed - indexed for MEDLINE]	the lesions of
□ 266	Fukuchi K, Sopher B, Furlong CE, Smith AC, Dang N, Martin GM	Related Articles, Links
	Selective neurotoxicity of COOH-terminal fragments of precursor protein. Neurosci Lett. 1993 May 14;154(1-2):145-8. PMID: 8361630 [PubMed - indexed for MEDLINE]	of the beta-amyloid
□ 267	Scott SA, Johnson SA, Zarow C, Perlmutter LS.	Related Articles, Links
	Inability to detect beta-amyloid protein precursor mRN plaque-associated microglia. Exp Neurol. 1993 May;121(1):113-8. PMID: 8495706 [PubMed - indexed for MEDLINE]	JA in Alzheimer
□ 268	Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H, McGeer PL.	Related Articles, Links
	Midkine, a novel neurotrophic factor, is present in seni Alzheimer disease. Biochem Biophys Res Commun. 1993 Apr 15;192(1):246-51. PMID: 8476427 [PubMed - indexed for MEDLINE]	le plaques of
□ 2 69	: Lahiri DK.	Related Articles, Links

The stability of beta-amyloid precursor protein in nine different cell types. Biochem Mol Biol Int. 1993 Apr;29(5):849-58

Entrez-PubMed Page 31 of 39

PMID: 8508138 [PubMed - indexed for MEDLINE]

270: Gaskin F. Finley J, Fang Q, Xu S, Fu SM.

Related Articles, Links

Hu

Human antibodies reactive with beta-amyloid protein in Alzheimer's disease.

J Exp Med. 1993 Apr 1;177(4):1181-6.

PMID: 8459212 [PubMed - indexed for MEDLINE]

T 271: Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I Related Articles, Links Rydel RE

Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein.

Neuron. 1993 Feb;10(2):243-54.

PMID: 8094963 [PubMed - indexed for MEDLINE]

7 272: Buee L, Ding W, Delacourte A. Fillit H.

Related Articles, Links

Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide.

Brain Res. 1993 Jan 22;601(1-2):154-63.

PMID: 8431762 [PubMed - indexed for MEDLINE]

17273: Scubert P. Oltersdorf T. Lee MG. Barbour R. Blomquist C. Davis Related Articles, Links DL. Bryant K. Fritz LC, Galasko D. Thal L.I. et al.

Secretion of beta-amyloid precursor protein cleaved at the amino terminus of the beta-amyloid peptide.

Nature. 1993 Jan 21;361(6409):260-3.

PMID: 7678698 [PubMed - indexed for MEDLINE]

7274: Nelson PT, Marton L, Saper CB.

Related Articles, Links

Alz-50 immunohistochemistry in the normal sheep striatum: a light and electron microscope study.

Brain Res. 1993 Jan 15;600(2):285-97.

PMID: 8094642 [PubMed - indexed for MEDLINE]

275: Wisniewski HM, Weigel J.

Related Articles, Links

Migration of perivascular cells into the neuropil and their involvement in beta-amyloid plaque formation.

Acta Neuropathol (Berl). 1993;85(6):586-95.

PMID: 8337937 [PubMed - indexed for MEDLINE]

276: Su JH, Cummings BJ, Cotman CW.

Related Articles, Links

Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease.

Neuroscience. 1992 Dec;51(4):801-13.

PMID: 1488123 [PubMed - indexed for MEDLINE]

277: Perlmutter L.S., Scott S.A., Barron E., Chui HC.

Related Articles, Links

MHC class II-positive microglia in human brain: association with Alzheimer lesions.

J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: J Neurosci Res 1993 Jun 15;35 (3):346.

PMID: 1484388 [PubMed - indexed for MEDLINE]

278: Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortegon M, Cotman C, Vaught JL, Neve RL.



Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain.

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61

Entrez-PubMed Page 32 of 39

PMID: 1438289 [PubMed - indexed for MEDLINE]

279: Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren Related Articles, Links SD. Civin WH. Brachova L, Bradt B, Ward P, et al.

Complement activation by beta-amyloid in Alzheimer disease.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20. PMID: 1438191 [PubMed - indexed for MEDLINE]

☐ 280: Brewer GJ, Ashford JW.

Related Articles, Links

neurons.

J Neurosci Res. 1992 Nov;33(3):355-69. PMID: 1335088 [PubMed - indexed for MEDLINE]

281: Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Sinha S., Schlossmacher M. Whaley J., Swindlehurst C. et al.

Human serum stimulates Alzheimer markers in cultured hippocampal

Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids.

Nature. 1992 Sep 24;359(6393):325-7. PMID: 1406936 [PubMed - indexed for MEDLINE]

17 282: Haass C, Schlossmacher MO, Flung AY, Vigo-Pelfrey C, Mellon Related Articles, Links A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, et al.

Amyloid beta-peptide is produced by cultured cells during normal metabolism.

Nature. 1992 Sep 24;359(6393):322-5. PMID: 1383826 [PubMed - indexed for MEDLINE]

283: Dooley NP, Gauthier S, Durham HD.

Related Adicles, Links

Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer's and control fibroblasts.

J Neurosci Res. 1992 Sep;33(1):60-7. PMID: 1453484 [PubMed - indexed for MEDLINE]

284: Askanas V, Engel WK, Alvarez RB.

Related Articles, Links

Strong immunoreactivity of beta-amyloid precursor protein, including the beta-amyloid protein sequence, at human neuromuscular junctions.

Neurosci Lett. 1992 Aug 31;143(1-2):96-100. PMID: 1436686 [PubMed - indexed for MEDLINE]

285: Murphy GM. Jr., Greenberg BD. Ellis WG. Forno LS. Salamat SM. Gonzalez-DeWhitt PA. Lowery DE. Tinklenberg JR. Eng

Alzheimer's disease. Beta-amyloid precursor protein expression in the nucleus basalis of Meynert.

Am J Pathol. 1992 Aug; 141(2):357-61.

PMID: 1386714 [PubMed - indexed for MEDLINE]

7 286: Lippa CF, Smith TW

Related Articles, Links

The indusium griseum in Alzheimer's disease: an immunocytochemical study.

J Neurol Sci. 1992 Aug;111(1):39-45.

PMID: 1328542 [PubMed - indexed for MEDLINE]

287: Festoff BW, Rao JS, Chen M.

Related Articles, Links

Protease nexin I, thrombin- and urokinase-inhibiting serpin, concentrated in normal human cerebrospinal fluid.

Neurology. 1992 Jul;42(7):1361-6.

Entrez-PubMed Page 33 of 39

PMID: 1620346 [PubMed - indexed for MEDLINE] 288: Rogers J, Schuitz J, Brachova L, Lue LF, Webster S, Bradt B. Related Articles, Links Cooper NR, Moss DE. Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res Immunol. 1992 Jul-Aug;143(6):624-30. Review. No abstract available. PMID: 1455054 [PubMed - indexed for MEDLINE] 289: Atai H. Schmidt ML, Lee VM, Hurtig HI, Greenberg BD, Adler Related Articles, Links CH, Trojanowski JQ. Epitope analysis of senile plaque components in the hippocampus of patients with Parkinson's disease. Neurology, 1992 Jul;42(7):1315-22. PMID: 1377804 [PubMed - indexed for MEDLINE] 290: Askanas V, Engel WK, Alvarez RB. Related Articles, Links Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis. Am J Pathol. 1992 Jul;141(1):31-6. PMID: 1321564 [PubMed - indexed for MEDLINE] 291: Caputo CB, Sobel IR, Scott CW, Brunner WF, Barth PT, Blowers Related Articles, Links Association of the carboxy-terminus of beta-amyloid protein precursor with Alzheimer paired helical filaments. Biochem Biophys Res Commun. 1992 Jun 30;185(3):1034-40. PMID: 1627127 [PubMed - indexed for MEDLINE] Related Articles, Links 292: Haass C, Koo EH, Mellon A, Hung AY, Selkoe DJ. Targeting of cell-surface beta-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 1992 Jun 11;357(6378):500-3. PMID: 1608449 [PubMed - indexed for MEDLINE] 293: Cummings BJ, Su JH, Goddes JW, Van Nostrand WE, Wagner Related Articles, Links SL, Cunningham DD. Cotman CW Aggregation of the amyloid precursor protein within degenerating neurons and dystrophic neurites in Alzheimer's disease. Neuroscience. 1992 Jun;48(4):763-77. PMID: 1378573 [PubMed - indexed for MEDLINE] 1294: McGeer PL, Akiyama H, Kawamata T, Yamada T, Walker DG, Related Articles, Links Ishu T. Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy. J Neurosci Res. 1992 Mar;31(3):428-42. PMID: 1640495 [PubMed - indexed for MEDLINE] 295: Askanas V, Engel WK, Alvarez RB, Glenner GG. Related Articles, Links beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet. 1992 Feb 29;339(8792):560-1. No abstract available. PMID: 1346915 [PubMed - indexed for MEDLINE] 296: Ohgami T, Kitamoto T, Tateishi J. Related Articles, Links

Alzheimer's amyloid precursor protein accumulates within axonal

swellings in human brain lesions.

Entrez-PubMed Page 34 of 39

Neurosci Lett. 1992 Feb 17;136(1):75-8. PMID: 1635670 [PubMed - indexed for MEDLINE]

7297: Wunderlich D. Lee A. Fracasso RP. Mierz DV. Bayney RM. Related Articles, Links Ramabhadran TV

Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Application to the Kunitz domain of human beta amyloid precursor protein.

J Immunol Methods. 1992 Feb 14;147(1):1-11.

PMID: 1371794 [PubMed - indexed for MEDLINE]

298: Delvaux A, Van der Elst L, Octave JN.

Related Articles, Links

Inhibition of trypsin by the beta-amyloid protein precursor. A comparative study between transfected cells, human brain and cerebrospinal fluid.

FEBS Lett. 1992 Feb 3;297(1-2):124-6.

PMID: 1551418 [PubMed - indexed for MEDLINE]

299: Choi-Miura NH, Thara Y, Fukuchi K, Takeda M, Nakano Y, Tohe Related Articles, Links T, Tomita M

SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol (Berl). 1992;83(3):260-4. PMID: 1373021 [PubMed - indexed for MEDLINE]

1 300: Barcikowska M, Kujawa M, Wisniewski H.

Related Articles, Links

beta-Amyloid deposits within the cerebellum of persons older than 80 years of age.

Neuropatol Pol. 1992;30(3-4):285-93.

PMID: 1340921 [PubMed - indexed for MEDLINE]

301: Frautschy SA, Baird A, Cole GM.

Related Articles, Links

Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6. PMID: 1924295 [PubMed - indexed for MEDLINE]

302: Ito H, Hirano H, Yen SH, Kato S.

Related Articles, Links

Demonstration of beta amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam.

Neuropathol Appl Neurobiol. 1991 Oct;17(5):365-73. PMID: 1758569 [PubMed - indexed for MEDLINE]

1303: Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Related Articles, Links Perry G

Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein.

Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7552-6. PMID: 1652752 [PubMed - indexed for MEDLINE]

304: Price JL, Davis PB, Morris JC, White DL.

Related Articles, Links

The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease.

Neurobiol Aging. 1991 Jul-Aug;12(4):295-312. PMID: 1961359 [PubMed - indexed for MEDLINE]


T 305: Enops J. Johnson-Wood K. Schenk DB, Sinha S. Lieberburg L. Related Articles, Links McConlogue L.



Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein.

J Biol Chem. 1991 Apr 15;266(11):7285-90

Entrez-PubMed Page 35 of 39



amyloid precursor protein of Alzheimer's disease. Biochem Biophys Res Commun. 1990 Sep 14;171(2):890-7. PMID: 2119582 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 36 of 39

Related Articles, Links 315: Kanemaru K, Hasegawa M, Shimada H, Ihara Y The presence of a novel protein in calf serum that recognizes beta amyloid in the formalin-fixed section. Am J Pathol. 1990 Sep;137(3):677-87. PMID: 1698030 [PubMed - indexed for MEDLINE] 316: Tate-Ostroff B, Majocha RE, Walcott EC, Ventosa-Michelman Related Articles, Links M, Marotta CA. Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plagues: evidence for coordinated processing of the amyloid precursor protein. J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45. PMID: 2126439 [PubMed - indexed for MEDLINE] 317: Shelton ER, Cohn R, Fish L. Obernolte R, Tahilramani R, Nestor Related Articles, Links JJ, Chan HW Characterization of beta-amyloid precursor proteins with or without the protease-inhibitor domain using anti-peptide antibodies. J Neurochem. 1990 Jul;55(1):60-9. PMID: 2113083 [PubMed - indexed for MEDLINE] 318. Wolf D. Quon D, Wang Y, Cordell B. Related Articles, Links Identification and characterization of C-terminal fragments of the betaamyloid precursor produced in cell culture. EMBO J. 1990 Jul;9(7):2079-84. PMID: 1694126 [PubMed - indexed for MEDLINE] Related Articles, Links 319: Stern RA, Trojanowski JQ, Lee VM. Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibrinogen subunits from peripheral blood. FEBS Lett. 1990 May 7;264(1):43-7. PMID: 1692541 [PubMed - indexed for MEDLINE] Related Articles, Links 320: Spillantini MG, Goedert M, Jakes R, Klug A. Different configurational states of beta-amyloid and their distributions relative to plagues and tangles in Alzheimer disease. Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51. PMID: 2111023 [PubMed - indexed for MEDLINE] 321: Singhrao S, Cole G, Henderson WJ, Newman GR. Related Articles, Links LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease. Histochem J. 1990 May;22(5):257-68. PMID: 1966829 [PubMed - indexed for MEDLINE] 322: Spillantini MG, Goedert M, Jakes R, Klug A. Related Articles, Links Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease. Proc Natl Acad Sci U S A. 1990 May;87(10):3952-6. PMID: 1692627 [PubMed - indexed for MEDLINE] Related Articles, Links 323: Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.

> Proc Natl Acad Sci U S A, 1990 May;87(10):3861-5. PMID: 1692625 [PubMed - indexed for MEDLINE]

> > Related Articles, Links

7324: Arai H. Lee VM. Otvos L. Jr., Greenberg BD, Lowery DE,

Entrez-PubMed Page 37 of 39

Sharma SK, Schmidt ML, Trojanowski JQ.



Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.

Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53. PMID: 1690426 [PubMed - indexed for MEDLINE]

T 325: Kitaguchi N. Tokushima Y. Oishi K. Takahashi Y. Shiojiri S. Related Articles, Links Nakamura S. Tanaka S. Kodaira R. Ito H.

Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA.

Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9. PMID: 2106318 [PubMed - indexed for MEDLINE]

T 326: Koo EU, Sisodia SS, Archer DR, Martin LJ, Weidemann A. Related Articles, Links Beyreuther K, Fischer P, Masters CL, Price DL.



Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.

Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5. PMID: 1689489 [PubMed - indexed for MEDLINE]

T 327: Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Related Articles, Links Benes FM, Marotta CA

Alzheimer cortical neurons containing abundant amyloid mRNA.

Relationship to amyloid deposition and senile plaques. J Psychiatr Res. 1990;24(1):37-50.

PMID: 2195164 [PubMed - indexed for MEDLINE]

T 328: Dewji NN, Shelton ER, Adler MJ, Chan HW, Seegmiller JE. Related Articles, Links Coronel C.

Processing of Alzheimer's disease-associated beta-amyloid precursor protein.

J Mol Neurosci. 1990;2(1):19-27. PMID: 2124135 [PubMed - indexed for MEDLINE]

17 329: Murphy GM Jr, Eng LF, Cordell B, Wang Y, Ellis WG, Meissner Related Articles, Links L, Tinklenberg JR

Beta-amyloid precursor detected in human cerebral cortex. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):309-17. PMID: 2113696 [PubMed - indexed for MEDLINE]

T 330: Takahashi H. Kurashima C. Utsuyama M. Hirokawa K. Related Articles, Links

Immunohistological study of senile brains by using a monoclonal antibody recognizing beta amyloid precursor protein: significance of granular deposits in relation with senile plaques.

Acta Neuropathol (Berl). 1990;80(3):260-5.

PMID: 1698004 [PubMed - indexed for MEDLINE]

T 331: Picken MM, Larrondo-Lillo M, Coria F, Gallo GR, Shelanski Related Articles, Links ML, Frangione B

Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid.

J Neuropathol Exp Neurol. 1990 Jan;49(1):41-8. PMID: 1688925 [PubMed - indexed for MEDLINE]

T 332: Sucnaga T, Hirano A, Llena JF, Ksiezak-Reding H, Yen SH, Dickson DW.

Related Articles, Links

Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer's disease.

J Neuropathol Exp Neurol. 1990 Jan;49(1):31-40.

Entrez-PubMed Page 38 of 39

PMID: 1688924 [PubMed - indexed for MEDLINE] 1333: Palmert MR, Siedlak St., Podlisny MB, Greenberg B, Shelton Related Articles, Links ER, Chan HW, Usiak M, Selkoe DJ, Perry G, Younkin SG. Soluble derivatives of the beta amyloid protein precursor of Alzheimer's disease are labeled by antisera to the beta amyloid protein. Biochem Biophys Res Commun. 1989 Nov 30;165(1):182-8. PMID: 2480122 [PubMed - indexed for MEDLINE] 334: Behrouz N. Defossez A. Delacourie A. Hublau P. Mazzuca M. Related Articles, Links An antiserum to the N-terminal subsequence of the Alzheimer amyloid beta protein does not react with neurofibrillary tangles. J Gerontol. 1989 Nov;44(6):B156-9. PMID: 2681356 [PubMed - indexed for MEDLINE] 7 335: Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin Related Articles, Links LH, Selkoe DJ, Younkin SG The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6338-42. PMID: 2503832 [PubMed - indexed for MEDLINE] 336: Anderson J. Wallace W. Snyder S. Haroutunian V. Roberts JL. Related Articles, Links Lieberburg L Cellular forms of the rat and human beta-amyloid precursor protein (BAPP). Brain Res. 1989 Jan 30;478(2):391-8. PMID: 2647209 [PubMed - indexed for MEDLINE] Related Articles, Links 337: Benes FM, Reifel JL, Majocha RE, Marotta CA. Evidence for a diffusional model of Alzheimer amyloid A4 (beta-≡ amyloid) deposition during neuritic plaque formation. Neuroscience, 1989;33(3):483-8. PMID: 2700016 [PubMed - indexed for MEDLINE] 338: Bird TD, Lampe TH, Nemens EJ, Sumi SM, Nochlin D, Related Articles, Links Schellenberg GD, Wijsman EM. Characteristics of familial Alzheimer's disease in nine kindreds of Volga German ancestry. Prog Clin Biol Res. 1989;317:229-34. PMID: 2602419 [PubMed - indexed for MEDLINE] 339: Gentleman SM, Bruton C, Allsop D, Lewis SJ, Polak JM, Related Articles, Links Roberts GW A demonstration of the advantages of immunostaining in the quantification of amyloid plaque deposits. Histochemistry, 1989;92(4):355-8. PMID: 2478507 [PubMed - indexed for MEDLINE] 340: Wisniewski HM, Wen GY, Kim KS. Related Articles, Links Comparison of four staining methods on the detection of neuritic plaques. Acta Neuropathol (Berl). 1989;78(1):22-7. PMID: 2472039 [PubMed - indexed for MEDLINE] 341: Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Younkin Related Articles, Links LH, Selkoe DJ, Younkin SG. Antisera to an amino-terminal peptide detect the amyloid protein

precursor of Alzheimer's disease and recognize senile plaques.

Biochem Biophys Res Commun. 1988 Oct 14;156(1):432-7. PMID: 3140814 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 39 of 39

Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues.

Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5.

PMID: 3140239 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 → Sort Send to Text One page.

Write to the Help Desk


NCBI | NLM | NIH

Department of Health & Human Services


Freedom of Information Act | Disclaimer

Oct. 30 2003-06/54:00

Entrez-PubMed Page 1 of 50








Related Articles, Links

PubMed Nucleotide PMC Protein Genome Structure Journals Book Search PubMed Go Clear for beta-amyloid antibody Limits Preview/Index History Details Clipboard About Entrez Show: |500 ₩ |Sort Display Summary Send to Items 1-446 of 446 One page. Text Version 1: Miller DL. Currie JR. Mehta PD. Potempska A. Hwang YW. Wegiel Related Articles, Links Entrez PubMed Overview Humoral immune response to fibrillar beta-amyloid peptide. Help | FAQ Biochemistry, 2003 Oct 14;42(40):11682-92. Tutorial PMID: 14529278 [PubMed - in process] New/Noteworkly E-Utilities 2: Wang DS, Iwata N, Hama E, Saido TC, Dickson DW. Related Articles, Links PubMed Services Oxidized neprilysin in aging and Alzheimer's disease brains. Journals Database Biochem Biophys Res Commun. 2003 Oct 10;310(1):236-41 MeSH Database PMID: 14511676 [PubMed - in process] Single Citation Matcher Batch Citation Matcher T 3: Xu D, Yang CH, Wang LN. Related Articles, Links **Clinical Queries LinkOut** Prevalence and characteristics of cerebral amyloid angiopathy in the Cubby elderly l Zhonghua Nei Ke Za Zhi. 2003 Aug;42(8):541-4. Chinese. Related Resources PMID: 14505543 [PubMed - in process] Order Documents **NLM Gateway** 4: Chauhan NB, Siegel GJ, Related Articles, Links TOXNET Consumer Health Intracerebroventricular passive immunization with anti-Abeta antibody in Clinical Alerts Tg2576. ClinicalTrials gov J Neurosci Res. 2003 Oct 1;74(1):142-7. PubMed Central PMID: 13130516 [PubMed - in process] Privacy Policy 5: Maddalena A. Papassotiropoulos A. Muller-Tillmanns B. Jung HH. Related Articles, Links Hegi T, Nitsch RM, Hock C Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch Neurol. 2003 Sep;60(9):1202-6. PMID: 12975284 [PubMed - indexed for MEDLINE] Related Articles, Links 6: LeVine H 3rd Y10W beta(1-40) fluorescence reflects epitope exposure in conformers of Alzheimer's beta-peptide. Arch Biochem Biophys. 2003 Sep 1;417(1):112-22. PMID: 12921787 [PubMed - indexed for MEDLINE] 7: Torp R, Ottersen OP, Cotman CW, Head E. Related Articles, Links Identification of neuronal plasma membrane microdomains that colocalize beta-amyloid and presenilin: implications for beta-amyloid precursor protein processing. Neuroscience. 2003;120(2):291-300. PMID: 12890502 [PubMed - indexed for MEDLINE] 8: Schwab C, Hosokawa M, Akiyama H, McGeer PL.

Familial British dementia: colocalization of furin and ABri amyloid.


Acta Neuropathol (Berl). 2003 Sep;106(3):278-84. Epub 2003 Jul 16.

PMID: 12883829 [PubMed - in process]



Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta 1-40:


a kinetic model.



Neutralization of TRAIL death pathway protects human neuronal cell line

Memo M


Entrez-PubMed Page 4 of 50



35: Matsuoka Y. Saito M, LaFrancois J, Saito M, Gaynor K, Olm V,

Related Articles, Links


Entrez-PubMed Page 5 of 50



1 44: Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel Related Articles, Links

S. Wei X, Buerger K, Hoft C, Hemmer B, Moller IIJ, Farlow M.

Oertel WH, Sommer N, Du Y



Advanced glycation end products (AGE) and their receptor (RAGE) in the


Entrez-PubMed Page 7 of 50

brain of patients with Creutzfeldt-Jakob disease with prion plaques. Neurosci Lett. 2002 Jun 28;326(2):117-20. PMID: 12057842 [PubMed - indexed for MEDLINE] 54: Stone JR, Okonkwo DO, Singleton RH, Mutlu LK, Helm GA, Related Articles, Links Povlishock JT Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid Beta peptide in traumatic axonal injury. J Neurotrauma. 2002 May;19(5):601-14. PMID: 12042095 [PubMed - indexed for MEDLINE] 55: DeGiorgio LA, Shimizu Y, Chun US, Kim YS, Sugama S, Son JH, Related Articles, Links Joh TH. Volpe BT Amyloid precursor protein gene disruption attenuates degeneration of substantia nigra compacta neurons following axotomy. Brain Res. 2002 May 31;938(1-2):38-44. PMID: 12031533 [PubMed - indexed for MEDLINE] 56: Frenkel D, Solomon B. Related Articles, Links Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5675-9. PMID: 11960022 [PubMed - indexed for MEDLINE] 57: Nagele RG, D'Andrea MR, Anderson WJ, Wang HY Related Articles, Links Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience. 2002;110(2):199-211. PMID: 11958863 [PubMed - indexed for MEDLINE] 58: Mbebi C, See V, Mereken L, Pradier L, Muller U, Loeffler JP. Related Articles, Links Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IVdependent signaling pathway. J Biol Chem. 2002 Jun 7;277(23):20979-90. Epub 2002 Mar 04. PMID: 11877414 [PubMed - indexed for MEDLINE] 59: Toro VC, Tehranian R, Zetterstrom M, Eriksson G, Langel U, Related Articles, Links Bartfai T, Iverfeld K Increased gene expression of interleukin-lalpha and interleukin-6 in rat primary glial cells induced by beta-amyloid fragment. J Mol Neurosci. 2001 Dec; 17(3):341-50. PMID: 11859930 [PubMed - indexed for MEDLINE] 60: Frenkel D, Solomon B Related Articles, Links Towards Alzheimer's beta-amyloid vaccination. Biologicals. 2001 Sep-Dec;29(3-4):243-7. PMID: 11851323 [PubMed - indexed for MEDLINE] 61: That DR, Ghebremedhin E, Haass C, Schultz C. Related Articles, Links UV light-induced autofluorescence of full-length Abeta-protein deposits in the human brain. Clin Neuropathol. 2002 Jan-Feb;21(1):35-40. PMID: 11846043 [PubMed - indexed for MEDLINE] 62: Nicolau C, Greferath R, Balaban TS, Lazarte JE, Hopkins RJ Related Articles, Links

pancreas of transgenic NORBA mice. Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2332-7. Epub 2002 Feb 12. PMID: 11842183 [PubMed - indexed for MEDLINE]


A liposome-based therapeutic vaccine against beta -amyloid plaques on the

Entrez-PubMed Page 8 of 50




PMID: 11758782 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 9 of 50



Science. 2001 Aug 24;293(5534):1491-5.


PMID: 11520988 [PubMed - indexed for MEDLINE]



Human brain carboxypeptidase B, which cleaves beta-amyloid peptides in

	vitro, is expressed in the endoplasmic reticulum of neuro Eur J Neurosci. 2001 May;13(9):1653-7. PMID: 11359517 [PubMed - indexed for MEDLINE]	ons.
□ 90:	Chung H, Brazil MI, Irizarry MC, Hyman BT, Maxfield FR	Related Articles, Links
	Uptake of fibrillar beta-amyloid by microglia isolated frand type II) knockout mice. Neuroreport. 2001 May 8;12(6):1151-4. PMID: 11338182 [PubMed - indexed for MEDLINE]	om MSR-A (type I
□ 91:	Chong YH, Sung JH, Shin SA, Chung JH, Suh YH.	Related Articles, Links
	Effects of the beta-amyloid and carboxyl-terminal fragmamyloid precursor protein on the production of the tumo alpha and matrix metalloproteinase-9 by human monocy J Biol Chem. 2001 Jun 29;276(26):23511-7. Epub 2001 Apr 16. PMID: 11306564 [PubMed - indexed for MEDLINE]	r necrosis factor-
□ 92:	England P. Jacobsson SO, Fowler CJ	Related Articles, Links
	Investigation into the effects of amyloid (1-42) beta-pep antigen-stimulated hexosaminidase and serotonin release 2H3 basophilic leukemia cells. Methods Find Exp Clin Pharmacol. 2000 Nov;22(9):657-61. PMID: 11294005 [PubMed - indexed for MEDLINE]	
□ 93:	Cedazo-Minguez A. Wichager B, Winblad B, Huttinger M, Cowburn RF	Related Articles, Links
	Effects of apolipoprotein E (apoE) isoforms, beta-amylo apoE/Abeta complexes on protein kinase C-alpha (PKC-translocation and amyloid precursor protein (APP) proce SH-SY5Y neuroblastoma cells and fibroblasts. Neurochem Int. 2001 Jun;38(7):615-25. PMID: 11290387 [PubMed - indexed for MEDLINE]	-alpha)
□ 94:	Frenkel D, Kariv N, Solomon B.	Related Articles, Links
	Generation of auto-antibodies towards Alzheimer's diseavaccine. 2001 Mar 21;19(17-19):2615-9. PMID: 11257400 [PubMed - indexed for MEDLINE]	ase vaccination.
□ 95:	Duker NJ, Sperling J, Soprano KJ, Druin DP, Davis A, Ashworth R	Related Articles, Links
	beta-Amyloid protein induces the formation of purine di DNA. J Cell Biochem. 2001;81(3):393-400. PMID: 11255222 [PubMed - indexed for MEDLINE]	mers in cellular
□ 96:	Gerlai R.	Related Articles, Links
	Alzheimer's disease: beta-amyloid hypothesis strengthen Trends Neurosci. 2001 Apr;24(4):199. No abstract available. PMID: 11249992 [PubMed - indexed for MEDLINE]	ed!
□ 97:	Matsumoto A, Motozaki K, Seki T, Sasaki R, Kawabe T.	Related Articles, Links
	Expression of human brain carboxypeptidase B, a possible enzyme for beta-amyloid precursor protein, in peripheral Neurosci Res. 2001 Mar;39(3):313-7. PMID: 11248371 [PubMed - indexed for MEDLINE]	
□ 98:	Husemann J. Silverstein SC.	Related Articles, Links

Expression of scavenger receptor class B, type I, by astrocytes and vascular



precursor protein.

Mol Cell Neurosci. 2000 Dec; 16(6): 708-23.

PMID: 11124892 [PubMed - indexed for MEDLINE]

Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing.

Brain Res Mol Brain Res. 2000 Dec 8;84(1-2):115-26. PMID: 11113538 [PubMed - indexed for MEDLINE]

107: Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, Stern D, Kim Related Articles, Links KS, Zlokovic B, Kalra VK



beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1.

Am J Physiol Cell Physiol. 2000 Dec;279(6):C1772-81. PMID: 11078691 [PubMed - indexed for MEDLINE]

108: Frenkel D. Katz O. Solomon B.

Related Articles, Links



Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration.

Proc Natl Acad Sci U S A. 2000 Oct 10;97(21):11455-9. PMID: 11027345 [PubMed - indexed for MEDLINE]

109: Tan J. Town T. Mori T. Wu Y, Saxe M, Crawford F, Mullan M. Related Articles, Links




CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

J Neurosci. 2000 Oct 15;20(20):7587-94.

PMID: 11027218 [PubMed - indexed for MEDLINE]

110: Rossner S, Bock M, Stahl T, Mendla K, Schliebs R, Bigl V. Related Articles, Links



Eur J Neurosci. 2000 Sep;12(9):3191-200.

PMID: 10998103 [PubMed - indexed for MEDLINE]

111: Ogawa K, Yamada T, Tsujioka Y, Taguchi J, Takahashi M, Tsuboi Y, Fujino Y, Nakajima M, Yamamoto T, Akatsu H. Mitsui S, Yamaguchi N

Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.

Psychiatry Clin Neurosci. 2000 Aug;54(4):419-26. PMID: 10997858 [PubMed - indexed for MEDLINE]

112: Simic G, Lucassen PJ, Krsnik Z, Kruslin B, Kostovic I, Winblad Related Articles, Links B, Bogdanovi.

nNOS expression in reactive astrocytes correlates with increased cell death related DNA damage in the hippocampus and entorhinal cortex in Alzheimer's disease.

Exp Neurol. 2000 Sep;165(1):12-26.

PMID: 10964481 [PubMed - indexed for MEDLINE]

113: Taguchi J, Fujin A, Fujino Y, Tsujioka Y, Takahashi M, Tsuboi Related Articles, Links Y, Wada I, Yamada T

Different expression of calreticulin and immunoglobulin binding protein in Alzheimer's disease brain.

Acta Neuropathol (Berl). 2000 Aug;100(2):153-60. PMID: 10963362 [PubMed - indexed for MEDLINE]

114: DeCiorgio LA, DeGiorgio N, Milner TA, Conti B, Volpe BT. Related Articles, Links

Neurotoxic APP C-terminal and beta-amyloid domains colocalize in the nuclei of substantia nigra pars reticulata neurons undergoing delayed degeneration.

Brain Res. 2000 Aug 25;874(2):137-46.

PMID: 10960598 [PubMed - indexed for MEDLINE]

Tanabe Y. Ishizu H, Ishiguro K, Itoh N, Terada S, Haraguchi T,

		rage 14 01 30
□ 115:	Kawai K, Kuroda S	Related Articles, Links
	Tau pathology in diffuse neurofibrillary tangles with ca (DNTC): biochemical and immunohistochemical investigation Neuroreport. 2000 Aug 3;11(11):2473-7. PMID: 10943706 [PubMed - indexed for MEDLINE]	
□ 116:	Helmuth L.	Related Articles, Links
	Alzheimer's congress. Further progress on a beta-amyloscience. 2000 Jul 21;289(5478):375. No abstract available. PMID: 10939941 [PubMed - indexed for MEDLINE]	oid vaccine.
□ 117:	Stone JR, Singleton RH, Povlishock JT.	Related Articles, Links
	Antibodies to the C-terminus of the beta-amyloid precu (APP): a site specific marker for the detection of traum Brain Res. 2000 Jul 21;871(2):288-302. PMID: 10899295 [PubMed - indexed for MEDLINE]	
□ 118:	Kaneko I, Kubo T, Morimoto K.	Related Articles, Links
	[Neurotoxicity of beta-amyloid] Nippon Yakurigaku Zasshi. 2000 Feb;115(2):67-77. Review. Japa PMID: 10876793 [PubMed - indexed for MEDLINE]	inese.
□ 119:	Horsburgh K, Cole GM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA	Related Articles, Links
	beta-amyloid (Abeta)42(43), abeta42, abeta40 and apol of plaques in fatal head injury. Neuropathol Appl Neurobiol. 2000 Apr;26(2):124-32. PMID: 10840275 [PubMed - indexed for MEDLINE]	E immunostaining
□ 120:	Rohn TT, Ivins KJ, Bahr BA, Cotman CW, Cribbs DH.	Related Articles, Links
	A monoclonal antibody to amyloid precursor protein in apoptosis. J Neurochem. 2000 Jun;74(6):2331-42. PMID: 10820193 [PubMed - indexed for MEDLINE]	nduces neuronal
□ 121:	Sparks DL, Kuo YM, Rober A, Martin T, Lukas RJ.	Related Articles, Links
	Alterations of Alzheimer's disease in the cholesterol-fe vascular inflammation. Preliminary observations. Ann N Y Acad Sci. 2000 Apr;903:335-44. PMID: 10818523 [PubMed - indexed for MEDLINE]	d rabbit, including
□ 122:	Brown WR, Moody DM, Thore CR, Challa VR.	Related Articles, Links
	Cerebrovascular pathology in Alzheimer's disease and Ann N Y Acad Sci. 2000 Apr;903:39-45. PMID: 10818487 [PubMed - indexed for MEDLINE]	leukoaraiosis.
□ 123:	Frenkel D, Solomon B, Benhar I.	Related Articles, Links
	Modulation of Alzheimer's beta-amyloid neurotoxicity single-chain antibody. J Neuroimmunol. 2000 Jul 1;106(1-2):23-31. PMID: 10814779 [PubMed - indexed for MEDLINE]	by site-directed
□ 124: —	Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC.	Related Articles, Links
	Evidence for seeding of beta -amyloid by intracerebral Alzheimer brain extracts in beta -amyloid precursor promise.	

mice.

J Neurosci. 2000 May 15;20(10):3606-11.

Entrez-PubMed Page 15 of 50

PMID: 10804202 [PubMed - indexed for MEDLINE] 125: Marzolo MP, von Bernhardi R. Bu G, Inestrosa NC. Related Articles, Links Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells. J Neurosci Res. 2000 May 1;60(3):401-11. PMID: 10797543 [PubMed - indexed for MEDLINE] 126: Head F. McCleary R. Hahn FF, Milgram NW, Cotman CW Related Articles, Links Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging. 2000 Jan-Feb;21(1):89-96. PMID: 10794853 [PubMed - indexed for MEDLINE] 127: Azizeh BY, Head E. Ibrahim MA, Torp R, Tenner AJ, Kim RC, Related Articles, Links Lott IT, Cotman CW Molecular dating of senile plaques in the brains of individuals with Down syndrome and in aged dogs. Exp Neurol. 2000 May;163(1):111-22. PMID: 10785449 [PubMed - indexed for MEDLINE] 128: Capell A. Steiner H. Romig H. Keck S. Baader M, Grim MG, Related Articles, Links Baumeister R, Haass C Presenilin-1 differentially facilitates endoproteolysis of the beta-amyloid precursor protein and Notch. Nat Cell Biol. 2000 Apr;2(4):205-11. PMID: 10783238 [PubMed - indexed for MEDLINE] 129: Brazil MI, Chung H. Maxfield FR. Related Articles, Links Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer's disease amyloid fibrils by microglia. J Biol Chem. 2000 Jun 2;275(22):16941-7. PMID: 10747968 [PubMed - indexed for MEDLINE] 130: Salinero O, Moreno-Flores MT, Wandosell F. Related Articles, Links Increasing neurite outgrowth capacity of beta-amyloid precursor protein proteoglycan in Alzheimer's disease. J Neurosci Res. 2000 Apr 1;60(1):87-97. PMID: 10723071 [PubMed - indexed for MEDLINE] 131: Lin X, Koelsch G, Wu S, Downs D. Dashti A, Tang J. Related Articles, Links Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1456-60. PMID: 10677483 [PubMed - indexed for MEDLINE] 132: Cescato R, Dumermuth E, Spiess M, Paganetti PA Related Articles, Links Increased generation of alternatively cleaved beta-amyloid peptides in cells expressing mutants of the amyloid precursor protein defective in endocytosis. J Neurochem. 2000 Mar;74(3):1131-9. PMID: 10693945 [PubMed - indexed for MEDLINE] 133: Matsumoto A. Related Articles, Links


The 68K protease has beta-secretase-like activity for lymphocyte precursor protein but not for brain substrate.

Neuroreport. 2000 Feb 7;11(2):373-7. PMID: 10674489 [PubMed - indexed for MEDLINE] Entrez-PubMed Page 16 of 50

		1 450 10 01 30
□ 134:	Yoshiyama Y, Asahina M, Hattori T.	Related Articles, Links
	Selective distribution of matrix metalloproteinase-3 (Malzheimer's disease brain. Acta Neuropathol (Berl). 2000 Feb;99(2):91-5. PMID: 10672313 [PubMed - indexed for MEDLINE]	fMP-3) in
□ 135:	Toro F, Lopera F, Ossa J, Madrigal L, Mira A, Diaz A, Parra S	Related Articles, Links
	[Detection of antibodies to beta-amyloid in carriers of the presenilin-1 gene] Rev Neurol. 1999 Dec 16-31;29(12):1104-7. Spanish. PMID: 10652730 [PubMed - indexed for MEDLINE]	E280A mutation in
□ 136:	Al-Abed Y, Bucala R.	Related Articles, Links
	Structure of a synthetic glucose derived advanced glyc that is immunologically cross-reactive with its naturall counterparts. Bioconjug Chem. 2000 Jan-Feb;11(1):39-45. PMID: 10639083 [PubMed - indexed for MEDLINE]	
□ 137:	Campbell E, Pearson RC, Parkinson D.	Related Articles, Links
	Methods to uncover an antibody epitope in the KPI dor Alzheimer's amyloid precursor protein for immunohist human brain. J Neurosci Methods. 1999 Nov 15;93(2):133-8. PMID: 10634498 [PubMed - indexed for MEDLINE]	
□ 138:	Frederikse PH, Zigler SJ Jr, Famsworth PN, Carper DA	Related Articles, Links
	Prion protein expression in mammalian lenses. Curr Eye Res. 2000 Feb;20(2):137-43. PMID: 10617916 [PubMed - indexed for MEDLINE]	
□ 139:	Webster SD, Tenner AJ, Poulos TL, Cribbs DH.	Related Articles, Links
	The mouse C1q A-chain sequence alters beta-amyloid-complement activation. Neurobiol Aging. 1999 May-Jun;20(3):297-304. PMID: 10588577 [PubMed - indexed for MEDLINE]	induced
□ 140:	Jung SS, Gauthier S, Cashman NR.	Related Articles, Links
	Beta-amyloid precursor protein is detectable on monocincreased in Alzheimer's disease. Neurobiol Aging. 1999 May-Jun;20(3):249-57. PMID: 10588572 [PubMed - indexed for MEDLINE]	ytes and is
□ 141:	Nakano S, Akiguchi I, Nakamura S, Satoi H, Kawashima S, Kimura J.	Related Articles, Links
	Aberrant expression of cyclin-dependent kinase 5 in in myositis. Neurology. 1999 Nov 10;53(8):1671-6. PMID: 10563611 [PubMed - indexed for MEDLINE]	clusion body
□ 142:	Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM.	Related Articles, Links
	The role of cholesterol in the biosynthesis of beta-amy. Neuroreport. 1999 Jun 3;10(8):1699-705. PMID: 10501560 [PubMed - indexed for MEDLINE]	loid.
□ 143:	Lippa CF, Ozawa K, Mann DM, Ishii K, Smith TW, Arawaka S, Mori H.	Related Articles, Links
	The 121 C1 / 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia

Entrez-PubMed Page 17 of 50



stimulates proliferation of neural stem cells.

Eur J Neurosci. 1999 Jun;11(6):1907-13.

Entrez-PubMed Page 18 of 50


PMID: 10336659 [PubMed - indexed for MEDLINE] Related Articles, Links 153: Ochmichen M, Theuerkauf I, Meissner C. Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI. Acta Neuropathol (Berl). 1999 May; 97(5): 491-4. PMID: 10334486 [PubMed - indexed for MEDLINE] 154: Johnson G, Moore SW. Related Articles, Links The adhesion function on acetylcholinesterase is located at the peripheral Biochem Biophys Res Commun. 1999 May 19;258(3):758-62. PMID: 10329459 [PubMed - indexed for MEDLINE] 155: Abraham CR, Marshall DC, Tibbles HE, Otto K, Long HJ. Related Articles, Links Billingslea AM, Hastev R, Johnson R, Fine RE, Smith SJ, Simons ER, Davies TA Platelets and DAMI megakaryocytes possess beta-secretase-like activity. J Lab Clin Med. 1999 May; 133(5):507-15. PMID: 10235134 [PubMed - indexed for MEDLINE] 156: Howlett DR, Perry AE, Godfrey F, Swatton JE, Jennings KIL Related Articles, Links Spitzfaden C, Wadsworth H, Wood SJ, Markwell RE Inhibition of fibril formation in beta-amyloid peptide by a novel series of benzofurans. Biochem J. 1999 May 15;340 (Pt 1):283-9. PMID: 10229684 [PubMed - indexed for MEDLINE] 157: Frenkel D. Balass M. Katchalski-Katzir F. Solomon B. Related Articles, Links High affinity binding of monoclonal antibodies to the sequential epitope EFRH of beta-amyloid peptide is essential for modulation of fibrillar aggregation. J Neuroimmunol. 1999 Mar 1;95(1-2):136-42. PMID: 10229123 [PubMed - indexed for MEDLINE] 158: Lin B, Schmidt-Kastner R, Busto R, Ginsberg MD Related Articles, Links Progressive parenchymal deposition of beta-amyloid precursor protein in rat brain following global cerebral ischemia. Acta Neuropathol (Berl). 1999 Apr;97(4):359-68. PMID: 10208275 [PubMed - indexed for MEDLINE] 159: Pike CJ. Related Articles, Links Estrogen modulates neuronal Bcl-xL expression and beta-amyloidinduced apoptosis: relevance to Alzheimer's disease. J Neurochem. 1999 Apr;72(4):1552-63. PMID: 10098861 [PubMed - indexed for MEDLINE] 160: Fabrizi C, Businaro R, Lauro GM, Starace G, Fumagalli L. Related Articles, Links Activated alpha2macroglobulin increases beta-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells. Exp Neurol. 1999 Feb;155(2):252-9. PMID: 10072300 [PubMed - indexed for MEDLINE] 161: Winkler K, Schamagl H, Tisljar U, Hoschutzky H, Friedrich I, Related Articles, Links Hoffmann MM, Huttinger M. Wieland H. Marz W.

Competition of Abeta amyloid peptide and apolipoprotein E for receptor-

mediated endocytosis.

J Lipid Res. 1999 Mar; 40(3): 447-55.


Entrez-PubMed Page 19 of 50



Detection of the membrane-retained carboxy-terminal tail containing

Related Articles, Links

170: Daly J 4th, Labiri DK, Justus DE, Kotwal GJ




Loss of endosomal/lysosomal membrane impermeability is an early event

Related Articles, Links

	in amyloid Abeta1-42 pathogenesis. J Neurosci Res. 1998 Jun 15;52(6):691-8.		
	PMID: 9669318 [PubMed - indexed for MEDLINE]		
□ 180:	Hoshino S. Tamaoka A. Takahashi M. Kobayashi S. Furukawa T. Related Articles, iLinks Oaki Y, Mori O. Matsuno S. Shoji S. Inomata M. Teramoto A		
	Emergence of immunoreactivities for phosphorylated tau and amyloid- beta protein in chronic stage of fluid percussion injury in rat brain. Neuroreport. 1998 Jun 1,9(8):1879-83. PMID: 9665619 [PubMed - indexed for MEDLINE]		
□ 181:	Terryberry JW, Thor G, Peter JB.	Related Articles, Links	
	Autoantibodies in neurodegenerative diseases: antigenfrequencies and intrathecal analysis. Neurobiol Aging. 1998 May-Jun;19(3):205-16. PMID: 9661995 [PubMed - indexed for MEDLINE]	specific	
□ 182:	McGillem GS, Guidry C, Dachoux RF	Related Articles, Links	
	Antigenic changes of rabbit retinal Muller cells in cultu Invest Ophthalmol Vis Sci. 1998 Jul;39(8):1453-61. PMID: 9660494 [PubMed - indexed for MEDLINE]	ıre.	
□ 183:	Miguel-Hidalgo JJ. Alvarez A, Cacabelos R.	Related Articles, Links	
	Plasticity of Congo red staining displayed by subpopular within the rat central nervous system. Cell Tissue Res. 1998 Jul;293(1):75-86. PMID: 9634599 [PubMed - indexed for MEDLINE]	ations of neurons	
□ 184:	Salinero O, Garrido II, Wandosell F	Related Articles, Links	
	Amyloid precursor protein proteoglycan is increased af Biochim Biophys Acta. 1998 Apr 28;1406(3):237-50. PMID: 9630651 [PubMed - indexed for MEDLINE]	ter brain damage.	
□ 185:	Nakamura Y. Yamamoto M. Kumamaru E.	Related Articles, Links	
	A variant very low density lipoprotein receptor lacking O-linked sugar domain in the human brain myelin. Brain Res. 1998 May 18;793(1-2):47-53. PMID: 9630508 [PubMed - indexed for MEDLINE]	84 base pairs of	
□ 186:	Sputer S. Emslie-Smith A. Engel AG	Related Articles, Links	
	Amyloid myopathy: an underdiagnosed entity. Ann Neurol. 1998 Jun;43(6):719-28. PMID: 9629841 [PubMed - indexed for MEDLINE]		
□ 187:	Alonzo NC, Hyman BT, Rebeck GW, Greenberg SM.	Related Articles, Links	
	Progression of cerebral amyloid angiopathy: accumulated beta 40 in affected vessels J Neuropathol Exp Neurol. 1998 Apr;57(4):353-9. PMID: 9600229 [PubMed - indexed for MEDLINE]	ion of amyloid-	
□ 188:	Honda S, Itoh F, Yoshimoto M, Hinoda Y, Imai K.	Related Articles, Links	
	Changes in morphology of neuroblastoma cells treated retinoic acid combined with transfer of the C-terminal ramyloid precursor protein. J Clin Lab Anal. 1998;12(3):172-8. PMID: 9591705 [PubMed - indexed for MEDLINE]		

189: Rossner S.

Entrez-PubMed Page 22 of 50



198: Bayer TA, Paliga K, Weggen S, Wiestler OD, Beyreuther K.

Related Articles, Links

Entrez-PubMed Page 23 of 50

Multhaup G. Amyloid precursor-like protein 1 accumulates in neuritic plaques in Alzheimer's disease. Acta Neuropathol (Berl). 1997 Dec;94(6):519-24. PMID: 9444352 [PubMed - indexed for MEDLINE] 199: Jen A. Wickenden C. Rohan de Silva HA. Patel A.J. Related Articles, Links Preparation and purification of antisera against different regions or isoforms of beta-amyloid precursor protein. Brain Res Brain Res Protoc. 1997 Dec 1;2(1):23-30. PMID: 9438067 [PubMed - indexed for MEDLINE] 7 200: Shalit F. Sredni B. Rosenblatt-Bin H, Kazimirsky G, Brodie C, Related Articles, Links Huberman M. Beta-amyloid peptide induces tumor necrosis factor-alpha and nitric oxide production in murine macrophage cultures. Neuroreport. 1997 Nov 10;8(16):3577-80. PMID: 9427329 [PubMed - indexed for MEDLINE] 201: Zambrano N. De Renzis S, Minopoli G, Faraonio R, Donini V, Related Articles, Links Scaloni A. Cimino F, Russo T DNA-binding protein Pur alpha and transcription factor YY1 function as transcription activators of the neuron-specific FE65 gene promoter. Biochem J. 1997 Nov 15;328 (Pt 1):293-300. PMID: 9359867 [PubMed - indexed for MEDLINE] 1 202: Pluta R. Misicka A. Januszewski S. Barcikowska M. Lipkowski Related Articles, Links Transport of human beta-amyloid peptide through the rat blood-brain barrier after global cerebral ischemia. Acta Neurochir Suppl (Wien). 1997;70:247-9. PMID: 9416336 [PubMed - indexed for MEDLINE] 203: Gearing M. Levey AI, Mirra SS. Related Articles, Links Diffuse plaques in the striatum in Alzheimer disease (AD): relationship to the striatal mosaic and selected neuropeptide markers. J Neuropathol Exp Neurol. 1997 Dec;56(12):1363-70. PMID: 9413285 [PubMed - indexed for MEDLINE] 1 204: An SF, Giometto B, Groves M, Miller RF, Beckett AA, Gray F. Related Articles, Links Tavolato B, Scaravilli F. Axonal damage revealed by accumulation of beta-APP in HIV-positive III individuals without AIDS. J Neuropathol Exp Neurol. 1997 Nov;56(11):1262-8. PMID: 9370237 [PubMed - indexed for MEDLINE] 205: Goodwin JL. Kehrli ME Jr. Uemura E. Related Articles, Links Integrin Mac-1 and beta-amyloid in microglial release of nitric oxide. Brain Res. 1997 Sep 12;768(1-2):279-86. PMID: 9369326 [PubMed - indexed for MEDLINE] 206: Lahiri DK, Farlow MR, Sambamorti K, Nall C. Related Articles, Links The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. Life Sci. 1997;61(20):1985-92. PMID: 9366505 [PubMed - indexed for MEDLINE]

The beta-amyloid epitope masking activity in human brain is identified as

Related Articles, Links

207: Matsumoto A. Minami M. Matsumoto R.

Entrez-PubMed Page 24 of 50

albumin. Neuroreport. 1997 Oct 20;8(15):3297-301. PMID: 9351660 [PubMed - indexed for MEDLINE] 208: Lahiri DK, Farlow MR, Numberger J Jr, Greig NH. Related Articles, Links Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci. 1997 Sep 26;826:416-21. PMID: 9329715 [PubMed - indexed for MEDLINE] 209: Sasaki S. Iwata M. Related Articles, Links Immunocytochemical and ultrastructural study of pericapillary rosettes in amyotrophic lateral sclerosis. Acta Neuropathol (Berl). 1997 Oct;94(4):338-44. PMID: 9341934 [PubMed - indexed for MEDLINE] 210: Garcia-Ladona FJ, Hiss Y, Frey P, Ghandour MS. Related Articles, Links Oligodendrocytes express different isoforms of beta-amyloid precursor protein in chemically defined cell culture conditions: in situ hybridization and immunocytochemical detection. J Neurosci Res. 1997 Oct 1;50(1):50-61. PMID: 9379493 [PubMed - indexed for MEDLINE] 211: Shea TB, Prabhakar S, Ekinci FJ. Related Articles, Links Beta-amyloid and ionophore A23187 evoke tau hyperphosphorylation by distinct intracellular pathways: differential involvement of the calpain/protein kinase C system. J Neurosci Res. 1997 Sep 15;49(6):759-68. PMID: 9335263 [PubMed - indexed for MEDLINE] 1212: Miller JD, Commings J, Marcsh GA, Walker DG, Castello GM, Related Articles, Links Ngo C, Kimata K, Kinsella MG, Wight TN, Snow AD. Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of beta-amyloid protein into rodent hippocampus. Glia. 1997 Oct;21(2):228-43. PMID: 9336237 [PubMed - indexed for MEDLINE] 213: Little SP, Dixon EP, Norris F, Buckley W, Becker GW, Johnson Related Articles, Links M, Dobbins JR, Wyrick T, Miller JR, MacKellar W, Hepburn D, Corvalan J, McClure D, Liu X, Stephenson D, Clemens J, Johnstone EM. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J Biol Chem. 1997 Oct 3;272(40):25135-42. PMID: 9312124 [PubMed - indexed for MEDLINE] 214: Brewer GJ. Related Articles, Links Effects of acidosis on the distribution of processing of the beta-amyloid precursor protein in cultured hippocampal neurons. Mol Chem Neuropathol. 1997 Jun;31(2):171-86. PMID: 9376023 [PubMed - indexed for MEDLINE] 215: Yamada T. Tsuboi Y. Takahashi M. Related Articles, Links Interrelationship between beta-amyloid deposition and complementactivated oligodendroglia.

Dement Geriatr Cogn Disord. 1997 Sep-Oct;8(5):267-72. PMID: 9298627 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 25 of 50

7 216: Dewji NN, Singer SJ.

Related Articles, Links



Cell surface expression of the Alzheimer disease-related presenilin proteins.

Proc Natl Acad Sci U S A. 1997 Sep 2;94(18):9926-31. PMID: 9275228 [PubMed - indexed for MEDLINE]

217: Cataldo AM, Barnett JL, Pieroni C, Nixon RA

Related Articles, Links



Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis.

J Neurosci. 1997 Aug 15;17(16):6142-51.

PMID: 9236226 [PubMed - indexed for MEDLINE]

17 218: Cutler P. Brown F. Camilleri P. Carpenter D. George A. Gray C. Related Articles, Links Haran M. Stewart B.



The recognition of haemoglobin by antibodies raised for the immunoassay of beta-amyloid.

FEBS Lett. 1997 Jul 28;412(2):341-5.

PMID: 9256248 [PubMed - indexed for MEDLINE]

219: Ohsawa I, Takamura C, Kohsaka S.

Related Articles, Links



The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture.

Biochem Biophys Res Commun. 1997 Jul 9;236(1):59-65. PMID: 9223426 [PubMed - indexed for MEDLINE]

220: Luth HJ, Arendt T.

Related Articles, Links



Co-expression of APP with cNOS but not iNOS after cortical injury in rat.

Neuroreport. 1997 Jul 7;8(9-10):2321-4. PMID: 9243633 [PubMed - indexed for MEDLINE]

1221: Giometto B, An SF, Groves M, Scaravilli T, Geddes JF, Miller R, Related Articles, Links Tavolato B, Beckett AA, Scaravilli F



Accumulation of beta-amyloid precursor protein in HIV encephalitis: relationship with neuropsychological abnormalities.

Ann Neurol, 1997 Jul;42(1):34-40.

PMID: 9225683 [PubMed - indexed for MEDLINE]

222: Haas C, Cazorla P, Miguel CD, Valdivieso F, Vazquez J.

Related Articles, Links



Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Biochem J. 1997 Jul 1;325 (Pt 1):169-75.

PMID: 9224643 [PubMed - indexed for MEDLINE]

223: Rohan de Silva HA, Jen A, Wickenden C, Jen LS, Wilkinson SL. Related Articles, Links Patel AJ.



Cell-specific expression of beta-amyloid precursor protein isoform mRNAs and proteins in neurons and astrocytes.


Brain Res Mol Brain Res. 1997 Jul;47(1-2):147-56. PMID: 9221912 [PubMed - indexed for MEDLINE]

1 224: Yamada T. Wakabayashi K. Kakihara T. Gejyo F. Takahashi H. Related Articles, Links Itoh Y



Further characterization of a monoclonal antibody recognizing apolipoprotein E peptides in amyloid deposits.

Ann Clin Lab Sci. 1997 Jul-Aug;27(4):276-81. PMID: 9210972 [PubMed - indexed for MEDLINE] Entrez-PubMed Page 26 of 50



PMID: 9003058 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 27 of 50

1 234: Walter J. Capell A, Hung AY, Langen H, Schnolzer M. Related Articles, Links Thinakaran G. Sisodia SS, Selkoe DJ, Haass C. Ectodomain phosphorylation of beta-amyloid precursor protein at two distinct cellular locations. J Biol Chem. 1997 Jan 17;272(3):1896-903. PMID: 8999878 [PubMed - indexed for MEDLINE] 235: McDermott JR, Gibson AM. Related Articles, Links Degradation of Alzheimer's beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res. 1997 Jan; 22(1):49-56. PMID: 9021762 [PubMed - indexed for MEDLINE] 1 236: Drache B, Diehl GE, Beyreuther K, Perlmutter LS, Konig G. Related Articles, Links Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states. J Neurosci Res. 1997 Jan 1;47(1):98-108. PMID: 8981243 [PubMed - indexed for MEDLINE] ☐ 237: Matsumoto A, Enomoto T, Fujiwara Y, Baba H, Matsumoto R. Related Adicles, Links Enhanced aggregation of beta-amyloid-containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from human brain. Neurosci Lett. 1996 Dec 20;220(3):159-62. PMID: 8994217 [PubMed - indexed for MEDLINE] 238: Sihag RK, Cataldo AM. Related Articles, Links Brain beta-spectrin is a component of senile plaques in Alzheimer's disease. Brain Res. 1996 Dec 16;743(1-2):249-57. PMID: 9017252 [PubMed - indexed for MEDLINE] 1 239: Hirai T, Kojima S, Shimada A, Umemura T, Sakai M, Itakura C. Related Articles, Links Age-related changes in the olfactory system of dogs. Neuropathol Appl Neurobiol. 1996 Dec;22(6):531-9. PMID: 9004244 [PubMed - indexed for MEDLINE] 240: Nielson KA, Cummings BJ, Cotman CW. Related Articles, Links Constructional apraxia in Alzheimer's disease correlates with neuritic neuropathology in occipital cortex. Brain Res. 1996 Nov 25;741(1-2):284-93. PMID: 9001734 [PubMed - indexed for MEDLINE] 241: Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Related Articles, Links Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5. PMID: 8917563 [PubMed - indexed for MEDLINE] Related Articles, Links 242: Su JH, Cummings BJ, Cotman CW. Plaque biogenesis in brain aging and Alzheimer's disease, I. Progressive changes in phosphorylation states of paired helical filaments and

neurofilaments.

Brain Res. 1996 Nov 11;739(1-2):79-87.


PMID: 8955927 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 28 of 50

Related Articles, Links 243: Jung SS, Nalbantoglu J, Cashman NR. Alzheimer's beta-amyloid precursor protein is expressed on the surface of immediately ex vivo brain cells: a flow cytometric study. J Neurosci Res. 1996 Nov 1;46(3):336-48. PMID: 8933373 [PubMed - indexed for MEDLINE] 7 244: Yokota M. Saido TC, Tani E. Yamaura I, Minami N. Related Articles, Links Cytotoxic fragment of amyloid precursor protein accumulates in hippocampus after global forebrain ischemia. J Cereb Blood Flow Metab. 1996 Nov;16(6):1219-23. PMID: 8898694 [PubMed - indexed for MEDLINE] 245: Dewji NN, Singer SJ. Related Articles, Links Specific transcellular binding between membrane proteins crucial to Alzheimer disease. Proc Natl Acad Sci U S A. 1996 Oct 29;93(22):12575-80. PMID: 8901624 [PubMed - indexed for MEDLINE] 246: Stephens DJ, Austen BM. Related Articles, Links Metabolites of the beta-amyloid precursor protein generated by betasecretase localise to the trans-Golgi network and late endosome in 293 cells J Neurosci Res. 1996 Oct 15;46(2):211-25. PMID: 8915898 [PubMed - indexed for MEDLINE] Related Articles, Links 247: De Bleecker JL, Ertl BB, Engel AG. Patterns of abnormal protein expression in target formations and unstructured cores. Neuromuscul Disord. 1996 Oct;6(5):339-49. PMID: 8938698 [PubMed - indexed for MEDLINE] 1 248: Mitake S, Katada E, Otsuka Y, Matsukawa N, Iwase T, Tsugu T, Related Articles, Links Fujimori O, Ojika K. Possible implication of hippocampal cholinergic neurostimulating peptide (HCNP)-related components in Hirano body formation. Neuropathol Appl Neurobiol. 1996 Oct;22(5):440-5. PMID: 8930956 [PubMed - indexed for MEDLINE] 1 249: Kuo H, Ingram DK, Walker LC, Tian M, Hengemihle JM, Jucker Related Articles, Links Similarities in the age-related hippocampal deposition of periodic acidschiff-positive granules in the senescence-accelerated mouse P8 and C57BL/6 mouse strains. Neuroscience. 1996 Oct;74(3):733-40. PMID: 8884769 [PubMed - indexed for MEDLINE] 250: Vodovotz Y, Lucia MS, Flanders KC, Chesier L, Xie QW, Smith Related Articles, Links TW, Weidner J. Mumford R, Webber R, Nathan C, Roberts AB, Lippa CF, Sporn MB. Inducible nitric oxide synthase in tangle-bearing neurons of patients with Alzheimer's disease. JExp Med. 1996 Oct 1;184(4):1425-33. PMID: 8879214 [PubMed - indexed for MEDLINE] 251: De La Monte SM, Carlson RI, Brown NV, Wands JR. Related Articles, Links Profiles of neuronal thread protein expression in Alzheimer's disease. J Neuropathol Exp Neurol. 1996 Oct;55(10):1038-50.


PMID: 8858001 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 29 of 50



Injections of okadaic acid, but not beta-amyloid peptide, induce Alz-50 immunoreactive dystrophic neurites in the cerebral cortex of sheep.

Neurosci Lett. 1996 Apr 19;208(2):77-80.



Ann N Y Acad Sci. 1996 Jan 17;777:213-20. Review. PMID: 8624086 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 31 of 50

Related Articles, Links 7 270: Solomon B, Koppel R, Hanan E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):452-5. PMID: 8552659 [PubMed - indexed for MEDLINE] Related Articles, Links 71: Lahiri DK, Farlow MR. Differential effect of tacrine and physostigmine on the secretion of the beta-amyloid precursor protein in cell lines. J Mol Neurosci. 1996 Spring;7(1):41-9. PMID: 8835781 [PubMed - indexed for MEDLINE] 72: Mena R. Edwards PC, Harrington CR, Mukactova-Ladinska EB. Related Articles, Links Wischik CM Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease. Acta Neuropathol (Berl). 1996;91(6):633-41. PMID: 8781663 [PubMed - indexed for MEDLINE] 73: Akaaboune M, Verdiere-Sahuque M, Lachkar S, Festoff BW, Related Articles, Links Hantai D. Serine proteinase inhibitors in human skeletal muscle: expression of betaamyloid protein precursor and alpha 1-antichymotrypsin in vivo and during myogenesis in vitro. J Cell Physiol. 1995 Dec;165(3):503-11. PMID: 7593229 [PubMed - indexed for MEDLINE] 7 274: Saito Y. Buciak J. Yang J. Pardridge WM. Related Articles, Links Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10227-31. PMID: 7479757 [PubMed - indexed for MEDLINE] **275:** Link CD. Related Articles, Links Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9368-72. PMID: 7568134 [PubMed - indexed for MEDLINE] 276: Matsumoto A, Matsumoto R, Baba H, Fujiwara Y. Related Articles, Links A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to beta-amyloid-N-terminus as natural substrate. Neurosci Lett. 1995 Aug 11;195(3):171-4. PMID: 8584202 [PubMed - indexed for MEDLINE] 77: Kounnas MZ, Moir RD, Rebeck GW, Bush AI, Argraves WS, Related Articles, Links Tanzi RE, Hyman BT, Strickland DK. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995 Jul 28;82(2):331-40. PMID: 7543026 [PubMed - indexed for MEDLINE] 1278: Banati RB, Gehrmann J, Wiessner C, Hossmann KA, Kreutzberg Related Articles, Links GW

Glial expression of the beta-amyloid precursor protein (APP) in global

ischemia

Entrez-PubMed Page 32 of 50

J Cereb Blood Flow Metab. 1995 Jul;15(4):647-54.

PMID: 7790414 [PubMed - indexed for MEDLINE] Related Articles, Links 279: Kida E, Wisniewski KE, Wisniewski HM. Early amyloid-beta deposits show different immunoreactivity to the amino- and carboxy-terminal regions of beta-peptide in Alzheimer's disease and Down's syndrome brain. Neurosci Lett. 1995 Jun 30;193(2):105-8. PMID: 7478152 [PubMed - indexed for MEDLINE] 280: Griffith LS, Mathes M, Schmitz B Related Articles, Links Beta-amyloid precursor protein is modified with O-linked N-≣ acetylglucosamine. J Neurosci Res. 1995 Jun 1;41(2):270-8. PMID: 7650762 [PubMed - indexed for MEDLINE] 7 281: Saito F. Tani A. Miyatake T. Yanagisawa K. Related Articles, Lanks N-linked oligosaccharide of beta-amyloid precursor protein (beta APP) of C6 glioma cells: putative regulatory role in beta APP processing. Biochem Biophys Res Commun. 1995 May 25;210(3):703-10. PMID: 7763244 [PubMed - indexed for MEDLINE] 282: Yamada T. Kobayashi T. Related Articles, Links The mutation in amyloid precursor protein inhibits both alpha- and beta-Neurosci Lett. 1995 May 19;191(1-2):103-6. PMID: 7659274 [PubMed - indexed for MEDLINE] 283: Fang Q, Kannapell CC, Fu SM, Xu S, Gaskin F. Related Articles, Links VH and VL gene usage by anti-beta-amyloid autoantibodies in Alzheimer's disease: detection of highly mutated V regions in both heavy and light chains. Clin Immunol Immunopathol. 1995 May;75(2):159-67. PMID: 7704974 [PubMed - indexed for MEDLINE] Related Articles, Links 284: Greenberg SM, Kosik KS. Secreted beta-APP stimulates MAP kinase and phosphorylation of tau in neurons. Neurobiol Aging. 1995 May-Jun;16(3):403-7; discussion 407-8. PMID: 7566349 [PubMed - indexed for MEDLINE] 285: Kimura T, Takamatsu J, Araki N, Goto M, Kondo A, Miyakawa Related Articles, Links T. Horiuchi S. Are advanced glycation end-products associated with amyloidosis in Alzheimer's disease? Neuroreport. 1995 Apr 19;6(6):866-8. PMID: 7612872 [PubMed - indexed for MEDLINE] 286: Oohira A, Kushima Y, Matsui F, Watanabe E. Related Articles, Links Detection of Alzheimer's beta-amyloid precursor related proteins bearing chondroitin sulfate both in the juvenile rat brain and in the conditioned medium of primary cultured astrocytes. Neurosci Lett. 1995 Apr 7;189(1):25-8.

Early association of reactive astrocytes with senile plaques in Alzheimer's

Related Articles, Links

PMID: 7603617 [PubMed - indexed for MEDLINE]

287: Pike CJ, Curnmings BJ, Cotman CW.

Entrez-PubMed Page 33 of 50

disease. Exp Neurol. 1995 Apr;132(2):172-9. PMID: 7789457 [PubMed - indexed for MEDLINE] 288: Yamazaki T, Selkoe DJ, Koo EII. Related Articles, Links Trafficking of cell surface beta-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J Cell Biol. 1995 Apr; 129(2):431-42. PMID: 7721945 [PubMed - indexed for MEDLINE] 7 289: Kim CS. Han YF, Etcheberrigaray R, Nelson TJ, Olds JL. Related Articles, Links Yoshioka T, Alkon DL Alzheimer and beta-amyloid-treated fibroblasts demonstrate a decrease in a memory-associated GTP-binding protein, Cp20. Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):3060-4. PMID: 7708775 [PubMed - indexed for MEDLINE] 290: Okamoto T, Takeda S, Murayama Y, Ogata E, Nishimoto I. Related Articles, Links Ligand-dependent G protein coupling function of amyloid transmembrane precursor. J Biol Chem. 1995 Mar 3;270(9):4205-8. PMID: 7876177 [PubMed - indexed for MEDLINE] Related Articles, Links 291: Qiu WQ, Ferreira A, Miller C, Koo EH, Selkoe DJ. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. J Neurosci. 1995 Mar; 15(3 Pt 2):2157-67. PMID: 7891158 [PubMed - indexed for MEDLINE] 292: Palacios G. Mengod G. Tortosa A. Ferrer I. Palacios JM. Related Articles, Links Increased beta-amyloid precursor protein expression in astrocytes in the gerbil hippocampus following ischaemia: association with proliferation of astrocytes. Eur J Neurosci. 1995 Mar 1;7(3):501-10. PMID: 7773447 [PubMed - indexed for MEDLINE] 293: Walker DG, Kim SU, McGeer PL. Related Articles, Links Complement and cytokine gene expression in cultured microglial derived from postmortem human brains. J Neurosci Res. 1995 Mar 1;40(4):478-93. PMID: 7616608 [PubMed - indexed for MEDLINE] 294: Van Gool D, De Strooper B, Van Leuven F, Dom R. Related Articles, Links Amyloid precursor protein accumulation in Lewy body dementia and Alzheimer's disease. Dementia. 1995 Mar-Apr;6(2):63-8. PMID: 7606281 [PubMed - indexed for MEDLINE] 295: Armstrong RA, Winsper SJ, Blair JA. Related Articles, Links Hypothesis: is Alzheimer's disease a metal-induced immune disorder? Neurodegeneration. 1995 Mar;4(1):107-11. PMID: 7600179 [PubMed - indexed for MEDLINE]


Related Articles, Links

296: McRae A, Gilland E, Bona E, Hagberg H.

Microglia activation after neonatal hypoxic-ischemia.

Brain Res Dev Brain Res. 1995 Feb 16;84(2):245-52. PMID: 7743644 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 34 of 50



Entrez-PubMed Page 35 of 50

Related Articles, Links 306: Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to beta-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res. 1994 Dec 19;667(1):138-42. PMID: 7895077 [PubMed - indexed for MEDLINE] 1 307: Oda T. Pasmetti GM. Osterburg HH, Anderson C. Johnson SA, Related Articles, Links Finch CE. Purification and characterization of brain clusterin. Biochem Biophys Res Commun. 1994 Nov 15;204(3):1131-6. PMID: 7980587 [PubMed - indexed for MEDLINE] 308: O'Brien TJ, McKelvie PA, Vrodos N Related Articles, Links Bilateral trigeminal amyloidoma: an unusual case of trigeminal neuropathy with a review of the literature. Case report. J Neurosurg. 1994 Nov;81(5):780-3. Review. PMID: 7931626 [PubMed - indexed for MEDLINE] 309: Katsetos CD, Krishna L, Friedberg E, Reidy J, Karkavelas G, Related Articles, Links Savory J Lobar pilocytic astrocytomas of the cerebral hemispheres: II. Pathobiology--morphogenesis of the eosinophilic granular bodies. Clin Neuropathol. 1994 Nov-Dec;13(6):306-14. PMID: 7851045 [PubMed - indexed for MEDLINE] 1 310: McGeer PL, Klegeris A, Walker DG, Yasuhara O, McGeer FG. Related Articles, Links Pathological proteins in senile plaques. Tohoku J Exp Med. 1994 Nov;174(3):269-77. PMID: 7761992 [PubMed - indexed for MEDLINE] 311: Yang F. Mak K., Vinters HV, Frautschy SA, Cole GM. Related Articles, Links Monoclonal antibody to the C-terminus of beta-amyloid. Neuroreport. 1994 Oct 27;5(16):2117-20. PMID: 7865758 [PubMed - indexed for MEDLINE] 7 312: Burke WJ, Galvin NJ, Chung HD, Stoff SA, Gillespie KN. Related Articles, Links Cataldo AM, Nison RA Degenerative changes in epinephrine tonic vasomotor neurons in Alzheimer's disease. Brain Res. 1994 Oct 24;661(1-2):35-42. PMID: 7834382 [PubMed - indexed for MEDLINE] Related Articles, Links 313: Sherriff FE, Bridges LR, De Souza DS. Non-Alzheimer neurofibrillary tangles show beta-amyloid-like immunoreactivity. Neuroreport. 1994 Oct 3;5(15):1897-900. PMID: 7531003 [PubMed - indexed for MEDLINE] 1314: Dreyer RN, Bausch KM, Fracasso P, Hammond LJ, Wunderlich Related Articles, Links D. Wirak DO, Davis G, Brini CM, Buckholz TM, Konig G, et al. Processing of the pre-beta-amyloid protein by cathepsin D is enhanced by ≡ a familial Alzheimer's disease mutation. Eur J Biochem. 1994 Sep 1;224(2):265-71. PMID: 7523115 [PubMed - indexed for MEDLINE] 1315: van de Nes JA, Sluiter AA, Pool CW, Kamphorst W, Ravid R, Related Articles, Links Swaab DF The monoclonal antibody Alz-50, used to reveal cytoskeletal changes in

Alzheimer's disease, also reacts with a large subpopulation of

Entrez-PubMed Page 36 of 50

somatostatin neurons in the normal human hypothalamus and adjoining Brain Res. 1994 Aug 29;655(1-2):97-109. PMID: 7812796 [PubMed - indexed for MEDLINE] 316: Durham HD, Minotti S, Dooley NP, Nalbantoglu L Related Articles, Links Expression of the intermediate filament-associated protein related to beta-amyloid precursor protein is developmentally regulated in cultured cells. J Neurosci Res. 1994 Aug 15;38(6):629-39. PMID: 7807580 [PubMed - indexed for MEDLINE] 1317: Heinonen O, Soiminen H, Syrjanen S, Neittaanmaki H, Paljarvi L., Related Articles, Links Kosunen O, Syrjanen K, Rickkinen P Sr. beta-Amyloid protein immunoreactivity in skin is not a reliable marker of Alzheimer's disease. An autopsy-controlled study. Arch Neurol. 1994 Aug; 51(8):799-804. PMID: 8042928 [PubMed - indexed for MEDLINE] 318: Friedland RP, Majocha RE, Reno JM, Lyle LR, Marotta CA Related Articles, Links Development of an anti-A beta monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease. Mol Neurobiol. 1994 Aug-Dec;9(1-3):107-13. PMID: 7888086 [PubMed - indexed for MEDLINE] 319: Singh VK. Related Articles, Links Studies of neuroimmune markers in Alzheimer's disease. Mol Neurobiol. 1994 Aug-Dec;9(1-3):73-81. PMID: 7534089 [PubMed - indexed for MEDLINE] 320: Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM. Related Articles, Links Krafft GA, Holzman RB, Holzman TF Complement C1q does not bind monomeric beta-amyloid. Exp Neurol. 1994 Jul;128(1):136-42. PMID: 8070518 [PubMed - indexed for MEDLINE] 321: Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Related Articles, Links Visualization of A beta 42(43) and A beta 40 in senile plaques with endspecific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron. 1994 Jul; 13(1):45-53. PMID: 8043280 [PubMed - indexed for MEDLINE] 322: Walker LC, Price DL, Voytko ML, Schenk DB. Related Articles, Links Labeling of cerebral amyloid in vivo with a monoclonal antibody. J Neuropathol Exp Neurol. 1994 Jul; 53(4):377-83. PMID: 8021711 [PubMed - indexed for MEDLINE] 323: Banati RB, Gehrmann J, Kreutzberg GW. Related Articles, Links Glial beta-amyloid precursor protein: expression in the dentate gyrus after entorhinal cortex lesion. Neuroreport. 1994 Jun 27;5(11):1359-61. PMID: 7919199 [PubMed - indexed for MEDLINE] 324: Saido TC, Yokota M, Maruyama K, Yamao-Harigaya W, Tani E. Related Articles, Links Ihara Y, Kawashima S

Spatial resolution of the primary beta-amyloidogenic process induced in

postischemic hippocampus.

J Biol Chem. 1994 May 27;269(21):15253-7.

Entrez-PubMed Page 37 of 50

PMID: 8195161 [PubMed - indexed for MEDLINE] 1 325: Tabaton M, Nunzi MG, Xue R, Usiak M. Autilio-Gambetti L. Related Articles, Links Gambetti P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun. 1994 May 16;200(3):1598-603. PMID: 8185615 [PubMed - indexed for MEDLINE] 326: Schmidt ML, DiDario AG, Lee VM, Trojanowski JQ. Related Articles, Links An extensive network of PHF tau-rich dystrophic neurites permeates neocortex and nearly all neuritic and diffuse amyloid plagues in Alzheimer disease. FEBS Lett. 1994 May 9;344(1):69-73. PMID: 8181568 [PubMed - indexed for MEDLINE] 1327: Murphy GM Jr, Forno I.S. Higgins L, Scardina JM, Eng LF. Related Articles, Links Cordell B. Development of a monoclonal antibody specific for the COOH-terminal of beta-amyloid 1-42 and its immunohistochemical reactivity in Alzheimer's disease and related disorders. Am J Pathol. 1994 May;144(5):1082-8. PMID: 8178931 [PubMed - indexed for MEDLINE] 328: Stanley LC, Mrak RE, Woody RC, Perrot LJ, Zhang S, Marshak Related Articles, Links DR, Nelson SJ, Griffin WS Glial cytokines as neuropathogenic factors in HIV infection: pathogenic similarities to Alzheimer's disease. J Neuropathol Exp Neurol. 1994 May;53(3):231-8. PMID: 8176406 [PubMed - indexed for MEDLINE] 329: Akaaboune M, Ma J. Festoff BW, Greenberg BD, Hantai D. Related Articles, Links Neurotrophic regulation of mouse muscle beta-amyloid protein precursor and alpha 1-antichymotrypsin as revealed by axotomy. J Neurobiol. 1994 May; 25(5): 503-14. PMID: 8071658 [PubMed - indexed for MEDLINE] 330: Matsumoto A, Fujiwara Y. Related Articles, Links Ca(2+)-dependent 68-kilodalton protease in familial Alzheimer's disease = cells cleaves the N-terminus of beta-amyloid. Biochemistry, 1994 Apr 5;33(13):3941-8. PMID: 8142398 [PubMed - indexed for MEDLINE] 331: Beeson JG, Shelton ER, Chan HW, Gage FH Related Articles, Links Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies. J Comp Neurol. 1994 Apr 1;342(1):78-96. PMID: 8207129 [PubMed - indexed for MEDLINE] 1 332: Roberts GW, Gentleman SM, Lynch A, Murray L, Landon M, Related Articles, Links Graham DI. Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):419-25. PMID: 8163989 [PubMed - indexed for MEDLINE] Related Articles, Links 333: Bilak M. Askanas V. Engel WK. Alpha 1-antichymotrypsin is strongly immunolocalized at normal human

and rat neuromuscular junctions.

Entrez-PubMed Page 38 of 50

Synapse. 1994 Apr; 16(4):280-3.

PMID: 8059338 [PubMed - indexed for MEDLINE]

1334: Hajimohammadreza I, Anderson VE, Cavanagh JB, Seville MP, Related Articles, Links Nolan CC, Anderton BH, Leigh PN

beta-Amyloid precursor protein fragments and lysosomal dense bodies are found in rat brain neurons after ventricular infusion of leupeptin.

Brain Res. 1994 Mar 21;640(1-2):25-32.

PMID: 8004453 [PubMed - indexed for MEDLINE]

335: Bickel U, Lee VM, Trojanowski JQ, Pardridge WM

Related Articles, Links

Development and in vitro characterization of a cationized monoclonal antibody against beta A4 protein: a potential probe for Alzheimer's disease.

Bioconjug Chem. 1994 Mar-Apr;5(2):119-25. PMID: 8031874 [PubMed - indexed for MEDLINE]

336: Loffler J. Langui D. Probst A. Huber G.

Related Articles, Links

Accumulation of a 50 kDa N-terminal fragment of beta-APP695 in Alzheimer's disease hippocampus and neocortex.

Neurochem Int. 1994 Mar;24(3):281-8.

PMID: 8025536 [PubMed - indexed for MEDLINE]

337: Snow AD, Sckignchi RT, Nochlin D, Kalaria RN, Kimata K. Related Articles, Links

Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.

Am J Pathol. 1994 Feb;144(2):337-47.

PMID: 8311117 [PubMed - indexed for MEDLINE]

338: Hartig W, Hausen D, Brauer K, Arendt T, Bigl V, Bruckner G. Related Articles, Links

Digoxigenin-tagged anti-GFAP and multiple labelling of human glia, vessels and beta-amyloid.

Neuroreport. 1994 Jan 31;5(5):573-6. Erratum in: Neuroreport 1994 Apr 14;5 (8):following 1014.

PMID: 8025246 [PubMed - indexed for MEDLINE]

339: Snow AD, Sekiguchi R, Nochlin D, Fraser P, Kimata K, Mizutani Related Articles, Links A, Arai M, Schreier WA, Morgan DG.

An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain.

Neuron. 1994 Jan;12(1):219-34.

PMID: 8292358 [PubMed - indexed for MEDLINE]

340: Askanas V, Engel WK, Bilak M, Alvarez RB, Selkoe DJ.

Related Articles, Links

Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.

Am J Pathol. 1994 Jan; 144(1): 177-87.

PMID: 8291607 [PubMed - indexed for MEDLINE]

T 341: Westarp ME, Foring B, Rasmussen H, Schraff S, Mertens T, Kornhuber HH

Retroviral synthetic peptide serum antibodies in human sporadic amyotrophic lateral sclerosis.

Peptides. 1994;15(2):207-14.

PMID: 8008625 [PubMed - indexed for MEDLINE]

Maat-Schieman ML, Radder CM, van Duinen SG, Haan J, Roos Related Articles, Links

Entrez-PubMed Page 39 of 50

RA Hereditary cerebral hemorrhage with amyloidosis (Dutch); a model for congophilic plague formation without neurofibrillary pathology. Acta Neuropathol (Berl). 1994;88(4):371-8. PMID: 7839831 [PubMed - indexed for MEDLINE] 343: Zemlan FP, Vogelsang GD, McLaughlin L, Dean GF. Related Articles, Links Alzheimer's paired helical filaments: amyloid precursor protein epitope mapping. Brain Res Bull. 1994;33(4):387-92. PMID: 7510209 [PubMed - indexed for MEDLINE] **344:** Cummings BJ, Su JH, Cotman CW. Related Articles, Links Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp Neurol. 1993 Dec; 124(2):315-25. PMID: 8287930 [PubMed - indexed for MEDLINE] 345: Sussman MA, Bilak M, Kedes L, Engel WK, Askanas V. Related Articles, Links Tropomodulin is highly concentrated at the postsynaptic domain of human and rat neuromuscular junctions. Exp Cell Res. 1993 Dec;209(2):388-91. PMID: 8262158 [PubMed - indexed for MEDLINE] 346: Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Related Articles, Links Wilson RS Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol Aging, 1993 Nov-Dec; 14(6):589-96. PMID: 8295661 [PubMed - indexed for MEDLINE] 347: Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk DB. Related Adicles, Links Characterization of beta-amyloid peptide from human cerebrospinal fluid. = J Neurochem. 1993 Nov;61(5):1965-8. PMID: 8229004 [PubMed - indexed for MEDLINE] Related Articles, Links 348: Jucker M, Walker LC, Kibbey MC, Kleinman HK, Ingram DK. Localization of a laminin-binding protein in brain. Neuroscience. 1993 Oct;56(4):1009-22. PMID: 8284032 [PubMed - indexed for MEDLINE] 349: Higgins LS, Catalano R, Quon D, Cordell B. Related Articles, Links Transgenic mice expressing human beta-APP751, but not mice expressing beta-APP695, display early Alzheimer's disease-like histopathology. Ann N Y Acad Sci. 1993 Sep 24;695:224-7. PMID: 8239286 [PubMed - indexed for MEDLINE] 350: Askanas V, Bilak M, Engel WK, Lecterc A, Tome F. Related Articles, Links Prion protein is strongly immunolocalized at the postsynaptic domain of human normal neuromuscular junctions. Neurosci Lett. 1993 Sep 3;159(1-2):111-4. PMID: 8264949 [PubMed - indexed for MEDLINE] 351: Uchida K. Okuda R. Yamaguchi R. Tateyama S. Nakayama H. Related Articles, Links Goto N. Double-labeling immunohistochemical studies on canine senile plaques

and cerebral amyloid angiopathy. J Vet Med Sci. 1993 Aug;55(4):637-42.

Related Articles, Links


PMID: 8399746 [PubMed - indexed for MEDLINE] 352: Holmes C. Webster MT, Procter AW, Francis PT, Bowen DM. Related Articles, Links Relationship between beta-amyloid precursor protein, pyramidal neurones and astrocytes in human neocortex. Biochem Soc Trans. 1993 Aug;21 (Pt 3)(3):238S. No abstract available. PMID: 8224394 [PubMed - indexed for MEDLINE] T 353: Miklossy L Related Articles, Links Alzheimer's disease--a spirochetosis? Neuroreport. 1993 Jul;4(7):841-8. PMID: 8369471 [PubMed - indexed for MEDLINE] 354: Leclerc A, Tome FM, Fardeau M. Related Articles, Links Ubiquitin and beta-amyloid-protein in inclusion body myositis (IBM), familial IBM-like disorder and oculopharyngeal muscular dystrophy: an immunocytochemical study. Neuromuscul Disord. 1993 Jul;3(4):283-91. PMID: 8268725 [PubMed - indexed for MEDLINE] 355: Singhrao SK, Neal JW, Newman GR. Related Articles, Links Corpora amylacea could be an indicator of neurodegeneration. Neuropathol Appl Neurobiol. 1993 Jun; 19(3):269-76. PMID: 8355813 [PubMed - indexed for MEDLINE] 7 356: Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor F Jr. Related Articles, Links The cellular pathology associated with Alzheimer beta-amyloid deposits in non-demented aged individuals. Neuropathol Appl Neurobiol. 1993 Jun; 19(3):261-8. PMID: 8355812 [PubMed - indexed for MEDLINE] **357:** DeWitt DA, Silver J, Canning DR, Perry G. Related Articles, Links Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol. 1993 Jun; 121(2):149-52. PMID: 8339766 [PubMed - indexed for MEDLINE] 7 358: Fukuchi K. Sopher B. Furlong CE, Smith AC, Dang N, Martin Related Articles, Links GM. Selective neurotoxicity of COOH-terminal fragments of the beta-amyloid precursor protein. Neurosci Lett. 1993 May 14;154(1-2):145-8. PMID: 8361630 [PubMed - indexed for MEDLINE] 359: Stoll J. Balbo A. Ault B. Rapoport SI, Fine A. Related Articles, Links Long-term transplants of mouse trisomy 16 hippocampal neurons, a model for Down's syndrome, do not develop Alzheimer's disease neuropathology. Brain Res. 1993 May 7;610(2):295-304. PMID: 8319091 [PubMed - indexed for MEDLINE] 360: Scott SA, Johnson SA, Zarow C, Perlmutter LS. Related Articles, Links Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia.

Yasuhara O, Muramatsu H, Kim SU, Muramatsu T, Maruta H.

PMID: 8495706 [PubMed - indexed for MEDLINE]

Exp Neurol. 1993 May;121(1):113-8.

Entrez-PubMed Page 41 of 50



MHC class II-positive microglia in human brain: association with


Alzheimer lesions

Entrez-PubMed Page 42 of 50

J Neurosci Res. 1992 Dec;33(4):549-58. Erratum in: J Neurosci Res 1993 Jun 15;35 (3):346.PMID: 1484388 [PubMed - indexed for MEDLINE] 371: Lahiri DK, Nall C, Farlow MR. Related Articles, Links The cholinergic agonist carbachol reduces intracellular beta-amyloid precursor protein in PC 12 and C6 cells. Biochem Int. 1992 Dec;28(5):853-60. PMID: 1288495 [PubMed - indexed for MEDLINE] T 372: Kammesheidt A. Boyce FM, Spanoyannis AF, Cummings BJ. Related Articles, Links Ortegon M, Cotman C, Vaught JL. Neve RL. Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61. PMID: 1438289 [PubMed - indexed for MEDLINE] 7373: Rogers J. Cooper NR, Webster S, Schultz J, McGeer PL, Styren Related Articles, Links SD, Civin WH, Brachova L, Bradt B, Ward P, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10016-20. PMID: 1438191 [PubMed - indexed for MEDLINE] Related Articles, Links 374: Brewer GJ. Ashford JW. Human serum stimulates Alzheimer markers in cultured hippocampal neurons. J Neurosci Res. 1992 Nov;33(3):355-69. PMID: 1335088 [PubMed - indexed for MEDLINE] 375: Palacios G. Palacios JM, Mengod G, Frey P. Related Articles, Links Beta-amyloid precursor protein localization in the Golgi apparatus in neurons and oligodendrocytes. An immunocytochemical structural and ultrastructural study in normal and axotomized neurons. Brain Res Mol Brain Res. 1992 Oct;15(3-4):195-206. PMID: 1331676 [PubMed - indexed for MEDLINE] 1376: Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D. Related Articles, Links Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature. 1992 Sep 24;359(6393):325-7. PMID: 1406936 [PubMed - indexed for MEDLINE] 177: Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, McIlon Related Articles, Links A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D. Teplow DB, et al Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 1992 Sep 24;359(6393):322-5. PMID: 1383826 [PubMed - indexed for MEDLINE] 378: Dooley NP, Gauthier S, Durham HD. Related Articles, Links Antibody to beta-amyloid precursor protein recognizes an intermediate filament-associated protein in Alzheimer's and control fibroblasts. J Neurosci Res. 1992 Sep;33(1):60-7.


PMID: 1453484 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 43 of 50



DP.

Entrez-PubMed Page 44 of 50



PMID: 1551418 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 45 of 50

7 397: Choi-Miura NH, Ihara Y, Fukuchi K, Takeda M, Nakano Y, Tobe Related Articles, Links T. Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathol (Berl). 1992;83(3):260-4. PMID: 1373021 [PubMed - indexed for MEDLINE] 398: Barcikowska M. Kujawa M. Wisniewski H. Related Articles, Links beta-Amyloid deposits within the cerebellum of persons older than 80 vears of age. Neuropatol Pol. 1992;30(3-4):285-93. PMID: 1340921 [PubMed - indexed for MEDLINE] 399: Frautschy SA, Baird A, Cole GM. Related Articles, Links Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8362-6. PMID: 1924295 [PubMed - indexed for MEDLINE] 400: Ito H, Hirano H, Yen SH, Kato S. Related Articles, Links Demonstration of beta amyloid protein-containing neurofibrillary tangles in parkinsonism-dementia complex on Guam. Neuropathol Appl Neurobiol. 1991 Oct;17(5):365-73. PMID: 1758569 [PubMed - indexed for MEDLINE] 17 401: Cras P, Kawai M, Lowery D, Gonzalez-DeWhitt P, Greenberg B, Related Articles, Links Perry G Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7552-6. PMID: 1652752 [PubMed - indexed for MEDLINE] 402: Price JL, Davis PB, Morris JC, White DL. Related Articles, Links The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging. 1991 Jul-Aug; 12(4):295-312. PMID: 1961359 [PubMed - indexed for MEDLINE] 403: Chen M, Yankner BA. Related Articles, Links An antibody to beta amyloid and the amyloid precursor protein inhibits cell-substratum adhesion in many mammalian cell types. Neurosci Lett. 1991 Apr 29;125(2):223-6. PMID: 1715534 [PubMed - indexed for MEDLINE] 1 404: Knops J. Johnson-Wood K. Schenk DB, Sinha S. Lieberburg J. Related Articles, Links McConlogue L. Isolation of baculovirus-derived secreted and full-length beta-amyloid precursor protein. J Biol Chem. 1991 Apr 15;266(11):7285-90. PMID: 1901866 [PubMed - indexed for MEDLINE] 17 405; Fraser PE, Duffy I.K., O'Malley MB, Nguyen J, Inouye H. Related Articles, Links Kirschner DA Morphology and antibody recognition of synthetic beta-amyloid peptides. J Neurosci Res. 1991 Apr;28(4):474-85. PMID: 1908024 [PubMed - indexed for MEDLINE] 406: Matsumoto A. Fujiwara Y. Related Articles, Links Abnormal and deficient processing of beta-amyloid precursor protein in

> familial Alzheimer's disease lymphoblastoid cells. Biochem Biophys Res Commun. 1991 Mar 15;175(2):361-5.

Entrez-PubMed Page 46 of 50

PMID: 1902089 [PubMed - indexed for MEDLINE] 1 407: Henriksson T, Barbour RM, Braa S, Ward P, Fritz LC, Johnson Related Articles, Links Wood K, Chung HD, Burke W, Reinikainen KJ, Riekkinen P, et Analysis and quantitation of the beta-amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients with a monoclonal antibody-based immunoassay. J Neurochem, 1991 Mar; 56(3):1037-42. PMID: 1899691 [PubMed - indexed for MEDLINE] 408: Pendlebury WW, Jole ED, Tracy RP, Dill BA. Related Articles, Links Intracerebral hemorrhage related to cerebral amyloid angiopathy and t-PA Ann Neurol. 1991 Feb;29(2):210-3. PMID: 1901466 [PubMed - indexed for MEDLINE] 409: Joachim C, Games D, Morris J, Ward P, Frenkel D, Selkoe D. Related Articles, Links Antibodies to non-beta regions of the beta-amyloid precursor protein detect a subset of senile plaques. Am J Pathol. 1991 Feb; 138(2): 373-84. PMID: 1704190 [PubMed - indexed for MEDLINE] 410: Takahashi H, Hirokawa K, Ando S, Obata K. Related Articles, Links Immunohistological study on brains of Alzheimer's disease using antibodies to fetal antigens, C-series gangliosides and microtubuleassociated protein 5. Acta Neuropathol (Berl). 1991;81(6):626-31. PMID: 1909079 [PubMed - indexed for MEDLINE] Related Articles, Links 411: Becker L. Mito T. Takashima S. Onodera K Growth and development of the brain in Down syndrome. Prog Clin Biol Res. 1991;373:133-52. Review. PMID: 1838182 [PubMed - indexed for MEDLINE] 412: Zhao XH, Schoenheit C, Duffy LK. Related Articles, Links A heparin-binding protein from neuroblastoma cells: immunological comparison to beta-amyloid precursor protein. Comp Biochem Physiol A. 1991;100(3):715-8. PMID: 1685979 [PubMed - indexed for MEDLINE] 413: Breen KC, Bruce M, Anderton BH. Related Articles, Links Beta amyloid precursor protein mediates neuronal cell-cell and cellsurface adhesion. J Neurosci Res. 1991 Jan;28(1):90-100. PMID: 1645774 [PubMed - indexed for MEDLINE] 414: Yankner BA, Caceres A, Duffy LK. Related Articles, Links Nerve growth factor potentiates the neurotoxicity of beta amyloid. Proc Natl Acad Sci U S A. 1990 Nov;87(22):9020-3. PMID: 2174172 [PubMed - indexed for MEDLINE] 415: Snow AD, Mar H, Nochlin D, Sekiguchi RT, Kimata K, Koike Y, Related Articles, Links Wight TN. Early accumulation of heparan sulfate in neurons and in the beta-amyloid

protein-containing lesions of Alzheimer's disease and Down's syndrome.

Am J Pathol. 1990 Nov; 137(5):1253-70.

PMID: 2146882 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 47 of 50

Related Articles, Links 416: Bodmer S, Podlisny MB, Selkoe DJ, Heid I, Fontana A. Transforming growth factor-beta bound to soluble derivatives of the beta amyloid precursor protein of Alzheimer's disease. Biochem Biophys Res Commun. 1990 Sep 14;171(2):890-7. PMID: 2119582 [PubMed - indexed for MEDLINE] 417: Kanemaru K, Hasegawa M, Shimada H, Ihara Y. Related Articles, Links The presence of a novel protein in calf serum that recognizes beta amyloid in the formalin-fixed section. Am J Pathol. 1990 Sep;137(3):677-87. PMID: 1698030 [PubMed - indexed for MEDLINE] 1 418: Tate-Ostroff B, Majocha RE, Walcott EC, Ventosa-Michelman Related Articles, Links M, Marotta CA Colocalization of amino terminal and A4 (beta-amyloid) antigens in Alzheimer plaques: evidence for coordinated processing of the amyloid precursor protein. J Geriatr Psychiatry Neurol. 1990 Jul-Sep;3(3):139-45. PMID: 2126439 [PubMed - indexed for MEDLINE] 1 419: Shelton ER, Cohn R, Eish L, Obernolte R, Tahilramani R, Nestor Related Adicles, Links JJ. Chan HW. Characterization of beta-amyloid precursor proteins with or without the protease-inhibitor domain using anti-peptide antibodies. J Neurochem. 1990 Jul;55(1):60-9. PMID: 2113083 [PubMed - indexed for MEDLINE] 17 420: Wolf D. Quon D. Wang Y. Cordell B. Related Articles, Links Identification and characterization of C-terminal fragments of the betaamyloid precursor produced in cell culture. EMBO J. 1990 Jul;9(7):2079-84. PMID: 1694126 [PubMed - indexed for MEDLINE] 421: Stein RA, Trojanowski JQ, Lee VM. Related Articles, Links Antibodies to the beta-amyloid peptide cross-react with conformational epitopes in human fibringen subunits from peripheral blood. FEBS Lett. 1990 May 7;264(1):43-7. PMID: 1692541 [PubMed - indexed for MEDLINE] 422: Spillantini MG, Goedert M, Jakes R, Klug A. Related Articles, Links Different configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer disease. Proc Natl Acad Sci U S A. 1990 May;87(10):3947-51. PMID: 2111023 [PubMed - indexed for MEDLINE] 423: Singhrao S, Cole G, Henderson WJ, Newman GR. Related Articles, Links LR White embedding allows a multi-method approach to the analysis of brain tissue from patients with Alzheimer's disease. Histochem J. 1990 May;22(5):257-68. PMID: 1966829 [PubMed - indexed for MEDLINE] 424: Spillantini MG, Goedert M, Jakes R, Klug A. Related Articles, Links Topographical relationship between beta-amyloid and tau protein epitopes in tangle-bearing cells in Alzheimer disease.

425: Cataldo AM, Nixon RA.

Proc Natl Acad Sci U S A. 1990 May;87(10):3952-6. PMID: 1692627 [PubMed - indexed for MEDLINE]

Related Articles, Links

Entrez-PubMed Page 48 of 50



Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain.

Proc Natl Acad Sci U S A. 1990 May;87(10):3861-5. PMID: 1692625 [PubMed - indexed for MEDLINE]

17 426: Arai H, Lee VM, Otvos L Jr. Greenberg BD, Lowery DF, Sharma SK, Schmidt ML, Trojanowski JQ.

Related Articles, Links



Defined neurofilament, tau, and beta-amyloid precursor protein epitopes distinguish Alzheimer from non-Alzheimer senile plaques.

Proc Natl Acad Sci U S A. 1990 Mar;87(6):2249-53. PMID: 1690426 [PubMed - indexed for MEDLINE]

T 427: Kitaguchi N, Tokushima Y, Orshi K, Takahashi Y, Shiojiri S, Nakamura S, Tanaka S, Kodaira R, Ito H.

Determination of amyloid beta protein precursors harboring active form of proteinase inhibitor domains in cerebrospinal fluid of Alzheimer's disease patients by trypsin-antibody sandwich ELISA.

Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-9.

Biochem Biophys Res Commun. 1990 Feb 14;166(3):1453-PMID: 2106318 [PubMed - indexed for MEDLINE]

1 428: Koo EH, Sisodia SS, Archer DR, Martin LJ, Weidemann A. Related Articles, Links Beyreuther K, Fischer P, Masters CL, Price DL



Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport.

Proc Natl Acad Sci U S A. 1990 Feb;87(4):1561-5. PMID: 1689489 [PubMed - indexed for MEDLINE]

T 429: Chou WG, Zain SB, Rehman S, Tate-Ostroff B, Majocha RE, Related Articles, Links Benes FM, Marotta CA

Alzheimer cortical neurons containing abundant amyloid mRNA. Relationship to amyloid deposition and senile plaques.

J Psychiatr Res. 1990;24(1):37-50.

PMID: 2195164 [PubMed - indexed for MEDLINE]

130: Dewji NN, Shelton ER, Adler MJ, Chan HW, Seegmiller JE. Related Articles, Links Coronel C.

Processing of Alzheimer's disease-associated beta-amyloid precursor protein.

J Mol Neurosci. 1990;2(1):19-27.

PMID: 2124125 [PubMod indoxed for MEDI II]

PMID: 2124135 [PubMed - indexed for MEDLINE]

431: Murphy GM Jr. Eng LF. Cordell B. Wang Y. Ellis WG. Meissner Related Articles. Links L. Tinklenberg JR.

Beta-amyloid precursor detected in human cerebral cortex. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14(3):309-17. PMID: 2113696 [PubMed - indexed for MEDLINE]

T 432: Takahashi H. Kurashima C. Utsuyania M. Hirokawa K. Related Articles, Links

Immunohistological study of senile brains by using a monoclonal antibody recognizing beta amyloid precursor protein: significance of granular deposits in relation with senile plaques.

Acta Neuropathol (Berl). 1990;80(3):260-5.


PMID: 1698004 [PubMed - indexed for MEDLINE]

433: Picken MM, Larrondo-Lillo M, Coria F, Gallo GR, Shelanski ML, Frangione B

Distribution of the protease inhibitor alpha 1-antichymotrypsin in cerebral and systemic amyloid.

J Neuropathol Exp Neurol. 1990 Jan;49(1):41-8. PMID: 1688925 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 49 of 50



1 443. Gentleman SM, Bruton C, Allsop D, Lewis SJ, Polak JM,

Roberts GW

Related Articles, Links

Entrez-PubMed Page 50 of 50 A demonstration of the advantages of immunostaining in the quantification of amyloid plaque deposits. Histochemistry, 1989;92(4):355-8. PMID: 2478507 [PubMed - indexed for MEDLINE] 1 444: Wisniewski HM, Wen GY, Kim KS. Related Articles, Links Comparison of four staining methods on the detection of neuritic plaques. Acta Neuropathol (Berl). 1989;78(1):22-7. PMID: 2472039 [PubMed - indexed for MEDLINE] 1 445: Palmert MR, Podlisny MB, Witker DS, Oltersdorf T, Youtkin Related Articles, Links LH, Selkoc DJ, Younkin SO Antisera to an amino-terminal peptide detect the amyloid protein precursor of Alzheimer's disease and recognize senile plaques. Biochem Biophys Res Commun. 1988 Oct 14;156(1):432-7. PMID: 3140814 [PubMed - indexed for MEDLINE] 1 446: Selkoe DJ. Podlisny MB. Joachim CL. Vickers EA. Lee G. Fritz Related Articles, Links LC, Oltersdorf T Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues. Proc Natl Acad Sci U S A. 1988 Oct;85(19):7341-5. PMID: 3140239 [PubMed - indexed for MEDLINE]

Display Summary

Items 1-446 of 446

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Show: 500 ▼ Sort

CCL 20 2003 06:54:00

One page.

Send to

Text

```
Connecting via Winsock to STN
Welcome to STN International!
                              Enter x:x
te se se in in in in to to to
FILE 'HOME' ENTERED AT 14:18:09 ON 29 OCT 2003
=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Adis Data Information BV
FILE 'ADISINSIGHT' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Adis Data Information BV
FILE 'ADISNEWS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Adis Data Information BV
FILE 'AGRICOLA' ENTERED AT 14:18:20 ON 29 OCT 2003
FILE 'ANABSTR' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)
FILE 'AQUASCI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved.
FILE 'BIOBUSINESS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS)
FILE 'BIOCOMMERCE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved
FILE 'BIOSIS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)
FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED
FILE 'BIOTECHDS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION
FILE 'BIOTECHNO' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'CABA' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI)
FILE 'CANCERLIT' ENTERED AT 14:18:20 ON 29 OCT 2003
FILE 'CAPLUS' ENTERED AT 14:18:20 ON 29 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'CEABA-VTB' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (c) 2003 DECHEMA eV
FILE 'CEN' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 American Chemical Society (ACS)
FILE 'CIN' ENTERED AT 14:18:20 ON 29 OCT 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)
FILE 'CONFSCI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'CROPB' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'CROPU' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DISSABS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved.
```

FILE 'DDFB' ACCESS NOT AUTHORIZED

```
FILE 'DDFU' ACCESS NOT AUTHORIZED
FILE 'DGENE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DRUGB' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DRUGLAUNCH' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'DRUGMONOG2' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'DRUGNL' ENTERED AT 14:18:20 ON 29 OCT 2003 COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'DRUGU' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DRUGUPDATES' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'EMBAL' ENTERED AT 14:18:20 ON 29 OCT 2003 COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.
FILE 'EMBASE' ENTERED AT 14:18:20 ON 29 OCT 2003 COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.
FILE 'ESBIOBASE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'FEDRIP' ENTERED AT 14:18:20 ON 29 OCT 2003
FILE 'FOMAD' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association
FILE 'FOREGE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association
FILE 'FROSTI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association
FILE 'FSTA' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 International Food Information Service
FILE 'GENBANK' ENTERED AT 14:18:20 ON 29 OCT 2003
FILE 'HEALSAFE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'IFIPAT' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)
FILE 'JICST-EPLUS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)
FILE 'KOSMET' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists
FILE 'LIFESCI' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'MEDICONF' ENTERED AT 14:18:20 ON 29 OCT 2003
```

FILE 'NTIS' ENTERED AT 14:18:20 ON 29 OCT 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government

COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 14:18:20 ON 29 OCT 2003

FILE 'NIOSHTIC' ENTERED AT 14:18:20 ON 29 OCT 2003

```
FILE 'NUTRACEUT' ENTERED AT 14:18:20 ON 29 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'OCEAN' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'PASCAL' ENTERED AT 14:18:20 ON 29 OCT 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.
FILE 'PCTGEN' ENTERED AT 14:18:20 ON 29 OCT 2003 COPYRIGHT (C) 2003 WIPO
FILE 'PHAR' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
FILE 'PHARMAML' ENTERED AT 14:18:20 ON 29 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'PHIC' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
FILE 'PHIN' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
FILE 'PROMT' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.
FILE 'RDISCLOSURE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.
FILE 'SCISEARCH' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT 2003 THOMSON ISI
FILE 'SYNTHLINE' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 Prous Science
FILE 'TOXCENTER' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 ACS
FILE 'USPATFULL' ENTERED AT 14:18:20 ON 29 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 14:18:20 ON 29 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'VETB' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'VETU' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'WPIDS' ENTERED AT 14:18:20 ON 29 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
=> s beta-amyloid AND antibody
 22 FILES SEARCHED...
  48 FILES SEARCHED...
          7430 BETA-AMYLOID AND ANTIBODY
=> DUP REM L1
           3417 DUP REM L1 (4013 DUPLICATES REMOVED)
=> S L2 AND human
          2495 L2 AND HUMAN
=> S L3 AND N-terminus
           391 L3 AND N-TERMINUS
```

=> D L4 1-391

```
ΑN
      2002:621745 BIOSIS
      PREV200200621745
DN
      Simple morphometry of axonal swellings cannot be used in isolation for
TI
      dating lesions after traumatic brain injury.
      Leclercq, Pascale D.; Stephenson, Matthew S.; Murray, Lillian S.; McIntosh, Tracy K.; Graham, David I.; Gentleman, Stephen M. [Reprint
ΑU
      Department of Neuroinflammation, Division of Neuroscience and
CS
      Psychological Medicine, Faculty of Medicine, Imperial College of Science,
      Technology and Medicine, St. Dunstan's Road, Charing Cross Campus, London,
      s.gentleman@ic.ac.uk
      Journal of Neurotrauma, (October, 2002) Vol. 19, No. 10, pp. 1183-1192.
SO
      print.
      ISSN: 0897-7151.
Article
DT
      English
LA
      Entered STN: 4 Dec 2002
ED
      Last Updated on STN: 4 Dec 2002
      ANSWER 2 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L4
      2001:121222 BIOSIS
AN
DN
      PREV200100121222
     Intraneuronal Abeta42 immunoreactivity in Down syndrome brain.

Mori, C. [Reprint author]; Spooner, E. T.; Lu, M.; Wisniewski, K.;

Wisniewski, T.; Yamaguchi, H.; Saido, T. C.; Selkoe, D. J.; Lemere, C. A.

Brigham "Women's Hospital, Harvard Medical School, Boston, MA, USA

Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract

No.-764.7. print.
TI
ΑU
CS
S0
      Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
      Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
      ISSN: 0190-5295.
      Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
DT
LA
      English
      Entered STN: 7 Mar 2001
ED
      Last Updated on STN: 15 Feb 2002
      ANSWER 3 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L4
      2001:87711 BIOSIS
AN
      PREV200100087711
DΝ
                        ***beta*** - ***amvloid***
                                                              peptide immunoreactivity in
ΤI
      Ischemia and
      rat brain.
      Lin, B. [Reprint author]; Ginsberg, M. D.; Busto, R.; Li, L.
ΑU
      University of Miami School of Medicine, Miami, FL, USA
CS
      Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-276.13. print.
50
      Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New
      orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
      ISSN: 0190-5295.
DT
      Conference; (Meeting)
      Conference; Abstract; (Meeting Abstract)
LA
      English
      Entered STN: 14 Feb 2001
ED
      Last Updated on STN: 12 Feb 2002
      ANSWER 4 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L4
                     BIOSIS
      2000:122846
AN
      PREV200000122846
DN
      The 68K protease has beta-secretase-like activity for lymphocyte precursor
TI
      protein but not for brain substrate.
      Matsumoto, Akira [Reprint author]
ΑU
      Department of Radiation Biophysics and Genetics, Kobe University School of
CS
      Medicine, Kusunoki-cho 7, Kobe, 650-0017, Japan
Neuroreport, (Feb. 7, 2000) Vol. 11, No. 2, pp. 373-377. print.
CODEN: NERPEZ. ISSN: 0959-4965.
SO
DT
      Article
      English
LA
      Entered STN: 5 Apr 2000
ΕD
      Last Updated on STN: 3 Jan 2002
      ANSWER 5 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. ON STN
L4
```

platelets and DAMI megakaryocytes possess beta-secretase-like activity.

AN

DN

TI

1999:271844 BIOSIS PREV199900271844 Kimberly; Long, Heidi J.; Billingslea, Andrea M.; Hastey, Ryan; Johnson, Robin; Fine, Richard E.; Smith, Sally J.; Simons, Elizabeth R.; Davies, Theresa A. [Reprint author]

BOSTON University School of Medicine, 80 East Concord St. K6. Boston, MA

CS Boston University School of Medicine, 80 East Concord St, K6, Boston, MA, 02118, USA

- SO Journal of Laboratory and Clinical Medicine, (May, 1999) Vol. 133, No. 5, pp. 507-515. print.

 CODEN: JLCMAK. ISSN: 0022-2143.
- DT Article LA English
- ED Entered STN: 15 Jul 1999 Last Updated on STN: 15 Jul 1999
- L4 ANSWER 6 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

AN 1997:202760 BIOSIS

- DN PREV199799501963
- TI Cathepsin D displays in vitro beta-secretase-like specificity.
- AU Chevallier, Nathalie; Vizzavona, Jean; Marambaud, Philippe; Baur, Claus Peter; Spillantini, Maria; Fulcrand, Pierre; Martinez, Jean; Goedert, Michel; Vincent, Jean-Pierre; Checler, Frederic [Reprint author]
- CS Institut de Pharmacologie Moleculaire et Celulaire, CNRS, 660 route des Lucioles. Sophia Antipolis. 06560 Valbonne. France
- Lucioles, Sophia Antipolis, 06560 Valbonne, France SO Brain Research, (1997) Vol. 750, No. 1-2, pp. 11-19. CODEN: BRREAP. ISSN: 0006-8993.
- DT Article
- LA English
- ED Entered STN: 12 May 1997 Last Updated on STN: 12 May 1997
- L4 ANSWER 7 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- AN 1997:69117 BIOSIS
- DN PREV199799368320
- TI Enhanced aggregation of ***beta*** ***amyloid*** -containing peptides by extracellular matrix and their degradation by the 68 kDa serine protease prepared from ***human*** brain.
- AU Matsumoto, Akira; Enomoto, Taira; Fujiwara, Yoshisada; Baba, Hitsamitsu; Matsumoto, Reiko
- CS Dep. Radiation Biophysics and Genetics, Kobe Univ. Sch. Med., Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650, Japan
- SO Neuroscience Letters, (1996) Vol. 220, No. 3, pp. 159-162. CODEN: NELED5. ISSN: 0304-3940.
- DT Article
- LA Enalish
- ED Entered STN: 11 Feb 1997
 - Last Updated on STN: 11 Feb 1997
- L4 ANSWER 8 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- AN 1996:562789 BIOSIS
- DN PREV199799292145
- TI Metabolites of the ***beta*** ***amyloid*** precursor protein generated by beta-secretase localise to the trans-Golgi network and late endosome in 293 cells.
- AU Stephens, David J.; Austen, Brian M. [Reprint author]
- CS Dep. Surg., St. George's Hosp. Med. Sch., Cranmer Terrace, Tooting, London SW17 ORE, UK
- SO Journal of Neuroscience Research, (1996) Vol. 46, No. 2, pp. 211-225. CODEN: JNREDK. ISSN: 0360-4012.
- DT Article
- LA Enalish
- ED Entered STN: 23 Dec 1996
 - Last Updated on STN: 23 Dec 1996
- L4 ANSWER 9 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- AN 1995:460388 BIOSIS
- DN PREV199598474688
- TI A serine protease in Alzheimer's disease cells cleaves a 16K-peptide with flanking residues upstream to ***beta*** ***amyloid*** ***N*** ***terminus*** as natural substrate.
- AU Matsumoto, Akira [Reprint author]; Matsumoto, Reiko; Baba, Hisamitsu; Fujiwara, Yoshisada
- CS Dep. Radiation Biophyscis Genetics, Kobe Univ. Sch. Med., Kusunoki-cho 7-5-1, Chuo-ku, Kobe 650, Japan
- SO Neuroscience Letters, (1995) Vol. 195, No. 3, pp. 171-174. CODEN: NELEDS. ISSN: 0304-3940.
- DT Article

ED Entered STN: 27 Oct 1995 Last Updated on STN: 27 Oct 1995 L4 ANSWER 10 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN ΑN 1995:221264 BIOSIS PREV199598235564 DN Characterisation of an TI ***antibodv*** relevant to the neuropathology of Alzheimer disease. ΑU Jakes, R.; Harrington, C. R.; Spillantini, M. G.; Goedert, M.; Kluq, A. [Reprint author] MRC Lab. Mol. Biol., Hills Road, Cambridge CB2 20H, UK Alzheimer Disease and Associated Disorders, (1995) Vol. 9, No. 1, pp. CS SO CODEN: ADADE2. ISSN: 0893-0341. DT Article English LA Entered STN: 31 May 1995 ED Last Updated on STN: 31 May 1995 L4 ANSWER 11 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN ΑN 1994:499033 BIOSIS DN PREV199497512033 TI Processing of the pre- ***beta*** - ***amyloid*** cathepsin D is enhanced by a familial Alzheimer's disease mutation. ΑU Dreyer, Robert N.; Bausch, Kathryn M.; Fracasso, Paul; Hammond, Lisa J.; Wunderlich, David; Wirak, Dana O.; Davis, Gary; Brini, Carla M.; Buckholz, Thomas M. P. P. Tamburini, Miles Inc., Pharmaceuticals Div., 400 Morgan Lane, West CS Haven, CT 06516, USA European Journal of Biochemistry, (1994) Vol. 224, No. 2, pp. 265-271. SO CODEN: EJBCAI. ISSN: 0014-2956. DT Article English LA Entered STN: 28 Nov 1994 ED Last Updated on STN: 29 Nov 1994 L4 ANSWER 12 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 1994:229461 BIOSIS ΑN DN PREV199497242461 ΤI Ca-2+-dependent 68-kilodalton protease in familial Alzheimer's disease cells cleaves the ***amyloid*** ***N*** - ***terminus*** of ***beta*** Matsumoto, Akira [Reprint author]; Fujiwara, Yoshisada Dep. Radiation Biophysics and Genetics, Kobe Univ. Sch. Med., Kusunoki-cho ΑU CS 7-5-1, Chuo-ku, Kobe 650, Japan Biochemistry, (1994) Vol. 33, No. 13, pp. 3941-3948. CODEN: BICHAW. ISSN: 0006-2960. SO Article DT LA English ED Entered STN: 24 May 1994 Last Updated on STN: 14 Jul 1994 L4 ANSWER 13 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 1994:181291 BIOSIS AN DN PREV199497194291 TI Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different ***antibodies*** ΑU Beeson, James G.; Shelton, Earl R.; Chan, Hardy W.; Gage, Fred H. [Reprint Univ. Calif., San Diego, 9500 Gilman Dr., La Jolla, CA 93093-0627, USA CS SO Journal of Comparative Neurology, (1994) Vol. 342, No. 1, pp. 78-96. CODEN: JCNEAM. ISSN: 0021-9967. DT Article English LA ED Entered STN: 26 Apr 1994 Last Updated on STN: 27 Apr 1994 L4 ANSWER 14 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN AN 1993:591363 BIOSIS DN PREV199497010733 ***beta*** - ***amyloid*** TI Characterization of peptide from ***human*** cerebrospinal fluid. ΑU Vigo-Pelfrey, Carmen [Reprint author]; Lee, poris; Lieberburg, Pam Vv

Athena Neurosciences, Inc., 800F Gateway Boulevard, South San Francisco,

Keiman; Schenk, Dale B.

CS

```
50
     Journal of Neurochemistry, (1993) Vol. 61, No. 5, pp. 1965-1968.
     CODEN: JONRA9. ISSN: 0022-3042.
DT
     Article
     English
LA
ED
     Entered STN: 28 Dec 1993
     Last Updated on STN: 28 Dec 1993
L4
     ANSWER 15 OF 391 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN
     1992:526911 BIOSIS
DN
     PREV199294134986; BA94:134986
                                   ***BETA***
                                                   ***AMYLOID***
                                                                    PRECURSOR
TI
     STRONG IMMUNOREACTIVITY OF
                                              ***AMYLOID***
     PROTEIN INCLUDING THE
                              ***BETA***
                                                               PROTEIN SEQUENCE AT
       ***HUMAN***
                     NEUROMUSCULAR JUNCTIONS.
ΑU
     ASKANAS V [Reprint author]; ENGEL W K; ALVAREZ R B
     USC NEUROMUSC CENT, 637 SOUTH LUCAS AVE, LOS ANGELES, CALIF 90017, USA
CS
     Neuroscience Letters, (1992) Vol. 143, No. 1-2, pp. 96-100. CODEN: NELED5. ISSN: 0304-3940.
SO
DT
     Article
FS
     RΑ
LA
     ENGLISH
     Entered STN: 19 Nov 1992
ED
     Last Updated on STN: 24 Dec 1992
L4
      ANSWER 16 OF 391 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT/ISI on STN
ΑN
      2003-14872 BIOTECHDS
      New Activity Dependent Neurotrophic Factor I complex polypeptide, useful
TI
      for reducing neuronal cell death, treating oxidative stress in a patient,
      or improving learning and/or memory in a subject with e.g. Alzheimer's
      disease;
                        ***antibody***
                                          useful for disease therapy and
         protein and
         diagnosis
      BRENNEMAN D E; CASTELLON R; SPONG C Y; HAUSER J M; GOZES I
ΑU
      UNIV RAMOT AT TEL AVIV LTD; US DEPT HEALTH and HUMAN SERVICES
PA
PΙ
      WO 2003022226 20 Mar 2003
ΑI
      wo 2002-US29146 12 Sep 2002
      us 2002-371961 10 Apr 2002; us 2001-322760 12 Sep 2001
PRAI
DT
      Patent
LA
      English
      WPI: 2003-354501 [33]
os
      ANSWER 17 OF 391 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
L4
      1996:26391320
                      BIOTECHNO
ΑN
                      .- ***amyloid***
         ***beta***
                                           protein precursor in Microcebus
TI
      murinus: Genotyping and brain localization
      Silhol S.; Calenda A.; Jallageas V.; Mestre-Frances N.; Bellis M.; Bons
ΑU
      Neuromorphologie Fonctionnelle, Ecole Pratique des Hautes Etudes, UMII,
CS
      Place Eugene Bataillon,34095 Montepellier Cedex 5, France.
      Neurobio logy of Disease, (1996), 3/3 (169-182)
CODEN: NUDIEM ISSN: 0969-9961
50
DT
      Journal; Article
      United States
CY
LA
      English
      English
SL
L4
     ANSWER 18 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
     2003:691919 CAPLUS
ΑN
     Demonstration by FRET of BACE interaction with the amyloid precursor
TI
     protein at the cell surface and in early endosomes
AU
     Kinoshita, Ayae; Fukumoto, Hiroaki; Shah, Tejal; Whelan, Christa M.;
     Irizarry, Michael C.; Hyman, Bradley T.
     Alzheimer Disease Research Laboratory, Harvard Medical School,
CS
     Massachusetts General Hospital, Charlestown, MA, 02129, USA
     Journal of Cell Science (2003), 116(16), 3339-3346
SO
     CODEN: JNCSAI; ISSN: 0021-9533
Company of Biologists Ltd.
PB
     Journal
DT
     English
LA
RE.CNT
       32
              THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT
L4
     ANSWER 19 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
     2003:300608 CAPLUS
AN
```

specific to amyloid .beta. peptide for treating

DN

TI

138:319696

Antibodies

```
Chain, Daniel G.
IN
PA
      Israel
      U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 402,820.
SO
      CODEN: USXXCO
DT
      Patent
      English
LA
FAN.CNT 2
      PATENT NO.
                            KIND DATE
                                                       APPLICATION NO.
                                                                             DATE
                                    20030417
                                                                              20020228
ΡI
      US 2003073655
                             Α1
                                                        us 2002-84380
                                                       wo 1998-US6900
      wo 9844955
                                    19981015
                                                                              19980409
                             Α1
                AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
                 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
            RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
                 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
                 CM, GA, GN, ML, MR, NE, SN, TD, TG
                                    20030912
                                                       wo 2002-US31590 20021021
      wo 2003074081
                             Α1
                AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
                CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
                 RU, TJ, TM
            RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
                 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
                 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
                 NE, SN, TD, TG
PRAI US 1997-41850P
                                     19970409
                             Р
      wo 1998-US6900
                             W
                                     19980409
      us 1999-402820
                                     19991012
                             A2
      US 2002-84380
                              Α
                                    20020228
L4
      ANSWER 20 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
AN
      2002:905741 CAPLUS
DN
      137:381934
      Detection of Alzheimer's amyloid by magnetic resonance imaging
TI
      Wisniewski, Thomas; Turnbull, Daniel; Sigurdsson, Einar M.
IN
      New York University, USA
PA
SO
      PCT Int. Appl., 48 pp.
      CODEN: PIXXD2
DT
      Patent
      English
LA
FAN.CNT 1
      PATENT NO.
                            KIND DATE
                                                       APPLICATION NO. DATE
PΙ
      wo 2002094191
                             A2
                                    20021128
                                                       wo 2002-US16057 20020523
                AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
                 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
                GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
                 TJ, TM
            RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
                 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
                      BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, L1 A1 20030807 US 2002-151614 20020523
                                                                                         TD, TG
                                                        ús 2002-151614
      US 2003147811
PRAI US 2001-292625P
                                    20010523
L4
      ANSWER 21 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
AN
      1998:755708 CAPLUS
ÐΝ
      130:137213
      Blood brain barrier endothelial cells express candidate amyloid precursor
TI
      protein-cleaving secretases
      Simons, Elizabeth R.; Marshall, Derek C. L.; Long, Heidi J.; Otto, Kim;
AU
      Billingslea, Andrea; Tibbles, Heather; Wells, John; Eisenhauer, Patricia;
      Fine, Richard E.; Cribbs, David H.; Davies, Theresa A.; Abraham, Carmela
      Department of Biochemistry, Boston University School of Medicine, Boston,
CS
```

MA, USA

Amyloid

(1998), 5(3), 153-162

SO

```
PB
      Parthenon Publishing Group
DT
      Journal
      English
LA
RE.CNT 41
                 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
                 ALL CITATIONS AVAILABLE IN THE RE FORMAT
L4
      ANSWER 22 OF 391 CAPLUS COPYRIGHT 2003 ACS ON STN
AN
      1997:348622 CAPLUS
      127:31883
DN
      Alzheimer's soluble amyloid .beta. is a normal component of ***human***
TI
      Ghiso, Jorge; Calero, Miguel; Matsubara, Etsuro; Governale, Samuel; Chuba, Joseph; Beavis, Ronald; Wisniewski, Thomas; Frangione, Blas Dep. of Pathology, New York Univ. Medical Center, New York, NY, 10016, USA FEBS Letters (1997), 408(1), 105-108 CODEN: FEBLAL; ISSN: 0014-5793
ΑU
CS
S0
PB
      Elsevier
      Journal
DT
LA
      English
      ANSWER 23 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
L4
      1997:227599 CAPLUS
ΑN
      126:291920
DN
      GM1 ganglioside-bound amyloid .beta. -protein: A possible form of
TI
      preamyloid
      Yanagisawa, Katsuhiko; Ihara, Yasuo
Dep. Dementia Res., Natl. Inst. Obu Sci., Obu, 474, Japan
ΑU
CS
SO
      Shinkei Kenkyu no Shinpo (1997), 41(1), 70-79
      CODEN: SKNSAF; ISSN: 0001-8724
PΒ
      Igaku Shoin
DT
      Journal
LA
      Japanese
      ANSWER 24 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
L4
      1996:489433 CAPLUS
ΑN
      125:139682
DN
      Overexpression of a COOH-terminal fragment of .
                                                                ***beta***
TI
                           precursor protein in HeLa cells results in accumulation in
         ***amyloid***
      a pre-Golgi compartment and generation of an A.beta.-like fragment
      Kuentzel, Sandra L.; Gonzalez-DeWhitt, Patty A.; Lowery, David E.; Altman,
ΑU
      Richard A.; Leone, Joseph W.; Heinrikson, Robert L.; Greenberg, Barry D.;
      Raub, Thomas J.
      Drug Delivery Systems Research, Upjohn Company, Kalamazoo, MI, 49001, USA
CS
      Amyloid (1996), 3(2), 86-99
CODEN: AIJIET; ISSN: 1350-6129
SO
      CODEN: AIJIET; ISSN: Parthenon Publishing
PB
DT
      Journal
LA
      English
      ANSWER 25 OF 391 CAPLUS COPYRIGHT 2003 ACS on STN
L4
      1996:304682 CAPLUS
ΑN
      125:7373
DN
      A novel brain cysteine protease forms an SDS stable complex with the .
TI
         ***beta*** .- ***amyloid***
                                                precursor protein
      Chang, Tien; Abraham, Carmela R. School of Medicine, Boston University, Boston, MA, 02118, USA Annals of the New York Academy of Sciences (1996), 777(Neurobiology of
ΑU
CS
SO
      Alzheimers Disease), 183-188
CODEN: ANYAA9; ISSN: 0077-8923
PB
      New York Academy of Sciences
DT
      Journal
      English
LA
      ANSWER 26 OF 391 DISSABS COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved on STN
L4
                            Order Number: AAI9607953
      96:22003 DISSABS
AN
      PROCESSING OF BETA-APP IN ALZHEIMER'S DISEASE AND DOWN SYNDROME: CATHEPSIN
TI
      S UPREGULATION AND A-BETA HETEROGENEITY (AMYLOID PRECURSOR PROTEIN)
      LEMERE, CYNTHIA ANN [PH.D.]; BLUSZTAJN, JAN KRZYSZTOF [advisor]
ΑU
      BOSTON UNIVERSITY (0017)
CS
      Dissertation Abstracts International, (1996) Vol. 56, No. 11B, p. 5961.
S0
      Order No.: AAI9607953. 196 pages.
      Dissertation
DT
```

FS

LA

DAI English

Last Updated on STN: 19960402 ANSWER 27 OF 391 DISSABS COPYRIGHT (C) 2003 ProQuest Information and Learning Company; All Rights Reserved on STN 93:54275 DISSABS Order Number: AAR9330150 L4 ΑN GENERATION OF POTENTIALLY AMYLOIDOGENIC FRAGMENTS FROM THE ***BETA*** TI ***AMYLOID*** PRECURSOR PROTEIN BY BRAIN SERINE PROTEASES (ALZHEIMER'S DISEASE) MARTIN, BRONWYN L. [PH.D.]; ABRAHAM, CARMELA R. [advisor] ΑU CS BOSTON UNIVERSITY (0017) Dissertation Abstracts International, (1994) Vol. 54, No. 6B, p. 3048. SO Order No.: AAR9330150. 342 pages. DT Dissertation FS DAI English LA Entered STN: 19931119 ED Last Updated on STN: 19931119 ANSWER 28 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN L4 ΑN ABU08509 peptide DGENE Enabling measurement of full length ***beta*** - ***amvloid*** TI peptide level for tracking progression of Alzheimer's disease, comprises capturing and binding terminus of ***beta*** - ***amyloid*** ***antibodies*** peptide with IN Fong K L (FONG-I) PΑ FONG K L US 2002182660 A1 20021205 PΙ 11p ΑI us 2002-51496 20020118 US 2000-183407P 20000218 PRAI US 2001-784854 20010216 DT **Patent** LA English 2003-328616 [31] os ***Human*** amyloid beta peptide (1-39). DESC ANSWER 29 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN L4 ABU08508 peptide ΑN **DGENE** Enabling measurement of full length ***beta*** - ***amyloid*** TI peptide level for tracking progression of Alzheimer's disease, comprises capturing and binding terminus of ***beta*** - ***amyloid*** ***antibodies*** peptide with IN Fong K L (FONG-I) FONG K L PA US 2002182660 A1 20021205 US 2002-51496 20020118 ΡI 11p ΑI US 2000-183407P PRAI 20000218 US 2001-784854 20010216 DT Patent English LA os 2003-328616 [31] ***Human*** amyloid beta peptide (1-40). DESC ANSWER 30 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN L4 AN ABU08507 peptide **DGENE** Enabling measurement of full length ***beta*** - ***amyloid*** TI peptide level for tracking progression of Alzheimer's disease, comprises capturing and binding terminus of ***beta*** - ***amyloid*** ***antibodies*** peptide with IN Fong K L PA (FONG-I) FONG K L. US 2002182660 A1 20021205 PΙ 11p US 2002-51496 ΑI 20020118 US 2000-183407P **PRAI** 20000218 US 2001-784854 20010216 Patent DT LA English 2003-328616 [31] os ***Human*** amyloid beta peptide (1-41). **DESC** ANSWER 31 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN L4 ABU08506 peptide DGENE AN Enabling measurement of full length ***beta*** - ***amyloid*** TI

peptide level for tracking progression of Alzheimer's disease, comprises capturing and binding terminus of ***beta*** - ***amyloid***

capturing and binding terminus of

antibodies

peptide with

```
PΑ
      (FONG-I)
                   FONG K L.
      US 2002182660 A1 20021205
PΙ
                                                   11p
      US 2002-51496
ΑI
                         20020118
PRAI
      US 2000-183407P
                         20000218
      US 2001-784854
                         20010216
DT
      Patent
      English
LA
      2003-328616 [31]
05
         ***Human***
                        amyloid beta peptide (1-42).
DESC
      ANSWER 32 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L4
      ABU08505 peptide
AN
                                DGENE
      Enabling measurement of full length
                                               ***beta***
                                                            - ***amvloid***
ΤI
      peptide level for tracking progression of Alzheimer's disease, comprises
      capturing and binding terminus of ***beta*** - ***amyloid***
peptide with ***antibodies*** -
      Fong K L
IN
PA
      (FONG-I)
                   FONG K L.
PΙ
      US 2002182660 A1 20021205
                                                   11p
      us 2002-51496
                         20020118
ΑI
      US 2000-183407P
                         20000218
PRAI
      US 2001-784854
                         20010216
DT
      Patent
LA
      English
os
      2003-328616 [31]
        ***Human***
                        amyloid beta peptide (1-43).
DESC
L4
      ANSWER 33 OF 391 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
                 Protein
                                 DGENE
      New purified recombinant catalytically active memapsin 2
TI
      (beta-secretase), useful for designing and screening of specific
      inhibitors for the diagnosis, prevention and/or treatment of Alzheimer's
      disease
IN
      Lin X; Koelsch G; Tang J J N
PA
      (OKLA-N)
                   OKLAHOMA MEDICAL RES FOUND.
      ùs 2002164760 A1 20021107
                                                   44p
PΙ
      us 2001-795903
ΑI
                         20010228
      US 1999-141363P
PRAI
                         19990628
      us 1999-168060P
                         19991130
      US 2000-177836P
                         20000125
                         20000127
      us 2000-178368P
      US 2000-210292P
                         20000608
      us 2000-604608
                         20000627
DT
      Patent
LA
      English
os
      2003-246668 [25]
         ***Human***
DESC
                       memapsin 2/T7 fusion protein.
L4
     ANSWER 34 OF 391 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     96343306 EMBASE
AN
DN
     1996343306
TI
     The 68 kDa .beta.-secretase with heparan sulfate is expressed in serum and
     lymphocyte cytosol of normal aged and Alzheimer's disease patients.
Matsumoto A.; Enamoto T.; Fujiwara Y.; Baba H.; Matsumoto R.
ΑU
     Dept. Radiation Biophysics Genetics, Kobe University School of Medicine, Kusunoki-cho 7-5-1,Chuo-Ku, Kobe 650, Japan
CS
     Alzheimer's Research, (1996) 2/4 (115-119).
SO
     ISSN: 1356-918X CODEN: ALREFB
CY
     United Kingdom
     Journal; Article
DΤ
FS
     005
              General Pathology and Pathological Anatomy
     800
              Neurology and Neurosurgery
     029
              Clinical Biochemistry
     English
LA
SL
     English
L4
     ANSWER 35 OF 391 FEDRIP COPYRIGHT 2003 NTIS ON STN
     2003:166129 FEDRIP
AN
NR
     CRISP 1Z01DK29029-06
     New Solid State Nmr Methodology For Structural Studies O
TT
SF
     Principal Investigator: TYCKO, ROBERT
CSS
     Supported By: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
     DISEASES
```

FYR

2002

of pirinixic acid after transient transfection with Swedish mutant APP. After a 16-hour treatment, the culture media was harvested and assayed for A beta-40 and A beta-42 by ELISA as described in the Methods and

Tukey's post hoc test at ***p lessthan 0.001.
FIG. 8 is a bar graph showing the effect of PPAR alpha and/or PPAR delta agonist pirinixic acid on A beta total and A beta42 from murine primary cortical neurons infected with APP 695. Cells were treated with 5-250 mu M pirinixic acid for 16 hours and A beta total and A beta-42 levels were quantitated by immunoprecipitation and ELISA, respectively. Data are expressed as mean+-SD with n=6 and statistical significance determined by ANOVA with Tukey's post hoc test at **p less-than 0.01, ***p less-than 0.001. ANSWER 37 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN 10347569 IFIPAT;IFIUDB;IFICDB
EPITOPE-TAGGED ***BETA*** - ***AMYLOID*** PRECURSOR PROTEIN AND METHODS FOR MONITORING CELLULAR PROCESSING THEREOF Mitchell Thomas J; Seiffert Dietmar A Unassigned Or Assigned To Individual (68000) US 2003091983 A1 20030515 US 2002-326049 20021220 US 2000-481980 20000112 DIVISION 6518011 US 1999-115749P US 2003091983 19990113 (Provisional) 20030515 us 6518011 Utility; Patent Application - First Publication CHEMICAL APPLICATION 18 12 Figure(s). FIG. 1 Shows a possible location of an epitope tag in the A-beta sequence of the beta-APP and predicted accumulation of epitope tagged cleavage fragments. The A-beta fragment (1-42), with the proposed proteolytic cleavage sites for secretases (alpha-, beta-, gamma 1 (40)-, and gamma 2 (42)), is indicated. The epitope tag in this example is centered on the alpha secretases site (amino acids 16 to 17 in A-beta). Cleavage by beta and gamma secretases is expected to lead to an accumulation of epitope tagged A-beta (1-40) and A-beta (1-42) in the conditioned medium, whereas cleavage by alpha secretase (within the epitope tag) is expected to destroy or reduce the accumulation of epitope tagged A-beta fragments in the conditioned medium. FIG. 2 Shows an immunoblot analysis of HEK 293 (***human*** embryonic kidney cell line, ATTC #CRL-1573) cell lysates after transfection with epitope-tagged beta-APP. Cell lysates were prepared by lysis of HEK 293 cells into SDS and were fractionated by SDS-PAGE, followed by transfer to nitrocellulose membranes. The membranes were developed with mAB 22C11 (epitope in the ***N*** - ***terminus*** of full-length beta-API of full-length beta-APP; (epitope in the lanes 1 and 2), mab anti HA 11 (influenza hemagglutinin epitope: YPYDVPDYA)(SEQ ID NO:6) (directed to the HA 11 epitope tag; lanes 3 and 4), and mAB 9E10 (directed to the myc epitope tag; lanes 3 and 4), and mAB 9E10 (directed to the myc epitope tag; lanes 5 and 6). Lane 1, HEK 293 cells transfected with HA 11 beta-APP 695; lane 2, HEK 293 cells transfected with vector alone ('Mock-transfection'); lane 3, HEK 293 cells transfected with HA 11 beta-APP 695; lane 4, HEK 293 cells transfected with vector alone; lane 5, HEK 293 cells transfected with myc betaAPP 695; lane 6, HEK 293 cells transfected with vector alone. The relative mobility of molecular weight standards is indicated to the left. FIG. 3 Shows an accumulation of beta-APP fragments into HEK 293 conditioned medium. The 24 hour serum-free conditioned medium (lanes 1 conditioned medium. The 24 hour serum-free conditioned medium (lanes 1 and 2) or cell lysates (lanes 3 and 4) of HEK 293 cells transfected with vector alone (lanes 1 and 3) or HA 11 beta-APP 695 (lanes 2 and 4) were harvested. The resulting polypeptides were fractionated by SDS-PAGE (10% acrylamide in separating gel) and transferred to nitrocellulose membranes. Panel A was developed with mAB anti-HA 11, whereas panel B was developed with mAB 22C11. The relative mobility of molecular weight standards is indicated to the right. FIG. 4 Shows the detection of epitope-tagged beta-APP fragments in HEK 293 conditioned medium after transfection with HA 11 beta-APP 695. Panel A: Microtiter wells were coated with mAB anti-HA 11 and after blocking, incubated with a dose-response of a synthetic HA 11 A-beta (1-40) peptide containing the HA 11 epitope centered on the alpha secretase cleavage site. Bound A-beta HA 11 was detected with polyclonal ***antibodies*** specific for position 1 (Serotec) or position 40 (QCB), followed by HRPlabeled anti-rabbit IgG and TMB substrate. The change of absorbance at 650 nM was monitored and results are corrected for binding of secondary ***antibodies*** to wells not incubated with the A-beta HA 11 peptide. Results are expressed as change of absorbance

fluorescence as a measure of total cell number. Data are expressed as mean+-SD with n=11 and statistical significance determined by ANOVA with

L4

AN

TI

IN PA

PΙ

ΑI

DT FS

GI

CLMN

RLI

PRAI FI

```
Panel B: Microtiter wells were coated as in panel A and incubated with the indicated dilutions of HEK 293/HA 11 betaAPP 695 conditioned medium (24 hours). Bound HA 11 beta-APP 695 fragments were detected with
             ***antibodies*** specific for position 1 and 40 as in panel A. Results
        are expressed and corrected as in panel A. FIG. 5 Shows a time-course of the accumulation of HA 11 A-beta (1-40) and
         A-beta (1-42) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK
         293/HA 11 beta-APP 695 was cultured in serum-free medium containing 0.2%
         bovine serum albumin in 96well microtiter plates for the indicated time
         intervals. The accumulation of HA 11 A-beta (1-40) and A-beta (1-42) was
         determined. For HA 11 A-beta polypeptides ending at position 40, microtiter wells were coated with mAB anti-HA 11 and bound polypeptides
         were detected with rabbit anti-A-beta 40 (QCB), followed by HRP-labeled anti-rabbit IgG. For the position 42specific ELISA, microtiter wells were coated with mAB anti-HA 11, and bound polypeptides were detected with biotin-labeled mAB 108 (position 42-specific), followed by
         streptavidin-HRP conjugate. Results are corrected for binding of secondary ***antibodies*** in the absence of conditioned medium and
         expressed as change of absorbance at 650 nm per minute (moD/minute).
        FIG. 6 Shows the effect of MDL 28170 and Brefeldin A on the accumulation of HA 11 A-beta (1-40) in HEK 293/HA 11 beta-APP 695 conditioned medium.
         HEK 293/HA 11 beta-APP 695 cells were plated at confluence in 96-well plates and the indicated doseresponse of either MDL 28170 (panel A), or Brefeldin A (panel B) was added for 16 hours. The accumulation of HA 11 A-beta (1-40) (position 40-specific "**antibody***; QCB) was determined as in FIG. 5. Results are expressed as percentage inhibition of HA 11 Abeta (1-40) accumulation in comparison to wells incubated with vehicle (dimethyl sulfoxide DMSO) alone
         vehicle (dimethyl sulfoxide, DMSO) alone.
        FIG. 7 Shows an isolation of HA 11 A-beta from HEK 293/HA 11 beta-APP 695
         cells. Conditioned medium (serum-free containing 0. 2% BSA) was passed
         over an mAB anti-HA 11 affinity matrix. After washing, the column was eluted with 5% formic acid in water. The peak fractions were pooled, dried in a Speed-Vac, resuspended in water and the pH was adjusted to 7.4
        Panel A: The starting material, flow-through, and the pooled elution fractions (after dilution to account for the concentration of the HA 11 A-beta on the column) were analyzed by ELISA specific for position 40 in
         HA 11 A-beta as in FIGS. 4 and 5.
        Panel B: The indicated dilutions of the pooled elution fractions were
         analyzed by ELISA specific for position 1, 40, and 42 in HA 11 A-beta.
         Note that approximately equal immunoreactivity is present for the
                                        ***antibodies***
                                                                     , whereas the 42specific reactivity
         position 1 and 40
         is lost with 10-fold lesser dilution.
        Panel C: The elution fractions were analyzed by SDS PAGE (16.5% polyacrylamide in separating gel), followed by immunoblotting with mAB anti-HA 11, followed by HRP-labeled anti-mouse Ig, and chemiluminescence detection (ECL tm, Amersham). Lane 1, elution fraction, stained with mAB
         anti-HA 11; lane 2, elution fraction spiked with HA 11 A-beta peptide (50
         ng); lane 3, purified A-beta HA 11 1-40 peptide; and lane 4, elution
         fraction, stained under omission of anti-HA 11.
        ANSWER 38 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
         10143206 IFIPAT; IFIUDB; IFICDB
                               ***ANTIBODIES***
                                                             SPECIFIC FOR
         RECOMBINANT
                                                                                   ***BETA***
         ***AMYLOID*** ENDS, DNA ENCODING AND METHODS OF USE THEREOF; DNA ENCODING A RECOMBINANT ***ANTIBODY*** MOLECULE END-SPECIFIC FOR AN
            ***AMYLOID***
         AMYLOID-BETA PEPTIDE FOR PREVENTING OR INHIBITING PROGRESSION OF
         ALZHEIMER'S DISEASE
         Chain Daniel G (IL)
         Mindset Biopharmaceuticals USA
         us 2002086847
                                 A1 20020704
         us 2001-975932
                                         20011015
         us 1999-402820
                                         19991012 DIVISION
                                                                                           PENDING
         wo 1998-US6900
                                         19980409 Section 371 PCT Filing UNKNOWN
         US 1997-41850P
US 2002086847
PRAI
                                         19970409 (Provisional)
                                         20020704
         Utility; Patent Application - First Publication
         CHEMICAL
         APPLICATION
CLMN
         30
           5 Figure(s).
        FIG. 1 shows a schematic representation of the ***beta*** -
            ***amyloid*** precursor protein (beta APP) and the products of alpha,
```

beta, and gamma-secretase cleavage. The general locations of various domains are indicated along with the cleavage sites (alpha, beta, gamma)

L4

ΑN

TI

IN

PA

PΙ

ΑI

FI

DT FS

GI

RLI

```
expression and secretion of ectopic A beta-end-specific
          ***antibodies*** in the CNS inhibits (1) the accumulation of A beta peptides and (2) the neurotoxic consequences of amyloid deposition without affecting the biological functions of the soluble ***beta***
              ***amyloid***
                                         precursor protein.
         FIG. 2 shows the amino acid sequence (SEQ ID NO:1) of the region in beta APP from which ***beta*** - ***amyloid*** peptides (A beta) are
          derived. The arrows indicate the alpha-, beta- or gammasecretase cleavage
          sites, and the amino acid residues corresponding to the synthetic
          peptides to be used as immunogens are indicated underneath the sequence
          by line segments.
        FIGS. 3A-3D schematically show the structure of a whole ***antibody*** (FIG. 3A) with the variable domain of heavy (VH) and light (VL) chains and the constant domain(s) of light (CL) and heavy (CH1, CH2, CH3) chains, a Fab fragment (FIG. 3B), a FV fragment (FIG. 3C), and a single chain FV fragment (scFV) (FIG. 3D). The Fab fragment shown in FIG. 3B consists of a variable domain of heavy VH and light VL chain and the first constant domain (CH1 and CL) joined by a disulfide bridge. The FV
          first constant domain (CH1 and CL) joined by a disulfide bridge. The Fv
          fragment shown in FIG. 3C represents the antigen binding portion of an
              ***antibody***
                                            formed by a non-covalently linked variable region
        complex (VHVL), whereas the single chain FV shown in FIG. 3D joins the variable heavy VH with the variable light VL chain via a peptide linker. FIG. 4 schematically shows the construction of a scFV ***antibody*** by cloning the variable region of an end-specific anti-A beta monoclonal ***antibody*** using the PCR amplification technique with primers A, B,
          C and D, and then joining together the variable heavy VL chain and the
          variable light VL chain with an interchain peptide linker (ICL). The
          shaded area represents hypervariable regions of the antigen binding site
          and LP designates the leader peptide of the heavy and light chains.
         FIG. 5 shows a schematic representation of the AAV ScFv alpha A beta vector with the inverted terminal repeats (ITR), ***human*** be
          promoter (Hu beta APPP), SV40 polyadenylation signal (SV40pA) indicated.
          The plasmid backbone is pSSV9.
         ANSWER 39 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN 10016325 IFIPAT; IFIUDB; IFICDB
          IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO
          NEURONS; PREVENTION COMPLEXING
          GIULIAN DANA
          Unassigned Or Assigned To Individual (68000)
          us 2001016327 A1 20010823
          US 1997-923055
                                               19970903
          us 1996-717551
                                               19960920 DIVISION
                                                                                                        6071493
          us 2001016327
                                               20010823
          us 6071493
          Utility; Patent Application - First Publication
          CHEMICAL
          APPLICATION
CLMN
          99
            29 Figure(s).
         FIG. 1 displays the chemical structure of NTox, a neurotoxin released by
          microglia and macrophages after exposure to senile plaques in vitro or in
        vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorescamine (fluram) or plasma amine oxidase (PAO). FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid bydrolysis and sequential gradient reverse phase high performance.
           acid hydrolysis and sequential gradient reverse phase high performance
          liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient,
           shows a peak with elution at about 14% acetonitrile. Importantly, this
          peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50= 10 mu M in the ultrafiltrate compared with 100 pM for highly purified toxin following acid hydrolysis and C18 RP-HPLC. From such preparations, estimations of greater-than 100,000 fold purification of toxin from ***human*** brain. The phenolic
           content is estimated by UVmax at 265 nm with a similar result obtained
          when values are normalized to amine content measured by fluorescamine.
         FIG. 3 shows the correlation between microglial clusters found in
```

Alzheimer brain and levels of extracted neurotoxins. NTox was isolated

from tissue blocks by aqueous extraction and 2step ion exchange chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of

L4 ΑN

TI

IN

PA

PΙ

ΑI

FI

DT FS

GI

RLI

number of clusters per mm2 in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0.0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia. FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Niss1 stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0 mu l fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

FIGS. 6A and B shows twenty four hour exposure of "*human"*" embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, DiI-ac-LDL Bar=40 mu m, FIG. 7A; 25 mu m FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding sphere implants. FIG. 8A reveals that at two weeks after implantation, there is a 5-fold increase in receptor mRNA surrounding the SphereA beta 1-42 when compared to undamaged control tissue or SphereBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.
FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with DiI-ac-LDL (0.5 nmoles injected. FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1. 0 nmole A beta 1-5 did not alter inflammation (FIG. 9C. Bar= 30 microns).

beta 1-5 did not alter inflammation (FIG. 9C, Bar= 30 microns).
FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10 mu M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100 mu M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100 mu M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal

acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury. FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons immuno-stained with anti-neurofilament and anti-MAP 2 ***antibodies*** found in control hippocampal cultures (1,200 cells per mm2) that were supplemented with microglia (500 per mm2). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic ***human*** A beta 1-42 (1 mu mole/l) for 72 hours resulting in a dramatic loss of neurons (Bar= 20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to ***human*** A beta 1-40, A beta 1-42, or A beta 1-42 coup hours to ***human*** A beta 1-40, A beta 1-42, or A beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the "**N*** - "**terminus*** of the peptide (A beta 1-11, A beta 1-16, and A beta 1-28) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1 mu mole/l) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)modification of Tyr10; diethylpyrocarbonate (DEPC)modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16. FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10 mu moles/1). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-BsA (which bind to scavenger receptors) or Spheres A beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor). inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive treatments each of 0.01 units/ml for 60 min), or with chondroitinase ABC (chondroitin ABC lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either Spheres A beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased SpheresA beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50 mu g/ml) or A beta 1-16 (10 mu mole/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500 mu g/ml) or acetylated LDL (ac-LDL, 200 mu g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mm), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely eliminated plaque activation. FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1 mu moles/1) in solution and or SpheresA beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10 mu moles/1). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta. Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque activation of neurotoxic microglia. FIG. 17 sets forth a table of the effects of ***beta*** ***Amyloid*** peptides upon microglia. All peptides which contain the

unmodified region encompassing residues 13-16 (shaded) block A beta 1-42

microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA= not applied in this neurotoxicity test, since the free peptide induces microglial toxicity. FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIGS. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18E). Bar= 25 mu m. FIG. 18G shows neurons (FIG. 18B) or astroglia (FIG. 18F). Bar= 25 mu m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values +/-standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification. FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400 mu moles/1) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10 mu m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/ core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta. FIGS. 20A-E displays soluble fractions of native plaques induce microglial reactivity. Bright field photomicrographs of rat microglia cultures exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta . As shown, aggregates of A beta are found throughout the cultures incubated with peak \$5 (Bar= 25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar= 5 microns). FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 mu moles/1 on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 mu mole/l) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm2 when incubated with 1 mu mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A microglia) also showed an efficient killing capacity in the presence of A beta . These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED50 of 10 nmoles/l compared to 80 nmoles/l for A beta 1-40 (500 microglia per mm2; FIG. 21E).
FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 mu mole/l A beta 1-42 (FIG. 22E); in contrast, 1 mu mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence

microscopy_of neuron plus microglia cultures showed robust NF(+) MAP2(+)

A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 mu mole/l A beta 1-42 (FIG. 22F). Bar= 25 microns. FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm2) After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar= 20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia. FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 mu moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm2) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuronspecific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve including galactocerebroside(+) oligodenroglia neuron-free optic nerve, including galactocerebroside(+) oligodenroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIG. 24E and 24G, respectively). Bar= 10 mu m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+ A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity. IGS. 25A-E displays ***human*** FIGS. 25A-Ĕ displays microglia and neuron killing. FIG. 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmole/l), S4 (220 mu mole/l), and S5 (250 mu mole/l)) elicit ***human*** microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 mu mole/liter concentrations, synthetic A beta 1-40 and A beta 142 also stimulated release of neurotoxin from ***human*** microglia, while smaller AP fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by ***human*** cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by ***human*** or rat microglia exposed to 1 mu mole/liter of the ***human*** forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of ***human*** A beta however, was inactive, as were fragments of A beta. including 128, 12-28, and 17-43. FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat ***human*** microglia. To investigate mechanisms of cell killing, rat microglia were stimulated with 1 mu mole/l A beta 1-42 (Rat/A beta 1-42) and ***human*** cells with fraction S5 (containing 250 mu mole/l of native A beta 1-42) from solubilized neuritic/core plaques (
Human /S5 Peak). FIG. 26A shows agents that act as free radical scavengers (vitamin E, 100 mu M; catalase, 25 units/ml; glutathione, 100 mu M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(limin-oethyl)ornithine hydrochloride (L-NIO, 10 mu M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (A beta 7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 mu M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH20 with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts

or from unstimulated microglial culture media.

FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A

conditioned media (10% vol/vol) from microglia incubated with 1 mu mole/l

A beta 1-42 peptides. FIG. 27B Sepharose bead coupled to ***human*** shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker DiI-ac-LDL; Bar= 20 microns. FIG. 27C shows rat microglial adherence to Sepharose-coupled beads after six hours. Plaque proteins derived from neuritic/core plaques provided an anchoring site for microglia, as did A beta 1-42. Importantly, A beta 1-28 also promoted bead binding, while A beta 17-43 did not. Controls included beads coupled to glycine (Control glycine) and to bovine serum albumin (Control-BSA). Data shown are expressed as the numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C. FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoxic microglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm2) after 4 hour incubation at 37 degrees C. Coupling of A beta peptides to fluorescent microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D), and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43 (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not. Quantitations of binding pattern (FIG. 28G) indicated that regions of the ***N*** - ***terminus**** -containing amino acid residues 10-16 were necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification. FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglia nor elicits toxicity) created a peptide, A beta 10-42, which both bound to microglia and stimulated microglia to kill neurons. FIG. 29B shows a diagram comparing the structures and functions of synthetic peptides. The shaded area illustrates the Nterminal portion of A beta that differs between ***human*** and rat forms and which appears necessary for microglial adherence. ! ANSWER 40 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN 10016324 IFIPAT; IFIUDB; IFICDB IDENTIFICATION OF AGENTS THAT PROTECT AGAINST INFLAMMATORY INJURY TO NEURONS; PREVENTION COMPLEXING GIULIAN DANA Unassigned Or Assigned To Individual (68000) us 2001016326 A1 20010823 US 1997-922930 19970903 US 1996-717551 19960920 DIVISION 6071493 US 2001016326 20010823 US 6071493 Utility; Patent Application - First Publication CHEMICAL **APPLICATION** 99 29 Figure(s). FIG. 1 displays the chemical structure of NTox, a neurotoxin released by microglia and macrophages after exposure to senile plaques in vitro or in vivo. Chemical and enzymatic modifications of the isolated toxin have identified within NTox a phenolic hydroxyl group sensitive to tyrosinase, a ring structure sensitive to reduction by rhodium, and a terminal amine sensitive to fluorescamine (fluram) or plasma amine oxidase (PAO). FIGS. 2A and B display steps in the isolation of NTox from frozen Alzheimer brain gray matter that involved extractions into ethyl acetate, acid hydrolysis and sequential gradient reverse phase high performance liquid chromatography (RP-HPLC). FIG. 2A shows the final step of purification by RP-HPLC, using a C18 column and an acetonitrile gradient, shows a peak with elution at about 14% acetonitrile. Importantly, this peak is found in Alzheimer but not in control brain and corresponds to activity which is highly toxic to ciliary neurons. FIG. 2B displays the degree of purification of neurotoxin from Alzheimer brain tissue. Dose response curves show that the ED50=10 mu M in the ultrafiltrate compared with 100 pm for highly purified toxin following acid hydrolysis and C18 From such preparations, estimations of greater-than 100,000 fication of toxin from ***human*** brain. The phenolic fold purification of toxin from ***human*** brain. The phenolic content is estimated by UVmax at 265 nm with a similar result obtained

when values are normalized to amine content measured by fluorescamine. FIG. 3 shows the correlation between microglial clusters found in Alzheimer brain and levels of extracted neurotoxins. NTox was isolated

chromatography (DOWEX and SP-SEPHADEX) while neighboring portions of adjacent tissue stained for HIA-DR(+) microalish livetons (coor d

from tissue blocks by aqueous extraction and 2step ion exchange

L4

AN TI

ΙN

PA

ΡI

ΑI

FI

DT FS

CLMN GI

RLI

number of clusters per mm2 in 50 random field. Spearman rank correlation was highly significant (n=71 tissue regions from 6 brains; rs less-than 0.0005) suggesting that significant amounts of NTox are found in Alzheimer brain within brain structures laden with reactive microglia. FIGS. 4A and B sets forth the results of neurotoxin infused directly into rat brain kills neurons in vivo. Niss1 stained rat hippocampus (CA3 region) 5 days after stereotaxic injection of neurotoxin. Dead and dying, pyknotic neurons are readily apparent as darkly stained, shrunken profiles in the side injected with a neurotoxin recovered from Alzheimer brain (FIG. 4B; Bar=40 micron), compared to the contralateral hippocampus injected with an identical non-toxic fraction from age matched normal brain (FIG. 4A). The inventor estimates about 100 pmoles of purified neurotoxin were contained in the 1.0 mu l fluid volume injected into the hippocampus.

FIG. 5 shows the specificity of A beta 1-42 to macrophages is seen by comparison with incubating either macrophages or kidney cells with microspheres coupled to A beta 1-42 for 4 hours at 37 degrees C. in the presence of increasing amounts of A beta 10-16 mixed with the culture media. As shown, competition occurs with the macrophages in a dose dependent manner while no changes in binding are seen for kidney cells. These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells.

These and similar data indicate a specificity for A beta binding to in microglia, macrophages, and other classes of microglia-like cells. FIGS. 6A and B shows twenty four hour exposure of "*human"" embryonic kidney (HEK) cells to 1 nM of NTox resulted in significant cell death as measured by trypan blue staining but only in those cells expressing heteromeric NMDA receptors. FIG. 6A) Photomicrograph of trypan blue(+) control HEK cells exposed to NTox. Few blue, dead cells are noted. FIG. 6B shows HEK cells expressing NMDA1b/2A were also exposed to NTox for 24 hours. As seen, far larger number of dying cells appear. This NTox killing effect was found in heteromeric expression (R1/R2) and could be blocked by MK-801.

FIGS. 7A, B, and C show SpheresA beta 1-42 in vivo. Weeks after implantation of large microspheres (250 micron diameter) remain embedded within brain neocortex (FIG. 7A). FIG. 7B shows an implanted SphereBSA with very few scavenger receptor(+) microglia abutting the control microsphere. In contrast, SpheresA beta 1-42 chronically stimulate the presence of reactive cells (FIG. 7C). Microglia were visualized by uptake of fluorescent labeled acetylated LDL, Dil-ac-LDL Bar=40 mu m, FIG. 7A; 25 mu m FIGS. 7B and C.

FIGS. 8A and B shows scavenger receptor II mRNA in tissue surrounding sphere implants. FIG. 8A reveals that at two weeks after implantation, there is a 5-fold increase in receptor mRNA surrounding the SphereA beta 1-42 when compared to undamaged control tissue or SphereBSA. FIG. 8B, in contrast, reveals that all sites had similar levels of the marker mRNA G3PDH. Data support histological changes.

FIGS. 9A, B, and C shows infusion of A beta 1-42 into the neocortex of adult rat produces an inflammatory response 5 days later at the site of injection as seen by the presence of reactive microglia and macrophages labeled with Dil-ac-LDL (0.5 nmoles injected. FIG. 9B reveals that co-infusion of 0.5 nmoles of A beta 1-42 plus 1.0 nmole of A beta 13-16 blocks the interaction of A beta 1-42 with microglia in vivo and reduces the local brain inflammatory response while co-infusion with 1.0 nmole A beta 1-5 did not alter inflammation (FIG. 9C. Bar=30 microns).

beta 1-5 did not alter inflammation (FIG. 9C, Bar=30 microns).

FIG. 10 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of immuno-suppressive drugs (0.1 to 10 mu M) showed that only chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs with therapeutic potential for Alzheimer Disease.

FIG. 11 shows in vitro screening of drugs which inactivate microglia stimulated by A beta 1-42. Test concentrations of signal transduction inhibitors (0.01 to 100 mu M) showed that only compounds that block the tyrosine kinases (damacanthal and genistein) chloroquine had a protective effect and prevented appearance of neurotoxic microglia when mixed with A beta peptides. Such in vitro assays permit rapid screening of drugs which serve as lead compounds for development of therapeutics for Alzheimer Disease.

FIG. 12 shows a comparison of NTox with other brain-derived compounds which contain a phenolic and terminal amine group. Tyramine appears to significant structural similarity with NTox. Tyramine, however, has no known neurotoxic or neuroprotective properties.

FIG. 13 reveals neuroprotective effects of NTox-like compounds. Test conditions include microglia stimulated with A beta 1-42, isolated NTox applied to neurons directly, or neurons mixed with 100 mu M of the toxin quinolinic acid (QUIN). As shown, only tyramine prevented neuronal

acid which points to existence of families of molecules which could prevent microglia-mediated neuron injury.

FIGS. 14A-D displays neurotoxic microglia activated by betaamyloid peptide. FIG. 14A shows a fluorescence photomicrograph of neurons

immuno-stained with anti-neurofilament and anti-MA beta 2
antibodies found in control hippocampal culture found in control hippocampal cultures (1,200 cells per mm2) that were supplemented with microglia (500 per mm2). FIG. 14B shows a culture identical to FIG. 13A exposed to synthetic "**human*** A beta 1-42 (1 mu mole/l) for 72 hours resulting in a dramatic loss of neurons (Bar=20 microns). FIG. 14C shows testing of various A beta peptides in a neurotoxicity assay using rat hippocampal cultures supplemented with microglia resulting in 70-80% killing of neurons after exposure for 72 hours to "**human*** A beta 1-40, A beta 1-42 on heta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination beta 1-42 coupled to microspheres (Spheres A beta 1-42) while elimination of microglia from the cultures prevented neuron death. The pattern of neuron killing by synthetic peptides was similar to that elicited by either isolated AD plaques or native A beta purified from plaques. Interestingly, rodent A beta 1-40 (Arg5, Phe10, and Arg13) did not activate microglia. The A beta peptides containing either the ***N***

- ***terminus*** of the peptide (A beta 1-11, A beta 1-16, and A beta 1-28) or C-terminus (A beta 17-43) alone also were inactive. FIG. 14D shows the capacity of A beta 1-42 (1 mu mole/1) to activate microglia examined after modification of the N-terminal region by chemical or enzymatic methods. Altering residues in the 13 to 16 domain blocked the A beta 1-42 induction of neurotoxic microglia. Cyclohexanedione (CHD)-modification of Arg5; tetranitromethane (TNM)modification of Tyr10; diethylpyrocarbonate (DEPC)-modification of His6, His13, His14 with hydroxylamine used to reverse the DEPC effect; transglutaminase (TNG) modification of Gln15; ethyl acetimidate (EAM)-modification of Lys16. FIGS. 15A-D depicts inhibition of A beta binding to microglia. FIG. 15A shows A beta 1-42 coupled to fluorescent microspheres and the Spheres A beta 1-42 monitored for binding to microglia after 4 hours at 37 degrees C. in the presence of peptides (all at 10 mu moles/l). Only peptides containing residues 13-16 were able to competitively block sphere binding. FIG. 15B shows that enzymatic treatments of microglia altered A beta binding to cells. Spheresmal-RSA (which hind to scavenger recentors) beta binding to cells. Spheresmal-BSA (which bind to scavenger receptors) or SpheresA beta 1-42 were incubated with microglia for 4 hours following pre-treatment of cells with trypsin (5000 units/ml at 37 degrees C. for 60 min followed by inactivation with soybean trypsin inhibitor), with heparinase (heparin lyase EC 4.2.2.7; two consecutive treatments each of 0.01 units/ml for 60 min), or with chondroitinase ABC (chondroitin ABC lyase EC 4.3.3.4; two consecutive treatments each of 0.02 units/ml for 60 min). Binding by either SpheresA beta 1-42 or Spheresmal-BSA to microglia were reduced by trypsin. Heparinase, however, only decreased SpheresA beta 1-42 while chondroitinase affected neither A beta or scavenger ligand binding sites. FIG. 15C shows that competition with ligands again suggest the involvement of a heparin sulfate-containing site on microglia with reduction of binding in the presence of heparin sulfate (50 mu g/ml) or A beta 1-16 (10 mu mole/l). In contrast, scavenger receptor binding of Spheresmal-BSA was blocked by known scavenger receptor ligands such as dextran sulfate (500 mu g/ml) or acetylated LDL (ac-LDL, 200 mu g/ml). FIG. 15D shows that plaque induction of neurotoxicity in microglia involves heparin sulfate-containing site. Microglia mixed with hippocampal neurons were treated with combinations of beta-Dxyloside (1 mm), heparinase (0.02 units/ml), or chondroitinase (0.04 units/ml) and then exposed to plaques. Enzyme treatments alone, particularly that of heparinase brought on some reduction in neurotoxic activity; however, a combination of both enzymatic degradation of heparin sulfate plus competitive blockade of glycosylation by beta-D-xyloside completely

eliminated plaque activation.

FIGS. 16A-C displays neurotoxic microglia blocked by A beta peptides. FIG. 16A shows both A beta 1-42 (1 mu moles/l) in solution and or SpheresA beta 1-42 (250,000 per well) added to hippocampal cultures supplemented with microglia in the presence of various synthetic A beta peptides (all at 10 mu moles/l). Peptides containing residues 13 to 16 prevented A beta induction of neurotoxic microglia. FIG. 16B shows that dose curves show a greater blocking capacity for those peptides containing residues within the 1-16 hydrophilic portion of A beta . Addition of more hydrophobic segments (beyond residue 16) diminish the ability of peptide to block A beta 1-42 interactions with microglia. FIG. 16C sets forth comparisons of various peptides confirm that the HHQK domain of A beta blocks plaque

activation of neurotoxic microglia. FIG. 17 sets forth a table of the effects of ***beta*** ***Amyloid*** peptides upon microglia. All peptides which contain the unmodified region encompassing residues 13-16 (shaded) block A beta 1-42

microglial neurotoxicity, and the ability of AD plaques to induce microglial neurotoxicity. NA=not applied in this neurotoxicity test, since the free peptide induces microglial toxicity. FIGS. 18A-G show selective elimination of microglia from mixed hippocampal cultures. Control cultures (FIGS. 18A, 18C, 18E) show complex neuronal networks revealed by MAP-2/neurofilament immunostaining (FIG. 18A), the presence of DiI-ac-LDL(+) microglia (FIG. 18B), and near confluent feeder layer of GFAP(+) astrocytes (FIG. 18C). After treatment of cultures with saporin coupled to acetylated LDL (FIG. 18B, 18D, 18F), there was an elimination of microglia (FIG. 18D) without effect on survival of either neurons (FIG. 18B) or astroglia (FIG. 18F). Bar=25 mu m. FIG. 18G shows counts of specific cell populations with and without Sap-ac-LDL treatment confirm the specific depletion of microglia. Data are expressed as mean values +/standard error obtained from 9 randomly selected fields from 3 to 18 to values +/standard error obtained from 9 randomly selected fields from at least 5 independent cultures viewed at 200 x magnification. FIGS. 19A-D displays constituents of solubilized native senile plaques elicit neuron killing. FIG. 19A shows neuritic/core or diffuse plaques were isolated from cortical gray matter, solubilized in formic acid, and dialyzed against a betaine buffer. Equal amounts of plaque protein (normalized to total amine content at 400 mu moles/l) were added to neuronal cultures in the presence (100,000 cells per culture) or absence of rat microglia. As shown, solubilized neuritic/core plaque proteins (Neuritic/Core Plaque) lead to significant killing of neurons, but only in the presence of microglia. Neither solubilized diffuse plaque proteins in the presence of microglia. Neither solubilized diffuse plaque proteins (Diffuse Plaque) nor the betaine buffer (Buffer Control) elicited neurotoxic activity. FIG. 19B shows size-exclusion chromatography of neuritic/core plaque proteins using two Superose 12 columns in tandem (300 mm x 10 mm x 2; beads 10 mu m diameter). The chromatogram was developed with 80% glass distilled formic acid at a flow rate of 0.3 ml per minute and monitored at 280 nm. The approximate molecular masses of the fractions were: S1, 200 kDa; S2, 45 kDa; S3, 15 kDa; S4, 10 kDa; and S5, 5 kDa. FIG. 19C shows a histogram in which exposure to peaks S3, S4, and S5 all elicited significant increases in the percent of reactive microglia as defined by morphologic criteria, whereas peaks S1 and S2 do not. FIG. 19D shows fractions of solubilized neuritic/ core plaques applied to hippocampal cultures in the presence or absence of microglia. No neuron killing was detected in cultures free of microglia. Neuron loss appeared, however, in microglia containing cultures exposed to peaks S3, S4, and S5, all which contain A beta FIGS. 20A-E displays soluble fractions of native plaques induce microglial reactivity. Bright field photomicrographs of rat microglia cultures exposed to peak S1 (FIG. 20A) or peak S5 (FIG. 20B) and immuno-stained for the presence of A beta. As shown, aggregates of A beta are found throughout the cultures incubated with peak S5 (Bar =25 microns). Phase photomicrographs show cultured microglia as process bearing cells with spinous surfaces typical of non-reactive cells despite exposure to peak S4 (FIG. 20C). In contrast, microglia exposed to peak S5 retract processes and take on a reactive cell morphology similar to that found in AD brain (FIG. 20D; Bar=5 microns). FIGS. 21A-D displays toxic actions of synthetic A beta peptides upon neurons. FIG. 21A and 21B shows high concentrations of most A beta peptides placed in hippocampal cultures containing neurons and astroglia (but depleted of microglia) show little effect. There is, however, a generalized cytotoxic action by A beta 25-35 at greater-than 30 mu moles/l on both neurons (FIG. 21A) and astroglia (FIG. 21B). In the absence of microglia, none of the A beta peptides (at 1 mu mole/l) produce destruction of neurons. When rat microglia are added to neuronal cultures, however, only A beta 1-40 and A beta 1-42 elicit neuron killing (FIG. 21C). As shown in FIG. 21D, addition of increasing numbers of microglia show a saturated neuron killing response at a density of 150 microglia per mm2 when incubated with 1 mu mole/liter A beta 1-42; microglia found within the E18 culture at the time of plating (endogenous microglia) also showed an efficient killing capacity in the presence of A beta. These observations point to the need to deplete neuron cultures of microglia when assessing mechanisms of A beta toxicity. Dose response curves reveal A beta 1-42 to be the most potent microglial stimulus with an estimated ED50 of 10 nmoles/l compared to 80 nmoles/1 for A beta 1-40 (500 microglia per mm2; FIG. 21E). FIGS. 22A-F depicts cellular responses upon exposure to synthetic A beta peptides. Phase microscopy shows that cultured rat microglia undergo morphological changes with retraction of processes when exposed to 1 mu mole/l A beta 1-42 (FIG. 22E); in contrast, 1 mu mole/l A beta 17-43 (FIG. 22C) does not alter microglial morphology which appear identical to untreated cells grown under control conditions (FIG. 22A). Fluorescence

microscopy of neuron plus microglia cultures showed robust NF(+) MAP2(+)

conditioned media (10% vol/vol) from microglia incubated with 1 mu mole/l A beta 17-43 (FIG. 22D). Significant neuron loss occurred, however, if hippocampal cultures were exposed to conditioned media from microglia incubated with 1 mu mole/l A beta 1-42 (FIG. 22F). Bar =25 microns. FIGS. 23A-E displays A beta activation of microglia after coupling to microspheres. Fluorescently labeled microspheres were covalently coupled to A beta 1-42 and placed in hippocampal cultures containing rat microglia (500 cells per mm2). After 72 hours, A beta 1-42-spheres (FIG. 23A) were localized specifically within DiI-ac-LDL(+) microglia (FIG. 23B, co-localization noted by arrows). In contrast, A beta 17-43microspheres (FIG. 23C) showed no consistent association with microglia (FIG. 23D; Bar=20 micron). FIG. 23E) Comparison of capacity of A beta in solution or coupled to microspheres (beadbound) to elicit neurotoxic microglia (250,000 microspheres per culture; 100,000 microglia per culture; 72 hour incubation). Neuronal loss was similar if A beta peptides were in solution or bound to beads, indicating that fibril formation, or other changes in tertiary structure, were not necessary to stimulate neurotoxic microglia. FIGS. 24A-H depicts fluorescent photomicrographs of hippocampal cultures after exposure to A beta 1-42. FIG. 24A shows control cultures show complex networks of NF(+), MAP-2(+) neurons. FIG. 24B shows exposure of cultures to 100 mu moles/liter A beta 142 in the absence of microglia has no effect on neuron number, while (FIG. 24C) addition of 100 nmoles/liter A beta 1-42 in the presence of rat microglia (500 cells per mm2) destroyed nearly all neurons. FIGS. 24D-G shows immunostaining for neuronspecific enolase (NSE) is not specific to neurons in CNS cultures as shown by immunofluorescent visualization of glia in cultures of neuron-free optic nerve, including galactocerebroside(+) oligodenroglia (FIG. 24D) and GFAP(+) astrocytes (FIG. 24F) which are both NSE(+) (FIGS. 24E and 24G, respectively). Bar=10 mu m. In FIG. 24H, ciliary neuron cultures showed that A beta 1-42 is not toxic to neurons in the absence of brain glia (A beta 1-42 only) after 48 hour exposure. Conditioned media from A beta 1-42-stimulated microglia (Microglia+A beta 1-42) did, however, kill neurons, indicating that astrocytes are not necessary to the microglial neurotoxicity. ***human*** microglia and neuron killing. FIG. FIGS. 25A-E displays 25A shows only A beta-containing fractions from solubilized neuritic/core plaques (peaks S3 (54 nmole/l), S4 (220 nmole/l), and S5 (250 nmole/l)) elicit ***human*** microglia to engage in neurotoxic behaviors. FIG. 25B shows that when tested at 1 mu mole/liter concentrations, synthetic A beta 1-40 and A beta 142 also stimulated release of neurotoxin from ***human*** microglia, while smaller A beta fragments had no effect. Despite neuron killing, there is no evidence of increased production of nitrate or nitrite by ***human*** cells stimulated with either native (FIG. 25C) or synthetic (FIG. 25D) AD. FIG. 25E shows that neuron killing could be induced by ***human*** or rat microglia exposed to 1 mu mole/liter of the ***human*** forms of either A beta 1-42 or A beta 1-40. The rodent form of A beta 1-40, however, was inactive, as were fragments of ***human*** A beta, including 128, 12-28, and 17-43. FIGS. 26A-C displays drug blockade of A beta induced neuron killing by rat microglia. To investigate mechanisms of cell killing, ***human*** rat microglia were stimulated with 1 mu mole/l A beta 1-42 (Rat/A beta ***human*** 1-42) and cells with fraction S5 (containing 250 nmole/l of native A beta 1-42) from solubilized neuritic/core plaques (***Human*** /S5 Peak). FIG. 26A shows agents that acct as free radical scavengers (vitamin E, 100 mu M; catalase, 25 units/ml; glutathione, 100 mu M) did not block microglial killing of neurons. No protective effects were observed with the nitric oxide synthetase inhibitors L-N-5-(limin-oethyl)ornithine hydrochloride (L-NIO, 10 mu M) or diphenyl iodonium (DPI, 300 nM), although the NMDA antagonist AP5 prevented neuron death. FIG. 26B shows other NMDA antagonists acting at the receptor site (AP7), at the polyamine regulatory site (ifenprodil), or at the ion channel (MK801) all blocked neuron death, while the non-NMDA glutamate antagonists (GAMS, BNQX) did not. All drugs were applied at 10 mu M. FIG. 26C shows isolation of neurotoxin from culture media conditioned by A beta-stimulated rat microglia (A beta 1-42/ Microglia) or from frozen AD gray matter (AD Brain) involved extractions in ethyl acetate (pH 10.5), acid hydrolysis, and sequential gradient RP-HPLC (C18 column using a 0 to 20% acetonitrile gradient in dH20 with 0.1% trifluoroacetic acid). Neurotoxin activities from microglial conditioned media copurifies with that from AD brain tissue with a co-elution using RP-HPLC at about 14% acetonitrile. Neurotoxicity was not found within control brain extracts or from unstimulated microglial culture media. FIG. 27 depicts A beta domains and interactions with microglia. FIG. 10A

shows a phase photomicrograph of rat microglial cell adhering to

```
shows a fluorescence photomicrograph of the same bead showing adherent cell labeled by the fluorescent microglial marker Dil-ac-LDL; Bar=20 microns. FIG. 27C shows rat microglial adherence to Sephanose-coupled
        beads after six hours. Plaque proteins derived from neuritic/core plaques
        provided an anchoring site for microglia, as did A beta 1-42.
        Importantly, A beta 1-28 also promoted bead binding, while A beta 17-43
        did not. Controls included beads coupled to glycine (Control glycine) and
        to bovine serum albumin (Control-BSA). Data shown are expressed as the
        numbers of adhering cells per 100 randomly selected beads +/-standard error after 6 hour incubation at 37 degrees C.
      FIGS. 28A-G displays that the A beta cell binding domain is required for activation of neurotoximicroglia. Fluorescent photomicrographs showing microsphere binding to enriched cultures of rat microglia (500/mm2) after 4 hour incubation at 37 C. Coupling of A beta peptides to fluorescent
        microspheres showed that A beta 1-42 (FIG. 28A), A beta 12-28 (FIG. 28D),
        and A beta 10-16 (FIG. 28E) readily bind, while peptides A beta 17-43
        (FIG. 28B), A beta 1-11 (FIG. 28C), and A beta 1-5 (FIG. 28F) did not.
        Quantitations of binding pattern (FIG. 28G) indicated that regions of the
           ***N*** - ***terminus*** -containing amino acid residues 10-16 were
       necessary for A beta binding to microglia. Data are expressed as mean values +/-standard error when viewed at 200 x magnification.
      FIG. 29 displays the comparison of A beta effects upon microglia. FIG. 29A shows dose response curves in which although A beta 10-16 is able to bind to microglia, it did not elicit neurotoxic microglia. The addition of this microglial binding domain to A beta 17-42 (which neither binds to microglial proposition to a beta 17-42).
        microglia nor elicits toxicity) created a peptide, A beta 10-42, which
        both bound to microglia and stimulated microglia to kill neurons. FIG.
        29B shows a diagram comparing the structures and functions of synthetic
        peptides. The shaded area illustrates the Nterminal portion of A beta
        that differs between ***human*** and rat forms and which appears
        necessary for microglial adherence. !
       ANSWER 41 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN
        3902755 IFIPAT; IFIUDB; IFICDB
        TRANSGENIC RODENTS HARBORING APP ALLELE HAVING SWEDISH MUTATION
        McLonlogue Lisa; Sinha Sukanto; Zhao Jun
        Elan Pharmaceuticals Inc
        Lilly, Eli and Co
        (49246, 49800)
        us 6586656
                                    20030701
        US 2001-838556
                                    20010418
                                                                                 5612486
        US 1993-148211
                                    19931101 CONTINUATION
                                                                                 5850003
        us 1997-785943
                                    19970122 CONTINUATION
                                    19981210 CONTINUATION
                                                                                 6245964
        US 1998-209647
        US 1993-143697
                                    19931027 CONTINUATION-IN-PART
                                                                                 5604102
        US 6586656
                                    20030701
        US 5612486
        us 5850003
        us 6245964
        us 5604102
        Utility
        CHEMICAL
        GRANTED
CLMN
         5 Drawing Sheet(s), 6 Figure(s).
       FIGS. 1(A-B), panels A and B are plasmid maps of pNSEAPPsw Delta 3' and
        pNSEAPPsw, respectively, which are used to produce transgenic mice as described herein.
       FIG. 2 is a Western blot of soluble fractions of transgenic and control
        animal brains probed for the presence of secreted beta APP fragments
        reactive with the Swedish 192 ***antibody*** . Lane 1: molecular
        weight markers; lane 2: non-transgenic line; lane 3: transgenic line.
       FIGS. 3(A-B), panels A and B are Western blots of brain homogenates from transgenic (+) and non-transgenic (-) animals depleted of 6C6

***antibody*** -reactive beta APP forms probed with ***antibody***

8E5 (panel A) and Swedish 192 ***antibody*** (panel B).
       FIG. 4 shows an immunoblot demonstrating specificity of the Swedish 192 ***antibody*** . Lanes 1, 3, 5 contain material eluted from heparin
                                . Lanes 1, 3, 5 contain material eluted from heparin
        agarose. Lanes 2, 4, 6 contain material eluted from the 6C6 resin. Lanes 1 and 2 were probed with ***antibody*** 8E5; Lanes 3 and 4 were
```

probed with the Swedish 192 ***antibody***; Lanes 5 and 6 were probed

L4

ΑN

TI

IN

PA

PΙ

ΑI

FI

DT

FS

GI

L4

ΑN

RLI

ANSWER 42 OF 391 IFIPAT COPYRIGHT 2003 IFI on STN 3827176 IFIPAT; IFIUDB; IFICDB

6C6.

antibody

with

```
PRODUCTION MODULATORS
ΙN
          Mitchell Thomas J; Seiffert Dietmar A
PA
          Bristol-Myers Squibb Co (22921)
PΙ
          US 6518011
                                           20030211
ΑI
          US 2000-481980
                                           20000112
PRAI
         US 1999-115749P
                                           19990113 (Provisional)
          US 6518011
FΙ
                                           20030211
DT
          Utility
FS
          CHEMICAL
          GRANTED
CLMN
            8 Drawing Sheet(s), 12 Figure(s).
GI
        FIG. 1 Shows a possible location of an epitope tag in the A-beta sequence
          of the beta-APP and predicted accumulation of epitope tagged cleavage
         fragments. The A-beta fragment (1-42), with the proposed proteolytic cleavage sites for secretases (alpha-, beta-, gamma 1 (40)-, and gamma 2 (42)), is indicated. The epitope tag in this example is centered on the alpha secretase site (amino acids 16 to 17 in A-beta). Cleavage by beta and gamma secretases is expected to lead to an accumulation of epitope tagged A-beta (1-40) and A-beta (1-42) in the conditioned medium, whereas
          cleavage by alpha secretase (within the epitope tag) is expected to
          destroy or reduce the accumulation of epitope tagged A-beta fragments in
          the conditioned medium.
        FIG. 2 Shows an immunoblot analysis of HEK 293 ( ***human*** embryon kidney cell line, ATTC #CRL-1573) cell lysates after transfection with
         epitope-tagged beta-APP. Cell lysates were prepared by lysis of HEK 293 cells into SDS and were fractionated by SDS-PAGE, followed by transfer to nitrocellulose membranes. The membranes were developed with mAB 22C11 (epitope in the ***N*** - ***terminus*** of full-length beta-APP;
         (epitope in the ***N*** - ***terminus*** of full-length beta-APP; lanes 1 and 2), mAB anti-HA 11 (influenza hemagglutinin epitope: YPYDVPDYA) (SEQ ID NO: 6) (directed to the HA 11 epitope tag; lanes 3 and
          4), and mAB 9E10 (directed to the myc epitope tag; lanes 5 and 6). Lane
          1, HEK 293 cells transfected with HA 11 beta-APP 695; lane 2, HEK 293
          cells transfected with vector alone ('Mock-transfection'); lane 3, HEK
         293 cells transfected with HA 11 beta-APP 695; lane 4, HEK 293 cells transfected with vector alone; lane 5, HEK 293 cells transfected with myc
        betaAPP 695; lane 6, HEK 293 cells transfected with vector alone. The relative mobility of molecular weight standards is indicated to the left. FIG. 3 Shows an accumulation of beta-APP fragments into HEK 293 conditioned medium. The 24 hour serum-free conditioned medium (lanes 1 and 2) or cell lysates (lanes 3 and 4) of HEK 293 cells transfected with
          vector alone (lanes 1 and 3) or HA 11 beta-APP 695 (lanes 2 and 4) were
          harvested. The resulting polypeptides were fractionated by SDS-PAGE (10%
          acrylamide in separating gel) and transferred to nitrocellulose
          membranes. Panel A was developed with mAB anti-HA 11, whereas panel B was
          developed with mAB 22C11. The relative mobility of molecular weight
          standards is indicated to the right.
        FIG. 4 Shows the detection of epitope-tagged beta-APP fragments in HEK 293 conditioned medium after transfection with HA 11 beta-APP 695.
Panel A: Microtiter wells were coated with mAB anti-HA 11 and after
          blocking, incubated with a dose-response of a synthetic HA 11 A-beta
          (1-40) peptide containing the HA 11 epitope centered on the alpha
          secretase cleavage site. Bound A-beta HA 11 was detected with polyclonal ***antibodies*** specific for position 1 (Serotec) or position 40
          (QCB), followed by HRPlabeled anti-rabbit IgG and TMB substrate. The
          change of absorbance at 650 nM was monitored and results are corrected
          for binding of secondary
                                                      ***antibodies*** to wells not incubated with
          the A-beta HA 11 peptide. Results are expressed as change of absorbance
          per minute (mOD/minute).
        Panel B: Microtiter wells were coated as in panel A and incubated with the indicated dilutions of HEK 293/HA 11 betaAPP 695 conditioned medium (24
          hours). Bound HA 11 beta-APP 695 fragments were detected with 
***antibodies*** specific for position 1 and 40 as in panel A. Results
          are expressed and corrected as in panel A.
        FIG. 5 Shows a time-course of the accumulation of HA 11 A-beta (1-40) and
          A-beta (1-42) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK
          293/HA 11 beta-APP 695 was cultured in serum-free medium containing 0.2%
         bovine serum albumin in 96well microtiter plates for the indicated time intervals. The accumulation of HA 11 A-beta (1-40) and A-beta (1-42) was determined. For HA 11 A-beta polypeptides ending at position 40, microtiter wells were coated with mAB anti-HA 11 and bound polypeptides were detected with rabbit anti-A-beta 40 (QCB), followed by HRP-labeled anti-rabbit IgG. For the position 42specific ELISA, microtiter wells were
```

coated with mAB anti-HA 11, and bound polypeptides were detected with

biotin-labeled mAB 108 (position_42-specific), followed by

antibodies in the absence of conditioned medium and expressed as change of absorbance at 650 nM per minute (moD/minute). FIG. 6 Shows the effect of MDL 28170 and Brefeldin A on the accumulation of HA 11 A-beta (1-40) in HEK 293/HA 11 beta-APP 695 conditioned medium. HEK 293/HA 11 beta-APP 695 cells were plated at confluence in 96-well plates and the indicated doseresponse of either MDL 28170 (panel A), or Brefeldin A (panel B) was added for 16 hours. The accumulation of HA 11 A-beta (1-40) (position 40-specific """antibody"" ; QCB) was A-beta (1-40) (position 40-specific ***antibody***; QCB) was determined as in FIG. 5. Results are expressed as percentage inhibition of HA 11 Abeta (1-40) accumulation in comparison to wells incubated with vehicle (dimethyl sulfoxide, DMSO) alone. FIG. 7 Shows an isolation of HA 11 A-beta from HEK 293/HA 11 beta-APP 695 cells. Conditioned medium (serum-free containing 0. 2% BSA) was passed over an mAB anti-HA 11 affinity matrix. After washing, the column was eluted with 5% formic acid in water. The peak fractions were pooled, dried in a Speed-Vac, resuspended in water and the pH was adjusted to 7.4 with Tris. Panel A: The starting material, flow-through, and the pooled elution fractions (after dilution to account for the concentration of the HA 11 A-beta on the column) were analyzed by ELISA specific for position 40 in HA 11 A-beta as in FIGS. 4 and 5. Panel B: The indicated dilutions of the pooled elution fractions were analyzed by ELISA specific for position 1, 40, and 42 in HA 11 A-beta. Note that approximately equal immunoreactivity is present for the ***antibodies*** , whereas the 42specific reactivity position 1 and 40 is lost with 10-fold lesser dilution. Panel C: The elution fractions were analyzed by SDS-PAGE (16.5% polyacrylamide in separating gel), followed by immunoblotting with mAB anti-HA 11, followed by HRP-labeled anti-mouse Ig, and chemiluminescence detection (ECL tm, Amersham). Lane 1, elution fraction, stained with mAB anti-HA 11; lane 2, elution fraction spiked with HA 11 A-beta peptide (50 ng); lane 3, purified A-beta HA 11 1-40 peptide; and lane 4, elution fraction, stained under omission of anti-HA 11. ANSWER 43 OF 391 JICST-EPlus COPYRIGHT 2003 JST on STN 930792511 JICST-EPlus Ca2+-Dependent 68 kDa Protease in Familial Alzheimer's Disease Cells ***N*** - ***terminus*** of . ***BETA*** Cleaves the ***Amyloid*** MATSUMOTO AKIRA; FUJIWARA YOSHISADA Kobe Univ., School of Medicine Kiso Roka Kenkyu (Biomedical Gerontology), (1993) vol. 17, no. 2, pp. 62-63. Journal Code: Y0748A (Ref. 4) ISSN: 0912-8921 Japan Journal; Short Communication Japanese New ANSWER 44 OF 391 LIFESCI COPYRIGHT 2003 CSA on STN 2000:62119 LIFESCI rereal rerese ***Terminus*** Generation of the Amyloid-beta Peptide Saccharomyces cerevisiae Expressing ***Human*** Alzheimer's Amyloidbeta Precursor Protein Greenfield, J.P.; Xu, H.; Greengard, P.; Gandy, S.; Seeger, M. Laboratory of Molecular and Cellular Neuroscience, and Fisher Center for Research on Alzheimer Disease, Rockefeller University, New York, New York 10021 Journal of Biological Chemistry [J. Biol. Chem.], (19991100) vol. 274, no. 48, pp. 33843-33846. ISSN: 0021-9258. Journal N3; N English English COPYRIGHT 2003 CSA on STN ANSWER 45 OF 391 LIFESCI 91:46552 LIFESCI Alzheimer patients: Preamyloid deposits are immunoreactive with ***antibodies*** to extracellular domains of the amyloid precursor Tagliavini, F.; Giaccone, G.; Verga, L.; Ghiso, J.; Frangione, B.;

Ist. Neurol. Carlo Besta, Via Celoria 11, 20133 Milano, Italy

NEUROSCI. LETT., (1991) vol. 128, no. 1, pp. 117-120.

L4

AN

TI

AU CS

SO

CY

DT

LA

L4

AN

TI

ΑU

CS

SO

DT

FS

LA SL

L4

AN TI

ΑU

CS

SO

Bugiani, O.

STA

```
FS
     N3
LA
     English
SL
     English
L4
     ANSWER 46 OF 391
                            MEDLINE on STN
AN
     2001286060
                     MEDLINE
DN
                 PubMed ID: 11162251
     Amino-terminal modification and tyrosine phosphorylation of [corrected]
TI
     carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's
     disease and Down's syndrome brain.
     Erratum in: Neurobio Dis 2001 Jun;8(3):540
CM
ΑU
     Russo C; Salis S; Dolcini V; Venezia V; Song X H; Teller J K; Schettini G
     Section of Pharmacology and Neuroscience, National Cancer Institute,
CS
     Genova, Italy.
AG08012 (NIA)
NC
     AG08155 (NIA)
     AG14359 (NIA)
     NS37392 (NINDS)
SO
     NEUROBIOLOGY OF DISEASE, (2001 Feb) 8 (1) 173-80.
     Journal code: 9500169. ISSN: 0969-9961.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
FS
     Priority Journals
EΜ
     200105
     Entered STN: 20010529
ED
     Last Updated on STN: 20010828
     Entered Medline: 20010524
     ANSWER 47 OF 391
                           MEDLINE on STN
L4
AN
     91128587
                   MEDLINE
     91128587 PubMed ID: 2126439
Colocalization of amino terminal and A4 ( ***beta*** - ***amyloid*** )
DN
TI
     antigens in Alzheimer plaques: evidence for coordinated processing of the
     amyloid precursor protein.
     Tate-Ostroff B; Majocha R E; Walcott E C; Ventosa-Michelman M; Marotta C A
ΑU
CS
     Department of Psychiatry, Harvard Medical School, Boston, MA.
NC
     AG02126 (NIA)
     JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, (1990 Jul-Sep) 3 (3)
SO
     139-45.
     Journal code: 8805645. ISSN: 0891-9887.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     English
     Priority Journals
FS
EΜ
     199103
ED
     Entered STN: 19910405
     Last Updated on STN: 19980206
     Entered Medline: 19910318
      ANSWER 48 OF 391 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.
L4
      on STN
      2002-0526261
                      PASCAL
      Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved.
CP
      Divergent pathways account for two distinct effects of amyloid .beta.
TIEN
      peptides on exocytosis and Ca.sup.2.sup.+ currents: involvement of ROS
      and NF-KB
ΑU
      GREEN Kim N.; PEERS Chris
      Institute for Cardiovascular Research, University of Leeds, Leeds, United
CS
      Journal of neurochemistry, (2002), 81(5), 1043-1051, refs. 1 p. 1/2
SO
      ISSN: 0022-3042 CODEN: JONRA9
DT
      Journal
      Analytic
BL
CY
      United States
ΙA
      English
      INIST-4037, 354000108919100160
ΑV
L4
      ANSWER 49 OF 391 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.
      on STN
      1998-0432550
AN
                      PASCAL
      Copyright .COPYRGT. 1998 INIST-CNRS. All rights reserved.
CP
      GM1 ganglioside-bound amyloid .beta.-protein in Alzheimer's disease brain
The molecular biology of Alzheimer's disease and animal models: routes to
```

TIEN

the development of new therapies

```
MORI Hiroshi (ed.)
Department of Dementia Research, National Institute for Longevity
CS
       Sciences, 36-3 Gengo, Morioka, Obu 474, Japan; Department of Neuropathology Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan Department of Molecular Biology, Tokyo Institute of Psychiatry, Japan Tokyo Institute of Psychiatry, Japan
       Tokyo Institute of Psychiatry, Japan (patr.)
       Neurobiology of aging, (1998), 19(1, SUP), 565-567, 14 refs.
Conference: 11 Annual Tokyo Institute of Psychiatry International
SO
       Symposium, Tokyo (Japan), 4 Mar 1997 ISSN: 0197-4580 CODEN: NEAGDO
DT
       Journal; Conference
BL
       Analytic
       United States
CY
       English
LA
       INIST-20387, 354000075429300130
ΑV
L4
       ANSWER 50 OF 391 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS RESERVED.
       1996-0219891
ΑN
                         PASCAL
CP
       Copyright .COPYRGT. 1996 INIST-CNRS. All rights reserved.
                     ***antibodies*** against the
                                                             ***human***
TIEN
       metalloprotease EC 3.4.24.15 label neurofibrillary tangles in Alzheimer's
       disease brain
ΑU
       CONN K. J.; PIETROPAOLO M.; JU S.-T.; ABRAHAM C. R.
       Arthritis Center, K-5, Boston University School of Medicine, 80 East
CS
       Concord Street, Boston, MA 02118, United States
SO
       Journal of neurochemistry, (1996), 66(5), 2011-2018, refs. 1 p.1/4
       ISSN: 0022-3042 CODEN: JONRA9
DT
       Journal
BL
       Analytic
CY
       United States
LA
       English
ΑV
       INIST-4037, 354000044329370290
L4
      ANSWER 51 OF 391 SCISEARCH COPYRIGHT 2003 THOMSON ISI On STN
      2001:73885 SCISEARCH
ΑN
      The Genuine Article (R) Number: 392HB
GΑ
      Immunomodulation of the
                                    ***human***
ΤI
                                                     prion peptide 106-126 aggregation
      Hanan E; Goren O; Eshkenazy M; Solomon B (Reprint)
ΑU
      Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel
CS
      Aviv, Israel (Reprint)
CYA
     Israel
SO
      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (12 JAN 2001) Vol.
           No. 1, pp. 115-120.
      Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA
      92101-4495 USA.
     ISSN: 0006-291x.
DT
      Article; Journal
LA
      English
REC
      Reference Count: 35
      *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L4
      ANSWER 52 OF 391 USPATFULL on STN
        2003:282760 USPATFULL
AN
        Novel amino acid sequences for ***human***
TI
                                                               epidermal growth
        factor-like polypeptides
Shimkets, Richard A., West Haven, CT, UNITED STATES
IN
        Fernandes, Elma, Branford, CT, UNITED STATES
        Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
        CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S.
PΑ
        corporation)
        us 2003199103
PΙ
                               Α1
                                     20031023
        us 2001-977639
                                    20011015 (9)
ΑI
                              Α1
        Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
RLI
                                20000503 (60)
        US 2000-201388P
PRAI
                                20000330 (60)
        US 2000-193086P
                                20000322 (60)
        US 2000-191158P
        US 2000-189810P
                                20000316 (60)
                                19990603 (60)
        US 1999-137322P
DT
        Utility
FS
        APPLICATION
LN.CNT 10459
```

INCL INCLM: 436/518.000

```
NCL
        NCLM:
               436/518.000
        NCLS:
               435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
        [7]
IC
        ICM: C07K014-485
        ICS: C07H021-04; C12P021-02; C12N005-06; G01N033-543
L4
     ANSWER 53 OF 391 USPATFULL ON STN
AN
        2003:282611 USPATFULL
          ***Human***
TI
                         cDNAs and proteins and uses thereof
        Bejanin, Stephane, Paris, FRANCE
ΙN
        Tanaka, Hiroaki, Antony, FRANCE
        GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PA
ΡI
        US 2003198954
                                  20031023
                            Α1
        US 2001-1142
ΑI
                            Α1
                                  20011114 (10)
        Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
RLI
        WO 2001-IB1715
                             20010806
PRAI
        US 2001-305456P
                              20010713 (60)
                              20010629 (60)
        US 2001-302277P
                              20010615 (60)
        US 2001-298698P
        US 2001-293574P
                              20010525 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 25681
INCL
        INCLM: 435/006.000
        INCLS: 536/023.200
NCL.
               435/006.000
        NCLM:
        NCLS:
               536/023.200
IC
        [7]
        ICM: C12Q001-68
        ICS: C07H021-04
L4
     ANSWER 54 OF 391 USPATFULL ON STN
ΑN
        2003:282304 USPATFULL
TI
        Stabilized HBc chimer particles as therapeutic vaccine for chronic
        hepatitis
       Page, Mark, Allestree, UNITED KINGDOM
Friede, Martin, Cardiff, CA, UNITED STATES
IN
PΙ
       US 2003198645
                                  20031023
                            Α1
ΑI
       US 2003-372076
                            Α1
                                  20030221 (10)
       Continuation-in-part of Ser. No. US 2002-82014, filed on 21 Feb 2002.
RLI
        PENDING Continuation-in-part of Ser. No. US 2002-80299, filed on 21 Feb
        2002, PENDING
       Utility
DT
FS
       APPLICATION
LN.CNT 5638
        INCLM: 424/192.100
INCL
        INCLS: 424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700
NCL
       NCLM:
               424/192.100
       NCLS:
               424/191.100; 530/826.000; 424/189.100; 536/023.720; 536/023.700
IC
        [7]
        ICM: C07H021-04
       ICS: A61K039-29; A61K039-00; A61K039-002; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 55 OF 391 USPATFULL on STN
       2003:271511 USPATFULL
ΑN
       N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
TI
       comprising same, and methods for inhibiting
                                                         `***beta***
          ***amyloid***
                           peptide release and/or its synthesis by use of such
       compounds
IN
       Wu, Jing, San Mateo, CA, UNITED STATES
       Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
       Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
       Mabry, Thomas E., Indianapolis, IN, UNITED STATES
       Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
                                  20031009
PΙ
       US 2003191119
                            A1
ΑI
       us 2002-314221
                            Α1
                                  20021209 (10)
RLI
       Division of Ser. No. US 2001-984834, filed on 31 Oct 2001, PENDING
       Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, GRANTED,
       Pat. No. US 6333351 Continuation of Ser. No. US 1997-976179, filed on 21
       Nov 1997, GRANTED, Pat. No. US 6117901
PRAI
       US 1996-98551P
                             19961122 (60)
```

```
APPLICATION
FS
LN.CNT 3753
INCL
       INCLM: 514/227.800
       INCLS: 514/357.000; 514/235.500; 514/563.000; 514/616.000
NCL
               514/227.800
       NCLM:
       NCLS:
               514/357.000; 514/235.500; 514/563.000; 514/616.000
IC
       171
       ICM: A61K031-541
       ICS: A61K031-5377; A61K031-44; A61K031-198; A61K031-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 56 OF 391 USPATFULL ON STN
       2003:271112 USPATFULL
ΑN
TI
       Novel proteins and nucleic acids encoding same
       Grosse, William M., Branford, CT, UNITED STATES
IN
       Alsobrook, John P., II, Madison, CT, UNITED STATES
       Lepley, Denise M., Branford, CT, UNITED STATES
       Burgess, Catherine E., Wethersfield, CT, UNITED STATES
       Mishra, Vishnu, Gainesville, FL, UNITED STATES
       Kekuda, Ramesh, Stamford, CT, UNITED STATES
       Li, Li, Branford, CT, UNITED STATES
       Padigaru, Muralidhara, Branford, CT, UNITED STATES
       Shimkets, Richard A., West Haven, CT, UNITED STATES Zerhusen, Bryan D., Branford, CT, UNITED STATES
       Spytek, Kimberly A., New Haven, CT, UNITED STATES
       Edinger, Shlomit R., New Haven, CT, UNITED STATES Gerlach, Valerie, Branford, CT, UNITED STATES
       MacDougall, John R., Hamden, CT, UNITED STATES
       Millet, Isabelle, Milford, CT, UNITED STATES
       Stone, David J., Guilford, CT, UNITED STATES
       Gunther, Erik, Branford, CT, UNITED STATES
       Ellerman, Karen, Branford, CT, UNITED STATES
       us 2003190715
PΙ
                                 20031009
                           Α1
ΑI
       US
          2001-976782
                                 20011012 (9)
                           Α1
                             20001012 (60)
PRAI
       US 2000-240113P
       US 2000-240662P
                             20001016 (60)
       US 2000-240732P
                             20001016 (60)
       US 2000-240625P
                             20001016 (60)
       us 2000-240648P
                             20001016 (60)
       US 2000-240703P
                             20001016 (60)
                             20001016 (60)
       US 2000-241190P
                             20001016 (60)
       US 2000-240637P
       US 2000-240669P
                             20001016
                                      (60)
       US 2001-262455P
                             20010118 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT
       9839
INCL
       INCLM: 435/183.000
       INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.200
NCL
       NCLM:
              435/183.000
              435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.200
       NCLS:
IC
       [7]
       ICM: C12N009-00
       ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 57 OF 391 USPATFULL ON STN
       2003:265931 USPATFULL
AN
TI
       O-linked N-acetylglucosamine pathway in the pathogenesis of
       neurodegeneration and diabetes
       Kudlow, Jeffrey, Birmingham, AL, UNITED STATES
ΙN
       Konrad, Robert, Carmel, IN, UNITED STATES
       us 2003186948
                                 20031002
PΙ
                           Α1
       us 2003-392508
                                 20030320 (10)
ΑI
                           Α1
       Continuation-in-part of Ser. No. US 2001-813534, filed on 21 Mar 2001,
RLI
       GRANTED, Pat. No. US 6589995
       US 2000-190785P
PRAI
                             20000321 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 1426
INCL
       INCLM: 514/150.000
       INCLS: 514/262.100; 514/062.000; 514/389.000
NCL
               514/150.000
       NCLM:
              514/262.100; 514/062.000; 514/389.000
       NCLS:
```

[7]

```
ICS: A61K031-655; A61K031-519; A61K031-4162
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 58 OF 391 USPATFULL ON STN 2003:264865 USPATFULL
L4
ΑN
                       ***human***
                                       cancers using cisplatin and other drugs or
TI
        Therapy for
        genes encapsulated into liposomes
        Boulikas, Teni, Palo Alto, CA, UNITED STATES
IN
PΙ
       US 2003185879
                             Α1
                                   20031002
                                   20030123 (10)
ΑI
       US 2003-350470
                             Α1
       Division of Ser. No. US 1999-434345, filed on 5 Nov 1999, GRANTED, Pat.
RLI
       No. US 6511676
       Utility
DT
FS
       APPLICATION
LN.CNT 1652
        INCLM: 424/450.000
INCL
        INCLS: 424/649.000
               424/450.000
NCL
       NCLM:
       NCLS:
               424/649.000
IC
        [7]
        ICM: A61K009-127
       ICS: A61K033-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 59 OF 391 USPATFULL on STN
        2003:264844 USPATFULL
ΑN
       Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
TI
       Birkett, Ashley J., Escondido, CA, UNITED STATES
IN
       us 2003185858
                             Α1
                                   20031002
PΙ
ΑI
                             Α1
                                   20020221 (10)
       Continuation-in-part of Ser. No. US 2001-930915, filed on 15 Aug 2001,
RLI
       PENDING
DT
       Utility
       APPLICATION
FS
LN.CNT 5511
        INCLM: 424/227.100
INCL
       INCLS: 424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720
NCL
       NCLM:
               424/227,100
               424/191.100; 530/350.000; 424/278.100; 435/320.100; 536/023.720
       NCLS:
IC
        [7]
        ICM: C07H021-04
       ICS: A61K039-002; A61K045-00; C12N015-00; C12N015-63; C12N015-74;
       C07K014-00; A61K039-00; A61K047-00; C12N015-70; C07K017-00; A61K039-29;
       C12N015-09; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 60 OF 391 USPATFULL on STN
       2003:260805 USPATFULL
ΑN
        .beta.-secretase enzyme compositions and methods
TI
IN
       Anderson, John P., San Francisco, CA, United States
       Basi, Guriqbal, Palo Alto, CA, United States
       Doan, Minh Tam, Hayward, CA, United States
       Frigon, Normand, Milbrae, CA, United States
       John, Varghese, San Francisco, CA, United States
Power, Michael, Fremont, CA, United States
Sinha, Sukanto, San Francisco, CA, United States
Tatsuno, Gwen, Oakland, CA, United States
Tung, Jay, Belmont, CA, United States
       Wang, Shuwen, Hersey, PA, United States
McConlogue, Lisa, Burlingame, CA, United States
       Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
PΙ
       US 6627739
                             В1
                                   20030930
                                   20001128 (9)
       us 2000-724566
ΑI
       Continuation of Ser. No. US 2000-501708, filed on 10 Feb 2000
RLI
       US 1999-119571P
PRAI
                              19990210 (60)
                              19990615 (60)
       US 1999-139172P
DT
       Utility
FS
       GRANTED
LN.CNT
       4793
INCL
       INCLM: 530/387.900
       INCLS: 530/388.100; 530/388.260; 530/389.100; 530/389.200
NCL
               530/387.900
       NCLM:
               530/388.100; 530/388.260; 530/389.100; 530/389.200
       NCLS:
```

[7]

```
EXF
        530/387.9; 530/388.1; 530/388.26; 530/389.1; 530/389.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 61 OF 391 USPATFULL on STN
       2003:257841 USPATFULL
AN
TI
        Interleukin-20
IN
       Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
       Murphy, Marianne, London, UNITED KINGDOM
       Ruben, Steven M., Brookeville, MD, UNITED STATES
       Hu, Jing-Shan, Mountain View, CA, UNITED STATES
       Duan, D. Roxanne, Bethesda, MD, UNITED STATES Florence, Kimberly A., Rockville, MD, UNITED STATES
       Rosen, Craig A., Laytonsville, MD, UNITED STATES
Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.
PA
       corporation)
       US 2003180892
PΙ
                                  20030925
                            Α1
       us 2002-277726
                                  20021023 (10)
ΑI
                            Α1
       Division of Ser. No. US 1999-231788, filed on 15 Jan 1999, GRANTED, Pat.
RLI
       No. US 6486301 Continuation-in-part of Ser. No. US 1998-115832, filed on
       15 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-115832,
        filed on 15 Jul 1998, PENDING
       US 1997-60140P
                             19970926 (60)
PRAI
       US 1997-55952P
                             19970818 (60)
       US 1997-52870P
                             19970716 (60)
       US 1997-60140P
                             19970926 (60)
       US 1997-55952P
                             19970818 (60)
       US 1997-52870P
                             19970716 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 5982
INCL
       INCLM: 435/069.520
       INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
NCL
       NCLM:
               435/069.520
       NCLS:
               435/320.100; 435/325.000; 530/351.000; 536/023.500
        [7]
IC
       ICM: C07K014-54
       ICS: C07H021-04; C12P021-04; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 62 OF 391 USPATFULL ON STN
       2003:257831 USPATFULL
AN
TT
       Expression of proteolytically-sensitive peptides
       Courchesne, William E., Soda Springs, CA, UNITED STATES
IN
       Schooley, David A., Reno, NV, UNITED STATES
Copley, Kathrin, San Diego, CA, UNITED STATES
                                  20030925
PΙ
       US 2003180882
                            Α1
       US 2002-278242
                                 20021023 (10)
AΤ
                            Α1
       Continuation of Ser. No. US 2000-661452, filed on 13 Sep 2000, ABANDONED
RLI
       Continuation of Ser. No. US 1999-237936, filed on 27 Jan 1999, ABANDONED
DT
       Utility
FS
       APPLICATION
LN.CNT 1347
INCL
       INCLM: 435/069.100
       INCLS: 435/219.000; 435/254.200; 435/320.100; 536/023.200; 435/483.000;
               530/350.000
NCL
       NCLM:
               435/069.100
       NCLS:
               435/219.000; 435/254.200; 435/320.100; 536/023.200; 435/483.000;
               530/350.000
IC
       ICM: C12P021-02
       ICS: C07H021-04; C12N001-18; C12N009-50; C12N015-74; C07K014-39
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 63 OF 391 USPATFULL ON STN 2003:257737 USPATFULL
L4
ΑN
       Avian and reptile derived polynucleotide encoding a polypeptide having
TI
       heparanase activity
       Goldshmidt, Orit, Jerusalem, ISRAEL
IN
       Pecker, Iris, Rishon LeZion, ISRAEL
       Vlodavsky, Israel, Mevaseret Zion, ISRAEL
       Michal, Israel, Ashkelon, ISRAEL
       Zcharia, Eyal, Jerusalem, ISRAEL
       Insight Strategy & Marketing Ltd. (non-U.S. corporation)
PA
       Hadasit Medical Research Services and Development Ltd. (non-U.S.
       corporation)
```

```
ΑI
                                   20030508 (10)
        US 2003-431438
                             Α1
        Division of Ser. No. US 2001-930218, filed on 16 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2000-666390, filed on 20 Sep 2000,
RLI
        ABANDONED
DT
        Utility
FS
        APPLICATION
LN.CNT 2265
INCL
        INCLM: 435/006.000
        INCLS: 435/069.100; 435/200.000; 435/325.000; 435/349.000; 536/023.200
NCL
        NCLM:
                435/006.000
                435/069.100; 435/200.000; 435/325.000; 435/349.000; 536/023.200
IC
        [7]
        ICM: C12Q001-68
        ICS: C07H021-04; C12N009-24; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 64 OF 391 USPATFULL on STN
AN
        2003:257671 USPATFULL
        Methods and materials relating to alpha-2-macroglobulin-like
TI
        polypeptides and polynucleotides
        Godbole, Shubhada D., Santa Clara, CA, UNITED STATES
IN
        Boyle, Bryan J., San Francisco, CA, UNITED STATES
        Mize, Nancy K., Mountain View, CA, UNITED STATES Deng, Cenhua, Cupertino, CA, UNITED STATES
        Goodrich, Ryle W., San Jose, CA, UNITED STATES
        Arterburn, Matthew C., Los Gatos, CA, UNITED STATES
        Zhou, Ping, Cupertino, CA, UNITED STATES
        Tang, Y. Tom, San Jose, CA, UNITED STATES
        Liu, Chenghua, San Jose, CA, UNITED STATES
        Yeung, George, Mountain View, CA, UNITED STATES
        Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
                                   20030925
PΙ
        us 2003180722
                             Α1
        US 2001-756247
                                   20010108 (9)
ΑI
                             Α1
        Continuation-in-part of Ser. No. US 2000-649167, filed on 23 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-540217, filed on 31
RLI
        Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-684711,
        filed on 6 Oct 2000, PENDING Continuation-in-part of Ser. No. US
        2000-560875, filed on 27 Apr 2000, PENDING Continuation-in-part of Ser.
        No. US 2000-496914, filed on 3 Feb 2000, ABANDONED
DT
        Utility
FS APPLICATION LN.CNT 7553
INCL
        INCLM: 435/006.000
        INCLS: 435/069.100; 435/320.100; 435/325.000; 530/386.000; 536/023.500
                435/006.000
NCL
        NCLM:
                435/069.100; 435/320.100; 435/325.000; 530/386.000; 536/023.500
        NCLS:
IC
        [7]
        ICM: C12Q001-68
        ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-795
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 65 OF 391 USPATFULL ON STN
ΑN
        2003:251133 USPATFULL
TI
        ITI-D1 Kunitz domain mutants as hNE inhibitors
        Ley, Arthur Charles, Newton, MA, UNITED STATES
IN
        Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
        Markland, William, Milford, MA, UNITED STATES
        Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
        Roberts, Bruce Lindsay, Milford, MA, UNITED STATES
        Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
        US 2003175919
ΡI
                                   20030918
                             Α1
ΑI
        us 2002-38722
                             Α1
                                   20020108 (10)
        Continuation of Ser. No. US 1999-849406, filed on 21 Jul 1999, PENDING A 371 of International Ser. No. WO 1995-US16349, filed on 15 Dec 1995,
RLI
        UNKNOWN Continuation-in-part of Ser. No. US 1994-358160, filed on 16 Dec
        1994, GRANTED, Pat. No. US 5663143 Continuation-in-part of Ser. No. US 1993-133031, filed on 13 Oct 1993, ABANDONED A 371 of International Ser.
        No. WO 1992-US1501, filed on 28 Feb 1992, UNKNOWN Division of Ser. No.
        US 1991-664989, filed on 1 Mar 1991, PATENTED Continuation-in-part of
        Ser. No. US 1990-487063, filed on 2 Mar 1990, ABANDONED
        Continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988,
        ABANDONED
        Utility
DT
        APPLICATION
FS
```

LN.CNT 3925

```
INCLS: 435/069.200; 435/320.100; 435/325.000; 536/023.200
NCL
       NCLM:
               435/184.000
       NCLS:
               435/069.200; 435/320.100; 435/325.000; 536/023.200
        [7]
IC
        ICM: c12N009-99
        ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 66 OF 391 USPATFULL on STN
       2003:250925 USPATFULL
AN
ΤI
       Molecular antigen array
       Renner, Wolfgang A., Zurich, SWITZERLAND
Bachmann, Martin, Winterthur, SWITZERLAND
IN
       Tissot, Alain, Zurich, SWITZERLAND
       Maurer, Patrick, Winterthur, SWITZERLAND
       Lechner, Franziska, Zurich, SWITZERLAND
       Sebbel, Peter, Zurich, SWITZERLAND
       Piossek, Christine, Winterthur, SWITZERLAND
       Ortmann, Rainer, Saint Louis, SWITZERLAND
       Luond, Rainer, Therwil, SWITZERLAND
       Staufenbiel, Matthias, Lorrach, GERMANY, FEDERAL REPUBLIC OF
       Frey, Peter, Bern, SWITZERLAND
PA
       Cytos Biotechnology AG (non-U.S. corporation)
PΙ
       US 2003175711
                                 20030918
                           Α1
       us 2002-50898
ΑI
                           Α1
                                 20020118 (10)
                            20011107 (60)
PRAI
       US 2001-331045P
                            20011005 (60)
       US 2001-326998P
       US 2001-288549P
                             20010504 (60)
       US 2001-262379P
                            20010119 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT
       14673
INCL
       INCLM: 435/006.000
       INCLS: 424/201.100; 435/005.000; 435/007.320
               435/006.000
NCL
       NCLM:
       NCLS:
               424/201.100; 435/005.000; 435/007.320
IC
       F73
       ICM: C12Q001-70
       ICS: G01N033-554; G01N033-569; A61K039-295; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 67 OF 391 USPATFULL ON STN
       2003:250504 USPATFULL
ΑN
ΤI
       Molecular antigen array
       Renner, Wolfgang A., Zurich, SWITZERLAND
ΙN
       Bachmann, Martin, Winterthur, SWITZERLAND
       Tissot, Alain, Zurich, SWITZERLAND
       Maurer, Patrick, Winterthur, SWITZERLAND
       Lechner, Franziska, Zurich, SWITZERLAND
       Sebbel, Peter, Zurich, SWITZERLAND
       Piossek, Christine, Winterthur, SWITZERLAND
PA
       Cytos Biotechnology AG (non-U.S. corporation)
PΙ
       US 2003175290
                           Α1
                                 20030918
                                 20020118 (10)
ΑI
       US 2002-50902
                           Α1
                            20011107 (60)
20011005 (60)
PRAI
       US 2001-331045P
       US 2001-326998P
       US 2001-288549P
                            20010504 (60)
       US 2001-262379P
                            20010119 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 15306
INCL
       INCLM: 424/186.100
       INCLS: 435/005.000; 435/007.900; 435/287.200; 435/006.000
NCL
       NCLM:
               424/186.100
       NCLS:
              435/005.000; 435/007.900; 435/287.200; 435/006.000
IC
       [7]
       ICM: A61K039-12
       ICS: C12Q001-70; G01N033-53; G01N033-542; C12M001-34; C12Q001-68;
       C12M003-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 68 OF 391 USPATFULL on STN
L4
ΑN
       2003:250493 USPATFULL
       Ubiquilin, a presenilin interactor and methods of using same
TI
```

Monteiro, Mervyn J., Columbia, MD, UNITED STATES

IN

```
Perry, George, University Heights, OH, UNITED STATES Smith, Mark A., Cleveland, OH, UNITED STATES
        US 2003175278
PΙ
                                   20030918
                             A1
ΑI
        US 2002-293000
                             Α1
                                   20021113 (10)
PRAI
        US 2001-338549P
                              20011113 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 2516
INCL
        INCLM: 424/146.100
        INCLS: 435/007.200; 435/069.100; 435/320.100; 435/325.000; 435/226.000;
                536/023.200; 530/388.260
        NCLM:
                424/146.100
NCL
        NCLS:
                435/007.200; 435/069.100; 435/320.100; 435/325.000; 435/226.000;
                536/023.200: 530/388.260
        [7]
IC
        ICM: A61K039-395
        ICS: G01N033-53; G01N033-567; C07H021-04; C12N009-64; C12P021-02;
        C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 69 OF 391 USPATFULL on STN
L4
        2003:244990 USPATFULL
AN
TI
        Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives
        thereof as aggrecanase inhibitors
IN
        Barta, Thomas E., Evanston, IL, UNITED STATES
        Arner, Elizabeth C., Wadsworth, IL, UNITED STATES
        Becker, Daniel, Glenview, IL, UNITED STATES
        Boehm, Terri L., Ballwin, MO, UNITED STATES
DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
McDonald, Joseph, Wildwood, MO, UNITED STATES
                                   20030911
PΙ
        US 2003171404
                             Α1
ΑT
        US 2002-194897
                                   20020712 (10)
                             Α1
PRAI
        US 2001-306629P
                              20010719 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 5693
INCL
        INCLM: 514/335.000
        INCLS: 514/422.000; 514/602.000; 514/255.050
NCL
        NCLM:
                514/335.000
        NCLS:
                514/422.000; 514/602.000; 514/255.050
        [7]
IC
        ICM: A61K031-4965
        ICS: A61K031-4439; A61K031-4025; A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 70 OF 391 USPATFULL on STN
ΑN
        2003:244942 USPATFULL
TI
        Methods for alzheimer's disease treatment and cognitive enhancement
IN
        Etcheberrigaray, Rene, Bethesda, MD, UNITED STATES
       Alkon, Daniel L., Bethesda, MD, UNITED STATES
Neurologic, Inc. (U.S. corporation)
PA
       us 2003171356
PΙ
                                   20030911
                             Α1
ΑI
       US 2002-167491
                                   20020613 (10)
                             A1
PRAI
        US 2002-362080P
                              20020307 (60)
DT
       Utility
        APPLICATION
FS
LN.CNT 1098
INCL
        INCLM: 514/212.030
        INCLS:
               514/424.000; 514/450.000
NCL
        NCLM:
                514/212.030
       NCLS:
               514/424.000; 514/450.000
IC
        [7]
        ICM: A61K031-55
        ICS: A61K031-4015; A61K031-353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 71 OF 391 USPATFULL on STN
        2003:244343 USPATFULL
ΑN
TI
       Alpha-fetoprotein peptides and uses thereof
       Andersen, Thomas T., Albany, NY, UNITED STATES
IN
       Bennett, James A., Delmar, NY, UNITED STATES
       Jacobson, Herbert I., Albany, NY, UNITED STATES Mesfin, Fassil B., Albany, NY, UNITED STATES
PI
                                   20030911
       US 2003170752
                             A1
```

US 2001-872623

Α1

20010602 (9)

ΑI

```
DT
       Utility
FS
       APPLICATION
LN.CNT 1173
INCL
       INCLM: 435/007.230
       INCLS: 530/326.000; 530/327.000; 530/328.000; 530/317.000
NCL
       NCLM:
              435/007.230
               530/326.000; 530/327.000; 530/328.000; 530/317.000
       NCLS:
       [7]
TC
       ICM: G01N033-574
       ICS: C07K007-08; C07K007-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 72 OF 391 USPATFULL on STN
L4
AN
       2003:244336 USPATFULL
TI
       Early detection marker for chronic inflammatory associated diseases
IN
       Pereira, Heloise Anne, Edmond, OK, UNITED STATES
PI
       us 2003170745
                                 20030911
                           Α1
       US 2003-384474
                                 20030307 (10)
ΑI
                           Α1
       US 2002-363114P
                            20020308 (60)
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 1079
       INCLM: 435/007.200
INCL
       NCLM: 435/007.200
NCL
       [7]
TC
       ICM: G01N033-53
       ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 73 OF 391 USPATFULL ON STN
14
       2003:244219 USPATFULL
ΑN
          ***Human***
TI
                        cDNAs and proteins and uses thereof
       Bejanin, Stephane, Paris, FRANCE
ΙN
       Tanaka, Hiroaki, Antony, FRANCE
       GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PA
PΙ
       US 2003170628
                                20030911
                           Α1
ΑI
       us 2001-999570
                                 20011114 (9)
                           Α1
       Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING WO 2001-IB1715 20010806
RLI
PRAI
                            20010713 (60)
       US 2001-305456P
                            20010629 (60)
       US 2001-302277P
       US 2001-298698P
                            20010615 (60)
       US 2001-293574P
                            20010525 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 25549
INCL
       INCLM: 435/006.000
       INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
               530/388.100; 536/023.500
               435/006.000
NCL
       NCLM:
       NCLS:
              435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000;
               530/388.100; 536/023.500
       [7]
IC
       ICM: C12Q001-68
       ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 74 OF 391 USPATFULL on STN
       2003:243794 USPATFULL
ΔN
       Death domain containing receptors
TI
       Yu, Guo-Liang, Berkeley, CA, UNITED STATES
TN
       Ni, Jian, Germantown, MD, UNITED STATES
       Gentz, Reiner L., Belo Horizonte, BRAZIL
       Dillon, Patrick J., Carlsbad, CA, UNITED STATES
PA
       Human Genome Sciences, Inc. (U.S. corporation)
PΙ
       us 2003170203
                           A1
                                20030911
       us 2002-189189
ΑI
                           Α1
                                20020705 (10)
       Continuation-in-part of Ser. No. US 2000-557908, filed on 21 Apr 2000,
RLI
       PENDING Continuation-in-part of Ser. No. US 1997-815469, filed on 11 Mar
       1997, GRANTED, Pat. No. US 6153402
PRAI
       US 2001-314314P
                            20010824 (60)
       US 2001-303155P
                            20010706 (60)
       US 1999-136741P
                            19990528 (60)
       US 1999-130488P
                            19990422 (60)
```

19970206 (60)

us 1997-37341P

```
US 1996-13285P
                           19960312 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 9858
INCL
       INCLM: 424/085.100
       INCLS: 424/145.100; 514/210.090; 514/011.000
NCL
       NCLM: 424/085.100
       NCLS:
              424/145.100; 514/210.090; 514/011.000
       [7]
IC
       ICM: A61K039-395
       ICS: A61K031-407; A61K038-19; A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 75 OF 391 USPATFULL on STN
L4
       2003:243518 USPATFULL
ΑN
TI
       Data relationship model
       Sonmez, Kemal, Menlo Park, CA, UNITED STATES
IN
       Toll, Lawrence R., Redwood City, CA, UNITED STATES
       Lincoln, Patrick Denis, Woodside, CA, UNITED STATES
       Karp, Peter D., San Mateo, CA, UNITED STATES
       us 2003169926
                          Α1
                                20030911
PΙ
       US 2001-4580
                                20011203 (10)
ΑI
                           Α1
                           20001201 (60)
PRAI
       US 2000-250743P
       Utility
DT
FS
       APPLICATION
LN.CNT 1575
INCL
       INCLM: 382/219.000
       INCLS: 382/228.000
              382/219.000
NCL
       NCLM:
              382/228.000
       NCLS:
       [7]
TC
       ICM: G06K009-68
     ANSWER 76 OF 391 USPATFULL on STN
L4
ΑN
       2003:240440 USPATFULL
TI
       Cysteinyl protease inhibitors
       Munoz, Benito, 10741 Frank Daniels Rd., San Diego, CA, United States
IN
       92131
       Srinivasan, Kuman, 7693 Palmilla Dr., Apt. #2116, San Diego, CA, United
       States 92122
       Wang, Bowei, 7825 Roan Rd., San Diego, CA, United States 92129
                                20030909
PΙ
       us 6617426
                        В1
       us 1999-338409
                                19990622 (9)
ΑI
       Utility
DT
FS
       GRANTED
LN.CNT 2060
       INCLM: 530/331.000
INCL
       INCLS: 514/018.000; 514/019.000
NCL
       NCLM:
              530/331.000
              514/018.000; 514/019.000
       NCLS:
IC
       [7]
       ICM: C07K005-08
EXF
       530/331; 514/18; 514/19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 77 OF 391 USPATFULL on STN
       2003:239326 USPATFULL
ΑN
                                                ***human***
TI
       Double transgenic mice overexpressing
                                                               beta secretase and
         ***human***
                       APP-London
TN
       Jacobsen, Helmut, Schopfheim, GERMANY, FEDERAL REPUBLIC OF
       Mosbach-Ozmen, Laurence, Saint-Louis, FRANCE
       Nelboeck-Hochstetter, Peter, Basel, SWITZERLAND
                                20030904
PΙ
       us 2003167486
                          Α1
       US 2003-372730
EP 2002-4331
ΑI
                           Α1
                                20030224 (10)
PRAI
                           20020301
DT
       Utility
       APPLICATION
FS
LN.CNT 2177
INCL
       INCLM: 800/012.000
       INCLS: 800/014.000
NCL
       NCLM:
              800/012.000
       NCLS: 800/014.000
IC
       [7]
       ICM: A01K067-027
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L4
     ANSWER 78 OF 391 USPATFULL ON STN 2003:238559 USPATFULL
AN
ΤI
       Hydroxy alkyl amines
IN
       Freskos, John, Clayton, MO, UNITED STATES
       Brown, David L., Chesterfield, MO, UNITED STATES
       Fobian, Yvette M., Wildwood, MO, UNITED STATES
       Fang, Larry, Foster City, CA, UNITED STATES
       Romero, Arthur Glenn, Kalamazoo, MI, UNITED STATES
       John, Varghese, San Francisco, CA, UNITED STATES
PΙ
       US 2003166717
                                  20030904
                            Α1
       US 2002-160777
                                  20020531 (10)
ΑI
                            Α1
PRAI
       US 2001-343772P
                             20011228 (60)
       US 2001-332639P
                             20011119 (60)
       US 2001-295332P
                             20010601 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 10078
INCL
       INCLM: 514/526.000
               514/629.000; 514/600.000; 514/601.000; 558/482.000; 564/095.000; 564/163.000; 564/503.000
       INCLS:
               514/526.000
NCL
       NCLM:
               514/629.000; 514/600.000; 514/601.000; 558/482.000; 564/095.000;
       NCLS:
               564/163.000: 564/503.000
       [7]
IC
       ICM: A61K031-275
       ICS: A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 79 OF 391 USPATFULL ON STN
L4
       2003:238482 USPATFULL
AN
TI
       Reverse-turn mimetics and methods relating thereto
       Urban, Jan, Kirkland, WA, UNITED STATES
IN
       Nakanishi, Hiroshi, Newcastle, WA, UNITED STATES
       Lee, Min S., Sammamish, WA, UNITED STATES
       Molecumetics, Ltd., Bellevue, WA (U.S. corporation)
PA
       us 2003166640
                                  20030904
ΡI
                            Α1
ΑI
       US 2002-150481
                            Α1
                                  20020516 (10)
       US 2001-291663P
                             20010516 (60)
PRAI
       Utility
DT
FS
       APPLICATION
LN.CNT 1913
       INCLM: 514/224.200
INCL
       INCLS: 514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;
               544/095.000; 544/014.000; 544/350.000; 544/345.000
       NCLM:
               514/224.200
NCL
               514/249.000; 514/250.000; 514/230.500; 435/007.100; 436/518.000;
       NCLS:
               544/095.000; 544/014.000; 544/350.000; 544/345.000
IC
       [7]
       ICM: G01N033-53
       ICS: C07D498-04; C07D487-04; A61K031-542; A61K031-5383; A61K031-498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 80 OF 391 USPATFULL ON STN
       2003:238478 USPATFULL
ΑN
       Hydroxyalkanoylaminolactams and related structures as inhibitors of
TI
       A-beta protein production
IN
       Olson, Richard E., Wilmington, DE, UNITED STATES
       Liu, Hong, Glen Mills, PA, UNITED STATES
       Thompson, Lorin A., Wilmington, DE, UNITED STATES
       US 2003166636
                                  20030904
PΙ
                            Α1
       US 2002-287117
                                  20021104 (10)
AT
                            Αl
       Division of Ser. No. US 2001-805645, filed on 14 Mar 2001, GRANTED, Pat.
RLI
       No. US 6503902 Continuation-in-part of Ser. No. US 2000-661008, filed on
       13 Sep 2000, ABANDONED
       Utility
DT
       APPLICATION
FS
LN.CNT 6969
       INCLM: 514/212.080
INCL
       INCLS: 514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500; 514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000;
               546/207.000
               514/212.080
NCL
       NCLM:
               514/183.000; 514/326.000; 514/327.000; 514/227.800; 514/235.500; 514/253.120; 540/524.000; 544/060.000; 544/360.000; 544/130.000;
       NCLS:
```

546/207.000

[7]

```
ICM: A61K031-55
       ICS: A61K031-541; A61K031-5377; A61K031-496; A61K031-4545; A61K031-454;
       C07D417-02; C07D413-02; C07D043-02; C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 81 OF 391 USPATFULL ON STN
ΑN
       2003:238422 USPATFULL
TI
       Substituted amino carboxamides for the treatment of alzheimer's disease
ΙN
       Warpehoski, Martha A., Portage, MI, UNITED STATES
       Jagodzinska, Barbara, Redwood City, CA, UNITED STATES
PΙ
       US 2003166580
                                20030904
                           Α1
ΑI
       US 2003-337075
                                20030106 (10)
                           Α1
PRAI
       US 2002-345316P
                            20020104 (60)
       US 2002-350419P
                            20020118 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 4157
       INCLM: 514/019.000
INCL
       INCLS: 560/041.000; 546/335.000
NCL
       NCLM:
               514/019.000
       NCLS:
               560/041.000; 546/335.000
       [7]
IC
       ICM: A61K038-04
       ICS: C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 82 OF 391 USPATFULL on STN
       2003:238400 USPATFULL
AN
TI
       Synthetic immunogenic but non-deposit-forming polypeptides and peptides
       homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or
       polyglutamine repeats for induction of an immune response thereto
ΙN
       Frangione, Blas, New York, NY, UNITED STATES
       Wisniewski, Thomas, Statent Island, NY, UNITED STATES
       Sigurdsson, Einar M., New York, NY, UNITED STATES
       NEW YORK UNIVERSITY (U.S. corporation)
PA
                                20030904
PI
       us 2003166558
                           Α1
       US 2002-301488
ΑI
                           Α1
                                20021121 (10)
       US 2001-331801P
PRAI
                           20011121 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 4966
       INCLM: 514/012.000
INCL
       INCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000;
               530/327.000; 530/328.000; 530/326.000
NCL
       NCLM:
               514/012.000
              514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000; 530/327.000; 530/328.000; 530/326.000
       NCLS:
IC
       [7]
       ICM: A61K038-16
       ICS: A61K038-10; A61K038-08; C07K014-00; C07K007-08; C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 83 OF 391 USPATFULL on STN
       2003:237862 USPATFULL
AN
                    ***antibody***
TI
       Monoclonal
       Wiltfang, Jens, Eddigehausen, GERMANY, FEDERAL REPUBLIC OF
IN
       Dyrks, Thomas, Berlin, GERMANY, FEDERAL REPUBLIC OF
       Monning, Ursula, Berlin, GERMANY, FEDERAL REPUBLIC OF
       US 2003166019
                                20030904
PΙ
                           Α1
ΑT
       US 2002-170272
                                20020611 (10)
                           Α1
       EP 2001-114192
PRAI
                            20010612
DT
       Utility
FS
       APPLICATION
LN.CNT 3683
INCL
       INCLM: 435/007.210
       INCLS: 530/388.260
              435/007.210
NCL
       NCLM:
              530/388.260
       NCLS:
IC
       [7]
       ICM: G01N033-567
       ICS: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 84 OF 391 USPATFULL on STN
L4
```

2003:237706 USPATFULL

AN

```
IN
       Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES
PA
       Millennium Pharmaceuticals, Inc. (U.S. corporation)
PΙ
                                20030904
       US 2003165863
                           Α1
AΤ
       US 2002-47855
                           A1
                                 20020115 (10)
PRAI
       US 2001-262306P
                            20010116 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 4471
INCL
       INCLM: 435/006.000
       INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL
       NCLM:
               435/006.000
               435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
       NCLS:
IC
       [7]
       ICM: C12Q001-68
       ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 85 OF 391 USPATFULL ON STN
L4
       2003:237324 USPATFULL
AN
TI
       Amyloid peptide inactivating enzyme to treat Alzheimer's disease
       Hersh, Louis B., Lexington, KY, UNITED STATES
IN
                                 20030904
PΙ
       us 2003165481
                           Α1
       us 2002-159279
ΑI
                           Α1
                                 20020603 (10)
       Division of Ser. No. US 2001-792079, filed on 26 Feb 2001, PENDING
RLI
       US 2000-184826P
PRAI
                            20000224 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1712
       INCLM: 424/093.210
TNCL
       INCLS: 435/455.000; 435/368.000
NCL
       NCLM:
              424/093.210
       NCLS:
              435/455.000; 435/368.000
IC
       [7]
       ICM: A61K048-00
       ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 86 OF 391 USPATFULL on STN
ΑN
       2003:232056 USPATFULL
ΤI
       PTH1R and PTH3R receptors, methods and uses thereof
       Juppner, Harald, Cambridge, MA, UNITED STATES
TN
       Rubin, David A., Needham, MA, UNITED STATES
The Massachusetts General Hospital (U.S. corporation)
PA
PΙ
       us 2003162256
                                 20030828
                           A1
       US 2003-372095
ΑI
                           Α1
                                 20030225 (10)
       Division of Ser. No. US 1999-449632, filed on 30 Nov 1999, GRANTED, Pat.
RLI
       No. US 6541220
PRAI
       US 1998-110467P
                            19981130 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 2869
INCL
       INCLM: 435/069.100
       INCLS: 514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL
       NCLM:
               435/069.100
       NCLS:
              514/012.000; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC
       [7]
       ICM: A61K038-17
       ICS: C07K014-72; C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 87 OF 391 USPATFULL on STN
AN
       2003:231986
                    USPATFULL
         ***Human***
                        cDNAs and proteins and uses thereof
TI
       Bejanin, Stephane, Paris, FRANCE
TN
       Tanaka, Hiroaki, Antony, FRANCE
               S.A., Paris, FRANCE (non-U.S. corporation)
PA
       GENSET,
                                20030828
       US 2003162186
PΙ
                           Α1
       us 2002-154678
                                 20020522 (10)
ΑI
                           A1
       US 2001-293574P
                            20010525 (60)
PRAI
       US 2001-298698P
                            20010615
                                      (60)
                                      (60)
       US 2001~302277P
                            20010629
       US 2001-305456P
                            20010713 (60)
       Utility
DT
       APPLICATION
FS
```

CNT 25533

LN

```
INCL
        INCLM: 435/006.000
        INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL
        NCLM:
               435/006.000
        NCLS:
               435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
        [7]
IC
        ICM: C12Q001-68
        ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 88 OF 391 USPATFULL ON STN
        2003:231625 USPATFULL
ΑN
       Therapeutic and cosmetic uses of heparanases
ΤI
ΙN
       Ilan, Neta, Rehovot, ISRAEL
       Vlodavsky, Israel, Mevaseret Zion, ISRAEL
       Yacoby-Zeevi, Oron, Moshav Bizaron, ISRAEL
       Pecker, Iris, Rishon LeZion, ISRAEL
Feinstein, Elena, Rehovot, ISRAEL
US 2003161823 A1 20030828
PΙ
ΑI
       US 2003-341582
                                 20030114 (10)
                           Α1
       Continuation-in-part of Ser. No. US 2001-988113, filed on 19 Nov 2001,
RLI
       PENDING Continuation of Ser. No. US 2001-776874, filed on 6 Feb 2001,
       PENDING Continuation of Ser. No. US 1999-258892, filed on 1 Mar 1999,
       ABANDONED Continuation-in-part of Ser. No. WO 1998-US17954, filed on 31
       Aug 1998, PENDING Continuation-in-part of Ser. No. WO 2001-IL830, filed
       on 5 Sep 2001, UNKNOWN
       Utility
DT
       APPLICATION
FS
LN.CNT 7437
INCL
       INCLM: 424/094.610
       INCLS: 435/006.000; 435/200.000
NCL
               424/094.610
       NCLM:
       NCLS:
              435/006.000; 435/200.000
IC
       [7]
       ICM: A61K038-47
       ICS: C12Q001-68; C12N009-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 89 OF 391 USPATFULL ON STN
AN
       2003:226348 USPATFULL
TI
       Substituted sapogenins and their use
ΙN
       Barraclough, Paul, Maidstone, UNITED KINGDOM
       Hanson, Jim, Steyning, UNITED KINGDOM
       Gunning, Phil, Grantchester, UNITED KINGDOM
       Rees, Daryl, Sandy, UNITED KINGDOM
       Xia, Zongqin, Shanghai, CHINA
       Hu, Yaer, Shanghai, CHINA
PA
       PHYTOPHARM PLC. (non-U.S. corporation)
                                 20030821
PΙ
       US 2003158161
                           Α1
ΑI
       US 2002-189024
                           Α1
                                 20020703 (10)
RLI
       Continuation-in-part of Ser. No. WO 2001-GB48, filed on 8 Jan 2001,
       UNKNOWN
PRAI
       GB 2000-228
                            20000106
DT
       Utility
FS
       APPLICATION
LN.CNT 2249
INCL
       INCLM: 514/173.000
              514/172.000
       INCLS:
NCL
               514/173.000
       NCLM:
       NCLS:
              514/172.000
IC
       [7]
       ICM: A61K031-58
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 90 OF 391 USPATFULL ON STN
       2003:225892
                    USPATFULL
AN
       Reagents and methods for identifying and modulating expression of genes
TI
       regulated by CDK inhibitors
       Roninson, Igor B., Wilmette, IL, UNITED STATES
IN
       Poole, Jason C., Chicago, IL, UNITED STATES
                                20030821
       us 2003157704
PΙ
                           Α1
       us 2002-233032
                                20020829 (10)
ΑI
                           Α1
PRAI
       US 2001-315791P
                            20010829 (60)
       utility
DT
FS
       APPLICATION
```

LN.CNT 3944

```
INCLS: 435/006.000; 435/325.000; 435/235.100; 435/239.000; 435/005.000
NCL
       NCLM:
              435/320.100
               435/006.000; 435/325.000; 435/235.100; 435/239.000; 435/005.000
       NCLS:
IC
       [7]
       ICM: C12Q001-70
       ICS: C12Q001-68; C12N007-00; C12N007-01; C12N007-02; C12N015-00;
       C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12N005-00; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 91 OF 391 USPATFULL on STN
       2003:225673 USPATFULL
ΑN
         ***Human***
                        cDNAs and proteins and uses thereof
TI
IN
       Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
US 2003157485 A1 20030821
PA
PΙ
       US 2001-992095
                                 20011113 (9)
ΑI
                           Α1
       Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
RLI
PRAI
       WO 2001-IB1715
                             20010806
       US 2001-305456P
                             20010713 (60)
                             20010629 (60)
       US 2001-302277P
       US 2001-298698P
                             20010615 (60)
                             20010525 (60)
       US 2001-293574P
DT
       Utility
FS
       APPLICATION
LN.CNT 25484
       INCLM: 435/006.000
INCL
       INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
               536/023.200; 530/388.260; 435/007.200
NCL
       NCLM:
               435/006.000
       NCLS:
               435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000;
               536/023.200; 530/388.260; 435/007.200
IC
       [7]
       ICM: C12Q001-68
       ICS: G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64;
       C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 92 OF 391 USPATFULL on STN
L4
       2003:220443 USPATFULL
AN
       Methods for producing pure perlecan and other heparan sulfate
TI
       proteoglycans
IN
       Castillo, Gerardo, Seattle, WA, UNITED STATES
       Snow, Alan D., Lynnwood, WA, UNITED STATES
                                 20030814
PΙ
       us 2003153734
                           Α1
       US 2002-323323
                                 20021218 (10)
ΑÏ
                           Α1
       Continuation of Ser. No. US 2000-698518, filed on 26 Oct 2000, PENDING
RLI
       Continuation of Ser. No. US 1998-36492, filed on 6 Mar 1998, ABANDONED
PRAI
       US 1997-38613P
                             19970306 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 2512
INCL
       INCLM: 530/370.000
       INCLS: 530/395.000
NCLM: 530/370.000
NCL
               530/395.000
       NCLS:
IC
       [7]
       ICM: C07K014-47
       ICS: C07K014-415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 93 OF 391 USPATFULL on STN
       2003:220436 USPATFULL
AN
       Controlling protein levels in eucaryotic organisms
TI
IN
       Kenten, John H., Boyds, MD, UNITED STATES
Roberts, Steven F., Bethesda, MD, UNITED STATES
       Proteinix, Inc. (U.S. corporation)
PA
PΙ
       US 2003153727
                                 20030814
                           Α1
       US 2003-345281
                                 20030116 (10)
ΑI
                           Α1
       Division of Ser. No. US 2001-880132, filed on 14 Jun 2001, GRANTED, Pat.
RLI
       No. US 6559280 Division of Ser. No. US 1999-406781, filed on 28 Sep
       1999, GRANTED, Pat. No. US 6306663
       US 1999-119851P
PRAI
                             19990212 (60)
       Utility
DT
```

FS

APPLICATION

```
INCL
       INCLM: 530/323.000
       INCLS: 435/106.000; 424/070.140; 530/330.000
NCL
               530/323.000
              435/106.000; 424/070.140; 530/330.000
       NCLS:
IC
       [7]
       ICM: A61K007-06
       ICS: A61k007-11; C12p013-04; C07k005-00; C07k007-00; C07k016-00;
       CO7KO17-00; A61KO38-00; A61KO38-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 94 OF 391 USPATFULL ON STN
       2003:219631 USPATFULL
AN
                      ***human***
                                     cDNAs encoding potentially secreted proteins
ΤI
       Full-length
       Dumas Milne Edwards, Jean-Baptiste, Paris, FRANCE
IN
       Bougueleret, Lydie, Petit Lancy, SWITZERLAND
       Jobert, Severin, Paris, FRANCE
       US 2003152921
PΙ
                           Α1
                                 20030814
       us 2001-876997
                                20010608 (9)
ΑI
                           Α1
       Continuation-in-part of Ser. No. US 2000-731872, filed on 7 Dec 2000,
RLI
       PENDING
       US 1999-169629P
                            19991208 (60)
PRAI
       US 2000-187470P
                            20000306 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 27600
INCL
       INCLM: 435/006.000
       INCLS: 435/183.000; 536/023.200
NCLM: 435/006.000
NCL
       NCLS:
              435/183.000; 536/023.200
       [7]
IC
       ICM: C12Q001-68
       ICS: C12N009-00; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 95 OF 391 USPATFULL ON STN
L4
       2003:214611 USPATFULL
AN
       Methods and compositions comprising Renilla GFP
ΤI
       Anderson, David, San Bruno, CA, UNITED STATES
IN
       Peelle, Beau, Sommerville, MA, UNITED STATES Rigel Pharmaceuticals, Inc. (U.S. corporation)
PA
                                 20030807
PΙ
       us 2003149254
                           Α1
       US 2002-133973
                                20020424 (10)
                           Α1
ΑI
       Continuation of Ser. No. US 2000-710058, filed on 10 Nov 2000, PENDING
RLI
                            20010510 (60)
PRAI
       US 2001-290287P
       US 1999-164592P
                            19991110 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 5908
INCL
       INCLM: 536/023.100
       INCLS: 435/006.000; 435/320.100; 435/325.000; 435/069.700; 530/350.000
NCL
               536/023.100
       NCLM:
               435/006.000; 435/320.100; 435/325.000; 435/069.700; 530/350.000
       NCLS:
IC
       [7]
       ICM: C12Q001-68
       ICS: G01N033-53; C07H021-04; C12P021-04; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 96 OF 391 USPATFULL on STN
       2003:213718
                    USPATFULL
ΑN
       Novel APP mutation associated with an unusual Alzheimer's disease
TI
       pathology
IN
       Cruts, Mare, Antwerpen, BELGIUM
       Jonghe, Chris De, Edegem, BELGIUM
       Singh, Samir Kumar, Edegem, BELGIUM
       Broeckhoven, Christine van, Edegem, BELGIUM
       us 2003148356
                                 20030807
PΙ
                           Α1
                                 20030106 (10)
ΑI
       us 2003-337970
                           Α1
       Continuation of Ser. No. WO 2001-EP7830, filed on 6 Jul 2001, UNKNOWN
RLI
DT
       Utility
       APPLICATION
FS
LN.CNT 1415
INCL
       INCLM: 435/006.000
       INCLS: 435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200
NCL
       NCLM:
              435/006.000
```

435/069.100; 435/226.000; 435/252.300; 435/320.100; 536/023.200

NCLS:

```
ICM: C12Q001-68
       ICS: C07H021-04; C12N009-64; C12N001-21; C12P021-02; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 97 OF 391 USPATFULL ON STN 2003:213627 USPATFULL
L4
AN
TI
       Phage displayed PDZ domain ligands
       Held, Heike A., Oakland, CA, UNITED STATES
TN
       Lasky, Laurence A., Sausalito, CA, UNITED STATES
       Laura, Richard P., San Bruno, CA, UNITED STATES
       Sidhu, Sachdev S., San Francisco, CA, UNITED STATES
       Wong, Wai Lee Tan, Los Altos, CA, UNITED STATES
       Wu, Yan, Foster City, CA, UNITED STATES
PA
       GENENTECH, INC. (U.S. corporation)
ΡI
       US 2003148264
                                 20030807
                           Α1
       US 2002-190082
ΑI
                           Α1
                                 20020703 (10)
       US 2001-303634P
                            20010706 (60)
PRAI
       Utility
DT
FS
       APPLICATION
LN.CNT 8976
INCL
       INCLM: 435/005.000
       INCLS: 435/007.100; 435/235.100; 536/023.720; 530/350.000
NCL
       NCLM:
              435/005.000
              435/007.100; 435/235.100; 536/023.720; 530/350.000
       NCLS:
IC
       [7]
       ICM: C12Q001-70
       ICS: G01N033-53; C07H021-04; C12N007-00; C07K014-005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 98 OF 391 USPATFULL on STN
ΑN
       2003:207362 USPATFULL
TI
       High throughput functional genomics
       Hickman, James J., Falls Church, VA, UNITED STATES
ΙN
PΙ
       US 2003143720
                           Α1
                                 20030731
       us 2002-286760
                                 20021104 (10)
ΑI
                           Α1
       Division of Ser. No. US 2000-575377, filed on 22 May 2000, PENDING
RLI
                            19990521 (60)
PRAI
       US 1999-135275P
       Utility
DT
FS
       APPLICATION
LN, CNT 2781
INCL
       INCLM: 435/287.100
       INCLS: 702/019.000; 205/777.500
               435/287,100
NCL
       NCLM:
              702/019.000; 205/777.500
       NCLS:
       [7]
IC
       ICM: G06F019-00
       ICS: G01N033-48; G01N033-50; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 99 OF 391 USPATFULL on STN
       2003:206852 USPATFULL
AN
       Targeted adenovirus vectors for delivery of heterologous genes Vigne, Emmanuelle, L'Hay-Les-Roses, FRANCE
TI
IN
       Dedieu, Jean-Francois, Paris, FRANCE
       Latta, Martine, Charenton Le pont, FRANCE
       Yeh, Patrice, Gif Sur Yvette, FRANCE
       Perricaudet, Michel, Ecrosnes, FRANCE
       US 2003143209
PΙ
                           Α1
                                 20030731
       us 2001-791524
                                 20010222 (9)
AΙ
                           Α1
       Continuation of Ser. No. WO 1999-IB1524, filed on 27 Aug 1999, UNKNOWN
RLI
PRAI
       US 1998-98028P
                            19980827 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 3374
       INCLM: 424/093.210
INCL
       INCLS: 435/235.100
              424/093.210
NCL
       NCLM:
       NCLS: 435/235.100
TC
       [7]
       ICM: A61K048-00
       ICS: C12N007-00; C12N007-01
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 100 OF 391 USPATFULL ON STN
```

2003:200784 USPATFULL

ΔN

```
ΙN
        Birkett, Ashley J., Escondido, CA, UNITED STATES
PΙ
        US 2003138769
                             Α1
                                    20030724
ΑI
        US 2001-930915
                                    20010815 (9)
                              Α1
RLI
        Continuation-in-part of ser. No. US 2000-226867, filed on 22 Aug 2000,
        PENDING Continuation-in-part of Ser. No. US 2000-225843, filed on 16 Aug
        2000, PENDING
DT
        Utility
        APPLICATION
FS
LN.CNT 6993
        INCLM: 435/005.000
INCL
        INCLS: 530/350.000; 435/069.300; 435/325.000; 435/320.100
                435/005.000
NCL
                530/350.000; 435/069.300; 435/325.000; 435/320.100
        NCLS:
        [7]
IC
        ICM: C12Q001-70
        ICS: C12P021-02; C12N005-06; C07K014-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 101 OF 391 USPATFULL on STN
14
ΑN
        2003:195233 USPATFULL
TI
        Novel gamma secretase inhibitors
        Asberom, Theodros, West Orange, NJ, UNITED STATES
ΤN
        Guzik, Henry S., Brooklyn, NY, UNITED STATES
        Josien, Hubert B., Hoboken, NJ, UNITED STATES
        Pissarnitski, Dmitri A., Scotch Plains, NJ, UNITED STATES SCHERING CORPORATION (U.S. corporation)
PA
                                    20030717
        us 2003135044
PΙ
                              Α1
        US 2002-210829
                                    20020801 (10)
ΑI
                              A1
        US 2002-355510P
                               20020206 (60)
PRAI
        US 2001-310013P
                               20010803 (60)
DT
        Utility
        APPLICATION
LN.CNT 1170
        INCLM: 540/593.000
INCL
        INCLS: 546/153.000; 548/494.000; 514/217.010; 514/312.000
                540/593.000
NCL
        NCLM:
        NCLS:
                546/153.000; 548/494.000; 514/217.010; 514/312.000
        [7]
IC
        ICM: A61K031-55
        ICS: C07D215-16; A61K031-47; C07D209-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 102 OF 391 USPATFULL on STN
        2003:195030 USPATFULL
AN
        Succinoylamino lactams as inhibitors of A-beta protein production
TI
        Olson, Richard E., Wilmington, DE, UNITED STATES Maduskuie, Thomas P., Wilmington, DE, UNITED STATES
IN
        Thompson, Lorin Andrew, Wilmington, DE, UNITED STATES
PΙ
        US 2003134841
                              Α1
                                    20030717
                                    20021101 (10)
ΑI
        us 2002-285776
                              Α1
        Division of Ser. No. US 2000-506360, filed on 17 Feb 2000, PENDING
RLI
        Continuation-in-part of Ser. No. US 1999-370089, filed on 6 Aug 1999,
        ABANDONED
        US 1999-120227P
                               19990215 (60)
PRAI
                                19981223 (60)
        US 1998-113558P
                               19980807 (60)
        US 1998-95698P
DT
        Utility
        APPLICATION
FS
LN.CNT 11008
INCL
        INCLM: 514/212.080
        INCLS: 514/316.000; 514/326.000; 514/327.000; 514/422.000; 514/212.030; 514/424.000; 540/524.000; 540/527.000; 546/188.000; 546/207.000; 546/216.000; 548/518.000; 548/550.000
                514/212.080
NCL
        NCLM:
                514/316.000; 514/326.000; 514/327.000; 514/422.000; 514/212.030; 514/424.000; 540/524.000; 540/527.000; 546/188.000; 546/207.000; 546/216.000; 548/518.000; 548/550.000
        NCLS:
IC
        ICM: A61K031-55
        ICS: A61K031-4545; A61K031-454; A61K031-4025; A61K031-4015; C07D043-02;
        C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 103 OF 391 USPATFULL ON STN
```

2003:194619 USPATFULL

AN

```
elegans-like protein polypeptides
IN
        Shimkets, Richard A., West Haven, CT, UNITED STATES
        Fernandes, Elma, Branford, CT, UNITED STATES
        Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
        CuraGen Corporation, New Haven, CT (U.S. corporation)
PA
PΙ
        US 2003134430
                                     20030717
                               A1
        US 2001-977751
ΑI
                                     20011015 (9)
                               Α1
        Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
RLI
                                20000503 (60)
PRAI
        US 2000-201388P
                                20000330 (60)
        US 2000-193086P
                                20000322 (60)
20000316 (60)
        US 2000-191158P
        US 2000-189810P
        US 1999-137322P
                                19990603 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 10285
INCL
        INCLM: 436/518.000
        INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
                 436/518.000
NCL
                435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
        NCLS:
IC
        [7]
        ICM: C12P021-02
        ICS: C12N005-06; C07K014-435; G01N033-543; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 104 OF 391 USPATFULL ON STN
ΑN
        2003:188691 USPATFULL
        Inhibitors and disassemblers of fibrillogenesis
TI
        Gordon, David J., Chicago, IL, UNITED STATES
ΙN
        Meredith, Stephen C., Chicago, IL, UNITED STATES
        us 2003130484
                                     20030710
PΙ
                              Α1
                                     20020320 (10)
ΑI
        us 2002-103658
                               Α1
PRAI
        US 2001-277477P
                                20010320 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 4503
        INCLM: 530/350.000
INCL
        INCLS: 514/012.000; 435/007.100
                 530/350.000
NCL
        NCLM:
        NCLS:
                 514/012.000; 435/007.100
        [7]
IC
        ICM: A61K038-17
        ICS: C07K014-435; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 105 OF 391 USPATFULL ON STN
AN
        2003:188458 USPATFULL
        Amino lactam sulfonamides as inhibitors of A-beta protein production
TI
        Thompson, Lorin A., Wilmington, DE, UNITED STATES
TN
        Han, Amy Qi, Hockessin, DE, UNITED STATES US 2003130251 A1 20030710
PΙ
        us 2002-287367
                                     20021104 (10)
ΑI
                               Α1
        Division of Ser. No. US 2000-684718, filed on 7 Oct 2000, GRANTED, Pat.
RLI
        No. US 6503901
PRAI
        US 1999-158565P
                                19991008 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 4917
INCL
        INCLM: 514/183.000
        INCLS: 514/212.080; 514/227.800; 514/231.500; 514/253.130; 514/254.010; 514/326.000; 514/327.000; 514/422.000; 514/424.000; 540/524.000; 544/060.000; 544/130.000; 544/141.000; 544/360.000; 544/372.000;
                 546/207.000; 546/243.000; 548/517.000; 548/543.000
NCL
        NCLM:
                 514/183.000
                 514/212.080; 514/227.800; 514/231.500; 514/253.130; 514/254.010;
        NCLS:
                 514/326.000; 514/327.000; 514/422.000; 514/424.000; 540/524.000; 544/060.000; 544/130.000; 544/141.000; 544/360.000; 544/372.000; 546/207.000; 546/243.000; 548/517.000; 548/543.000
IC
        [7]
        ICM: A61K031-55
        ICS: A61K031-541; A61K031-5377; A61K031-496; A61K031-4439; A61K031-454;
C07D417-02; C07D413-02; C07D043-02 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
AN
        2003:188395 USPATFULL
TI
        Heterocyclic compounds, pharmaceutical compositions comprising same, and
                                    ***beta*** - ***amyloid***
        methods for inhibiting
                                                                        peptide release
        and/or its synthesis by use of such compounds
        Thorsett, Eugene D., Moss Beach, CA, UNITED STATES Porter, Warren J., Indianapolis, IN, UNITED STATES
IN
        Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
        Latimer, Lee H., Oakland, CA, UNITED STATES
        Audia, James E., Indianapolis, IN, UNITED STATES
        Droste, James, Indianapolis, IN, UNITED STATES
PΙ
        US 2003130188
                                   20030710
                              Α1
ΑI
        US 2002-246558
                                   20020919 (10)
                              Α1
RLI
        Division of Ser. No. US 1998-32019, filed on 27 Feb 1998, PENDING
        Utility
DT
        APPLICATION
FS
LN.CNT 11320
INCL
        INCLM: 514/012.000
        INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000;
                514/018.000; 514/019.000; 514/400.000; 514/419.000
NCL
        NCLM:
                514/012.000
                514/013.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000; 514/018.000; 514/019.000; 514/400.000; 514/419.000
        NCLS:
        [7]
IC
        ICM: A61K038-10
        ICS: A61K038-08; A61K038-06; A61K038-05; A61K031-4172; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 107 OF 391 USPATFULL on STN
ΑN
        2003:181532
                      USPATFULL
TT
        Hydroxypropylamines
        Fisher, Jed F., Kalamazoo, MI, UNITED STATES Jacobs, Jon S., Kalamazoo, MI, UNITED STATES Sherer, Brian, Ballston Spa, NY, UNITED STATES US 2003125365 A1 20030703
IN
PΙ
                                   20021004 (10)
ΑI
        us 2002-264707
                              Α1
PRAI
        US 2001-327149P
                               20011004 (60)
        US 2001-334058P
                               20011128 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 4089
INCL
        INCLM:
                514/374.000
        INCLS:
                514/602.000; 514/617.000; 548/215.000; 564/176.000; 564/084.000;
                564/503.000
NCL
        NCLM:
                514/374.000
        NCLS:
                514/602.000; 514/617.000; 548/215.000; 564/176.000; 564/084.000;
                564/503.000
IC
        [7]
        ICM: A61K031-421
        ICS: A61K031-165; C07D263-02; C07C311-15
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 108 OF 391 USPATFULL on STN
AN
        2003:181424
                      USPATFULL
TI
        Assay for identifying beta secretase inhibitors
IN
        Brockhaus, Manfred, Bettingen, SWITZERLAND
        Doebeli, Heinz, Ziefen, SWITZERLAND
        Grueninger, Fiona, Arlesheim, SWITZERLAND
        Huguenin, Philipp, Liestal, SWITZERLAND
        Kitas, Eric Argirios, Aesch, SWITZERLAND
        Nelboeck-Hochstetter, Peter, Basel, SWITZERLAND US 2003125257 A1 20030703
PΤ
ΑI
        us 2002-322684
                              Α1
                                   20021218 (10)
        EP 2001-130282
PRAI
                               20011220
DT
        Utility
FS
        APPLICATION
LN.CNT 1045
INCL
        INCLM: 514/012.000
        INCLS:
                514/013.000; 514/014.000; 514/015.000; 435/023.000; 435/184.000
NCL
                514/012.000
        NCLM:
                514/013.000; 514/014.000; 514/015.000; 435/023.000; 435/184.000
        NCLS:
TC
        [7]
        ICM: A61K038-55
        ICS: C12Q001-37: C12N009-99
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ΑN
        2003:174039 USPATFULL
TI
        Lactacystin analogs
        Schreiber, Stuart L., Boston, MA, UNITED STATES Standaert, Robert F., Bryan, TX, UNITED STATES
IN
        Fenteany, Gabriel, Cambridge, MA, UNITED STATES
Jamison, Timothy F., Cambridge, MA, UNITED STATES
PΙ
        US 2003119887
                             Á1
                                   20030626
ΑI
        US 2001-924993
                             Α1
                                   20010808 (9)
        Continuation of Ser. No. US 1998-945092, filed on 26 Jan 1998, PENDING A
RLI
        371 of International Ser. No. WO 1996-US5072, filed on 12 Apr 1996.
        PENDING Continuation-in-part of Ser. No. US 1995-421583, filed on 12 Apr
        1995, GRANTED, Pat. No. US 6335358
DT
        Utility
FS
        APPLICATION
LN.CNT 3836
        INCLM: 514/369.000
INCL
        INCLS: 514/376.000; 514/386.000; 514/409.000; 514/424.000; 514/438.000;
                514/471.000; 514/473.000; 548/182.000; 548/190.000; 548/229.000;
                548/233.000; 548/316.400; 548/321.500; 548/543.000; 548/558.000;
                549/062.000; 549/321.000
                514/369.000
NCL
        NCLM:
                514/376.000; 514/386.000; 514/409.000; 514/424.000; 514/438.000; 514/471.000; 514/473.000; 548/182.000; 548/190.000; 548/229.000; 548/233.000; 548/316.400; 548/321.500; 548/543.000; 548/558.000; 549/062.000; 549/321.000
        NCLS:
IC
        [7]
        ICM: C07D333-32
        ICS: C07D333-34; C07D277-12; C07D277-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 110 OF 391 USPATFULL ON STN
AN
        2003:173967
                      USPATFULL
TI
        Lactams substituted by cyclic succinates as inhibitors of A-beta protein
        production
       Olson, Richard E., Wilmington, DE, UNITED STATES US 2003119815 A1 20030626
IN
PΙ
                                   20030626
ΑI
        us 2002-287099
                             Α1
                                   20021104 (10)
        Division of Ser. No. US 2001-871840, filed on 1 Jun 2001, GRANTED, Pat.
RLI
        No. US 6509333
PRAI
        US 2000-208536P
                               20000601 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 6497
        INCLM: 514/212.030
INCL
        INCLS: 514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;
                540/524.000; 540/527.000; 546/207.000; 546/216.000
NCL
                514/212.030
                514/212.080; 514/183.000; 514/327.000; 514/326.000; 540/451.000;
        NCLS:
                540/524.000; 540/527.000; 546/207.000; 546/216.000
IC
        [7]
        ICM: A61K031-55
        ICS: A61K031-454; C07D043-02; C07D041-02; C07D223-12; C07D211-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 111 OF 391 USPATFULL ON STN
L4
        2003:173922 USPATFULL
ΑN
        Intercellular delivery of a herpes simplex virus VP22 fusion protein
TI
        from cells infected with lentiviral vectors
        Lai, Zhennan, N. Potomac, MD, UNITED STATES
IN
        Reiser, Jakob, New Orleans, LA, UNITED STATES
        Brady, Roscoe O., Rockville, MD, UNITED STATES US 2003119770 A1 20030626
PΙ
        us 2002-212634
                                   20020802 (10)
ΑI
                             Α1
        US 2001-310012P
PRAI
                               20010802 (60)
       Utility
DT
        APPLICATION
FS
LN.CNT 2103
        INCLM: 514/044.000
INCL
        INCLS: 424/093.200; 435/456.000; 435/320.100; 435/235.100
NCL
        NCLM:
                514/044.000
                424/093.200; 435/456.000; 435/320.100; 435/235.100
        NCLS:
        [7]
        ICM: A61K048-00
        ICS: C12N007-00; C12N015-867
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L4
      ANSWER 112 OF 391 USPATFULL ON STN
ΑN
         2003:165862
                       USPATFULL
TI
        Directed evolution of novel binding proteins
        Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
IN
        Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
        Roberts, Bruce Lindsay, Milford, MA, UNITED STATES Markland, William, Milford, MA, UNITED STATES
         Ley, Arthur Charles, Newton, MA, UNITED STATES
        Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
PΙ
        US 2003113717
                                A1
                                      20030619
                                      20010629 (9)
ΑI
        US 2001-893878
                                Α1
        Continuation of Ser. No. US 1997-993776, filed on 18 Dec 1997, PENDING Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
RLI
        ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
        Sep 1988, ABANDONED
PRAI
        wo 1989-US3731
                                 19890901
        Utility
DT
        APPLICATION
FS
LN.CNT 15933
INCL
         INCLM: 435/006.000
         INCLS: 435/007.200; 435/455.000; 435/091.200
                 435/006.000
NCL
                435/007.200; 435/455.000; 435/091.200
        NCLS:
         [7]
IC
         ICM: C12Q001-68
         ICS: G01N033-53; G01N033-567; C12P019-34; C12N015-87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
1.4
      ANSWER 113 OF 391 USPATFULL on STN
         2003:159944 USPATFULL
ΑN
TI
        N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds
        Gailunas, Andrea, Burlingame, CA, UNITED STÁTES
IN
         Tucker, John A., San Mateo, CA, UNITED STATES
         TenBrink, Ruth, Kalamazoo, MI, UNITED STATES
        Mickelson, John, Mattawan, MI, UNITED STATES
        US 2003109559
                                      20030612
ΡI
                                Α1
        US 2002-193044
                                      20020711 (10)
ΑI
                                Α1
                                 20011217 (60)
        US 2001-341341P
PRAI
                                 20020514 (60)
20010730 (60)
        us 2002-380574P
        US 2001-308756P
                                 20011217 (60)
         US 2001-341416P
        US 2001-344872P
                                 20011221 (60)
        US 2001-304525P
                                 20010711 (60)
DT
        Utility
         APPLICATION
FS
LN.CNT
        5746
INCL
         INCLM: 514/357.000
        INCLS: 514/408.000; 514/617.000; 514/114.000; 514/517.000; 514/521.000; 514/563.000; 514/603.000; 548/567.000; 548/413.000; 546/330.000; 546/336.000; 558/166.000; 558/167.000; 558/414.000; 564/152.000
                 514/357.000
NCL
         NCLM:
                 514/408.000; 514/617.000; 514/114.000; 514/517.000; 514/521.000;
         NCLS:
                 514/563.000; 514/603.000; 548/567.000; 548/413.000; 546/330.000;
                 546/336.000; 558/166.000; 558/167.000; 558/414.000; 564/152.000
IC
         [7]
         ICM: A61K031-66
         ICS: A61K031-44; A61K031-40; A61K031-277; A61K031-198; A61K031-165;
         A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 114 OF 391 USPATFULL ON STN
         2003:159842 USPATFULL
AN
         Multi-component antioxidant compounds, pharmaceutical compositions
TI
         containing same and their use for reducing or preventing oxidative
         stress
         Atlas, Daphne, Jerusalem, ISRAEL
IN
         Yissum Research Development Company of the Hebrew University of
PA
         Jerusalem (non-U.S. corporation)
         us 2003109457
PΙ
                                Α1
                                      20030612
         us 2002-234319
                                      20020905 (10)
ΑI
                                Α1
         WO 2001-IL984
PRAI
                                 20011025
```

Utility

DT

```
LN.CNT 1867
       INCLM: 514/018.000
INCL
       INCLS: 514/017.000; 530/330.000; 530/331.000
NCL
       NCLM:
               514/018.000
       NCLS:
               514/017.000; 530/330.000; 530/331.000
       [7]
IC
       ICM: A61K038-06
       ICS: A61K038-05; C07K005-06; C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 115 OF 391 USPATFULL ON STN
L4
AN
       2003:159365 USPATFULL
       Whole cell assay systems for cell surface proteases
Ciambrone, Gary J., Redwood City, CA, UNITED STATES
TT
IN
       Gibbons, Ian, Portola Valley, CA, UNITED STATES
                            Α1
                                  20030612
PΙ
       us 2003108978
       us 2002-281458
                                  20021025 (10)
                            Α1
AΙ
PRAI
       US 2001-337641P
                             20011025 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 2061
INCL
       INCLM: 435/024.000
       INCLS: 435/810.000
               435/024.000
NCL
       NCLM:
              435/810.000
       NCLS:
       [7]
IC
       ICM: C12Q001-37
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 116 OF 391 USPATFULL ON STN
L4
       2003:159291 USPATFULL
AN
TI
       Novel scavenger receptors
       Wakamiya, Nobutaka, Hokkaido, JAPAN
IN
                                  20030612
       US 2003108904
PΙ
                            Α1
       US 2002-203860
                                  20020930 (10)
                            Α1
ΑI
       WO 2001-JP874
                                  20010208
                             20000214
PRAI
       JP 2000-35155
                             20001010
       JP 2000-309068
DT
       Utility
       APPLICATION
FS
LN.CNT 3200
       INCLM: 435/006.000
INCL
        INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
               435/006.000
NCL
        NCLM:
               435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
       NCLS:
IC
        [7]
        ICM: C12Q001-68
        ICS: C07H021-04; C12P021-02; C12N005-06; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 117 OF 391 USPATFULL ON STN
L4
AN
        2003:158903 USPATFULL
TI
       Death domain containing receptor 4
       Ni, Jian, Rockville, MD, UNITED STATES
IN
        Rosen, Craig A., Laytonsville, MD, UNITED STATES
        Pan, James G., Belmont, CA, UNITED STATES
        Gentz, Reiner L., Rockville, MD, UNITED STATES
       Dixit, Vishva M., Los Altos Hills, CA, UNITED STATES
       Human Genome Sciences, Inc., Rockville, MD (U.S. corporation)
PA
                                  20030612
       US 2003108516
                            Α1
ΡI
        us 2002-175902
                            Α1
                                  20020621 (10)
ΑI
       Division of Ser. No. US 2000-565918, filed on 5 May 2000, GRANTED, Pat. No. US 6433147 Division of Ser. No. US 1998-13895, filed on 27 Jan 1998,
RLI
        GRANTED, Pat. No. US 6342363
        US 1999-132922P
                             19990506 (60)
PRAI
        US 1997-37829P
                             19970205 (60)
        US 1997-35722P
                             19970128 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 9230
        INCLM: 424/085.100
INCL
        INCLS: 424/155.100; 514/012.000
               424/085.100
NCL
        NCLM:
               424/155.100; 514/012.000
        NCLS:
        [7]
```

IC

```
ICS: A61K038-19: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 118 OF 391 USPATFULL on STN
ΑN
       2003:152699 USPATFULL
TI
       Method of reducing cellular production of amyloid beta
ΙN
       Gurney, Mark E., Grand Rapids, MI, UNITED STATES
       Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
       Parodi, Luis A., Stockholm, SWEDEN
       Yan, Riqiang, Kalamazoo, MI, UNITED STATES
US 2003104365 A1 20030605
       us 2003104365
PΙ
       US 2000-548366
ΑI
                           Α1
                                 20000412 (9)
       Division of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
RLI
       Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
       ABANDONED Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23
       Sep 1999, UNKNOWN
       US 1998-101594P
PRAI
                            19980924 (60)
       US 1999-155493P
                            19990923 (60)
DT
       Utility
       APPLICATION
FS
      5578
LN.CNT
       INCLM: 435/006.000
INCL
       INCLS: 435/069.100; 435/226.000; 435/320.100; 435/368.000; 536/023.200
NCL
              435/006.000
              435/069.100; 435/226.000; 435/320.100; 435/368.000; 536/023.200
       NCLS:
IC
       [7]
       ICM: C12Q001-68
       ICS: C07H021-04; C12N009-64; C12N005-08; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 119 OF 391 USPATFULL on STN
       2003:146795
                    USPATFULL
ΑN
       5-hydroxysapogenin derivatives with anti-dementia activity
TI
TN
       Barraclough, Paul, Maidstone, UNITED KINGDOM
       Hanson, Jim, Steyning, UNITED KINGDOM
       Gunning, Phil, Grantchester, UNITED KINGDOM
       Rees, Daryl, Sandy, UNITED KINGDOM
       Xia, Zongqin, Shanghai, CHINA
       Hu, Yaer, Shanghai, CHINA
US 2003100542 A1 20
PΙ
                                 20030529
       us 2002-108737
                                 20020328 (10)
ΑI
                           Α1
       Continuation-in-part of Ser. No. WO 2000-GB3750, filed on 29 Sep 2000,
RLI
       UNKNOWN
DT
       Utility
FS
       APPLICATION
LN.CNT 887
       INCLM: 514/172.000
INCL
NCL
       NCLM: 514/172.000
IC
       [7]
       ICM: A61K031-58
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 120 OF 391 USPATFULL ON STN
       2003:146345 USPATFULL
AN
       Metalloprotease-disintegrin ADAM23 (SVPH3-17)
TI
       Cerretti, Douglas P., Seattle, WA, UNITED STATES
IN
       Immunex Corporation (U.S. corporation)
PA
       us 2003100091
                           Α1
                                 20030529
PΙ
       us 2002-202675
                                 20020723 (10)
ΑI
                           Α1
       Division of Ser. No. US 634252, PENDING Continuation of Ser. No. WO
RLI
       1999-US3016, filed on 11 Feb 1999, PENDING
       US 1998-74310P
                            19980211 (60)
PRAI
DT
       utility
       APPLICATION
FS
LN.CNT 3070
INCL
       INCLM: 435/196.000
       INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
              435/196.000
NCL
       NCLM:
       NCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC
       [7]
       ICM: C12N009-16
       ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
AN
       2003:146281 USPATFULL
ΤI
       Methods and compositions using coiled binding partners
       Colyer, John, West Yorkshire, UNITED KINGDOM
Lightowler, Joanne, York, UNITED KINGDOM
IN
PΙ
       US 2003100027
                                 20030529
                            Α1
                                 20000126 (9)
ΑI
       US 2000-491614
                            Α1
       Continuation-in-part of Ser. No. US 1999-259474, filed on 26 Feb 1999,
RLI
DT
       Utility
       APPLICATION
FS
LN.CNT 2588
       INCLM: 435/007.400
INCL
NCL
       NCLM: 435/007.400
        [7]
IC
       ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 122 OF 391 USPATFULL on STN
ΑN
       2003:145900 USPATFULL
       CD40 ligand and CD40 agonist compositions and methods of use
TI
IN
       Ahuja, Seema A., San Antonio, TX, UNITED STATES
       Bonewald, Lynda F., San Antonio, TX, UNITED STATES
Board of Regents, The University of Texas System (U.S. corporation)
PA
       us 2003099644
                                 20030529
PΙ
                            Α1
       us 2002-242212
ΑI
                            Α1
                                 20020912 (10)
       Division of Ser. No. US 2000-645926, filed on 24 Aug 2000, GRANTED, Pat.
RLI
       No. US 6482411
                             19990827 (60)
PRAI
       US 1999-151250P
DT
       Utility
       APPLICATION
FS
LN.CNT 5263
INCL
       INCLM: 424/144.100
       INCLS: 514/012.000
NCL
       NCLM:
               424/144.100
               514/012.000
       NCLS:
        [7]
IC
       ICM: A61K039-395
       ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 123 OF 391 USPATFULL ON STN
       2003:140906 USPATFULL
AN
       Methods and compositions for the treatment of diseases associated with
TI
       signal transduction aberrations
       Holoshitz, Joseph, Ann Arbor, MI, UNITED STATES
IN
       Ling, Song, Ann Arbor, MI, UNITED STATES
PA
       The Regents Of The University Of Michigan (U.S. corporation)
       us 2003096748
                                  20030522
PΙ
                            A1
       us 2002-161959
                            Α1
                                  20020603 (10)
ΑI
                             20010604 (60)
PRAI
       us 2001-295691P
DT
       Utility
FS
       APPLICATION
LN.CNT 2986
        INCLM: 514/012.000
INCL
       INCLS: 530/359.000
               514/012.000
       NCLM:
NCL
               530/359.000
        NCLS:
        [7]
IC
        ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 124 OF 391 USPATFULL on STN 2003:140551 USPATFULL
L4
AN
                         ***human***
                                       prolyl oligopeptidase and uses therefor
        21163, a novel
TI
       Hunter, John Joseph, Somerville, MA, UNITED STATES
TN
       Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
PA
       Millennium Pharmaceuticals, Inc. (U.S. corporation)
        US 2003096392
                                  20030522
PΙ
                            Α1
       us 2001-25950
                                  20011219 (10)
ΑI
                            Α1
       US 2000-257736P
PRAI
                             20001222 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 4648
        INCLM: 435/226.000
INCL
```

INCLS: 435/069.100; 435/006.000; 435/320.100; 435/325.000; 536/023.200

```
435/069.100; 435/006.000; 435/320.100; 435/325.000; 536/023.200
IC
       [7]
       ICM: C12N009-64
       ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 125 OF 391 USPATFULL ON STN
       2003:140515 USPATFULL
ΑN
       Novel G-protein-coupled receptor like proteins and polynucleotides
ΤI
       encoded by them, and methods of using same
       Ozenberger, Bradley A., Newtown, PA, UNITED STATES
Kajkowski, Eileen M., Ringoes, NJ, UNITED STATES
IN
       Lo, Ching-Hsiung Frederick, reminingeon, o., sofia, Heidi, Walla Walla, WA, UNITED STATES
           Ching-Hsiung Frederick, Pennington, NJ, UNITED STATES
       Wyeth, Madison, NJ (U.S. corporation)
PA
       us 2003096356
                            Α1
                                 20030522
ΡI
                                 20020718 (10)
ΑI
       US 2002-199881
                            Α1
       Continuation of Ser. No. US 2001-833503, filed on 12 Apr 2001, PENDING
RLI
       wo 1999-US21621
                             19991013
PRAI
       US 1998-104104P
                             19981013 (60)
DT
       Utility
       APPLICATION
FS
       1744
LN.CNT
       INCLM: 435/069.100
INCL
       INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
               435/069.100
NCL
       NCLM:
       NCLS:
               435/320.100; 435/325.000; 530/350.000; 536/023.500
IC
       [7]
       ICM: C07K014-705
       ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 126 OF 391 USPATFULL ON STN
L4
       2003:140406
ΑN
                     USPATFULL
          ***Human***
                         cDNAs and proteins and uses thereof
TI
IN
       Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
       GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PA
       us 2003096247
                                 20030522
PΙ
                            Α1
       US 2001-986
                                  20011114 (10)
ΑI
                            Α1
       Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
RLI
       WO 2001-IB1715
                             20010806
PRAI
       US
          2001-305456P
                             20010713 (60)
          2001-302277P
                             20010629 (60)
       US
       US 2001-298698P
                             20010615 (60)
                             20010525 (60)
       US 2001-293574P
DT
       Utility
       APPLICATION
FS
LN.CNT 25656
       INCLM: 435/006.000
INCL
       INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
               536/023.200; 800/008.000
NCL
       NCLM:
               435/006.000
               435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
       NCLS:
               536/023.200; 800/008.000
IC
       [7]
       ICM: C12Q001-68
       ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 127 OF 391 USPATFULL ON STN
AN
       2003:135733 USPATFULL
TI
       Transgenic animal model of neurodegenerative disorders
IN
       St. George-Hyslop, Peter H., Toronto, CANADA
       Fraser, Paul E., Toronto, CANADA
Westaway, David, Etobicoke, CANADA
                                 20030515
PΙ
       US 2003093822
                            Α1
                                  20010619 (9)
ΑI
       US 2001-884629
                            Α1
                             20000620 (60)
PRAI
       US 2000-212534P
DT
       Utility
FS
       APPLICATION
LN.CNT 1380
       INCLM: 800/018.000
INCL
       INCLS: 800/012.000
```

NCL

NCLM:

800/018.000

```
IC
        [7]
        ICM: A01K067-027
L4
      ANSWER 128 OF 391 USPATFULL ON STN 2003:134658 USPATFULL
ΑN
TI
        Aminediols for the treatment of Alzheimer's disease
        Schostarez, Heinrich Josef, Portage, MI, UNITED STATES
IN
        Chrusciel, Robert Alan, Portage, MI, UNITED STATES
PΤ
        US 2003092747
                              A1
                                    20030515
        US 2002-171343
ΑI
                              A1
                                    20020613 (10)
                               20010613 (60)
20011119 (60)
PRAI
        US 2001-297827P
        US 2001-333084P
DT
        Utility
        APPLICATION
FS
LN.CNT 4779
        INCLM: 514/357.000
INCL
        INCLS: 514/428.000; 514/651.000; 514/620.000; 514/603.000; 514/522.000; 514/534.000; 546/329.000; 546/330.000; 548/561.000; 558/415.000;
                560/037.000; 564/355.000; 564/086.000; 564/164.000
                514/357.000
NCL
        NCLM:
                514/428.000; 514/651.000; 514/620.000; 514/603.000; 514/522.000; 514/534.000; 546/329.000; 546/330.000; 548/561.000; 558/415.000; 560/037.000; 564/355.000; 564/086.000; 564/164.000
        NCLS:
IC
        ICM: A61K031-44
        ICS: A61K031-40; A61K031-277; A61K031-165; A61K031-137; A61K031-24;
        A61K031-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 129 OF 391 USPATFULL on STN
AN
        2003:134570 USPATFULL
        Antisense compounds which prevent cell death and uses thereof
TI
IN
        Troy, Carol M., Hastings-on-Hudson, NY, UNITED STATES
        Shelanski, Michael L., Brooklyn, NY, UNITED STATES
ΡI
        us 2003092659
                              Α1
                                    20030515
ΑI
        us 2002-185084
                              Α1
                                    20020628 (10)
        Continuation of Ser. No. US 1999-397711, filed on 3 Sep 1999, PENDING Continuation of Ser. No. WO 1998-US4128, filed on 3 Mar 1998, PENDING
RLI
        Continuation-in-part of Ser. No. US 1997-810540, filed on 3 Mar 1997,
        GRANTED, Pat. No. US 5929042
DT
        Utility
        APPLICATION
FS
LN.CNT 1113
        INCLM: 514/044.000
INCL
                514/014.000; 536/023.100; 530/326.000
        INCLS:
NCL
        NCLM:
                514/044.000
        NCLS:
                514/014.000; 536/023.100; 530/326.000
        [7]
TC
        ICM: A61K048-00
        ICS: A61K038-10; C07H021-04; C07K007-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 130 OF 391 USPATFULL on STN
        2003:134541
                      USPATFULL
AN
        Inhibitors of memapsin 2 and use thereof
TI
IN
        Tang, Jordan J. N., Edmond, OK, UNITED STATES
        Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
        Ghosh, Arun K., River Forest, IL, UNITED STATES
        Oklahóma Medical Research Foundation, Oklahóma City, OK (U.S.
PA
        corporation)
        us 2003092629
PΙ
                                    20030515
                              Α1
        us 2001-32818
                                    20011228 (10)
ΑI
                              Α1
                                20010314 (60)
PRAI
        US 2001-275756P
        US 2000-258705P
                               20001228 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 2203
INCL
        INCLM: 514/013.000
        INCLS: 530/326.000
NCL
                514/013.000
        NCLM:
        NCLS:
                530/326.000
IC
        [7]
        ICM: A61K038-10
        ICS: C07K007-08
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L4
     ANSWER 131 OF 391 USPATFULL ON STN 2003:134526 USPATFULL
AN
TI
       ADPI-41, a novel protein isolated from brain tissue homogenate and uses
       therefor
IN
       Herath, Herath Mudiyanselage Athula Chandrasiri, Abingdon, UNITED
       KINGDOM
       Parekh, Rajesh Bhikhu, Near Wendlebury, UNITED KINGDOM
       Rohlff, Christian, Oxford, UNITED KINGDOM
       Terrett, Jonathan Alexander, Abingdon, UNITED KINGDOM
       Tyson, Kerry Louise, Caversham, UNITED KINGDOM
PΙ
       US 2003092614
                                20030515
                           Α1
                                20011210 (10)
ΑI
       us 2001-14338
                           Α1
       US 2000-254431P
PRAI
                            20001208 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 4183
       INCLM: 514/012.000
INCL
       INCLS: 530/350.000; 435/069.700; 435/325.000; 435/320.100; 536/023.500
              514/012.000
NCL
       NCLM:
              530/350.000; 435/069.700; 435/325.000; 435/320.100; 536/023.500
       NCLS:
IC
       [7]
       ICM: C12P021-02
       ICS: C12N005-06; A61K038-17; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 132 OF 391 USPATFULL ON STN
       2003:133985 USPATFULL
ΑN
TI
       Genetic construct intracellular monitoring system
       Zhao, Sharon, Union City, CA, UNITED STATES
IN
       Vainshtein, Inna, Palo Alto, CA, UNITED STATES
       Eglen, Richard, Los Altos, CA, UNITED STATES
US 2003092070 A1 20030515
PΙ
       us 2002-229747
                                 20020827 (10)
ΑI
                           Α1
       US 2001-316428P
                            20010830 (60)
PRAI
       US 2001-343156P
                            20011021 (60)
       US 2002-353086P
                            20020130 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1578
       INCLM: 435/007.200
INCL
       INCLS: 435/200.000; 435/207.000
              435/007.200
NCL
       NCLM:
       NCLS:
              435/200.000; 435/207.000
       [7]
IC
       ICM: G01N033-53
       ICS: G01N033-567: C12N009-24: C12N009-38
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 133 OF 391 USPATFULL on STN
       2003:133926
AN
                    USPATFULL
         ***Human***
TI
                        cDNAs and proteins and uses thereof
       Bejanin, Stephane, Paris, FRANCE
IN
       Tanaka, Hiroaki, Antony, FRANCE
PΑ
       GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
       us 2003092011
                                20030515
PΙ
                           Α1
ΑI
       US 2001-489
                           Α1
                                 20011114 (10)
       Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
RLI
PRAI
       WO 2001-IB1715
                            20010806
       US 2001-305456P
                            20010713 (60)
       US 2001-302277P
                            20010629 (60)
       US 2001-298698P
                            20010615 (60)
       US 2001-293574P
                            20010525 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 25607
       INCLM: 435/006.000
INCL
       INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;
               435/325.000; 536/023.200
NCL
              435/006.000
       NCLM:
               800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100;
       NCLS:
               435/325.000; 536/023.200
IC
       [7]
       ICM: C12Q001-68
       ICS: G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02;
```

C12N005-06

```
L4
     ANSWER 134 OF 391 USPATFULL ON STN
AN
       2003:127194 USPATFULL
       Peptides and pharmaceutical compositions thereof for treatment of
TI
       disorders or diseases associated with abnormal protein folding into
       amyloid or amyloid-like deposits
       Soto-Jara, Claudio, New York, NY, UNITED STATES
IN
       Baumann, Marc H., Helsinki, FINLAND
       Frangione, Blas, New York, NY, UNITED STATES
       New York University, New York, NY (U.S. corporation)
PA
       US 2003087407
                           Α1
                                 20030508
PΙ
       US 2002-235483
                           Α1
                                 20020906 (10)
ΑI
       Continuation of Ser. No. US 1996-766596, filed on 12 Dec 1996, GRANTED,
RLI
       Pat. No. US 6462171 Continuation-in-part of Ser. No. US 1996-630645,
       filed on 10 Apr 1996, GRANTED, Pat. No. US 5948763 Continuation-in-part of Ser. No. US 1995-478326, filed on 7 Jun 1995, ABANDONED
       Utility
DT
       APPLICATION
FS
LN.CNT 1973
INCL
       INCLM: 435/184.000
       INCLS: 435/069.200; 435/320.100; 435/325.000
               435/184.000
NCL
              435/069.200; 435/320.100; 435/325.000
       NCLS:
       [7]
IC
       ICM: C12N009-99
       ICS: C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 135 OF 391 USPATFULL ON STN
                    USPATFULL
       2003:121034
ΑN
       Substituted alcohols useful in treatment of Alzheimer's disease
TT
       John, Varghese, San Francisco, CA, UNITED STATES
IN
       Hom, Roy, San Francisco, CA, UNITED STATES
       Tucker, John, San Mateo, CA, UNITED STATES
       US 2003083518
                                 20030501
PΙ
                           A1
       US 2002-183126
                                 20020627 (10)
ΑT
                            Α1
       US 2001-301210P
                             20010627 (60)
PRAI
                             20010918 (60)
       us 2001-323396P
                             20011119 (60)
       us 2001-332736P
DT
       Utility
       APPLICATION
FS
LN.CNT 3285
       INCLM: 558/390.000
INCL
       INCLS: 560/037.000; 564/355.000
               558/390.000
NCL
       NCLM:
       NCLS:
               560/037.000; 564/355.000
IC
        [7]
        ICM: C07C255-58
        ICS: C07C317-26; C07C229-52; C07C215-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 136 OF 391 USPATFULL ON STN
        2003:120872 USPATFULL
ΑN
        Statine derivatives for the treatment of Alzheimer's disease
TI
        Schostarez, Heinrich Josef, Portage, MI, UNITED STATES
IN
       Chrusciel, Robert Alan, Portage, MI, UNITED STATES
       us 2003083356
PI
                            A1
                                 20030501
       us 2002-192424
                                 20020710 (10)
ΑI
                            A1
                             20010710 (60)
PRAI
       US 2001-304128P
       US 2001-327424P
                             20011005 (60)
DT
       Utility
FS
        APPLICATION
LN.CNT 4084
        INCLM: 514/357.000
INCL
        INCLS: 514/428.000; 514/620.000; 514/626.000; 546/336.000; 548/567.000;
               564/164.000; 564/193.000
               514/357.000
NCL
        NCLM:
               514/428.000; 514/620.000; 514/626.000; 546/336.000; 548/567.000; 564/164.000; 564/193.000
        NCLS:
IC
        ICM: A61K031-44
        ICS: A61K031-40; A61K031-165; A61K031-16; C07D207-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ANSWER 137 OF 391 USPATFULL ON STN

L4

```
TI
        Diaminediols for the treatment of Alzheimer's disease
IN
        Schostarez, Heinrich Josef, Portage, MI, UNITED STATES
        Chrusciel, Robert A., Portage, MI, UNITED STATES
PΙ
       US 2003083353
                                   20030501
                             Α1
       US 2002-192625
ΑI
                                   20020710 (10)
                             Α1
PRAI
        US 2001-304305P
                              20010710 (60)
        US 2001-334480P
                              20011130 (60)
DT
        Utility
FS
       APPLICATION
LN.CNT 4041
        INCLM: 514/349.000
INCL
        INCLS: 514/426.000; 514/485.000; 514/519.000; 514/567.000; 514/669.000;
                514/646.000; 548/557.000; 546/304.000; 558/453.000; 560/024.000;
                560/157.000; 564/506.000
        NCLM:
                514/349.000
NCL
               514/426.000; 514/485.000; 514/519.000; 514/567.000; 514/669.000; 514/646.000; 548/557.000; 546/304.000; 558/453.000; 560/024.000; 560/157.000; 564/506.000
        NCLS:
        [7]
IC
        ICM: C07D213-72
        ICS: A61K031-44; A61K031-275; A61K031-325; A61K031-13; A61K031-135;
        A61K031-195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 138 OF 391 USPATFULL on STN
L4
        2003:120793 USPATFULL
ΑN
        Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's
TI
        disease in patients
       Hersh, Louis B., Lexington, KY, UNITED STATES US 2003083277 A1 20030501
IN
PΙ
        us 2001-792079
                                   20010226 (9)
ΑI
                              Α1
        US 2000-184826P
                              20000224 (60)
PRAI
        Utility
DT
        APPLICATION
FS
LN.CNT 1117
        INCLM: 514/044.000
INCL
        INCLS: 424/094.630; 424/093.210
        NCLM:
                514/044.000
NCL
               424/094.630; 424/093.210
        NCLS:
IC
        [7]
        ICM: A61K048-00
        ICS: A61K038-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 139 OF 391 USPATFULL on STN
ΑN
        2003:120290 USPATFULL
        Nucleic acids encoding
                                    ***human***
                                                    adamalysin SVPH1-8
TI
        Cerretti, Douglas P., Seattle, WA, UNITED STATES Immunex Corporation (U.S. corporation)
IN
PA
        us 2003082771
us 2002-265125
                                   20030501
PI
                              Α1
ΑI
                              Α1
                                   20021003 (10)
        Division of Ser. No. US 2000-617145, filed on 14 Jul 2000, GRANTED, Pat.
RLI
        No. US 6485956 Continuation of Ser. No. WO 1999-US603, filed on 12 Jan
        1999, PENDING
PRAI
        US 1998-71505P
                               19980114 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 2031
        INCLM: 435/189.000
INCL
        INCLS: 435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
                435/189.000
NCL
        NCLM:
                435/006.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
        NCLS:
        [7]
IC
        ICM: C120001-68
        ICS: C07H021-04: C12N009-02: C12P021-02: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 140 OF 391 USPATFULL ON STN
AN
        2003:120089 USPATFULL
TI
        High-throughput transcriptome and functional validation analysis
IN
        Melcher, Thorsten, San Francisco, CA, UNITED STATES
        McFarland, K. C., Davis, CA, UNITED STATES
Gan, Li, San Francisco, CA, UNITED STATES
Ye, Shiming, Albany, CA, UNITED STATES
```

Gonzalez-Zulueta, Mirella, Pacifica, CA, UNITED STATES

```
ΑI
       US 2002-116437
                                  20020403 (10)
                            Α1
        Continuation-in-part of Ser. No. US 2001-27807, filed on 19 Oct 2001.
RLI
        PENDING Continuation-in-part of Ser. No. US 2000-627362, filed on 28 Jul
       2000, ABANDONED
PRAI
        US 1999-146640P
                              19990730 (60)
       Utility
DT
FS
        APPLICATION
LN.CNT 3093
        INCLM: 435/006.000
INCL
        INCLS: 435/091.200
NCL
        NCLM:
               435/006.000
               435/091.200
        NCLS:
        [7]
IC
        ICM: C12Q001-68
        ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 141 OF 391 USPATFULL ON STN 2003:120071 USPATFULL
L4
AN
                                                    ***human***
        Novel nucleic acid sequences encoding
                                                                    cell adhesion
TI
       molecule protein-like polypeptides
ΙN
        Shimkets, Richard A., West Haven, CT, UNITED STATES
        Fernandes, Elma, Branford, CT, UNITED STATES
       Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
        CuraGen Corporation, New Haven, CT, 06511
PA
       us 2003082554
PΙ
                            A1
                                   20030501
       US 2001-977033 A1 20011015 (9)
Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
US 2000-201388P 20000503 (60)
US 2000-193086P 20000330 (60)
ΑI
RLI
PRAI
       US 2000-191158P
                              20000322 (60)
       US 2000-189810P
                              20000316 (60)
        US 1999-137322P
                              19990603 (60)
       Utility
DT
FS
        APPLICATION
LN.CNT 7063
INCL
        INCLM: 435/006.000
        INCLS: 435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500
               435/006.000
NCL
        NCLM:
               435/069.100; 435/325.000; 435/320.100; 530/350.000; 536/023.500
        NCLS:
        [7]
IC
        ICM: C07K014-435
        ICS: C12Q001-68; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 142 OF 391 USPATFULL on STN
L4
ΑN
        2003:113499 USPATFULL
        Phosphinylmethyl and phosphorylmethyl succinic and glutaric acid analogs
TI
        as beta-secretase inhibitors
       Etcheberrigaray, Rene, Columia, MD, UNITED STATES Qiao, Lixin, Arlington, VA, UNITED STATES
IN
       Neurologic, Inc. (U.S. corporation)
PA
PΙ
        us 2003078240
                            Α1
                                   20030424
ΑI
        us 2002-274523
                             Α1
                                   20021021 (10)
        Division of Ser. No. US 2001-866764, filed on 30 May 2001, PENDING
RLI
DT
        Utility
FS
        APPLICATION
LN.CNT 776
INCL
        INCLM: 514/114.000
               514/120.000; 562/011.000; 562/015.000; 562/024.000
        INCLS:
                514/114.000
NCL
        NCLM:
               514/120.000; 562/011.000; 562/015.000; 562/024.000
        NCLS:
        [7]
IC
        ICM: A61K031-66
        ICS: A61k031-663; C07F009-22; C07F009-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 143 OF 391 USPATFULL ON STN
L4
        2003:113462 USPATFULL
AΝ
        Covalently reactive transition state analogs and methods of use thereof
TI
        Paul, Sudhir, Missouri City, TX, UNITED STATES
ΙN
        Nishiyama, Yasuhiro, Houston, TX, UNITED STATES
       us 2003078203
                                   20030424
PΙ
                            A1
```

20020401 (10)

Α1

US 2002-114716

AI

```
PENDING Division of Ser. No. US 1998-46373, filed on 23 Mar 1998.
       GRANTED, Pat. No. US 6235714
PRAI
       US 2001-280624P
                            20010331 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 2260
INCL
       INCLM: 514/012.000
       INCLS: 530/350.000; 530/351.000; 424/085.100; 424/085.200; 424/189.100;
              424/190.100
              514/012.000
NCL
       NCLM:
       NCLS:
              530/350.000; 530/351.000; 424/085.100; 424/085.200; 424/189.100;
              424/190.100
IC
       [7]
       ICM: A61K039-29
       ICS: A61K039-02; A61K038-20; A61K038-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 144 OF 391 USPATFULL on STN
L4
ΑN
       2003:112961 USPATFULL
       DEATH DOMAIN CONTAINING RECEPTORS
TI
IN
       YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
       NI, JIAN, ROCKVILLE, MD, UNITED STATES
       DIXIT, VISHVA, ANN ARBOR, MI, UNITED STATES
       GENTZ, REINER L., SILVER SPRING, MD, UNITED STATES
       DILLON, PATRICK J., GAITHERSBURG, MD, UNITED STATES
ΡI
       us 2003077694
                          Α1
                                20030424
ΑI
       US 1999-314889
                          Α1
                                19990519 (9)
       Continuation of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED.
RLI
       Pat. No. US 6153402
       US 1996-13285P
                           19960312 (60)
PRAI
       US 1996-28711P
                           19961017 (60)
       US 1997-37341P
                           19970206 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 3011
INCL
       INCLM: 435/069.100
       INCLS: 536/023.500; 435/320.100; 530/324.000; 530/387.900; 514/002.000
NCL
       NCLM:
              435/069.100
       NCLS:
              536/023.500; 435/320.100; 530/324.000; 530/387.900; 514/002.000
       [7]
IC
       ICM: A01N037-18
       ICS: A61K038-00; C07H021-04; C12P021-06; C12N015-00; C12N015-09;
       C12N015-63; C12N015-70; C12N015-74; C07K005-00; C07K007-00; C07K016-00;
       C07K017-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 145 OF 391 USPATFULL on STN
       2003:112496 USPATFULL
ΑN
TI
       Alzheimer's disease, secretase, app substrates therefor, and uses
       therefor
       Gurney, Mark E, Gran Rapids, MI, UNITED STATES
IN
       Bienkowski, Michael J, Kalamazoo, MI, UNITED STATES
       Heinrikson, Robert L, Plainwell, MI, UNITED STATES
       Parodi, Luis A, Stockholm, SWEDEN
       Yan, Riqiang, Kalamazo, MI, UNITED STATES
PI
       US 2003077226
                                20030424
                          Α1
                                         (9)
ΑI
       us 2001-869414
                          Α1
                                20010627
       WO 2001-IB797
                                20010509
DT
       Utility
       APPLICATION
FS
LN.CNT
      5976
INCL
       INCLM: 424/009.600
       INCLS: 530/350.000; 435/366.000; 435/069.100; 435/320.100
NCL
       NCLM:
              424/009.600
       NCLS:
              530/350.000; 435/366.000; 435/069.100; 435/320.100
IC
       [7]
       ICM: A61K049-00
       ICS: C12N005-08: C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
    ANSWER 146 OF 391 USPATFULL on STN
AN
       2003:106932
                    USPATFULL
       Sulfonyl aryl hydroxamates and their use as matrix metalloprotease
TI
       inhibitors
IN
       Barta, Thomas E., Evanston, IL, UNITED STATES
```

```
Bedell, Louis J., Prospect Heights, IL, UNITED STATES
        DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES
        Freskos, John N., Clayton, MO, UNITED STATES
         Getman, Daniel P., Chesterfield, MO, UNITED STATES
        McDonald, Joseph J., Wildwood, MO, UNITED STATES
        Mischke, Brent V., Defiance, MO, UNITED STATES
        Rao, Shashidhar N., Saint Louis, MO, UNITED STATES
        Villamil, Clara I., Glenview, IL, UNITED STATES
                                      20030417
PΙ
        US 2003073845
                                Α1
        US 2001-909227
ΑI
                                      20010719 (9)
                                A1
        Continuation-in-part of Ser. No. US 2000-569034, filed on 11 May 2000,
RLI
        PENDING Continuation-in-part of Ser. No. US 1999-310813, filed on 12 May
        1999, ABANDONED Continuation-in-part of Ser. No. US 1999-230209, filed
        on 24 Jun 1999, GRANTED, Pat. No. US 6380258 A 371 of International Ser.
        No. WO 1998-US4300, filed on 4 Mar 1998, UNKNOWN Continuation-in-part of
        Ser. No. US 2000-728408, filed on 1 Dec 2000, PENDING Continuation of Ser. No. US 1999-310813, filed on 12 May 1999, ABANDONED
                                 19970304 (60)
PRAI
        US 1997-35182P
        Utility
DT
FS
        APPLICATION
LN.CNT
        5507
        INCLM: 546/216.000
INCL
        INCLS: 546/223.000; 534/751.000
                 546/216.000
NCL
        NCLM:
        NCLS:
                 546/223.000: 534/751.000
IC
        [7]
        ICM: C07D211-54
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 147 OF 391 USPATFULL on STN 2003:106806 USPATFULL
L4
ΑN
        Aromatic sulfone hydroxamic acids and their use as protease inhibitors
TI
        Barta, Thomas E., Evanston, IL, UNITED STATES
IN
        Becker, Daniel P., Glenview, IL, UNITED STATES
        Bedell, Louis J., Mt.Prospect, IL, UNITED STATES
        Boehm, Terri L., Ballwin, MO, UNITED STATES
        Carroll, Jeffery N., Columbia, IL, UNITED STATES
        DeCrescenzo, Gary A., St. Charles, MO, UNITED STATES Fobian, Yvette M., Wildwood, MO, UNITED STATES
        Freskos, John N., Clayton, MO, UNITED STATES
Getman, Daniel P., Chesterfield, MO, UNITED STATES
McDonald, Joseph J., Wildwood, MO, UNITED STATES
        Li, Madeleine H., Vernon Hills, MO, UNITED STATES
        Hockerman, Susan L., Chicago, IL, UNITED STATES
        Howard, Carol Pearcy, Fenton, MO, UNITED STATES
        Kolodziej, Steve A., Ballwin, MO, UNITED STATES
        Mischke, Deborah A., Defiance, MO, UNITED STATES
        Rico, Joseph G., Ballwin, MO, UNITED STATES
        Stehle, Nathan W., Grafton, WI, UNITED STATES
Tollefson, Michael B., Hainesville, IL, UNITED STATES
Vernier, William F., St.Louis, MO, UNITED STATES
Villamil, Clara I., Glenview, IL, UNITED STATES
Kassab, Darren J., Wildwood, MO, UNITED STATES
Kassab, Darren J., Wildwood, MO, UNITED STATES
PΙ
        us 2003073718
                               A1
                                      20030417
ΑI
        us 2001-989943
                               Α1
                                      20011121 (9)
        Continuation-in-part of Ser. No. US 2000-570731, filed on 12 May 2000,
RLI
        PENDING
DT
        Utility
FS
        APPLICATION
LN.CNT
        4996
INCL
        INCLM:
                 514/316.000
                 514/317.000; 514/326.000; 546/189.000; 546/207.000
        INCLS:
NCL
                 514/316.000
        NCLM:
        NCLS:
                 514/317.000; 514/326.000; 546/189.000; 546/207.000
IC
        [7]
        ICM: A61K031-4545
        ICS: C07D047-02; C07D041-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 148 OF 391 USPATFULL ON STN
AN
        2003:106789 USPATFULL
TI
        Succinoylamino heterocycles as inhibitors of a beta protein production
        Thompson, Lorin A., Wilmington, DE, UNITED STATES Kasireddy, Padmaja, Kennett Square, PA, UNITED STATES
IN
```

20030417

A1

us 2003073701

PI

```
Utility
DT
        APPLICATION
FS
LN.CNT 3957
INCL
        INCLM: 514/255.010
        INCLS: 514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000;
                514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000; 544/333.000; 546/208.000
                514/255.010

514/253.010; 514/252.140; 514/256.000; 514/330.000; 514/318.000;

514/343.000; 514/423.000; 544/295.000; 544/360.000; 544/386.000;

544/333.000; 546/208.000
NCL
        NCLM:
        NCLS:
        [7]
IC
        ICM: A61K031-496
        ICS: A61K031-506; A61K031-4545
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 149 OF 391 USPATFULL ON STN
        2003:106698 USPATFULL
AN
       Yeast screens for treatment of ***human*** disease Lindquist, Susan, Chestnut Hill, MA, UNITED STATES Krobitsch, Sylvia, Berlin, GERMANY, FEDERAL REPUBLIC OF
TI
ΙN
        Outeiro, Tiago Fleming, Cambridge, MA, UNITED STATES
PA
        The University of Chicago (U.S. corporation)
PI
        us 2003073610
                                   20030417
                             Α1
ΑI
        us 2002-77584
                             Α1
                                   20020215 (10)
PRAI
        US 2001-269157P
                              20010215 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 3198
INCL
        INCLM: 514/001.000
        INCLS: 435/007.310; 435/254.200; 435/483.000
NCL
                514/001.000
        NCLM:
        NCLS:
               435/007.310; 435/254.200; 435/483.000
TC
        [7]
        ICM: A61K031-00
        ICS: G01N033-53; G01N033-569; C12N001-18; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 150 OF 391 USPATFULL ON STN
        2003:106163 USPATFULL
ΑN
        DIAGNOSTIC ASSAY FOR ALZHEIMER'S DISEASE: ASSESSMENT OF AB ABNORMALITIES
TI
IN
        TANZI, RUDOLPH E., CANTON, MA, UNITED STATES
        BUSH, ASHLEY I., SOMERVILLE, MA, UNITED STATES
        MOIR, ROBERT D., BOSTON, MA, UNITED STATES
ΡI
        us 2003073074
                             Α1
                                   20030417
ΑI
        us 1999-425956
                             Α1
                                   19991025 (9)
        Continuation of Ser. No. US 1997-817423, filed on 4 Aug 1997, GRANTED,
RLI
        Pat. No. US 5972634 A 371 of International Ser. No. WO 1994-US11895,
        filed on 19 Oct 1994, UNKNOWN
DT
        Utility
FS
        APPLICATION
LN.CNT 2343
INCL
        INCLM: 435/006.000
        INCLS: 435/287.200; 435/007.900
NCL
               435/006.000
        NCLM:
               435/287.200; 435/007.900
        NCLS:
TC
        [7]
        ICM: C12Q001-68
        ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
1.4
     ANSWER 151 OF 391 USPATFULL ON STN
AN
        2003:105883 USPATFULL
        Encapsulation of plasmid DNA (lipogenes.TM.) and therapeutic agents with
TI
        nuclear localization signal/fusogenic peptide conjugates into targeted
        liposome complexes
IN
        Boulikas, Teni, Mountain View, CA, UNITED STATES
        US 2003072794
PΙ
                                   20030417
                             Α1
       us 2001-876904
                                   20010608 (9)
ΑI
                             Α1
PRAI
        US 2000-210925P
                              20000609 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 4201
INCL
        INCLM: 424/450.000
        INCLS: 435/458.000; 435/320.100; 514/044.000; 264/004.000
```

```
NCLs: 435/458.000; 435/320.100; 514/044.000; 264/004.000
        [7]
IC
        ICM: A61K048-00
        ICS: A61K009-127; C12N015-88
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 152 OF 391 USPATFULL ON STN
ΑN
        2003:102440 USPATFULL
        Stable macroscopic membranes formed by self-assembly of amphiphilic
ΤI
        peptides and uses therefor
IN
        Zhang, Shuguang, Cambridge, MA, United States
        Lockshin, Curtis, Lexington, MA, United States
Rich, Alexander, Cambridge, MA, United States
        Holmes, Todd, Cambridge, MA, United States
       Massachusettes Insitute of Technology, Cambridge, MA, United States
PA
        (U.S. corporation)
PΙ
        us 6548630
                             в1
                                  20030415
       US 1997-898300
ΑI
                                  19970722 (8)
        Continuation of Ser. No. US 1994-346849, filed on 30 Nov 1994,
RLI
        patented, Pat. No. US 5670483 Continuation of Ser. No. US 1992-973326,
        filed on 28 Dec 1992, now abandoned
DT
        Utility
        GRANTED
FS
LN.CNT 2187
INCL
        INCLM: 530/300.000
        INCLS: 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000;
                514/012.000; 514/013.000; 514/014.000
               530/300.000
NCL
       NCLM:
       NCLS:
               530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
IC
        [7]
        ICM: C07K007-00
        ICS: C07K016-00; A61K038-00
        514/12; 514/13; 514/14; 530/300; 530/324; 530/325; 530/326; 530/327;
EXF
        530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 153 OF 391 USPATFULL ON STN
ΑN
       2003:102126 USPATFULL
TT
        Lipopeptide stabilized microbubbles as diagnostic/therapeutic agents
IN
        Cuthbertson, Alan, Oslo, NORWAY
       Solbakken, Magne, Oslo, NORWAY Wolfe, Henry Raphael, Glenmoore, PA, United States
       Amersham Health AS, Oslo, NORWAY (non-U.S. corporation)
PA
       US 6548048
                            в1
                                  20030415
PΙ
ΑI
       US 2000-695273
                                  20001025 (9)
       Continuation of Ser. No. WO 1999-GB1247, filed on 22 Apr 1999
RLI
       GB 1998-9084
                              19980428
PRAI
       US 1998-84833P
                              19980508 (60)
       Utility
DT
        GRANTED
FS
LN.CNT
       1281
INCL
        INCLM: 424/009.520
        INCLS: 424/009.510; 424/450.000; 424/489.000; 424/499.000
NCL
       NCLM:
               424/009.520
        NCLS:
               424/009.510; 424/450.000; 424/489.000; 424/499.000
        [7]
IC
        ICM: A61B008-00
       ICS: A61K009-127; A61K009-14
424/9.51; 424/9.52; 424/9.5; 424/450; 424/489; 424/499; 600/441; 600/458
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 154 OF 391 USPATFULL on STN
AN
        2003:100334 USPATFULL
       Biological reagents and methods for determining the mechanism in the generation of ***beta*** - ***amyloid*** peptide
TI
       Audia, James E., Indianapolis, IN, UNITED STATES
IN
       Hyslop, Paul A., Indianapolis, IN, UNITED STATES
       Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
Thompson, Richard C., Frankfort, IN, UNITED STATES
       Tung, Jay S., Belmont, CA, UNITED STATES
       Tanner, Laura I., San Francisco, CA, UNITED STATES
       us 2003069445
PΙ
                                  20030410
                            A1
       US 2002-217459
ΑI
                            Α1
                                  20020814 (10)
RLI
       Division of Ser. No. US 1999-408283, filed on 29 Sep 1999, GRANTED, Pat.
       No. US 6486350
```

```
DΤ
        Utility
         APPLICATION
FS
LN.CNT 2200
INCL
         INCLM: 564/059.000
         INCLS: 530/333.000; 560/157.000; 564/152.000
NCL
        NCLM:
                 564/059.000
         NCLS:
                 530/333.000; 560/157.000; 564/152.000
IC
         [7]
         ICM: C07K007-00
         ICS: C07C275-14; C07C271-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 155 OF 391 USPATFULL ON STN
         2003:100060 USPATFULL
AN
TI
         Pharmaceutical compositions of drug-oligomer conjugates and methods of
         treating diseases therewith
        Soltero, Richard, Holly Springs, NC, UNITED STATES
ΙN
        Ekwuribe, Nnochiri N., Cary, NC, UNITED STATES
Opawale, Foyeke, Raleigh, NC, UNITED STATES
        Rehlander, Bruce, Chapel Hill, NC, UNITED STATES
        Hickey, Anthony, Chapel Hill, NC, UNITED STATES Li Li, Bovet, Chapel Hill, NC, UNITED STATES
        us 2003069170
PΙ
                               Α1
                                     20030410
ΑI
        US 2002-235284
                               Α1
                                     20020905 (10)
                                20010907 (60)
PRAI
        US 2001-318193P
        US 2002-377865P
                                20020503 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 3615
INCL
        INCLM: 514/002.000
                 514/012.000; 514/171.000; 514/560.000
NCL
        NCLM:
                 514/002.000
                 514/012.000; 514/171.000; 514/560.000
        NCLS:
         [7]
TC
        ICM: A61K038-23
        ICS: A61K031-56: A61K031-202: A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 156 OF 391 USPATFULL on STN
AN
        2003:99221 USPATFULL
        Immunogenic peptide composition for the prevention and treatment of
TT
        Altzheimers Disease
        Wang, Chang Yi, Cold Spring Harbor, NY, UNITED STATES
IN
        us 2003068325
ΡI
                               Α1
                                     20030410
ΑI
        us 2001-865294
                               Α1
                                     20010525 (9)
DT
        Utility
        APPLICATION
FS
LN.CNT 2076
INCL
        INCLM: 424/185.100
        INCLS: 435/226.000
NCL
                424/185.100
        NCLM:
        NCLS:
                435/226.000
         [7]
IC
        ICM: A61K039-00
        ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 157 OF 391 USPATFULL ON STN
        2003:99212 USPATFULL
AN
                      ***antibodies***
        Anti-ADDL
TI
                                             and uses thereof
        Klein, William L., Winnetka, IL, UNITED STATES
IN
        Krafft, Grant A., Glenview, IL, UNITED STATES Lambert, Mary P., Glenview, IL, UNITED STATES Viola, Kirsten L., Chicago, IL, UNITED STATES Chromy, Brett A., Pleasanton, CA, UNITED STATES
        Gong, Yue Song, Evanston, IL, UNITED STATES
        Chang, Lei, Evanston, IL, UNITED STATES
        Morgan, Todd E., Los Angeles, CA, UNITED STATES
        Rozofsky, Irina, Pasadena, CA, UNITED STATES
        Finch, Caleb E., Altadena, CA, UNITED STATES US 2003068316 A1 20030410
PΙ
                                     20020611 (10)
ΑI
        US 2002-166856
                               Α1
        Continuation-in-part of Ser. No. US 1999-369236, filed on 4 Aug 1999, PENDING Continuation-in-part of Ser. No. US 1997-796089, filed on 5 Feb
RLI
        1997, GRANTED, Pat. No. US 6218506
```

```
DT
       Utility
       APPLICATION
FS
LN.CNT 2982
INCL
       INCLM: 424/130.100
NCL
       NCLM: 424/130.100
IC
        [7]
       ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 158 OF 391 USPATFULL ON STN
AN
        2003:96167 USPATFULL
       Catalytically active recombinant memapsin and methods of use thereof
ΤI
       Tang, Jordan J. N., Edmond, OK, United States
Lin, Xinli, Edmond, OK, United States
IN
       Koelsch, Gerald, Oklahoma City, OK, United States
       Hong, Lin, Oklahoma City, OK, United States
       Oklahoma Medical Research Foundation, Oklahoma City, OK, United States
PA
        (U.S. corporation)
       us 6545127
PΙ
                                 20030408
       us 2000-604608
                                 20000627 (9)
ΑI
                             19990628 (60)
       US 1999-141363P
PRAI
       US 1999-168060P
                             19991130 (60)
       US 2000-177836P
                             20000125 (60)
                             20000127
                                      (60)
       US 2000-178368P
       US 2000-210292P
                             20000608 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 2563
INCL
       INCLM: 530/350.000
       INCLS: 702/019.000; 530/300.000; 536/023.100
NCL
               530/350.000
       NCLM:
               530/300.000; 536/023.100; 702/019.000
       NCLS:
        [7]
TC
       ICM: G01N033-48
       ICS: G01N031-00; G06F019-00; A16K038-00; C07K001-00; C07K014-00;
       CO7KO17-00; CO7MO21-02; CO7MO21-04
EXF
       435/212; 435/183; 435/7.1; 435/226; 435/15; 530/300; 536/350; 536/23.1;
       702/19; 702/27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 159 OF 391 USPATFULL ON STN
L4
       2003:94733 USPATFULL
AN
       Transgenic animals and cell lines for screening drugs effective for the
TI
       treatment or prevention of Alzheimer's Disease
       Monte, Suzanne De La, East Greenwich, RI, UNITED STATES
IN
       wands, Jack R., Waban, MA, UNITED STATES
PΙ
                                 20030403
       US 2003066097
                           Al
ΑI
       us 2001-964678
                           Α1
                                 20010928 (9)
       Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371
RLI
       of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
       US 1997-38908P
PRAI
                             19970226 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 2091
INCL
       INCLM: 800/012.000
       INCLS: 435/325.000; 435/320.100; 536/023.200
NCL
       NCLM:
              800/012.000
              435/325.000; 435/320.100; 536/023.200
       NCLS:
        [7]
IC
       ICM: A01K067-027
       ICS: C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 160 OF 391 USPATFULL ON STN
L4
AN
       2003:94089 USPATFULL
TI
       High throughput functional genomics
       Hickman, James J., Falls Church, VA, UNITED STATES
IN
       us 2003065452
                                 20030403
PΙ
                           Α1
       US 2002-286761 A1 20021104 (10)
Division of Ser. No. US 2000-575377, filed on 22 May 2000, PENDING
ΑI
RLI
       US 1999-135275P
PRAI
                            19990521 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 2780
```

INCLM: 702/019.000

INCL

```
NCL
        NCLM:
                702/019.000
        NCLS:
                435/007.210
IC
        [7]
        ICM: G01N033-567
        ICS: G06F019-00: G01N033-48: G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 161 OF 391 USPATFULL ON STN
        2003:93790 USPATFULL
AN
TI
        Secreted protein HCEJQ69
IN
        Ruben, Steven M., Olney, MD, UNITED STATES
        Ni, Jian, Germantown, MD, UNITED STATES
        Rosen, Craig A., Laytonsville, MD, UNITED STATES
        Wei, Ying-Fei, Berkeley, CA, UNITED STATES
        Young, Paul, Gaithersburg, MD, UNITED STATES Florence, Kimberly, Rockville, MD, UNITED STATES
        Soppet, Daniel R., Centreville, VA, UNITED STATES
        Brewer, Laurie A., St. Paul, MN, UNITED STATES
        Endress, Gregory A., Florence, MA, UNITED STATES
        Carter, Kenneth C., North Potomac, MD, UNITED STATES Mucenski, Michael, Cincinnati, OH, UNITED STATES Ebner, Reinhard, Gaithersburg, MD, UNITED STATES LaFleur, David W., Washington, DC, UNITED STATES
        Olsen, Henrik, Gaithersburg, MD, UNITED STATES
        Shi, Yanggu, Gaithersburg, MD, UNITED STATES
        Moore, Paul A., Germantown, MD, UNITED STATES
        Komatsoulis, George, Silver Spring, MD, UNITED STATES
        Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.
PA
        corporation)
PΙ
        us 2003065151
                              A1
                                    20030403
        US 2002-115123
                                    20020404 (10)
ΑI
                              Α1
        Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999,
RLI
PRAI
        US 1998-89507P
                               19980616 (60)
        US 1998-89508P
                               19980616 (60)
        US 1998-89509P
                               19980616 (60)
        US 1998-89510P
                               19980616 (60)
        US 1998-90112P
                               19980622 (60)
        US 1998-90113P
                               19980622 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 18779
INCL
        INCLM: 530/388.260
NCL
        NCLM:
                530/388.260
        [7]
IC
        ICM: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 162 OF 391 USPATFULL on STN
ΑN
        2003:93780 USPATFULL
        Mutant presenilin 1 and presenilin 2 polypeptides
TI
        Carter, Donald Bainbridge, Kalamazoo, MI, UNITED STATES
IN
        Tomasselli, Alfredo Giuseppe, Kalamazoo, MI, UNITED STATES
PΙ
        US 2003065141
                             Α1
                                   20030403
        US 2001-896621
ΑI
                              Α1
                                    20010629 (9)
                               20000630 (60)
PRAI
        US 2000-215345P
        Utility
DT
FS
        APPLICATION
LN.CNT
       2497
        INCLM: 530/350.000
INCL
        INCLS: 435/069.100; 435/007.200
NCL
        NCLM:
                530/350.000
        NCLS:
               435/069.100; 435/007.200
        [7]
IC
        ICM: C07K014-435
        ICS: G01N033-53; G01N033-567; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 163 OF 391 USPATFULL ON STN
        2003:93067 USPATFULL
ΑN
        Reagents and methods for identifying and modulating expression of genes
TI
        regulated by CDK inhibitors
        Poole, Jason, Chicago, IL, UNITED STATES
IN
```

Chang, Bey-Dih, Lombard, IL, UNITED STATES

```
PΙ
       US 2003064426
                           Α1
                                 20030403
ΑI
       US 2001-861925
                            Α1
                                 20010521 (9)
       US 2001-265840P
PRAI
                             20010201 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 3443
INCL
       INCLM: 435/008.000
       INCLS: 435/184.000; 435/320.100; 435/325.000; 435/069.100
NCL
       NCLM:
              435/008.000
       NCLS:
               435/184.000; 435/320.100; 435/325.000; 435/069.100
       [7]
IC
       ICM: C12Q001-66
       ICS: C12N009-99; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 164 OF 391 USPATFULL ON STN
       2003:93057 USPATFULL
ΑN
TI
       Process for differential diagnosis of Alzheimer's dementia in patients
       exhibiting mild cognitive impairment
ΙN
       Jackowski, George, Kettleby, CANADA
       Takahashi, Miyoko, North York, CANADA
       US 2003064416
US 2002-246383
                                 20030403
PΙ
                           Α1
       US 2002-246383 A1 20020917 (10)
Continuation-in-part of Ser. No. US 2001-971740, filed on 4 Oct 2001, PENDING Continuation of Ser. No. US 2001-842079, filed on 25 Apr 2001,
ΑI
RLI
       GRANTED, Pat. No. US 6451547
DT
       Utility
FS
       APPLICATION
LN.CNT 888
TNCL
       INCLM: 435/007.210
NCL
       NCLM: 435/007.210
       [7]
IC
       ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 165 OF 391 USPATFULL ON STN
AN
       2003:89258 USPATFULL
TI
       Nucleic acid encoding PTH1R receptor
IN
       Juppner, Harald, Cambridge, MA, United States
       Rubin, David A., Needham, MA, United States
PA
       The General Hospital Corporation, Boston, MA, United States (U.S.
       corporation)
PΙ
       US 6541220
                            В1
                                 20030401
       US 1999-449632
                                 19991130 (9)
ΑI
       US 1998-110467P
PRAI
                             19981130 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 2932
       INCLM: 435/069.100
INCL
       INCLS: 536/023.500; 536/024.300; 536/024.310; 530/350.000; 435/071.100;
               435/071.200; 435/471.000; 435/325.000; 435/320.100; 435/252.300;
               435/254.110
NCL
       NCLM:
               435/069.100
               435/071.100; 435/071.200; 435/252.300; 435/254.110; 435/320.100;
       NCLS:
               435/325.000; 435/471.000; 530/350.000; 536/023.500; 536/024.300;
               536/024.310
IC
       ICM: C12N015-12
       ICS: c12N015-63; c12N005-10; c07K014-705
       536/23.1; 536/23.5; 536/24.3; 536/24.31; 530/350; 435/69.1; 435/71.1;
EXF
       435/71.2; 435/471; 435/325; 435/252.3; 435/254.11; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 166 OF 391 USPATFULL ON STN
       2003:89115 USPATFULL
AN
       Methods for using elk-L to enhance neuronal survival
TI
IN
       Lyman, Stewart, Seattle, WA, United States
       Beckmann, M. Patricia, Poulsbo, WA, United States
       Baum, Peter R., Seattle, WA, United States
       Carpenter, Melissa K., Issaquah, WA, United States
PA
       Genentech, Inc., South San Francisco, CA, United States (U.S.
       corporation)
PΙ
       us 6540992
                                 20030401
                            В1
ΑI
       US 1998-39642
                                 19980316 (9)
```

pivision of Ser. No. US 1996-747240, filed on 12 Nov 1996, now patented,

RLI

```
1995, now patented, Pat. No. US 5670625 Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented, Pat. No. US 5512457 Continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
        now abandoned
DT
        Utility
FS
         GRANTED
LN.CNT 1752
INCL
         INCLM: 424/085.100
        INCLS: 424/130.100; 424/134.100; 424/184.100; 424/185.100; 424/192.100; 530/350.000; 530/351.000; 530/387.100; 530/387.300
NCL
                 424/085.100
                 424/130.100; 424/134.100; 424/184.100; 424/185.100; 424/192.100; 530/350.000; 530/351.000; 530/387.100; 530/387.300
        NCLS:
         [7]
TC
         ICM: A61K038-19
         ICS: C07K014-52
         530/387.3; 530/351; 530/350; 530/387.1; 424/85.1; 424/192.1; 424/134.1;
EXF
         424/130.1; 424/184.1; 424/185.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 167 OF 391 USPATFULL ON STN 2003:86317 USPATFULL
L4
AN
        Polynucleotide encoding a novel
                                                  ***human***
TI
                                                                   potassium channel
        alpha-subunit, K+alphaM1, and variants thereof
        Feder, John N., Belle Mead, NJ, UNITED STATES
IN
        Lee, Liana M., North Brunswick, NJ, UNITED STATES
        Chen, Jian, Princeton, NJ, UNITED STATES
        Jackson, Donald, Lawrenceville, NJ, UNITED STATES
        Ramanathan, Chandra, Wallingford, CT, UNITED STATES
        Siemers, Nathan, Pennington, NJ, UNITED STATES
Chang, Han, Princeton Junction, NJ, UNITED STATES
US 2003059923 A1 20030327
PΙ
        US 2001-999220
ΑI
                                      20011101 (9)
                                Α1
                                 20001102 (60)
PRAI
        US 2000-245383P
        US 2000-257780P
                                 20001221 (60)
        US 2001-269854P
                                 20010220 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 16037
        INCLM: 435/252.300
INCL
        INCLS: 536/023.100
                 435/252.300
NCL
        NCLM:
        NCLS: 536/023.100
        [7]
IC
        ICM: C07H021-02
        ICS: C07H021-04; C12N001-20
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 168 OF 391 USPATFULL on STN
        2003:78523 USPATFULL
ΑN
              ***human***
TI
                               secreted proteins
        Ruben, Steven M., Olney, MD, UNITED STATES Soppet, Daniel R., Centreville, VA, UNITED STATES
IN
        Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
        Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
        Young, Paul E., Gaithersburg, MD, UNITED STATES
        Greene, John M., Gaithersburg, MD, UNITED STATES
        Ferrie, Ann M., Painted Post, NY, UNITED STATES
        Yu, Guo-Liang, Berkeley, CA, UNITED STATES
        Ni, Jian, Germantown, MD, UNITED STATES
        Rosen, Craig A., Laytonsville, MD, UNITED STATES
        Brewer, Laurie A., St. Paul, MN, UNITED STATES
        Janat, Fouad, Westerly, RI, UNITED STATES
        Birse, Charles E., North Potomac, MD, UNITED STATES
PI
        US 2003054443
                               Α1
                                      20030320
                                      20011004 (9)
ΑI
        US 2001-969730
                                A1
        Continuation-in-part of Ser. No. US 2001-774639, filed on 1 Feb 2001, PENDING Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999,
RLI
        ABANDONED Continuation-in-part of Ser. No. wo 1998-US16235, filed on 4
        Aug 1998, UNKNOWN US 2000-238291P
                                 20001006 (60)
PRAI
        US 1997-55386P
                                 19970805 (60)
        US 1997-54807P
                                 19970805 (60)
        US 1997-55312P
                                 19970805 (60)
```

19970805 (60)

us 1997-55309P

```
US 1997-55310P
                             19970805
                                      (60)
       US 1997-54806P
                             19970805
                                      (60)
       US 1997-54809P
                            19970805
                                      (60)
       US 1997-54804P
                            19970805
                                      (60)
       US 1997-54803P
                            19970805
                                      (60)
       US 1997-54808P
                            19970805
                                      (60)
       US 1997-55311P
                            19970805
                                      (60)
          1997-55986P
                            19970818
       US
                                      (60)
          1997-55970P
       US
                            19970818
                                      (60)
       US
          1997-56563P
                            19970819
                                      (60)
       US 1997-56557P
                             19970819
                                      (60)
       US 1997-56731P
                            19970819
                                      (60)
       US 1997-56365P
                            19970819
                                      (60)
       US 1997-56367P
                            19970819
                                      (60)
       US 1997-56370P
                            19970819
                                      (60)
       US 1997-56364P
                            19970819
                                      (60)
       US 1997-56366P
                            19970819 (60)
       US 1997-56732P
                            19970819 (60)
       US 1997-56371P
                            19970819 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT
       26693
       INCLM: 435/069.100
INCL
       INCLS: 435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000;
               536/023.100; 530/350.000
NCL
       NCLM:
               435/069.100
       NCLS:
               435/006.000; 435/007.100; 435/325.000; 435/320.100; 435/183.000;
               536/023.100; 530/350.000
IC
       [7]
       ICM: C12P021-02
       ICS: C12Q001-68; G01N033-53; C07H021-04; C12N009-00; C07K014-435;
       C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 169 OF 391 USPATFULL ON STN
AN
       2003:72975
                   USPATFULL
       Animal models for neurodegenerative disease
TI
TN
       Greenfield, Susan Adele, Oxford, UNITED KINGDOM
       Rawlins, John Nicholas Pepys, Oxford, UNITED KINGDOM
       Deacon, Robert Michael John, Oxford, UNITED KINGDOM
       us 2003051262
                                 20030313
PΙ
                           Α1
ΑI
       US 2002-169343
                           Α1
                                 20020911 (10)
       WO 2000-GB4991
                                 20001222
PRAI
       GB 1999-30825
                            19991230
DT
       Utility
FS
       APPLICATION
LN.CNT 1016
       INCLM: 800/009.000
INCL
       INCLS: 800/012.000; 800/018.000
NCL
               800/009.000
       NCLM:
       NCLS:
               800/012.000; 800/018.000
       [7]
IC
       ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 170 OF 391 USPATFULL on STN
AN
       2003:72015
                   USPATFULL
       Treatment of conditions associated with amyloid processing using PKC
TI
       activators
IN
       Etcheberrigaray, Rene, Columbia, MD, UNITED STATES
       Qiao, Lixin, Arlington, VA, UNITED STATES
       Kozikowski, Alan P., Princeton, NJ, UNITED STATES
PA
       Neurologic,
                   Inc. (U.S. corporation)
PΙ
       us 2003050302
                           Α1
                                20030313
ΑI
       us 2002-254916
                                20020926 (10)
                           Α1
RLI
       Division of Ser. No. US 2000-652656, filed on 31 Aug 2000, ABANDONED
DT
       Utility
FS
       APPLICATION
LN.CNT 933
INCL
       INCLM: 514/212.070
NCL
              514/212.070
       NCLM:
       [7]
IC
       ICM: A61K031-55
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ΑN
        2003:71403 USPATFULL
TI
        Protein fragment complementation assays for the detection of biological
        or drug interactions
IN
        Michnick, Stephen William Watson, Westmount, CANADA
        Pelletier, Joelle Nina, Westmount, CANADA
        Remy, Ingrid, Montreal, CANADA
PA
        Odyssey Pharmaceuticals, Inc., San Ramon, CA (non-U.S. corporation)
PΙ
        US 2003049688
                                   20030313
                             Α1
ΑI
        US 2002-154758
                                   20020524 (10)
                             Α1
        Continuation of Ser. No. US 2000-499464, filed on 7 Feb 2000, GRANTED, Pat. No. US 6428951 Continuation of Ser. No. US 1998-17412, filed on 2
RLI
        Feb 1998, GRANTED, Pat. No. US 6270964
                              19970131
PRAI
        CA 1997-2196496
DΤ
        Utility
FS
        APPLICATION
LN.CNT 2757
INCL
        INCLM: 435/007.100
        INCLS: 435/007.900; 702/019.000
               435/007.100
NCL
        NCLM:
        NCLS:
               435/007.900; 702/019.000
        [7]
IC
        ICM: G01N033-53
        ICS: G01N033-542; G06F019-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 172 OF 391 USPATFULL ON STN
        2003:70968 USPATFULL
ΑN
TI
        Polymeric conjugates for delivery of MHC-recognized epitopes via peptide
        vaccines
IN
        Li, Frank Q., Montgomery Village, MD, UNITED STATES
        Chu, Yong-Liang, Rockville, MD, UNITED STATES
        Qiu, Jian-Tai, Rockville, MD, UNITED STATES
        us 2003049253
PΙ
                                   20030313
                             Α1
                                   20020205 (10)
ΑI
        US 2002-62710
                             Α1
PRAI
        US 2001-310498P
                              20010808 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 1790
INCL
        INCLM: 424/144.100
        INCLS: 424/178.100
               424/144.100
NCL
        NCLM:
        NCLS:
               424/178.100
        [7]
IC
        ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 173 OF 391 USPATFULL ON STN
14
AN
        2003:67840 USPATFULL
        Genetic sequences related to Alzheimer's Disease
TI
IN
        St. George-Hyslop, Peter H., Toronto, CANADA
        Rommens, Johanna M., Toronto, CANADA
        Fraser, Paul E., Toronto, CANADA
The Hospital for Sick Children, Toronto, CANADA (non-U.S. corporation)
PA
        HSC Research and Development Limited Partnership, Toronto, CANADA
        (non-U.S. corporation)
        The Governing Council of the University of Toronto, Toronto, CANADA
        (non-U.S. corporation)
        US 6531586
US 1995-431048
Utility
PΙ
                             В1
                                   20030311
ΑI
                                   19950428 (8)
DT
        GRANTED
FS
LN.CNT 3650
        INCLM: 536/023.500
INCL
        INCLS: 536/023.100; 435/320.100; 435/325.000; 435/069.100
NCL
                536/023.500
        NCLS:
               435/069.100; 435/320.100; 435/325.000; 536/023.100
IC
        [7]
        ICM: C12N015-11
        ICS: C12N015-63; C12N015-85; C07H021-04
435/6; 435/69.1; 435/172.1; 435/172.3; 435/320.1; 435/325; 435/375;
435/252.3; 435/254.11; 800/2; 800/DIG.1; 800/DIG.2; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 174 OF 391 USPATFULL on STN
L4
```

2003:64775 USPATFULL

AN

```
IN
        Courchesne, William E., Soda Springs, CA, UNITED STATES
        Schooley, David A., Reno, NV, UNITED STATES Copley, Kathrin, San Diego, CA, UNITED STATES
PΙ
        US 2003044896
                            Α1
                                  20030306
ΑI
        US 2001-7447
                             Α1
                                  20011105 (10)
RLI
        Continuation of Ser. No. US 2000-661452, filed on 13 Sep 2000, PENDING
        Continuation of Ser. No. US 1999-237936, filed on 27 Jan 1999, ABANDONED
PRAI
        US 1998-72691P
                              19980127 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 1389
INCL
        INCLM: 435/069.100
        INCLS: 435/226.000; 435/254.200
NCL
        NCLM:
               435/069.100
        NCLS:
               435/226.000; 435/254.200
        [7]
IC
        ICM: C12P021-02
        ICS: C12N009-64; C12N001-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 175 OF 391 USPATFULL on STN
        2003:64730 USPATFULL
ΑN
TI
        Secreted protein HCEJQ69
IN
        Ruben, Steven M., Olney, MD, UNITED STATES
        Ni, Jian, Germantown, MD, UNITED STATES
        Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Wei, Ying-Fei, Berkeley, CA, UNITED STATES
       Young, Paul E., Gaithersburg, MD, UNITED STATES Florence, Kimberly A., Rockville, MD, UNITED STATES
       Soppet, Daniel R., Centreville, VA, UNITED STATES Brewer, Laurie A., St. Paul, MN, UNITED STATES Endress, Gregory A., Florence, MA, UNITED STATES
       Carter, Kenneth C., North Potomac, MD, UNITED STATES
       Mucenski, Michael, Cincinnati, OH, UNITED STATES
       Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
       LaFleur, David W., Washington, DC, UNITED STATES
       Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
       Shi, Yanggu, Gaithersburg, MD, UNITED STATES
       Moore, Paul A., Germantown, MD, UNITED STATES
       Komatsoulis, George A., Silver Spring, MD, UNITED STATES
PA
       Human Genome Sciences, Inc., Rockville, MD, UNITED STATES (U.S.
       corporation)
       US 2003044851
PΙ
                             A1
                                  20030306
       US 6627741
                                  20030930
                             В2
AΙ
       US 2001-12542
                            Α1
                                  20011212 (10)
       Division of Ser. No. US 1999-461325, filed on 14 Dec 1999, PENDING
RLI
       Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999,
       UNKNOWN
                              19980616 (60)
PRAI
       US 1998-89507P
       US 1998-89508P
                              19980616 (60)
       US 1998-89509P
                              19980616 (60)
                              19980616 (60)
       US 1998-89510P
       US 1998-90112P
                              19980622 (60)
       US 1998-90113P
                             19980622 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 18831
       INCLM: 435/007.200
INCLS: 530/387.100; 435/326.000
INCL
NCL
       NCLM:
               530/389.200
               530/387.100; 530/387.300; 530/387.700; 530/388.100; 530/388.150;
       NCLS:
               530/387.900; 530/389.200; 530/389.100
IC
       [7]
       ICM: G01N033-53
       ICS: C07K016-00; C12N005-16; C12N005-06; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 176 OF 391 USPATFULL on STN
L4
AN
       2003:46308 USPATFULL
       Transgenic animals and cell lines for screening drugs effective for the
TI
       treatment or prevention of Alzheimer's disease
IN
       De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
       Wands, Jack R., Waban, MA, UNITED STATES
PI
                                  20030213
       US 2003033621
                            A1
```

20010928 (9)

A1

ΑI

US 2001-964667

```
of International Ser. No. wo 1998-US3685, filed on 26 Feb 1998, UNKNOWN US 1997-38908P 19970226 (60)
PRAI
DT
           Utility
           APPLICATION
FS
LN.CNT 2088
INCL
           INCLM: 800/012.000
           INCLS: 800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100
NCL
                      800/012.000
                      800/014.000; 435/325.000; 435/456.000; 536/023.200; 435/320.100
           NCLS:
IC
           [7]
           ICM: A01K067-027
           ICS: C07H021-04; C12N005-06; C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
        ANSWER 177 OF 391 USPATFULL on STN
           2003:45292 USPATFULL
ΑN
TI
           Smilagenin and its use
           Xia, Žongqin, Shanghai, CHINA
Rubin, Ian, Leicester, UNITED KINGDOM
IN
           whittle, Brian, East Yorkshire, UNITED KINGDOM
           Gunning, Philip, Essex, UNITED KINGDOM
           Hu, Yaer, Shanghai, CHÍNA
Brostoff, Jonathan, London, UNITED KINGDOM
           Wang, Weijun, Cambridgeshire, UNITED KINGDOM
                                                 20030213
           us 2003032604
PΙ
                                        Α1
           US 2002-228153
                                        Α1
                                                20020826 (10)
ΑI
           Continuation of Ser. No. US 2001-866234, filed on 25 May 2001, ABANDONED
RLI
           Division of Ser. No. US 1999-362328, filed on 28 Jul 1999, GRANTED, Pat.
           No. US 6258386
GB 1999-5275
Utility
PRAI
                                          19990308
DT
           APPLICATION
FS
LN.CNT 682
INCL
           INCLM: 514/026.000
NCL
           NCLM: 514/026.000
IC
           [7]
           ICM: A61K031-704
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 178 OF 391 USPATFULL ON STN 2003:38351 USPATFULL
L4
AN
TI
           Novel genes encoding proteins having prognostic, diagnostic, preventive,
           therapeutic, and other uses
           Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES
IN
           Barnes, Thomas M., Brookline, MA, UNITED STATES
PΙ
           US 2003027998
                                        Α1
                                                 20030206
           us 2001-796753
ΑI
                                                20010301 (9)
                                        Α1
          Continuation-in-part of Ser. No. US 1998-183175, filed on 30 oct 1998, ABANDONED Continuation-in-part of Ser. No. US 2000-599596, filed on 22 Jun 2000, ABANDONED Division of Ser. No. US 1998-223546, filed on 30 Dec 1998, ABANDONED Division of Ser. No. US 1999-471179, filed on 23 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1998-223546, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474072, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-474072, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1999-474072,
RLI
           filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US
           1998-224246, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474071, filed on 29 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-223094, filed on 30 Dec 1998,
          ABANDONED Continuation-in-part of Ser. No. US 2000-514010, filed on 25 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-259388, filed on 26 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-516745, filed on 1 Mar 2000, ABANDONED Continuation-in-part of Ser.
           No. US 2000-597993, filed on 19 Jun 2000, PENDING Continuation-in-part
           of Ser. No. US 1999-336536, filed on 18 Jun 1999, PENDING
           Continuation-in-part of Ser. No. US 2000-630334, filed on 31 Jul 2000,
           PENDING Continuation-in-part of Ser. No. US 1999-365164, filed on 30 Jul
           1999, ABANDONED Continuation-in-part of Ser. No. US 2000-665666, filed
           on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-399723,
          filed on 20 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-667751, filed on 21 Sep 2000, PENDING Continuation-in-part of Ser. No. US 1999-409634, filed on 30 Sep 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-572002, filed on 15 May 2000, PENDING Continuation-in-part of Ser. No. US 1999-312359, filed on 14 May 1999,
           ABANDONED Continuation-in-part of Ser. No. US 2000-606565, filed on 29
           Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-342687, filed
```

on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US

```
No. US 1999-345464, filed on 30 Jun 1999, ABANDONED
PRAI
       US 1999-122458P
                            19990301 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 22222
INCL
       INCLM: 536/023.100
NCL
       NCLM: 536/023.100
IC
       [7]
       ICM: C07H021-02
       ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 179 OF 391 USPATFULL ON STN
14
       2003:37643 USPATFULL
ΑN
TI
       Methods of screening for agents that inhibit aggregation of polypeptides
       Housman, David E., Newton, MA, UNITED STATES
IN
       Preisinger, Elizabeth A., Roslindale, MA, UNITED STATES
       Kazantsev, Aleksey G., Boston, MA, UNITED STATES
PA
       Massachusetts Institute of Technology, a Massachusetts corporation (U.S.
       corporation)
       US 2003027288
US 2002-194584
PΙ
                           Α1
                                20030206
                                 20020712 (10)
ΑI
                           Α1
       Division of Ser. No. US 1999-405048, filed on 27 Sep 1999, GRANTED, Pat.
RLI
       No. US 6420122
       Utility
DT
       APPLICATION
FS
LN.CNT 1058
INCL
       INCLM: 435/091.100
       INCLS: 435/091.330; 424/186.100; 424/208.100
NCL
              435/091.100
       NCLM:
       NCLS:
              435/091.330; 424/186.100; 424/208.100
       [7]
IC
       ICM: C12P019-34
       ICS: A61K039-12; A61K039-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 180 OF 391 USPATFULL ON STN
ΑN
       2003:37614 USPATFULL
       Novel ABCG4 transporter and uses thereof
TI
IN
       Chen, Hongyun, Vancouver, CANADA
       Le Bihan, Stephane, Vancouver, CANADA
PA
       Active Pass Pharmaceuticals, Inc., Vancouver, CANADA (non-U.S.
       corporation)
ΡI
       US 2003027259
                                20030206
                           Α1
       US 2002-90455
                           Α1
                                20020301 (10)
ΑT
       US 2001-272886P
                            20010302 (60)
PRAI
       US 2001-309262P
                            20010731 (60)
       US 2001-316339P
                            20010829 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 4484
INCL
       INCLM: 435/069.100
       INCLS: 435/320.100; 435/325.000; 435/006.000; 530/350.000; 536/023.500
              435/069.100
NCL
       NCLM:
       NCLS:
              435/320.100; 435/325.000; 435/006.000; 530/350.000; 536/023.500
       [7]
IC
       ICM: C12Q001-68
       ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 181 OF 391 USPATFULL ON STN
       2003:37603 USPATFULL
ΑN
         ***Human***
TT
                       cDNAs and proteins and uses thereof
IN
       Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
PA
       GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
                                20030206
PΙ
       US 2003027248
                           Α1
       US 2001-924340
                                20010806 (9)
ΑI
                           Α1
                            20010713 (60)
PRAI
       US 2001-305456P
                            20010629 (60)
20010615 (60)
       US 2001-302277P
       US 2001-298698P
       US 2001-293574P
                            20010525 (60)
DT
       Utility
       APPLICATION
FS
```

LN.CNT 25650

```
INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
                435/006.000
        NCLM:
NCL
                435/069.100
        NCLS:
                435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
                435/006.000
IC
        [7]
        ICM: C12P021-02
        ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 182 OF 391 USPATFULL on STN
ΑN
        2003:37523 USPATFULL
TI
        High-throughput transcriptome and functional validation analysis
        Gan, Li, San Francisco, CA, UNITED STATES
Gonzalez-Zulueta, Mirella, Pacifica, CA, UNITED STATES
IN
        Anton, Kristin, San Ramon, CA, UNITED STATES
        Wilson, Richa, San Francisco, CA, UNITED STATES
        Melcher, Thorsten, San Francisco, CA, UNITED STATES
        Chin, Daniel, Foster City, CA, UNITED STATES
AGY Therapeutics, Inc., South San Francisco, CA, UNITED STATES, 94080
PA
        (U.S. corporation)
        US 2003027168
US 2001-27807
PΙ
                                    20030206
                              Α1
                                    20011019 (10)
ΑI
                              Α1
        Continuation-in-part of Ser. No. US 2000-627362, filed on 28 Jul 2000,
RLI
        PENDING
PRAI
        US 1999-146640P
                               19990730 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 2696
        INCLM: 435/006.000
INCL
        INCLS: 435/091.200
NCL
        NCLM:
                435/006.000
                435/091.200
        NCLS:
IC
        [7]
        ICM: C12Q001-68
        ICS: C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 183 OF 391 USPATFULL ON STN
        2003:37516 USPATFULL
AN
          ***Human***
TI
                         cDNAs and proteins and uses thereof
IN
        Bejanin, Stephane, Paris, FRANCE
        Tanaka, Hiroaki, Antony, FRANCE
        GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PA
PΙ
        US 2003027161
                             Á1
                                   20030206
        US 2001-992600
                                    20011113 (9)
ΑI
                             Α1
        Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
RLI
        WO 2001-IB1715
                               20010806
PRAI
        US 2001-305456P
                               20010713 (60)
                               20010629 (60)
20010615 (60)
        US 2001-302277P
        US 2001-298698P
                               20010525 (60)
        US 2001-293574P
        Utility
DT
FS
        APPLICATION
LN.CNT 25529
INCL
        INCLM: 435/006.000
        INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
                536/023.200; 800/008.000
NCL
        NCLM:
                435/006.000
                435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
        NCLS:
IC
        [7]
        ICM: C12Q001-68
        ICS: A01K067-00; C07H021-04: C12N009-00; C12P021-02: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 184 OF 391 USPATFULL on STN
        2003:37513 USPATFULL
AN
        Novel nucleic acid sequences encoding
                                                      ***human***
TI
                                                                      breast
        tumor-associated protein 47-like polypeptides
Shimkets, Richard A., West Haven, CT, UNITED STATES
Fernandes, Elma, Branford, CT, UNITED STATES
ΙN
        Herrman, John, Guilford, CT, UNITED STATES
Vernet, Corine, Gainesville, FL, UNITED STATES
PA
        CuraGen Corporation, New Haven, CT, UNITED STATES, 06511 (U.S.
```

```
PΙ
       US 2003027158
                           Al
                                20030206
ΑI
       US 2001-977418
                                20011015 (9)
                           Α1
RLI
       Continuation of Ser. No. US 2000-584411, filed on 31 May 2000, PENDING
PRAI
       US 2000-201388P
                            20000503 (60)
       US 2000-193086P
                            20000330 (60)
       US 2000-191158P
                            20000322 (60)
                            20000316 (60)
       US 2000-189810P
       US 1999~137322P
                            19990603 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 7101
INCL
       INCLM: 435/006.000
       INCLS: 435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL
       NCLM:
              435/006.000
       NCLS:
              435/007.230; 435/069.100; 435/325.000; 435/320.100; 536/023.200
       [7]
IC
       ICM: C12Q001-68
       ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 185 OF 391 USPATFULL on STN
       2003:32043
                   USPATFULL
ΑN
TI
       TRANSGENIC C. ELEGANS AS A MODEL ORGANISM FOR INVESTIGATIONS ON
       ALZHEIMER'S DISEASE
IN
       PERAUS, GISELA, MUNCHEN, GERMANY, FEDERAL REPUBLIC OF
       HOPPE, EDMUND, KRAILING, GERMANY, FEDERAL REPUBLIC OF
       BAUMEISTER, RALF, GROBENZELL, GERMANY, FEDERAL REPUBLIC OF
PΙ
       US 2003023997
                          Α1
                                20030130
       US 1999-422569
                                19991021 (9)
ΑI
                           Α1
       DE 1998-19849073
PRAI
                            19981024
       Utility
DT
       APPLICATION
FS
LN.CNT 841
INCL
       INCLM: 800/013.000
       INCLS: 536/023.500; 435/320.100; 435/325.000; 435/069.100; 435/069.700;
              435/455.000
NCL
       NCLM:
              800/013.000
       NCLS:
              536/023.500; 435/320.100; 435/325.000; 435/069.100; 435/069.700;
              435/455.000
IC
       [7]
       ICM: A01K067-00
       ICS: C07H021-04; C12P021-04; C12N015-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 186 OF 391 USPATFULL on STN
       2003:30408 USPATFULL
AN
TI
       Vectors and methods for gene transfer
IN
       Wickham, Thomas J., Germantown, MD, UNITED STATES
       Kovesdi, Imre, Rockville, MD, UNITED STATES
       Brough, Douglas E., Gaithersburg, MD, UNITED STATES
       GenVec, Inc., Gaithersburg, MD (U.S. corporation) US 2003022355 A1 20030130
PA
PΙ
       US 2001-999724
AI
                                20011024 (9)
                           Αl
RLI
       Continuation of Ser. No. US 1999-101751, filed on 29 Jan 1999, PENDING A
       371 of International Ser. No. WO 1996-US19150, filed on 27 Nov 1996
       UNKNOWN Continuation-in-part of Ser. No. US 1995-563368, filed on 28 Nov
       1995, PATENTED Continuation-in-part of Ser. No. US 1996-701124, filed on
       21 Aug 1996, PATENTED Continuation-in-part of Ser. No. US 1996-700846,
       filed on 21 Aug 1996, PATENTED Continuation-in-part of Ser. No. US
       1996-634060, filed on 17 Apr 1996, PATENTED Continuation-in-part of Ser.
       No. US 1994-303162, filed on 8 Sep 1994, PATENTED
DT
       Utility
       APPLICATION
FS
LN.CNT 3106
INCL
       INCLM: 435/235.100
       INCLS: 435/456.000
NCL
       NCLM:
              435/235.100
              435/456.000
       NCLS:
       [7]
TC
       ICM: C12N015-861
       ICS: C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 187 OF 391 USPATFULL on STN
14
```

AN

2003:30205 USPATFULL

```
ΙN
       Thinakaran, Gopal, Chicago, IL, UNITED STATES
PΙ
       US 2003022151
                                 20030130
                            Α1
ΑI
       US 2002-51767
                            Α1
                                 20020117 (10)
       US 2001-262353P
PRAI
                            20010117 (60)
DT
       Utility
FS
       APPLICATION
       3900
LN.CNT
       INCLM: 435/004.000
INCL
       INCLS: 435/006.000; 435/007.200
NCL
              435/004.000
       NCLM:
       NCLS: 435/006.000; 435/007.200
TC
       [7]
       ICM: C12Q001-00
       ICS: C12Q001-68; G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 188 OF 391 USPATFULL on STN
ΑN
       2003:26157 USPATFULL
                      ***human***
TT
       Therapy for
                                     cancers using cisplatin and other drugs or
       genes encapsulated into liposomes
ΙN
       Boulikas, Teni, 249 Matadero Ave., Palo Alto, CA, United States 94306
       US 6511676
US 1999-434345
                                 20030128
PΙ
                           в1
ΑI
                                 19991105 (9)
       Utility
DT
       GRANTED
FS
LN.CNT 1642
       INCLM: 424/450.000
INCL
       INCLS: 264/004.100; 264/004.300
       NCLM: 424/450.000
NCL
       NCLS: 264/004.100; 264/004.300
IC
       [7]
       ICM: A61K009-127
EXF
       424/450; 264/4.1; 264/4.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 189 OF 391 USPATFULL on STN
AN
       2003:18018 USPATFULL
TI
       Composition, synthesis and therapeutic applications of polyamines
IN
       Murphy, Michael A., La Jolla, CA, UNITED STATES
       MaLachowski, Mitchell R., San Diego, CA, UNITED STATES
       US 2003013772
US 2001-17235
                                 20030116
PΙ
                           Α1
ΑI
                            Α1
                                 20011218 (10)
       Continuation-in-part of Ser. No. US 2000-486310, filed on 23 Feb 2000,
RLI
       PENDING A 371 of International Ser. No. WO 1998-US17301, filed on 21 Aug
       1998, UNKNOWN A 371 of International Ser. No. US 1997-915660, filed on
       21 Aug 1997, GRANTED, Pat. No. US 5906996
DT
       Utility
FS
       APPLICATION
LN.CNT 3034
INCL
       INCLM: 514/674.000
       INCLS: 564/512.000
               514/674.000
NCL
       NCLM:
               564/512.000
       NCLS:
       [7]
IC
       ICM: A61K031-13
       ICS: C07C211-14
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 190 OF 391 USPATFULL on STN
       2003:17384 USPATFULL
ΑN
         ***Human***
TI
                       KCR1 regulation of HERG potassium channel block
       Balser, Jeffrey R., Brentwood, TN, UNITED STATES
George, Alfred L., JR., Brentwood, TN, UNITED STATES
IN
       Roden, Dan M., Nashville, TN, UNITED STATES
PΙ
       us 2003013136
                           Α1
                                 20030116
       US 2001-151
                                 20011030 (10)
ΑI
                            Α1
       US 2000-244340P
PRAI
                            20001030 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 5075
       INCLM: 435/007.210
INCL
       INCLS: 435/006.000; 435/455.000; 435/325.000
               435/007.210
NCL
       NCLM:
               435/006.000; 435/455.000; 435/325.000
       NCLS:
IC
       [7]
```

```
ICS: C12Q001-68; C12P021-02; C12N005-06; C12N015-85
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 191 OF 391 USPATFULL on STN
AN
        2003:13325 USPATFULL
        Heterocyclic compounds, pharmaceutical compositions comprising same, and
TI
        methods for inhibiting . ***beta*** .- ***amyloid***
release and/or its synthesis by use of such compounds
        Thorsett, Eugene D., Moss Beach, CA, United States Porter, Warren J., Indianapolis, IN, United States Nissen, Jeffrey S., Indianapolis, IN, United States Latimer, Lee H., Oakland, CA, United States Audia, James E., Indianapolis, IN, United States
IN
        Droste, James, Indianapolis, IN, United States
PA
        Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
        corporation)
        Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
                                     20030114
        US 6506782
PΙ
                               в1
        US 1998-32019
ΑI
                                     19980227 (9)
        Utility
DT
        GRANTED
FS
LN.CNT 9870
INCL
        INCLM: 514/364.000
        NCLM: 514/364.000
NCL
IC
        [7]
        ICM: A61K031-4245
EXF
        514/364
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 192 OF 391 USPATFULL on STN
        2003:11397 USPATFULL
ΑN
        In vivo multiphoton diagnostic detection and imaging of a
TI
        neurodegenerative disease
        Hyman, Bradley T., Charlestown, MA, UNITED STATES
Christie, Richard, New York, NY, UNITED STATES
IN
        Bacskai, Brian, Charlestown, MA, UNITED STATES
        Webb, watt W., Ithaca, NY, UNITED STATES
        Zipfel, Warren R., Ithaca, NY, UNITED STATES
        US 2003009104
US 2001-1643
US 2000-245306P
ΡI
                                     20030109
                               A1
ΑI
                               Α1
                                     20011031 (10)
                                20001102 (60)
PRAI
        Utility
DT
        APPLICATION
FS
LN.CNT 1919
INCL
        INCLM: 600/476.000
        NCLM: 600/476.000
NCL
        [7]
IC
        ICM: A61B006-00
      ANSWER 193 OF 391 USPATFULL ON STN
L4
ΑN
        2003:6903 USPATFULL
        Amino lactam sulfonamides as inhibitors of A.beta. protein production
TI
        Thompson, Lorin Andrew, Wilmington, DE, United States
IN
        Han, Amy Qi, Hockessin, DE, United States
PA
        Bristol Myers Squibb Pharma Company, United States (U.S. corporation)
PΙ
        us 6503901
                                     20030107
                               В1
        US 2000-684718
US 1999-158565P
ΑI
                                     20001007 (9)
PRAI
                                19991008 (60)
DT
        Utility
FS
        GRANTED
LN.CNT 5315
        INCLM: 514/221.000
INCL
        INCLS: 540/509.000
                514/221.000
NCL
        NCLM:
                540/509.000
        NCLS:
IC
        [7]
        ICM: C07D413-12
        ICS: C07D409-12; C07D401-12; A61K031-55; A61P025-28
        540/509; 514/221
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 194 OF 391 USPATFULL ON STN
L4
        2003:4108 USPATFULL
ΑN
        5-beta-sapogenin and pseudosapogenin derivatives and their use in the
TI
```

treatment of dementia

```
Hanson, Jim, West Sussex, UNITED KINGDOM
        Gunning, Phil, Cambs, UNITED KINGDOM
        Rees, Daryl, Sandy, UNITED KINGDOM
       Xia, Zongqin, Shanghai, CHINA
       Hu, Yaer, Shanghai, CHINA
PΙ
       US 2003004147
                                  20030102
                            A1
ΑI
       US 2002-109095
                                  20020328 (10)
                            Α1
RLI
       Continuation-in-part of Ser. No. WO 2000-GB37367, filed on 29 Sep 2000,
       UNKNOWN
       GB 1999-23076
Utility
PRAI
                             19990929
DT
FS
       APPLICATION
LN.CNT 1261
INCL
        INCLM: 514/172.000
       INCLS: 514/173.000
       NCLM:
               514/172.000
NCL
       NCLS:
               514/173.000
IC
        [7]
        ICM: A61K031-58
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 195 OF 391 USPATFULL ON STN
       2003:4068 USPATFULL
ΑN
TT
       Method of preventing cell death using segments of neural thread proteins
       Averback, Paul A., Beaconsfield, CANADA
IN
                                  20030102
PΙ
       us 2003004107
                            Α1
ΑI
       US 2002-146130
                            Α1
                                  20020516 (10)
PRAI
       US 2001-290971P
                             20010516 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 1698
INCL
        INCLM: 514/012.000
               514/013.000; 514/014.000; 514/015.000; 514/016.000
       INCLS:
NCL
               514/012.000
       NCLM:
       NCLS:
               514/013.000; 514/014.000; 514/015.000; 514/016.000
        [7]
IC
       ICM: A61K038-17
       ICS: A61K038-10; A61K038-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 196 OF 391 USPATFULL ON STN
       2003:3520 USPATFULL
AN
             ***human***
                            secreted proteins
TI
       Ruben, Steven M., Olney, MD, UNITED STATES
IN
       Soppet, Daniel R., Centreville, VA, UNITED STATES
       Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
       Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
       Young, Paul E., Gaithersburg, MD, UNITED STATES
       Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
Yu, Guo-Liang, Berkeley, CA, UNITED STATES
Ni, Jian, Rockville, MD, UNITED STATES
       Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Brewer, Laurie A., St. Paul, MN, UNITED STATES
       Janat, Fouad, Westerly, RI, UNITED STATES
ΡI
       US 2003003555
                            A1
                                  20030102
ΑI
       us 2001-774639
                            Α1
                                  20010201 (9)
       Continuation of Ser. No. US 1999-244112, filed on 4 Feb 1999, ABANDONED
RLI
       Continuation-in-part of Ser. No. WO 1998-US16235, filed on 4 Aug 1998,
       UNKNOWN
                             19970805 (60)
PRAI
       US 1997-55386P
       US 1997-54807P
                             19970805
                                       (60)
       US 1997-55312P
                             19970805
                                       (60)
       US 1997-55309P
                             19970805
                                       (60)
                             19970805 (60)
       US 1997-54798P
       US 1997-55310P
                             19970805 (60)
       US 1997-54806P
                             19970805 (60)
       US 1997-54809P
                             19970805 (60)
       US 1997-54804P
                             19970805
                                       (60)
       US
          1997-54803P
                             19970805
                                       (60)
          1997-54808P
       US
                             19970805
                                       (60)
       US 1997-55311P
                             19970805
                                       (60)
       US 1997-55986P
                             19970818
                                       (60)
                             19970818 (60)
       US 1997-55970P
```

US 1997-56563P

19970819 (60)

```
US 1997-56731P
                            19970819 (60)
       US 1997-56365P
                            19970819 (60)
       US 1997-56367P
                            19970819 (60)
       US 1997-56370P
                            19970819
                                     (60)
       US 1997-56364P
                            19970819 (60)
       US 1997-56366P
                            19970819 (60)
       US 1997-56732P
                            19970819 (60)
       US 1997-56371P
                            19970819 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 15472
INCL
       INCLM: 435/183.000
       INCLS: 435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100;
               536/023.200
NCL
       NCLM:
              435/183.000
       NCLS:
              435/006.000; 435/069.100; 435/325.000; 435/320.100; 530/388.100;
              536/023.200
IC
       [7]
       ICM: C12Q001-68
       ICS: C07H021-04; C12N009-00; C12N005-06; C07K016-40; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 197 OF 391 USPATFULL ON STN
       2003:3410 USPATFULL
ΑN
       Method of preventing cell death using
                                                 ***antibodies***
TI
                                                                    to neural
       thread proteins
       Averback, Paul A., Quebec, CANADA
IN
PΙ
       US 2003003445
                           Α1
                                20030102
       US 2002-138516
ΑI
                           Α1
                                20020506 (10)
PRAI
       US 2001-288463P
                            20010504 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1705
INCL
       INCLM: 435/005.000
       INCLS: 435/069.100; 435/345.000; 435/007.100
NCL
       NCLM:
              435/005.000
       NCLS:
              435/069.100; 435/345.000; 435/007.100
IC
       [7]
       ICM: C12Q001-70
       ICS: G01N033-53; C12P021-06; C12N005-06; C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 198 OF 391 USPATFULL on STN
       2002:346816 USPATFULL
ΑN
TI
       Aspartyl protease 2 (Asp2) antisense oligonucleotides
IN
       Gurney, Mark E., Grand Rapids, MI, United States
       Bienkowski, Michael J., Portage, MI, United States
       Heinrikson, Robert L., Plainwell, MI, United States
       Parodi, Luis A., Stockholm, SWEDEN
       Yan, Riqiang, Kalamazoo, MI, United States
PΑ
       Pharmacía & Upjohn Company, Kalamazoo, MI, United States (U.S.
       corporation)
PΙ
       us 6500667
                           В1
                                20021231
       US 2000-551853
                                20000418 (9)
ΑI
       Division of Ser. No. US 1999-416901, filed on 13 Oct 1999
RLI
       Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
       Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23 Sep 1999
       US 1998-101594P
PRAI
                            19980924 (60)
       US 1999-155493P
                            19990923 (60)
DT
       Utility
FS
       GRANTED
LN.CNT
       5638
       INCLM: 435/375.000
INCL
       INCLS: 536/023.100; 536/024.100; 536/024.500; 514/044.000
              435/375.000
NCL
       NCLM:
              514/044.000; 536/023.100; 536/024.100; 536/024.500
       NCLS:
IC
       [7]
       ICM: C12N005-00
EXF
       536/23.1; 536/24.1; 536/24.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 199 OF 391 USPATFULL ON STN
       2002:343880
                    USPATFULL
AN
       Compositions and methods for monitoring the modification of modification
TI
```

dependent binding partner polypeptides

```
PΙ
        US 2002197606
                             Α1
                                  20021226
ΑI
        US 2001-770102
                                  20010125 (9)
                             Α1
PRAI
        US 2000-179283P
                              20000131 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 3550
INCL
        INCLM: 435/006.000
NCL
        NCLM: 435/006.000
        [7]
IC
        ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 200 OF 391 USPATFULL on STN
AN
        2002:339256 USPATFULL
        Transgenic knockouts of BACE-1
TI
        McConlogue, Lisa, Burlingame, CA, UNITED STATES
IN
        Gurney, Mark E., Reykjavik, ICELAND
        Elan Pharmaceuticals, Inc., South San Francisco, CA, UNITED STATES,
PA
        94080 (U.S. corporation)
PΙ
        US 2002194632
                                  20021219
                             Α1
        us 2002-82804
                                  20020222 (10)
ΑI
                             Α1
                              20010223 (60)
PRAI
        US 2001-271092P
        US 2001-271514P
                              20010226 (60)
        US 2001-293762P
                              20010525 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 1051
INCL
        INCLM: 800/012.000
        INCLS: 800/018.000
NCL
        NCLM:
               800/012.000
        NCLS:
               800/018.000
        [7]
IC
        ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 201 OF 391 USPATFULL on STN
ΑN
        2002:337952 USPATFULL
TI
        Steroidal sapogenins and their derivatives for treating alzheimer's
ΙN
        Xia, Zongqin, Shanghai, CHINA
        Hu, Yaer, Shanghai, CHINA
        Rubin, Ian, Nottingham, UNITED KINGDOM
       Brostoff, Jonathan, London, UNITED KINGDOM
Whittle, Brian, East Yorkshire, UNITED KINGDOM
       Wang, Weijun, Huntingdon, UNITED KINGDOM
Gunning, Phil, Grantchester, UNITED KINGDOM
                                  20021219
PI
        us 2002193317
                             Α1
ΑI
        US 2002-77493
                                  20020215 (10)
                             A1
        Continuation of Ser. No. US 2001-647110, filed on 11 Jan 2001, ABANDONED
RLI
PRAI
        GB 1998-6513
                              19980326
                              19990308
        GB 1999-5275
DT
        Utility
        APPLICATION
FS
LN.CNT 885
        INCLM: 514/026.000
INCL
        INCLS: 514/033.000
NCL
        NCLM:
               514/026.000
               514/033.000
        NCLS:
IC
        [7]
        ICM: A61K031-704
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 202 OF 391 USPATFULL ON STN 2002:337363 USPATFULL
L4
AN
TI
        Modular molecular clasps and uses thereof
        Rizzuto, Carlo Dante, Cambridge, MA, UNITED STATES
IN
        Afeyan, Noubar Boghos, Lexington, MA, UNITED STATES
        Lee, Frank Don, Chestnut Hill, MA, UNITED STATES
        Church, George McDonald, Brookline, MA, UNITED STATES
        Gupta, Ruchira Das, Jamaica Plain, MA, UNITED STATES
        Schwartz, John Jacob, Newtonville, MA, UNITED STATES
        Zhang, Bin, Belmont, CA, UNITED STATES
       Lugovskoy, Alexey Alexandrovich, Brighton, MA, UNITED STATES engeneOS, Inc., Waltham, MA (U.S. corporation)
PA
        us 2002192721
```

Α1

20021219

PΙ

```
PRAI
        US 2001-279524P
                              20010328 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 2440
INCL
        INCLM: 435/007.900
        INCLS: 435/287.200
               435/007.900
NCL
        NCLM:
        NCLS:
                435/287.200
        [7]
IC
        ICM: G01N033-53
        ICS: G01N033-542; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 203 OF 391 USPATFULL on STN
14
AN
        2002:330416 USPATFULL
TI
        CHIMERIC DNA-BINDING/DNA METHYLTRANSFERASE NUCLEIC ACID AND POLYPEPTIDE
        AND USES THEREOF
IN
        BESTOR, TIMOTHY H., NEW YORK, NY, UNITED STATES
PΙ
        US 2002188103
                            A1
                                   20021212
        US 1998-51013
                                   19981009 (9)
AΙ
                             A1
        wo 1996-us15576
                                   19960927
DT
        Utility
FS
        APPLICATION
LN.CNT 2050
INCL
        INCLM: 530/350.000
        INCLS: 435/320.100; 435/325.000; 435/455.000; 435/456.000; 435/458.000;
                435/459.000; 435/461.000; 424/093.200; 514/044.000; 536/023.100;
                536/023.200; 536/023.500; 800/013.000
NCL
        NCLM:
                530/350.000
                435/320.100; 435/325.000; 435/455.000; 435/456.000; 435/458.000; 435/459.000; 435/461.000; 424/093.200; 514/044.000; 536/023.100; 536/023.200; 536/023.500; 800/013.000
        NCLS:
        [7]
IC
        ICM: C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 204 OF 391 USPATFULL ON STN
L4
ΑN
        2002:330327 USPATFULL
        Method for treating Alzheimer's disease
TI
IN
        Bisgaier, Charles Larry, Ann Arbor, MI, UNITED STATES
        Emmerling, Mark Richard, Chelsea, MI, UNITED STATES US 2002188012 A1 20021212
PΙ
ΑI
        US 2002-71663
                                   20020208 (10)
                             Α1
        Continuation of Ser. No. US 2000-554994, filed on 23 May 2000, ABANDONED
RLI
        A 371 of International Ser. No. WO 1998-US25495, filed on 2 Dec 1998,
        UNKNOWN
PRAI
        US 1998-72912P
                              19980128 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 822
INCL
        INCLM: 514/356.000
        INCLS: 514/369.000; 514/381.000; 514/560.000; 514/572.000; 514/574.000
NCL
        NCLM:
                514/356.000
        NCLS:
                514/369.000; 514/381.000; 514/560.000; 514/572.000; 514/574.000
        [7]
IC
        ICM: A61K031-455
        ICS: A61K031-426; A61K031-41; A61K031-202; A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 205 OF 391 USPATFULL ON STN
        2002:330245 USPATFULL
AN
TT
        Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid
        analogs as B-secretase inhibitors
IN
        Qiao, Lixin, Arlington, VA, UNITED STATES
        Etcheberrigaray, Rene, Columbia, MD, UNITED STATES
PΙ
        US 2002187928
                                   20021212
                             Α1
        us 6562783
                             B2
                                   20030513
ΑI
        us 2001-866764
                             Α1
                                   20010530 (9)
DT
        Utility
        APPLICATION
FS
LN.CNT 824
        INCLM: 514/007.000
INCL
               514/080.000; 514/081.000; 514/120.000; 530/331.000; 544/243.000; 544/244.000; 546/021.000; 562/011.000; 562/024.000; 562/012.000
        INCLS:
```

NCL

NCLM:

514/007.000

```
[7]
IC
       ICM: A61K038-06
        ICS: C07F009-28; A61K031-675; C07F009-6512
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 206 OF 391 USPATFULL ON STN
ΑN
       2002:323128
                    USPATFULL
TI
       Sapogenin derivatives and their use in the treatment of cognitive
       dysfunction
IN
       Barraclough, Paul, Maidstone, UNITED KINGDOM
       Hanson, Jim, Steyning, UNITED KINGDOM
Gunning, Phil, Grantchester, UNITED KINGDOM
       Rees, Daryl, Sandy, UNITED KINGDOM
       Xia, Zongqin, Shanghai, CHINA
       Hu, Yaer, Shanghai, CHINA
PΙ
       US 2002183294
                           Α1
                                 20021205
       us 2002-109204
                           Α1
                                 20020328 (10)
AΙ
RLI
       Continuation-in-part of Ser. No. WO 2000-GB3745, filed on 29 Sep 2000,
       UNKNOWN
PRAI
       GB 1999-23077
                            19990929
       Utility
DT
       APPLICATION
FS
LN.CNT 1039
INCL
       INCLM: 514/172.000
       INCLS: 514/178.000
NCL
       NCLM:
               514/172.000
       NCLS:
              514/178.000
       [7]
IC
       ICM: A61K031-58
       ICS: A61K031-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 207 OF 391 USPATFULL on STN
AN
       2002:314710
                    USPATFULL
         ***HUMAN***
TT
                        SEL-10 POLYPEPTIDES AND POLYNUCLEOTIDES THAT ENCODE THEM
IN
       GURNEY, MARK E., GRAND RAPIDS, MI, UNITED STATES
       PAULEY, ADELE M., PLAINWELL, MI, UNITED STATES
       LI, JINHE, KALAMAZOO, MI, UNITED STATES
       US 2002177187
PΙ
                         Α1
                                20021128
       US 1999-328877
US 1997-68243P
                                 19990609 (9)
ΑI
                           Α1
PRAI
                            19971219 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 2859
INCL
       INCLM: 435/069.100
       INCLS: 435/320.100; 435/325.000; 530/350.000; 424/130.100; 435/007.100
NCL
       NCLM:
              435/069.100
       NCLS:
              435/320.100; 435/325.000; 530/350.000; 424/130.100; 435/007.100
       [7]
IC
       ICM: C07K017-00
       ICS: C07K014-00; C07K001-00; C12N005-02; C12N005-00; C12N015-74
       C12N015-70; C12N015-63; C12N015-09; C12N015-00; A61K039-395; C12P021-06;
       G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 208 OF 391 USPATFULL ON STN
AN
       2002:314672 USPATFULL
TI
       Systems and methods for automated analysis of cells and tissues
       Rimm, David L., Branford, CT, UNITED STATES
IN
       Camp, Robert L., Stamford, CT, UNITED STATES
PΙ
       us 2002177149
                                 20021128
                           Α1
ΑI
       us 2002-62308
                                 20020201 (10)
                           Α1
       US 2001-334723P
                            20011031 (60)
PRAI
       US 2001-285155P
                            20010420 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1254
INCL
       INCLM: 435/006.000
       INCLS: 435/007.200; 702/019.000; 702/020.000; 382/128.000
NCL
       NCLM:
              435/006.000
       NCLS:
              435/007.200; 702/019.000; 702/020.000; 382/128.000
IC
       ICM: C12Q001-68
       ICS: G01N033-53; G01N033-567; G06F019-00; G01N033-48; G01N033-50;
```

G06K009-00

```
L4
     ANSWER 209 OF 391 USPATFULL ON STN
AN
       2002:311059
                    USPATFULL
ΤI
       Biological reagents and methods for determining the mechanism in the
       generation of . ***beta*** .- ***amyloid***
                                                          peptide
IN
       Audia, James E., Indianapolis, IN, United States
       Hyslop, Paul A., Indianapolis, IN, United States
       Nissen, Jeffrey S., Indianapolis, IN, United States
       Thompson, Richard C., Frankfort, IN, United States
       Tung, Jay S., Belmont, CA, United States
       Tanner, Laura I., San Francisco, CA, United States
PA
       Elan Pharmaceuticals Inc., So. San Francisco, CA, United States (U.S.
       corporation)
       Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PΙ
       US 6486350
                           в1
                                20021126
                                19990929 (9)
       US 1999-408283
ΑI
PRAI
       US 1998-160082P
                            19980930 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 2017
       INCLM: 564/153.000
INCLS: 560/025.000; 560/027.000; 560/029.000; 540/522.000
INCL
              564/153.000
NCL
       NCLM:
       NCLS:
              540/522.000; 560/025.000; 560/027.000; 560/029.000
       [7]
IC
       ICM: C07C233-05
EXF
       564/153; 560/25; 560/27; 560/29; 540/522
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 210 OF 391 USPATFULL on STN
       2002:311025
AN
                    USPATFULL
TI
       Interleukin-20
       Ebner, Reinhard, Gaithersburg, MD, United States
IN
       Murphy, Marianne, Richmond, UNITED KINGDOM
       Ruben, Steven M., Olney, MD, United States
       Hu, Jing-Shan, Sunnyvale, CA, United States
       Duan, D. Roxanne, Bethesda, MD, United States
       Florence, Kimberly A., Rockville, MD, United States
       Rosen, Craig A., Laytonsville, MD, United States
PA
       Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
       corporation)
PΙ
       us 6486301
                           В1
                                20021126
       US 1999-231788
ΑI
                                19990115 (9)
       Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998
RLI
                        19970716 (60)
PRAI
       US 1997-52870P
       US 1997-60140P
                            19970926 (60)
       US 1997-55952P
                            19970818 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 5643
INCL
       INCLM: 530/351.000
       INCLS: 424/085.100
NCL
              530/351.000
       NCLM:
       NCLS: 424/085.100
       [7]
IC
       ICM: C07K014-475
       ICS: A61K038-19
EXF
       530/351; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 211 OF 391 USPATFULL on STN
       2002:310800
                    USPATFULL
ΑN
       Testis-specific
                         ***human***
TI
                                       SVPH1-8 proteinase
IN
       Cerretti, Douglas P., Seattle, WA, United States
       Immunex Corporation, Seattle, WA, United States (U.S. corporation)
PA
ΡI
       US 6485956
                           в1
                                20021126
ΑI
       US 2000-617145
                                20000714 (9)
DT
       Utility
FS
       GRANTED
LN.CNT 2072
INCL
       INCLM: 435/219.000
       INCLS: 435/069.100; 435/183.000; 435/218.000
NCL
       NCLM: 435/219.000
       NCLS: 435/069.100; 435/183.000; 435/218.000
```

IC

[7]

```
ICS: C12N009-00; C12N009-66; C12N009-50
EXF
          435/69.1; 435/183; 435/212; 435/219
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
       ANSWER 212 OF 391 USPATFULL ON STN
AN
         2002:310766 USPATFULL
TI
         Methods for determining risk of developing alzheimer's disease by
         detecting mutations in the presentlin 2 (PS-2) gene
IN
         St. George-Hyslop, Peter H., Toronto, CANADA
         Rommens, Johanna M., Toronto, CANADA
Fraser, Paul E., Toronto, CANADA
HSC Research and Development Limited Partnership, CANADA (non-U.S.
PA
         corporation)
         The Governing Council of the University of Toronto, CANADA (non-U.S.
         corporation)
PΙ
         US 6485911
                                        20021126
                                  В1
ΑI
         us 2000-636796
                                        20000811 (9)
         Division of Ser. No. US 1998-127480, filed on 31 Jul 1998, now patented, Pat. No. US 6194153 Division of Ser. No. US 1996-592541, filed on 26 Jan 1996, now patented, Pat. No. US 5986054 Continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995, now abandoned Continuation-in-part of Ser. No. US 1995-496841, filed on 28 Jun 1995, now patented, Pat. No. US 6210919 Continuation-in-part of Ser. No. US 1995-431048, filed on 28
RLI
         Apr 1995
         Utility
DT
FS
         GRANTED
LN.CNT 6790
INCL
         INCLM: 435/006.000
         INCLS: 435/091.200; 435/091.210; 435/091.510; 536/023.500; 536/024.310;
                  536/024.330
         NCLM:
NCL
                  435/006.000
                  435/091.200; 435/091.210; 435/091.510; 536/023.500; 536/024.310;
         NCLS:
                  536/024.330
IC
         [7]
         ICM: C12Q001-68
EXF
         435/6; 435/91.2; 435/91.21; 435/91.51; 536/24.31; 536/24.33; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 213 OF 391 USPATFULL ON STN 2002:309311 USPATFULL
L4
AN
TI
         Identification of genes involved in alzheimer's disease using drosophila
         melanogaster
IN
         Cohen, Dalia, Livingston, NJ, UNITED STATES
         Dengler, Uwe Jochen, Loerrach, GERMANY, FEDERAL REPUBLIC OF
         Finelli, Alyce Lynn, Parsippany, NJ, UNITED STATES
         Freuler, Felix, Riehen, SWITZERLAND
         Konsolaki, Mary, Westfield, NJ, UNITED STATES
         Reinhardt, Mischa Werner Henri Marie, Bantzenheim, FRANCE
         Zusman, Susan, Sudbury, MA, UNITED STATES US 2002174446 A1 20021121
PI
ΑI
         US 2001-964899
                                        20010927 (9)
                                 Α1
                                  20000929 (60)
20010614 (60)
         US 2000-236893P
PRAI
         US 2001-298309P
         Utility
DT
         APPLICATION
FS
LN.CNT 5722
         INCLM: 800/008.000
INCL
         INCLS: 514/001.000
NCL
         NCLM:
                  800/008.000
         NCLS:
                  514/001.000
IC
         [7]
         ICM: A01K067-033
         ICS: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 214 OF 391 USPATFULL ON STN
ΑN
         2002:307925 USPATFULL
TI
         Controlling protein levels in eucaryotic organisms
         Kenten, John H., Boyds, MD, UNITED STATES
Roberts, Steven F., Bethesda, MD, UNITED STATES
IN
         Proteinix, Inc. (U.S. corporation)
PA
         US 2002173049
PI
                                 Α1
                                        20021121
         US 6559280
                                        20030506
                                 В2
         US 2001-880132
                                       20010614 (9)
ΑI
                                Α1
         Division of Ser. No. US 1999-406781, filed on 28 Sep 1999, PATENTED
RLI
```

```
DT
        Utility
FS
        APPLICATION
LN.CNT
        3227
INCL
        INCLM: 436/501.000
        INCLS: 435/041.000; 435/106.000; 435/004.000; 435/007.720; 514/002.000;
                530/300.000; 530/350.000; 930/020.000; 424/094.100
NCL
        NCLM:
                530/323.000
        NCLS:
                424/070.140; 435/004.000; 435/106.000; 435/108.000; 435/109.000;
                435/115.000; 435/116.000; 436/501.000; 530/329.000; 530/330.000; 530/331.000; 530/332.000
IC
        [7]
        ICM: A01N037-18
        ICS: C12Q001-00; C12P001-00; C12P013-04; C07K004-00; C07K007-00;
        C07K016-00; C07K001-00; A61K038-00; G01N033-53; A61K038-43; C07K002-00;
        C07K005-00: C07K014-00: C07K017-00: G01N033-566
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 215 OF 391 USPATFULL ON STN
AN
        2002:307880 USPATFULL
        Novel ABCA6 transporter and uses thereof
TI
IN
        Chen, Hongyun, Vancouver, CANADA
        Le Bihan, Stephane, Vancouver, CANADA
Kulhanek, Barbara, Surrey, CANADA
        Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S.
PA
        corporation)
PΙ
        US 2002173004
                                   20021121
                              Α1
ΑI
        US 2002-90453
                              Α1
                                   20020304 (10)
PRAI
        US 2001-273650P
                               20010305 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 3798
        INCLM: 435/069.100
INCL
        INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.200; 536/024.300
NCL
                435/069.100
        NCLM:
        NCLS:
                435/320.100; 435/325.000; 530/350.000; 536/023.200; 536/024.300
IC
        [7]
        ICM: C12P021-02
        ICS: C12N005-06; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 216 OF 391 USPATFULL on STN
L4
ΑN
        2002:307870 USPATFULL
ΤI
              ***human***
                              secreted proteins
IN
        Ruben, Steven M., Olney, MD, UNITED STATES
        Rosen, Craig A., Laytonsville, MD, UNITED STATES
        Li, Yi, Sunnyvale, CA, UNITED STATES
        Zeng, Zhizhen, Lansdale, PA, UNITED STATES
        Kyaw, Hla, Frederick, MD, UNITED STATES
        Fischer, Carrie L., Burke, VA, UNITED STATES
        Li, Haodong, Gaithersburg, MD, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
        Wei, Ying-Fei, Berkeley, CA, UNITED STATES
        Moore, Paul A., Germantown, MD, UNITED STATES
        Young, Paul E., Gaithersburg, MD, UNITED STATES
        Greene, John M., Gaithersburg, MD, UNITED STATES
        Ferrie, Ann M., Tewksbury, MA, UNITED STATES US 2002172994 A1 20021121
PΙ
        US 2001-852797
                                   20010511 (9)
ΑI
                             Α1
        Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998, PENDING Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar
RLI
        1998, UNKNOWN
        US 2001-265583P
PRAI
                               20010202 (60)
        US 1997-40762P
                               19970314 (60)
                               19970314 (60)
        US 1997-40710P
        US 1997-50934P
                               19970530 (60)
        US 1997-48100P
                               19970530 (60)
        US 1997-48357P
                               19970530 (60)
        US 1997-48189P
                               19970530 (60)
                              19970905 (60)
19970606 (60)
        US
           1997-57765P
        US 1997-48970P
        US 1997-68368P
                               19971219 (60)
        Utility
DT
       APPLICATION
FS
```

LN.CNT 17794

```
INCLS: 435/226.000; 435/325.000; 435/320.100; 536/023.200
NCL
        NCLM:
               435/069.100
        NCLS:
               435/226.000; 435/325.000; 435/320.100; 536/023.200
        [7]
IC
        ICM: C12P021-02
        ICS: C12N005-06; C07H021-04; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 217 OF 391 USPATFULL ON STN
        2002:303718 USPATFULL
ΑN
TI
        Methods of reducing bone loss with CD40 ligand
       Ahuja, Seema A., San Antonio, TX, United States
Bonewald, Lynda F., San Antonio, TX, United States
Board of Regents, The University of Texas System, Austin, TX, United
IN
PA
        States (U.S. corporation)
        US 6482411
PΙ
                                   20021119
                            в1
       US 2000-645926
ΑI
                                   20000824 (9)
       US 1999-151250P
PRAI
                              19990827 (60)
       Utility
DT
FS
        GRANTED
LN.CNT 5120
INCL
        INCLM: 424/185.100
        INCLS: 424/085.100; 424/184.100; 424/192.100; 424/178.100; 514/002.000;
                514/008.000; 514/012.000; 514/885.000; 530/350.000; 530/351.000
               424/185.100
NCL
       NCLM:
        NCLS:
               424/085.100; 424/178.100; 424/184.100; 424/192.100; 514/002.000;
                514/008.000; 514/012.000; 514/885.000; 530/350.000; 530/351.000
        [7]
IC
        ICM: A61K038-17
       ICS: A61K038-19; C07K014-435; C07K014-52
EXF
        424/85.1; 424/185.1; 424/278.1; 514/2; 514/8; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 218 OF 391 USPATFULL on STN
        2002:301592 USPATFULL
AN
TI
       Regulation of amyloid precursor protein expression by modification of
       ABC transporter expression or activity
       Reiner, Peter B., Vancouver, CANADA Connop, Bruce P., Vancouver, CANADA
IN
       Pollard, Michelle, Vancouver, CANADA
Active Pass Pharmaceuticals, Inc., Vancouver, CANADA, V5Z 4H5 (non-U.S.
PA
       corporation)
PΙ
       US 2002169137
                                  20021114
                             Α1
       US 2002-72621
                                  20020208 (10)
AΤ
                             Α1
PRAI
       US 2001-267975P
                              20010209 (60)
       US 2001-309256P
                              20010731 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 3827
INCL
       INCLM: 514/044.000
       INCLS: 514/002.000
               514/044.000
NCL
       NCLM:
               514/002.000
       NCLS:
        [7]
IC
       ICM: A61K048-00
        ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 219 OF 391 USPATFULL on STN
L4
       2002:301144 USPATFULL
AN
       Inhibition of tau-tau-association
TI
       Wischik, Claude Michel, Cambridge, UNITED KINGDOM
Edwards, Patricia Carol, Cambridge, UNITED KINGDOM
IN
       Harrington, Charles Robert, Cambridge, UNITED KINGDOM
       Roth, Martin, Cambridge, UNITED KINGDOM
       Klug, Aaron, Cambridge, UNITED KINGDOM
PA
       University Court of the University of Aberdeen, Aberdeen, UNITED KINGDOM
        (3)
       us 2002168687
PΙ
                             A1
                                  20021114
ΑI
       US 2002-107181
                                  20020328 (10)
                             Α1
       Division of Ser. No. US 1997-913915, filed on 12 Dec 1997, GRANTED, Pat.
RLI
       No. US 6376205 A 371 of International Ser. No. WO 1996-EP1307, filed on
       25 Mar 1996, UNKNOWN
PRAI
       GB 1995-6197
                              19950327
```

Utility

DT

```
LN.CNT 2030
INCL
       INCLM: 435/007.100
NCL
       NCLM: 435/007.100
IC
       [7]
       ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 220 OF 391 USPATFULL ON STN
AN
       2002:300827 USPATFULL
TI
       Methods and compositions for treating secondary tissue damage and other
       inflammatory conditions and disorders
IN
       McDonald, John R., Calgary, AB, UNITED STATES
       Coggins, Philip J., Calgary, AB, UNITED STATES US 2002168370 A1 20021114
       us 2002168370
PΙ
ΑI
       US 2001-792793
                                20010222 (9)
                           Α1
       Division of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING
RLI
       Division of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING
       Continuation of Ser. No. US 1998-120523, filed on 22 Jul 1998, ABANDONED
                            19990721
       WO 1999-CA659
PRAI
       US 1998-155186P
                            19980722 (60)
       Utility
DT
       APPLICATION
LN.CNT 7972
       INCLM: 424/178.100
INCL
       INCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;
              435/325.000
              424/178.100
NCL
       NCLM:
       NCLS:
              514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;
              435/325.000
IC
       [7]
       ICM: A61K039-395
       ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 221 OF 391 USPATFULL ON STN
       2002:295299 USPATFULL
AN
TI
       Iron regulating protein -2 (IRP-2) as a diagnostic for neurodegenerative
IN
       Kirsch, Wolff M., Redlands, CA, UNITED STATES
       Lennart, Anto, Loma Linda, CA, UNITED STATES
       Kelln, Wayne J., Loma Linda, CA, UNITED STATES
       Kang, Dae-Kyung, Rockville, MD, UNITED STATES
       Levine, Rodney L., Rockville, MD, UNITED STATES
       Rouault, Tracey A., North Bethesda, MD, UNITED STATES
PΙ
       US 2002165349
                                20021107
                          Α1
       US 2001-924396
                                20010806 (9)
ΑI
                           Α1
PRAI
       US 2000-222863P
                            20000804 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 3514
INCL
       INCLM: 530/350.000
              536/023.500; 435/006.000; 435/007.100
              530/350.000
NCL
       NCLM:
       NCLS:
              536/023.500; 435/006.000; 435/007.100
       [7]
IC
       ICM: C12Q001-68
       ICS: G01N033-53; C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 222 OF 391 USPATFULL ON STN
ΑN
       2002:294717
                    USPATFULL
       Catalytically active recombinant memapsin and methods of use thereof
TI
IN
       Lin, Xinli, Edmond, OK, UNITED STATES
       Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
       Tang, Jordan J.N., Edmond, OK, UNITED STATES
PA
       Oklahoma Medical Research Foundation
PΙ
       US 2002164760
                           Α1
                                20021107
       US 2001-795903
ΑI
                                20010228 (9)
                           Α1
       Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING
RLI
                            19990628 (60)
PRAI
       US 1999-141363P
       US 1999-168060P
                            19991130
                                     (60)
       US 2000-177836P
                            20000125
                                     (60)
       US 2000-178368P
                            20000127 (60)
       US 2000-210292P
                            20000608 (60)
```

DT

Utility

```
LN.CNT 2440
INCL
         INCLM: 435/220.000
         INCLS: 435/069.100; 435/252.300; 435/320.100
         NCLM: 435/220.000
NCL
         NCLS: 435/069.100; 435/252.300; 435/320.100
IC
         [7]
         ICM: C12N009-52
         ICS: C12P021-02; C12N001-21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 223 OF 391 USPATFULL ON STN 2002:294625 USPATFULL
ΑN
         Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
TI
         Durham, L. Kathryn, New London, CT, UNITED STATES
IN
         Friedman, David L., Madison, CT, UNITED STATES
         Chandrasiri Herath, Herath Mudiyanselage Athula, Abingdom, UNITED
         KINGDOM
         Kimmel, Lida H., Chester, CT, UNITED STATES
         Parekh, Rajesh Bhikhu, New Wendlebury, UNITED KINGDOM
        Potter, David M., Ledyard, CT, UNITED KINGDO
Potter, David M., Ledyard, CT, UNITED STATES
Rohlff, Christian, Oxford, UNITED KINGDOM
Silber, B. Michael, Madison, CT, UNITED STATES
Stiger, Thomas R., Pawcatuck, CT, UNITED STATES
Sunderland, P. Trey, Chevy Chase, MD, UNITED STATES
Townsend, Robert Reid, Oxford, UNITED KINGDOM
         White, W. Frost, Ledyard, CT, UNITED STATES
         Williams, Stephen A., Groton, CT, UNITED STATES
PΙ
         US 2002164668
                                        20021107
                                Α1
         US 2001-826290
                                        20010403 (9)
ΑI
                                 Α1
        US 2000-194504P
US 2000-253647P
                                 20000403 (60)
PRAI
                                  20001128 (60)
DT
         Utility
         APPLICÁTION
FS
LN.CNT 5696
INCL
         INCLM: 435/007.920
         INCLS: 435/069.100; 435/325.000; 435/226.000; 536/023.200
                 435/007.920
NCL
                  435/069.100; 435/325.000; 435/226.000; 536/023.200
         NCLS:
IC
         [7]
         ICM: G01N033-53
         ICS: G01N033-537; G01N033-543; C07H021-04; C12N009-64; C12P021-02;
         C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 224 OF 391 USPATFULL on STN
AN
         2002:291111 USPATFULL
         Compounds for inhibiting .
                                            ***beta*** .- ***amyloid***
                                                                                      peptide
TI
         release and/or its synthesis
IN
         Wu, Jing, San Mateo, CA, United States
         Tung, Jay S., Belmont, CA, United States
Thorsett, Eugene D., Moss Beach, CA, United States
Reel, Jon K., Carmel, IN, United States
         Porter, Warren J., Indianapolis, IN, United States
         Nissen, Jeffrey S., Indianapolis, IN, United States
         Mabry, Thomas E., Indianapolis, IN, United States
         Latimer, Lee H., Oakland, CA, United States
         John, Varghese, San Francisco, CA, United States
         Folmer, Beverly K., Newark, DE, United States
        Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PA
         corporation)
         Eli Lilly Company, Indianapolis, IN, United States (U.S. corporation)
         US 6476263
PΙ
                                        20021105
                                в1
ΑI
         US 2001-826412
                                        20010403 (9)
         Continuation of Ser. No. US 1998-164448, filed on 30 Sep 1998, now
RLI
         patented, Pat. No. US 6211235 Continuation-in-part of Ser. No. US
         1997-976289, filed on 21 Nov 1997, now patented, Pat. No. US 6191166
                                  19961122 (60)
19970228 (60)
         US 1996-108166P
PRAI
         US 1997-64859P
         US 1997-108161P
                                  19970228 (60)
         US 1997-98558P
                                  19970228 (60)
```

Utility

DT

```
LN.CNT 12409
        INCLM: 564/152.000
INCL
        INCLS: 564/153.000;
                               564/159.000; 564/160.000; 564/161.000; 564/041.000;
                560/041.000; 562/450.000
NCL
        NCLM:
                564/152.000
        NCLS:
                560/041.000; 562/450.000; 564/041.000; 564/153.000; 564/159.000;
                564/160.000; 564/161.000
        [7]
IC
        ICM: C07C233-00
        564/152; 564/153; 564/159; 564/160; 564/161; 560/41; 562/450
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 225 OF 391 USPATFULL ON STN
AN
        2002:290742 USPATFULL
TI
             ***Human***
                              Secreted Proteins
IN
        Ruben, Steven M., Olney, MD, United States
        Ni, Jian, Rockville, MD, United States
        Rosen, Craig A., Laytonsville, MD, United States
        Wei, Ying-Fei, Berkeley, CA, United States
        Young, Paul, Gaithersburg, MD, United States
Florence, Kimberly, Rockville, MD, United States
Soppet, Daniel R., Centreville, VA, United States
Brewer, Laurie A., St. Paul, MN, United States
        Endress, Gregory A., Potomac, MD, United States
        Carter, Kenneth C., Potomac, MD, United States
        Mucenski, Michael, Cincinnati, OH, United States
        Ebner, Reinhard, Gaithersburg, MD, United States
        Lafleur, David W., Washington, DC, United States
        Olsen, Henrik, Gaithersburg, MD, United States
        Shi, Yanggu, Gaithersburg, MD, United States
       Moore, Paul A., Germantown, MD, United States
Komatsoulis, George, Silver Spring, MD, United States
Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
PA
        corporation)
PΙ
        us 6475753
                                   20021105
                              В1
        us 1999-461325
ΑI
                                   19991214 (9)
        Continuation-in-part of Ser. No. WO 1999-US13418, filed on 15 Jun 1999
RLI
PRAI
        US 1998-89507P
                               19980616 (60)
        US 1998-89508P
                               19980616 (60)
        US 1998-89509P
                               19980616 (60)
        US 1998-89510P
                               19980616 (60)
        US 1998-90112P
                               19980622 (60)
        US 1998-90113P
                               19980622 (60)
DT
        Utility
FS
        GRANTED
LN.CNT 18031
INCL
        INCLM: 435/069.100
        INCLS: 435/069.400; 435/071.100; 435/252.300; 435/032.500; 435/320.100; 435/471.000; 536/023.500; 530/350.000
NCL
        NCLM:
                435/069.100
        NCLS:
                435/069.400; 435/071.100; 435/252.300; 435/320.100; 435/325.000;
                435/471.000; 530/350.000; 536/023.500
IC
        [7]
        ICM: C12P021-02
        ICS: C12N015-12; C12N005-10; C07K014-47
EXF
        435/69.1; 435/69.4; 435/71.1; 435/91.1; 435/252.3; 435/325; 435/320.1;
        435/471; 536/23.5; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 226 OF 391 USPATFULL ON STN
        2002:290736 USPATFULL
AN
TT
        Identification of agents that protect against inflammatory injury to
        neurons
IN
        Giulian, Dana, Houston, TX, United States
        Baylor College of Medicine, Houston, TX, United States (U.S.
PA
        corporation)
        us 6475745
PΙ
                                   20021105
                              В1
        us 1997-922889
                                   19970903 (8)
ΑI
RLI
        Division of Ser. No. US 1996-717551, filed on 20 Sep 1996
DΤ
        Utility
FS
        GRANTED
LN.CNT 2755
INCL
        INCLM: 435/007.200
        INCLS: 530/300.000; 530/350.000; 530/402.000
```

NCL

NCLM: 435/007.200

```
IC
        ICM: G01N033-53
        ICS: C07K007-00; C07K004-12
EXF
        435/7.2; 435/7.1; 530/300; 530/350; 530/402; 424/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 227 OF 391 USPATFULL ON STN
ΑN
        2002:287562 USPATFULL
TI
        Process for differential diagnosis of Alzheimer's dementia and device
        therefor
       Jackowski, George, Kettleby, CANADA
Takahashi, Miyoko, North York, CANADA
ΙN
        US 2002160425
PΙ
                                  20021031
                            A1
ΑI
        US 2001-971740
                            A1
                                  20011004 (9)
        Continuation of Ser. No. US 2001-842079, filed on 25 Apr 2001, PENDING
RLI
       Utility
DT
FS
       APPLICATION
LN.CNT 940
        INCLM: 435/007.100
INCL
        INCLS: 435/007.200
              435/007.100
NCL
        NCLM:
              435/007.200
       NCLS:
IC
        [7]
        ICM: G01N033-53
        ICS: G01N033-567; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 228 OF 391 USPATFULL ON STN
L4
        2002:273382
                     USPATFULL
ΑN
       Methods and compositions for the treatment of
TI
                                                            ***human***
        immunodeficiency virus infection
TN
        Ikezu, Tsuneya, Omaha, NE, UNITED STATES
        Leisman, Gary, Omaha, NE, UNITED STATES
       Carlson, Kimberly A., Omaha, NE, UNITED STATES
       Gendelman, Howard E., Omaha, NE, UNITED STATES
PΙ
                                  20021017
       US 2002151510
                            Α1
       US 2001-828648
US 2000-246331P
AΤ
                                  20010406 (9)
                            Α1
PRAI
                            20001106 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 1948
       INCLM: 514/044.000
INCL
       INCLS: 514/012.000; 536/023.720; 435/069.100; 435/325.000; 435/320.100;
               435/219.000; 530/388.260; 424/207.100; 424/208.100
NCL
       NCLM:
               514/044.000
       NCLS:
               514/012.000; 536/023.720; 435/069.100; 435/325.000; 435/320.100;
               435/219.000; 530/388.260; 424/207.100; 424/208.100
        [7]
IC
        ICM: A61K038-17
       ICS: C12N009-50; C07H021-02; C12N005-06; C12P021-02; C12N015-867
       A61K038-00; C07H021-04; A61K031-70; A01N043-04; C12P021-06; A61K039-21; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12N005-00;
       C12N005-02; C07K016-00; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 229 OF 391 USPATFULL on STN
       2002:273336 USPATFULL
AN
TI
       Methods for preventing neural tissue damage and for the treatment of
       alpha-synuclein diseases
ΙN
       Wolozin, Benjamin, Hinsdale, IL, UNITED STATES
       Ostretova-Golts, Natalie, Forrest Park, IL, UNITED STATES
       Lebowitz, Michael S., Baltimore, MD, UNITED STATES
PΙ
       US 2002151464
                            Α1
                                 20021017
                                  20010709 (9)
ΑI
       US 2001-901187
                            Α1
                             20000707 (60)
20010328 (60)
PRAI
       US 2000-217319P
       US 2001-279199P
DT
       Utility
       APPLICATION
LN.CNT 1374
       INCLM: 514/002.000
INCL
       INCLS: 435/007.200; 435/025.000
NCL
       NCLM:
               514/002.000
       NCLS:
               435/007.200; 435/025.000
IC
        [7]
        ICM: A61K038-16
```

A4 A5

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
       ANSWER 230 OF 391 USPATFULL ON STN
ΑN
          2002:272761 USPATFULL
TI
          Directed evolution of novel binding proteins
IN
          Ladner, Robert Charles, Ijamsville, MD, UNITED STATES
          Guterman, Sonia Kosow, Belmont, MA, UNITED STATES
         Roberts, Bruce Lindsay, Milford, MA, UNITED STATES Markland, William, Milford, MA, UNITED STATES
         Ley, Arthur Charles, Newton, MA, UNITED STATES
Kent, Rachel Baribault, Boxborough, MA, UNITED STATES
          US 2002150881
PΙ
                                          20021017
                                   Α1
ΑI
         US 2001-781988
                                          20010214 (9)
                                   Α1
         Continuation of Ser. No. US 1998-192067, filed on 16 Nov 1998, ABANDONED
RLI
         Continuation of Ser. No. US 1995-415922, filed on 3 Apr 1995, PATENTED Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, PATENTED Division of Ser. No. US 1991-664989, filed on 1 Mar 1991, PATENTED Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
         ABANDONED Continuation-in-part of Ser. No. US 1988-240160, filed on 2
         Sep 1988, ABANDONED
         wo 1989-ús3731
PRAI
                                    19890901
         Utility
DT
         APPLICATION
FS
LN.CNT 15696
INCL
         INCLM: 435/005.000
         INCLS: 435/006.000; 435/007.100; 435/235.100
NCL
                  435/005.000
         NCLS: 435/006.000; 435/007.100; 435/235.100
IC
          [7]
         ICM: C12Q001-70
         ICS: C12Q001-68; G01N033-53; C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 231 OF 391 USPATFULL on STN
AN
         2002:268610 USPATFULL
TI
         Vectors and methods for gene transfer to cells
         Wickham, Thomas J., Falls Church, VA, United States
TN
         Kovesdi, Imre, Rockville, MD, United States
         Brough, Douglas E., Olney, MD, United States
         GenVec, Inc., Gaithersburg, MD, United States (U.S. corporation) US 6465253 B1 20021015
PA
PΙ
         wo 9720051 19970605
         US 1999-101751
ΑI
                                          19990129 (9)
         wo 1996-US19150
                                         19961127
                                         19990129
                                                      PCT 371 date
         Continuation-in-part of Ser. No. US 1996-700846, filed on 21 Aug 1996,
RLI
         now patented, Pat. No. US 5962311 Continuation-in-part of Ser. No. US
         1996-634060, filed on 17 Apr 1996, now patented, Pat. No. US 5712136
         Continuation-in-part of Ser. No. US 1996-701124, filed on 21 Aug 1996, now patented, Pat. No. US 5846782 Continuation-in-part of Ser. No. US 1995-563368, filed on 28 Nov 1995, now patented, Pat. No. US 5965541 Continuation-in-part of Ser. No. US 634060 Continuation-in-part of Ser.
         No. US 1994-303162, filed on 8 Sep 1994, now patented, Pat. No. US
         5559099
DT
         Utility
         GRANTED
FS
LN.CNT 3207
INCL
         INCLM: 435/456.000
         INCLS: 435/320.100; 435/325.000; 435/455.000; 530/330.000; 530/329.000; 530/328.000; 530/327.000; 530/326.000; 530/324.000; 530/350.000
NCL
         NCLM:
                   435/456.000
                   435/320.100; 435/325.000; 435/455.000; 530/324.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000; 530/350.000
         NCLS:
IC
         [7]
         ICM: C12N015-861
         ICS: C12N015-63; C12N005-10; C07K007-04; C07K014-075 435/69.1; 435/235.1; 435/320.1; 435/325; 435/366; 435/455; 435/456;
EXF
         530/350; 530/330; 530/329; 530/328; 530/327; 530/326; 530/324; 424/93.1; 424/93.2; 424/93.6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 232 OF 391 USPATFULL ON STN
ΑN
         2002:265967
                         USPATFULL
TI
         Controlling protein levels in eucaryotic organisms
TN
         Kenten, John H., Boyds, MD, UNITED STATES
```

```
PA
        Proteinix, Inc. (U.S. corporation)
ΡI
        US 2002146843
                                  20021010
                            Α1
ΑI
        US 2001-880149
                                  20010614 (9)
                            Α1
RLI
        Continuation of Ser. No. US 1999-406781, filed on 28 Sep 1999, GRANTED,
        Pat. No. US 6306663
PRAI
        US 1999-119851P
                             19990212 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT
       3226
INCL
        INCLM: 436/501.000
       INCLS: 424/094.100; 435/106.000; 435/004.000; 435/041.000; 435/007.720; 514/002.000; 530/300.000; 530/350.000; 930/020.000
        NCLM:
               436/501.000
NCL
        NCLS:
               424/094.100; 435/106.000; 435/004.000; 435/041.000; 435/007.720;
               514/002.000; 530/300.000; 530/350.000; 930/020.000
IC
        [7]
        ICM: A01N037-18
        ICS: C12Q001-00; C12P001-00; C12P013-04; C07K004-00; C07K007-00;
        C07K016-00; C07K001-00; A61K038-00; A61K038-43; C07K005-00; C07K017-00;
G01N033-53; C07K014-00; C07K002-00; G01N033-566 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 233 OF 391 USPATFULL on STN
        2002:265884 USPATFULL
AN
TI
        Novel G-protein-coupled receptor-like proteins and polynucleotides
        encoded by them, and methods of using same
        Ozenberger, Bradley A., Newtown, PA, UNITED STATES
IN
        Kajkowski, Eileen M., Ringoes, NJ, UNITED STATES
        Lo, Ching-Hsiung Frederick, Pennington, NJ, UNITED STATES
       Walker, Stephen G., East Windsor, NJ, UNITED STATES
        Sofia, Heidi, Walla Walla, WA, UNITED STATES
PA
       American Home Products Corporation, Madison, NJ, 07940-0874 (U.S.
        corporation)
PΙ
       us 2002146760
                                  20021010
                            Α1
                                  20010412 (9)
ΑI
       US 2001-833503
                            Α1
       wo 1999-us21621
                            19991013
PRAI
        US 1998-104104P
                             19981013 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT
       1524
INCL
        INCLM: 435/069.100
        INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL
        NCLM:
               435/069.100
               435/320.100; 435/325.000; 530/350.000; 536/023.500
       NCLS:
IC
        [7]
        ICM: C12P021-02
        ICS: C12N005-06; C07K014-705; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 234 OF 391 USPATFULL on STN
       2002:265848 USPATFULL
AN
TI
       Biopolymer sequence comparison
       Toll, Lawrence R., Redwood City, CA, UNITED STATES
ΤN
       Lincoln, Patrick Denis, Woodside, CA, UNITED STATES
       Karp, Peter, San Mateo, CA, UNITED STATES
Sonmez, Kemal, Menlo Park, CA, UNITED STATES
                                  20021010
PΙ
       us 2002146724
                            Α1
ΑI
       US 2001-6492
                            Α1
                                  20011203 (10)
       US 2000-250743P
PRAI
                             20001201 (60)
       Utility
DT
       APPLICATION
FS
       1796
LN.CNT
       INCLM: 435/006.000
INCL
       INCLS: 702/020.000
NCL
               435/006.000
       NCLM:
               702/020.000
       NCLS:
IC
        [7]
       ICM: C12Q001-68
       ICS: G06F019-00; G01N033-48; G01N033-50
     ANSWER 235 OF 391 USPATFULL on STN
L4
        2002:262446 USPATFULL
ΑN
TI
        Peptides and pharmaceutical compositions thereof for treatment of
```

disorders or diseases associated with abnormal protein folding into

amyloid or amyloid-like deposits

```
Baumann, Marc H., Helsinki, FINLAND
Frangione, Blas, New York, NY, United States
New York University, New York, NY, United States (U.S. corporation)
PA
ΡI
                                 B1
                                        20021008
         US 6462171
ΑI
         US 1996-766596
                                        19961212 (8)
RLI
         Continuation-in-part of Ser. No. US 1996-630645, filed on 10 Apr 1996,
         now patented, Pat. No. US 5948763 Continuation-in-part of Ser. No. US 1995-478326, filed on 7 Jun 1995, now abandoned
DT
         Utility
FS
         GRANTED
LN.CNT 1979
INCL
         INCLM: 530/326.000
         INCLS: 530/327.000; 530/238.000; 530/329.000; 530/330.000; 514/014.000;
                  514/015.000; 514/016.000; 514/017.000; 514/018.000
         NCLM:
                  530/326.000
NCL
                  530/327.000; 530/328.000; 530/329.000; 530/330.000
         NCLS:
         [7]
IC
         ICM: A61K038-00
        ICS: C07K016-00
514/2; 514/12; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18; 530/300;
530/324; 530/325; 530/326; 530/327; 530/328; 530/330; 530/331; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 236 OF 391 USPATFULL on STN
         2002:254378 USPATFULL
AN
TI
         Lactacystin analogs
         Fenteany, Gabriel, Cambridge, MA, United States
Jamison, Timothy F., Cambridge, MA, United States
ΙN
        Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
President and Fellows of Harvard College, Cambridge, MA, United States
PΑ
         (U.S. corporation)
        ùs 6458825
PΙ
                                        20021001
                                 В1
ΑI
        US 2000-639242
                                        20000815 (9)
         Continuation of Ser. No. US 1995-421583, filed on 12 Apr 1995, now
RLI
         patented, Pat. No. US 6335358
DT
         Utility
FS
         GRANTED
LN.CNT 2298
INCL
         INCLM: 514/421.000
         INCLS: 514/444.000; 514/470.000
                  514/421.000
NCL
         NCLM:
        NCLS:
                  514/444.000; 514/470.000
         [7]
IC
         ICM: A61K031-40
         ICS: A61K031-38; A61K031-34
         514/421; 514/444; 514/470
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 237 OF 391 USPATFULL on STN
AN
         2002:251790 USPATFULL
         N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
TI
         comprising same, and methods for inhibiting
                                                                    ***beta***
           ***amyloid***
                                peptide release and/or its synthesis by use of such
IN
        Wu, Jing, San Mateo, CA, UNITED STATES
         Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
        Nissen, Jeffrey S., Indianapolis, IN, UNITED STATES
        Mabry, Thomas E., Indianapolis, IN, UNITED STATES
        Latimer, Lee H., Oakland, CA, UNITED STATES
John, Varghese, San Francisco, CA, UNITED STATES
Fang, Lawrence Y., Foster City, CA, UNITED STATES
Audia, James E., Indianapolis, IN, UNITED STATES
PΙ
         US 2002137743
                                        20020926
                                 Α1
ΑI
        US 2001-984834
                                 Α1
                                        20011031 (9)
        Continuation of Ser. No. US 1999-303655, filed on 3 May 1999, PATENTED
RLI
         Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, PATENTED
DT
        Utility
FS
         APPLICATION
LN.CNT 3784
         INCLM: 514/227.500
INCL
        INCLS: 514/237.800; 514/252.120; 514/357.000; 514/534.000; 514/561.000; 544/059.000; 544/159.000; 544/400.000; 546/336.000; 560/041.000;
                  560/155.000
NCL.
                  514/227.500
        NCLM:
```

```
544/059.000; 544/159.000; 544/400.000; 546/336.000; 560/041.000;
               560/155.000
IC
        [7]
        ICM: A61K031-54
        ICS: A61K031-535; A61K031-495; A61K031-44; A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 238 OF 391 USPATFULL ON STN
        2002:251784 USPATFULL
ΑN
TT
        Lactams substituted by cyclic succinates as inhibitors of a beta protein
        Olson, Richard E., Wilmington, DE, UNITED STATES
IN
PΙ
        US 2002137737
                                 20020926
                            Α1
        us 6509333
                            В2
                                 20030121
       US 2001-871840
AΤ
                                 20010601 (9)
                            Α1
PRAI
       US 2000-208536P
                             20000601 (60)
       Utility
DT
       APPLICATION
LN.CNT 6581
INCL
       INCLM: 514/212.030
        INCLS: 514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000
               514/221.000
NCL
        NCLM:
        NCLS:
               540/509.000
        [7]
IC
        ICM: A61K031-55
        ICS: A61K031-445; A61K031-4015; C07D211-54; C07D223-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 239 OF 391 USPATFULL on STN
        2002:243784 USPATFULL
ΑN
TI
       VEGF-modulated genes and methods employing them
IN
       Gerber, Hans-Peter, San Francisco, CA, UNITED STATES
       Rastelli, Luca, Guilford, CT, UNITED STATES
PΙ
       us 2002132978
                            Α1
                                 20020919
       US 2001-815153
ΑI
                            Α1
                                 20010321 (9)
PRAI
       US 2000-191201P
                             20000322 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 5514
INCL
        INCLM: 530/350.000
               536/023.500; 530/388.100; 435/325.000; 435/320.100; 435/069.100
       INCLS:
NCL
       NCLM:
               530/350.000
       NCLS:
               536/023.500; 530/388.100; 435/325.000; 435/320.100; 435/069.100
        [7]
IC
       ICM: C07K014-705
       ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 240 OF 391 USPATFULL on STN
       2002:243133 USPATFULL
ΑN
                            ***human***
       Peptide mutant of
TI
                                           ERAB or HADH2, its X-ray crystal
       structure, and materials and method for identification of inhibitors
       Abreo, Melwyn A., Jamul, CA, UNITED STATES
IN
       Agree, Charles S., San Diego, CA, UNITED STATES
       Aust, Robert M., Alpine, CA, UNITED STATES
       Kissinger, Charles R., San Diego, CA, UNITED STATES
       Margosiak, Stephen, Escondido, CA, UNITED STATES
Meng, Jerry J., San Diego, CA, UNITED STATES
       Pelletier, Laura A., Escondido, CA, UNITED STATES
Rejto, Paul Abraham, Carlsbad, CA, UNITED STATES
       Showalter, Richard Edward, Santee, CA, UNITED STATES
       Thomson, James Arthur, San Diego, CA, UNITED STATES
       Tempczyk-Russell, Anna, Ramona, CA, UNITED STATES
       Vanderpool, Darin, San Diego, CA, UNITED STATES
       Villafranca, Jesus Ernesto, San Diego, CA, UNITED STATES
                                 20020919
PΙ
       us 2002132319
                           Α1
       us 2001-931186
                                 20010817 (9)
AΙ
                            Α1
       US 2000-226123P
                            20000818 (60)
PRAI
DT
       Utility
FS
       APPLICATION
LN.CNT 12914
INCL
       INCLM: 435/189.000
       INCLS: 435/226.000; 536/023.200; 435/069.100; 702/019.000
```

NCL

NCLM:

435/189.000

```
IC
        [7]
        ICM: C12N009-02
        ICS: C12N009-64; G06F019-00; G01N033-48; G01N033-50; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 241 OF 391 USPATFULL ON STN
ΑN
        2002:238832
                      USPATFULL
TI
        Process for differential diagnosis of Alzheimer's dementia and device
        therefor
ΙN
        Jackowski, George, Kettleby, CANADA
        Takahashi, Miyoko, North York, CANADA
PA
        Syn X Pharma, CANADA (non-U.S. corporation)
                                   20020917
PΙ
        US 6451547
                            в1
ΑI
        US 2001-842079
                                   20010425 (9)
        Utility
DT
        GRANTED
FS
LN.CNT 817
        INCLM: 435/007.400
INCL
        INCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.930; 435/007.940; 435/007.950; 530/387.200; 530/388.100; 530/388.250; 530/388.260; 530/389.100; 530/389.300; 530/391.100
NCL
                435/007.400
        NCLM:
        NCLS:
                435/007.100; 435/007.900; 435/007.920; 435/007.930; 435/007.940;
                435/007.950; 530/387.200; 530/388.100; 530/388.250; 530/388.260;
                530/389.100; 530/389.300; 530/391.100
        [7]
IC
        ICM: C07K016-18
        ICS: C07K016-40; G01N033-48; G01N033-49; G01N033-53
        530/387.2; 530/388.1; 530/388.25; 530/388.26; 530/389.1; 530/389.3; 530/391.1; 435/7.1; 435/7.4; 435/7.9; 435/7.92; 435/7.93; 435/7.94;
EXF
        435/7.95
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 242 OF 391 USPATFULL ON STN
ΑN
        2002:237182 USPATFULL
TI
        Transgenic animals and cell lines for screening drugs effective for the
        treatment or prevention of alzheimer's disease
IN
        De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
        Wands, Jack R., Waban, MA, UNITED STATES
                                   20020912
PΙ
        US 2002129391
                             Α1
ΑI
        US 2001-964412
                             Α1
                                   20010928 (9)
        Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371
RLI
        of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI
        US 1997-38908P
                              19970226 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 2087
INCL
        INCLM: 800/012.000
        INCLS: 800/018.000; 435/368.000; 435/320.100; 536/023.200
NCL
        NCLM:
                800/012.000
        NCLS:
                800/018.000; 435/368.000; 435/320.100; 536/023.200
        [7]
IC
        ICM: A01K067-027
        ICS: C07H021-04; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 243 OF 391 USPATFULL on STN
AN
        2002:236057
                      USPATFULL
TI
        Compounds to treat alzheimer's disease
IN
        Beck, James P., Kalamazoo, MI, UNITED STATES
        Fang, Lawrence Y., Foster City, CA, UNITED STATES
Freskos, John N., Clayton, MO, UNITED STATES
Gailunas, Andrea, San Francisco, CA, UNITED STATES
        Hom, Roy, San Francisco, CA, UNITED STATES
        Jagodzinska, Barbara, Redwood City, CA, UNITED STATES
        John, Varghese, San Francisco, CA, UNITED STATES
        Maillard, Michel, Redwood Shores, CA, UNITED STATES
        Pulley, Shon R., Hickory Corners, MI, UNITED STATES
        TenBrink, Ruth E., Kalamazoo, MI, UNITED STATES
        US 2002128255
PΙ
                             Α1
                                   20020912
        US 2001-896139
ΑI
                             A1
                                   20010629 (9)
        US 2000-215323P
PRAI
                              20000630 (60)
        US 2000-252736P
                              20001122 (60)
        US 2000-255956P
                              20001215 (60)
```

20010213 (60)

US 2001-268497P

```
US 2001-295589P
                             20010604 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 21437
INCL
        INCLM: 514/211.150
        INCLS: 514/396.000; 514/423.000; 514/357.000; 514/438.000; 514/616.000
NCL
       NCLM:
               514/211.150
        NCLS:
               514/396.000; 514/423.000; 514/357.000; 514/438.000; 514/616.000
IC
        ICM: A61K031-553
        ICS: A61K031-554; A01N043-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 244 OF 391 USPATFULL on STN
        2002:235353 USPATFULL
ΑN
       Alzheimer's related proteins and methods of use
TI
       St. George-Hyslop, Peter H., Toronto, CANADA
IN
       Fraser, Paul E., Toronto, CANADA
       The Governing Council of the University of Toronto (non-U.S.
PA
       corporation)
       US 2002127541
ΡI
                            Α1
                                  20020912
       US 2002-71900
                                  20020208 (10)
ΑI
                            Α1
       Division of Ser. No. US 1999-227725, filed on 8 Jan 1999, GRANTED, Pat.
RLI
       No. US 6383758
PRAI
       US 1998-70948P
                             19980109 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1479
INCL
       INCLM: 435/004.000
       INCLS: 435/023.000; 435/007.200
              435/004.000
NCL
       NCLM:
       NCLS:
              435/023.000; 435/007.200
        [7]
IC
       ICM: C12Q001-00
       ICS: C12Q001-37; G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 245 OF 391 USPATFULL ON STN
       2002:235107 USPATFULL
ΑN
                               ***beta*** - ***amyloid***
ΤI
       Methods of reducing
                                                                 polypeptides
       Eckman, Christopher B., Ponte Vedra Beach, FL, UNITED STATES Yager, Debra, Jacksonville, FL, UNITED STATES Haugabook, Sharie, Jacksonville, FL, UNITED STATES
IN
       Fauq, Abdul, Jacksonville, FL, UNITED STATES
PΙ
       US 2002127290
                            Α1
                                 20020912
ΑI
       us 2001-804420
                            Α1
                                 20010312 (9)
DT
       Utility
       APPLICATION
FS
LN.CNT 934
INCL
       INCLM: 424/773.000
       INCLS: 424/764.000
              424/773.000
NCL
       NCLM:
       NCLS: 424/764.000
IC
       [7]
       ICM: A61K035-78
L4
     ANSWER 246 OF 391 USPATFULL on STN
ΑN
       2002:230959 USPATFULL
TI
       Testis expressed polypeptide
       Ruben, Steven M., Olney, MD, United States
IN
       Rosen, Craig A., Laytonsville, MD, United States
       Zeng, Zhizhen, Gaithersburg, MD, United States
PA
       Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
       corporation)
       us 6448230
PΙ
                            В1
                                 20020910
ΑI
       us 1998-152060
                                 19980911 (9)
       Continuation-in-part of Ser. No. WO 1998-US4858, filed on 12 Mar 1998
RLI
PRAI
                             19970314 (60)
       US 1997-40762P
       US 1997-40710P
                             19970314 (60)
       US 1997-50934P
                             19970530 (60)
       US 1997-48100P
                             19970530 (60)
       US
          1997-48357P
                             19970530 (60)
       US 1997-48189P
                             19970530 (60)
       US 1997-57765P
                             19970905 (60)
```

19970606 (60)

US 1997-48970P

```
DT
        Utility
FS
        GRANTED
       7777
LN.CNT
INCL
        INCLM: 514/021.000
        INCLS: 514/012.000; 514/002.000; 514/044.000; 530/300.000; 530/350.000;
                 530/305.000; 530/324.000; 424/185.100; 424/193.100; 424/194.100;
                 424/234.100
NCL
        NCLM:
                 514/021.000
        NCLS:
                424/185.100; 424/193.100; 424/194.100; 424/234.100; 514/002.000;
                 514/012.000; 514/044.000; 530/300.000; 530/305.000; 530/324.000;
                 530/350.000
IC
        [7]
        ICM: A61K038-00
        ICS: C07K001-00; C07K005-00; C07K007-00

435/6; 435/69.1; 435/252.3; 435/320.1; 435/325; 514/12; 514/2; 514/44;

514/21; 530/300; 530/350; 530/305; 530/324; 530/333; 530/344; 530/345;

530/356; 530/358; 530/362; 530/391.5; 424/234.1; 424/184.1; 424/185.1;
EXF
        424/193.1; 424/194.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 247 OF 391 USPATFULL ON STN
ΑN
        2002:227919 USPATFULL
TI
        Assay for disease related conformation of a protein and isolating same
IN
        Prusiner, Stanley B., San Francisco, CA, UNITED STATES
        Safar, Jiri G., Walnut Creek, CA, UNITED STATES
                                     20020905
PΙ
        US 2002123072
                               Α1
        us 2002-47431
                                     20020114 (10)
ΑI
                               Α1
        Continuation of Ser. No. US 2001-754443, filed on 3 Jan 2001, PENDING
RLI
        Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,
        Pat. No. US 6214565 Continuation of Ser. No. US 1998-26967, filed on 20
        Feb 1998, GRANTED, Pat. No. US 5977324
        Utility
DT
FS
        APPLICATION
LN.CNT 1643
        INCLM: 435/007.100
INCL
        INCLS: 435/007.200
NCL
        NCLM:
                435/007.100
                435/007.200
        NCLS:
IC
        [7]
        ICM: G01N033-53
        ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 248 OF 391 USPATFULL ON STN 2002:227617 USPATFULL
L4
ΑN
        Stable radiopharmaceutical compositions and methods for preparation
TI
        thereof
IN
        Liu, Shuang, Chelmsford, MA, UNITED STATES
        Barrett, John A., Groton, MA, UNITED STATES
        Carpenter, Alan P., JR., Carlisle, MA, UNITED STATES
PΙ
                                     20020905
        US 2002122768
                               Α1
ΑI
        us 2001-899629
                                     20010705 (9)
                               Α1
        US 2000-216396P
                                20000706 (60)
PRAI
DT
        Utility
FS
        APPLICATION
LN.CNT 4115
INCL
        INCLM: 424/001.110
NCL
        NCLM: 424/001.110
IC
        [7]
        ICM: A61K051-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 249 OF 391 USPATFULL ON STN 2002:224705 USPATFULL
L4
ΑN
TI
        Hydrophobically-modified hedgehog protein compositions and methods
        Pepinsky, R. Blake, Arlington, MA, United States
IN
        Baker, Darren P., Hingham, MA, United States
        Wen, Dingyi, Waltham, MA, United States
        Williams, Kevin P., Natick, MA, United States
Garber, Ellen A., Cambrdige, MA, United States
        Taylor, Frederick R., Milton, MA, United States
       Galdes, Alphonse, Lexington, MA, United States
Porter, Jeffrey, Cambridge, MA, United States
Curis, Inc., Cambridge, MA, United States (U.S. corporation)
PA
```

Biogen, Inc., Cambridge, MA, United States (U.S. corporation)

```
ΑI
       US 1999-325256
                                19990603 (9)
RLI
       Continuation of Ser. No. WO 1998-US25676, filed on 3 Dec 1998
PRAI
       US 1998-99800P
                           19980910 (60)
       US 1998-89685P
                            19980617 (60)
       US 1998-78935P
                            19980320 (60)
       US 1997-67423P
                            19971203 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 5426
INCL
       INCLM: 530/402.000
       INCLS: 530/350.000; 530/399.000; 530/359.000; 436/071.000; 514/012.000;
               514/506.000; 514/762.000
              530/402.000
NCL
       NCLM:
       NCLS:
              436/071.000; 530/350.000; 530/359.000; 530/399.000
       [7]
IC
       ICM: C07K014-435
       ICS: C07K001-107
       436/71; 530/350; 530/399; 530/402; 530/359; 514/12; 514/506; 514/762
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 250 OF 391 USPATFULL on STN
L4
       2002:221784
                    USPATFULL
ΑN
       Inhibitors of IAPP fibril formation and uses thereof
ΤI
IN
       Fraser, Paul, Toronto, CANADA
PΙ
       us 2002119926
                                20020829
                          Α1
       us 2001-956625
ΑI
                           Α1
                                20010919 (9)
PRAI
       US 2000-233482P
                            20000919 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT
       1753
INCL
       INCLM: 514/012.000
       INCLS: 435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
              514/012.000
NCL
       NCLM:
       NCLS:
              435/184.000; 514/014.000; 514/015.000; 514/016.000; 514/017.000
       [7]
TC
       ICM: A61K038-17
       ICS: A61K038-10; A61K038-08; C12N009-99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 251 OF 391 USPATFULL on STN
ΑN
       2002:217052
                    USPATFULL
TI
       Alzheimer's disease secretase, APP substrates therefor, and uses
       therefor
IN
       Gurney, Mark E., 910 Rosewood Ave. SE., Grand Rapids, MI, United States
       49506
       Bienkowski, Michael J., 3431 Hollow Wood, Portage, MI, United States
       49024
       Heinrikson, Robert L., 81 S. Lake Doster Dr., Plainwell, MI, United
       States 49080
       Parodi, Luis A., Grevgafar 24, S-11543 Stockholm, SWEDEN
       Yan, Riqiang, 5026 Queen Victoria St., Kalamazoo, MI, United States
       49009
ΡI
       US 6440698
                                20020827
                           В1
ΑI
       us 2000-548367
                                20000412 (9)
RLI
       Division of Ser. No. US 1999-416901, filed on 13 Oct 1999
       Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
       Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23 Sep 1999
       US 1999-155493P
                           19990923 (60)
PRAI
       US 1998-101594P
                           19980924 (60)
       Utility
DT
       GRANTED
FS
LN.CNT
       5651
INCL
       INCLM: 435/069.100
       INCLS: 435/252.300; 435/325.000; 435/320.100; 536/023.100
NCL
              435/069.100
       NCLM:
       NCLS:
              435/252.300; 435/320.100; 435/325.000; 536/023.100
IC
       [7]
       ICM: C12P021-06
       ICS: C12N001-20; C12N018-00; C07H021-04
EXF
       435/70.1; 435/69.1; 435/252.3; 435/320.1; 435/325; 435/183; 435/212;
       435/219; 536/23.1; 536/23.4; 536/23.7; 536/23.5; 536/24.3; 514/2;
       424/94.63; 530/300; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

ANSWER 252 OF 391 USPATFULL ON STN

L4

```
ΤI
       Inhibitors of memapsin 2 and use thereof
IN
       Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
       Tang, Jordan J.N., Edmond, OK, UNITED STATES
       Hong, Lin, Oklahoma City, OK, UNITED STATES
       Ghosh, Arun K., River Forest, IL, UNITED STATES
PA
       Oklahoma Medical Research Foundation (U.S. corporation)
PΙ
       US 2002115600
                          Α1
                                20020822
       US 2001-845226
ΑI
                                20010430 (9)
                          Α1
RLI
       Division of Ser. No. US 2000-603713, filed on 27 Jun 2000, PENDING
       US 1999-141363P
                            19990628 (60)
PRAI
       US 1999-168060P
                            19991130 (60)
       US 2000-177836P
                            20000125 (60)
       US 2000-178368P
                            20000127 (60)
       US 2000-210292P
                            20000608 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 2377
INCL
       INCLM: 514/012.000
       INCLS: 435/184.000; 530/326.000
              514/012.000
NCL
       NCLM:
              435/184.000; 530/326.000
       NCLS:
       [7]
IC
       ICM: A61K038-17
       ICS: A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 253 OF 391 USPATFULL on STN
AN
       2002:206604
                   USPATFULL
TI
       PREVENTION OF FETAL ALCOHOL SYNDROME AND NEURONAL CELL DEATH WITH ADNF
       POLYPEPTIDES
ΙN
       BRENNEMAN, DOUGLAS E., DAMASCUS, MD, UNITED STATES
       SPONG, CATHERINE Y., ARLINGTON, VA, UNITED STATES
       GOZES, ILLANA, RAMAT HASHARON, ISRAEL
       BASSAN, MERAV, RAMAT HASHARON, ISRAEL
       ZAMOSTIANO, RACHEL, HOD HASHARON, ISRAEL
PΙ
       US 2002111301
                          Α1
                                20020815
ΑI
       US 1999-267511
                          Α1
                                19990312 (9)
       Utility
DT
FS
       APPLICATION
LN.CNT 1861
       INCLM: 514/012.000
INCL
       INCLS: 514/002.000
              514/012.000
NCL
       NCLM:
       NCLS:
              514/002.000
IC
       [7]
       ICM: A61K038-00
       ICS: A01N037-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 254 OF 391 USPATFULL on STN
ΑN
       2002:202241
                   USPATFULL
TI
       Death domain containing receptor-4
IN
       Ni, Jian, Rockville, MD, United States
       Rosen, Craig A., Laytonsville, MD, United States
       Pan, James G., Belmont, CA, United States
       Gentz, Reiner L., Rockville, MD, United States
       Dixit, Vishva M., Los Altos Hills, CA, United States
       Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
PA
       corporation)
       The Regents of the University of Michigan, Ann Arbor, MI, United States
       (U.S. corporation)
       us 6433147
PΙ
                                20020813
                          в1
       us 2000-565918
                                20000505 (9)
ΑI
       Continuation-in-part of Ser. No. US 1998-13895, filed on 27 Jan 1998,
RLI
       now patented, Pat. No. US 6342363
       US 1999-132922P
PRAI
                           19990506 (60)
       US 1997-35722P
                           19970128 (60)
       US 1997-37829P
                           19970205 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 8675
       INCLM: 530/387.300
INCL
       INCLS: 530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500;
              435/069.100; 435/325.000; 435/252.300; 435/254.110; 424/178.100
```

530/387.300

NCL

NCLM:

```
530/300.000; 530/350.000; 530/402.000; 536/023.100; 536/023.500
IC
       [7]
       ICM: C07K014-705
EXF
       530/300; 530/350; 530/402; 530/387.3; 536/23.1; 536/23.5; 536/23.4;
       435/69.1; 435/375; 435/252.3; 435/254.11; 424/178.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 255 OF 391 USPATFULL ON STN 2002:201837 USPATFULL
L4
ΑN
TI
       Diagnostic applications of perlecan domain I splice variants
       Maresh, Grace A., River Ridge, LA, United States
IN
       Snow, Alan D., Lynnwood, WA, United States
University of Washington, Seattle, WA, United States (U.S. corporation)
PA
                                 20020813
PΙ
       us 6432636
                           В1
       US 1997-918428
US 1996-25030P
                                 19970826 (8)
ΑI
PRAI
                            19960826 (60)
       Utility
DT
       GRANTED
FS
LN.CNT 3479
INCL
       INCLM: 435/006.000
       INCLS: 435/091.200; 536/023.500; 536/024.310; 536/024.330
NCL
       NCLM:
              435/006.000
       NCLS:
              435/091.200; 536/023.500; 536/024.310; 536/024.330
IC
       [7]
       ICM: C12Q001-68
       ICS: C12Q019-34; C07H021-04; C07H021-02
EXF
       435/6; 435/91.2; 536/23.5; 536/24.31; 536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 256 OF 391 USPATFULL on STN
ΑN
                    USPATFULL
       2002:194691
TI
       Protein fragment complementation assays for the detection of biological
       or drug interactions
ΙN
       Michnick, Stephen William Watson, Westmount, CANADA
       Pelletier, Joelle Nina, Westmount, CANADA
       Remy, Ingrid, Montreal, CANADA
PA
       Odyssey Pharmaceuticals, Inc., San Ramon, CA, United States (U.S.
       corporation)
PΙ
       US 6428951
                                 20020806
                           в1
       US 2000-499464
                                 20000207 (9)
ΑI
RLI
       Continuation of Ser. No. US 1998-17412, filed on 2 Feb 1998, now
       patented, Pat. No. US 6270964
PRAI
       CA 1997-2196496
                            19970131
DT
       Utility
       GRANTED
FS
LN.CNT 2595
INCL
       INCLM: 435/004.000
       INCLS: 435/006.000; 530/350.000; 536/023.200; 536/023.400
              435/004.000
NCL
       NCLM:
       NCLS:
              435/006.000; 530/350.000; 536/023.200; 536/023.400
       [7]
IC
       ICM: C12Q001-25
       ICS: C12Q001-68; C07K014-00; C12N015-11
       435/4; 435/6; 530/350; 536/23.2; 536/23.4
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 257 OF 391 USPATFULL ON STN
L4
       2002:193030 USPATFULL
ΑN
       Transgenic animals and cell lines for screening drugs effective for the
TI
       treatment or prevention of alzheimer's disease
       De La Monte, Suzanne, East Greenwich, RI, UNITED STATES
IN
       Wands, Jack R., Waban, MA, UNITED STATES
       US 2002104108
                                20020801
PΙ
                           Α1
ΑI
       US 2001-964666
                           Α1
                                20010928 (9)
       Division of Ser. No. US 2000-380203, filed on 25 Apr 2000, PENDING A 371
RLI
       of International Ser. No. WO 1998-US3685, filed on 26 Feb 1998, UNKNOWN
PRAI
       US 1997-38908P
                            19970226 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 2100
       INCLM: 800/012.000
INCL
       INCLS: 800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200
              800/012.000
NCL
       NCLM:
              800/018.000; 435/325.000; 435/368.000; 435/320.100; 536/023.200
       NCLS:
```

IC

Γ71

```
ICS: C07H021-04; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 258 OF 391 USPATFULL on STN
ΑN
       2002:192279 USPATFULL
TI
       Sequences characteristic of hypoxia-regulated gene transcription
IN
       Einat, Paz, Nes-Ziona, ISRAEL
       Skaliter, Rami, Nes-Zional, ISRAEL
       Feinstein, Elena, Rehovot, ISRAEL
US 2002103353 A1 20020801
       US 2002103353
PΙ
       US 2001-802472
ΑI
                           Α1
                                20010309 (9)
       Continuation-in-part of Ser. No. US 1999-384096, filed on 27 Aug 1999.
RLI
       ABANDONED Continuation-in-part of Ser. No. US 1998-138109, filed on 21
       Aug 1998, ABANDONED
       US 1998-98158P
                            19980827 (60)
PRAI
       US 2001-132684P
                            20010905 (60)
       US 1997-56453P
                            19970821 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT
       5096
       INCLM: 536/023.200
INCL
       INCLS: 435/320.100; 435/325.000; 435/069.100
NCL
              536/023.200
       NCLM:
       NCLS: 435/320.100; 435/325.000; 435/069.100
IC
       [7]
       ICM: C07H021-04
       ICS: C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 259 OF 391 USPATFULL ON STN
ΑN
       2002:192113
                    USPATFULL
       Cyclic malonamides as inhibitors of a beta protein production
ΤI
       Olson, Richard E., Wilmington, DE, UNITED STATES
IN
       Yang, Michael G., Wilmington, DE, UNITED STATES
       US 2002103184
PΙ
                                20020801
                          Α1
ΑI
       us 2001-825211
                           Α1
                                20010403 (9)
       US 2000-194503P
                            20000403 (60)
PRAI
       Utility
DT
FS
       APPLICATION
LN.CNT 6436
INCL
       INCLM: 514/212.030
              514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000
       INCLS:
              514/212.030
NCL
       NCLM:
       NCLS:
              514/327.000; 514/424.000; 540/527.000; 546/216.000; 548/550.000
IC
       [7]
       ICM: A61K031-55
       ICS: A61K031-445; A61K031-4015; C07D223-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 260 OF 391 USPATFULL on STN
ΑN
       2002:191539
                    USPATFULL
       Full-length
                      ***human***
TI
                                   cDNAs encoding potentially secreted proteins
       Milne Edwards, Jean-Baptiste Dumas, Paris, FRANCE
IN
       Bougueleret, Lydie, Petit Lancy, SWITZERLAND
       Jobert, Severin, Paris, FRANCE
ΡI
       US 2002102604
                                20020801
                           Α1
       US 2000-731872
                                20001207 (9)
ΑI
                           Α1
                            19991208 (60)
PRAI
       US 1999-169629P
       US 2000-187470P
                            20000306 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 28061
       INCLM: 435/007.100
INCL
       INCLS: 536/023.100; 530/350.000
              435/007.100
NCL
       NCLM:
             536/023.100; 530/350.000
       NCLS:
       [7]
IC
       ICM: G01N033-53
       ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 261 OF 391 USPATFULL on STN
L4
       2002:185265 USPATFULL
ΑN
       Modulators of amyloid aggregation
TI
       Findeis, Mark A., Cambridge, MA, UNITED STATES
```

ΙN

```
Garnick, Marc B., Brookline, MA, UNITED STATES
       Gefter, Malcolm L., Lincoln, MA, UNITED STATES
       Hundal, Arvind, Brighton, MA, UNITED STATES
       Kasman, Laura, Athens, GA, UNITED STATES
       Musso, Gary, Hopkinton, MA, UNITED STATES
       Signer, Ethan R., Cambridge, MA, UNITED STATES
       Wakefield, James, Brookline, MA, UNITED STATES
       Reed, Michael J., Marietta, GA, UNITED STATES
Praecis Pharmaceuticals, Inc. (U.S. corporation)
US 2002098173 A1 20020725
PA
PΙ
       US 2001-972475
                                  20011004 (9)
ΑI
                            Α1
       Continuation of Ser. No. US 1996-617267, filed on 14 Mar 1996, PATENTED Continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun 1995,
RLI
       PATENTED Continuation-in-part of Ser. No. US 1995-404831, filed on 14
       Mar 1995, PATENTED Continuation-in-part of Ser. No. US 1995-548998,
       filed on 27 Oct 1995, ABANDONED
       Utility
DT
       APPLICATION
FS
LN.CNT 4009
INCL
       INCLM: 424/094.300
       INCLS: 435/226.000
NCL
       NCLM:
               424/094.300
       NCLS:
               435/226.000
        [7]
IC
        ICM: A61K038-54
        ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 262 OF 391 USPATFULL ON STN
        2002:178549
ΑN
                     USPATFULL
       Vaccine for the prevention and treatment of alzheimer's and amyloid
IT
       related diseases
IN
       Chalifour, Robert, Ile Bizard, CANADA
       Hebert, Lise, Brossard, CANADA
       Kong, Xiangi, Dollard-des-Oremaux, CANADA
       Gervais, Francine, Ile Bizard, CANADA
       us 2002094335
                                 20020718
PΙ
                            Α1
       us 2001-867847
ΑI
                            Α1
                                  20010529 (9)
       Continuation-in-part of Ser. No. US 2000-724842, filed on 28 Nov 2000,
RLI
       PENDING
PRAI
       US 1999-168594P
                             19991129 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 1946
INCL
       INCLM: 424/185.100
NCL
       NCLM: 424/185.100
        [7]
IC
        ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 263 OF 391 USPATFULL on STN
L4
AN
       2002:175286
                     USPATFULL
TI
       Alzheimer's disease secretase, APP substrates therefor, and uses thereof
IN
       Gurney, Mark E., Grand Rapids, MI, United States
       Bienkowski, Michael J., Portage, MI, United States
       Heinrikson, Robert L.,
                                Plainwell, MI, United States
       Parodi, Luis A., Stockholm, SWEDEN
       Yan, Riqiang, Kalamazoo, MI, United States
PA
       Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S.
       corporation)
ΡI
       US 6420534
                                  20020716
                            в1
       US 2000-548372
                                  20000412 (9)
ΑI
       Division of Ser. No. US 1999-416901, filed on 13 Oct 1999
RLI
       Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999
       Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23 Sep 1999
       US 1999-155493P
PRAI
                             19990923 (60)
       US 1998-101594P
                             19980924 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 5653
       INCLM: 530/827.000
INCL
       INCLS: 530/350.000; 435/023.000; 435/024.000
NCL
       NCLM:
               435/226.000
               435/023.000; 435/024.000; 435/069.100; 530/350.000
       NCLS:
```

IC

[7]

```
ICS: C07K014-00; C07K017-00; C12Q001-37
EXF
        530/300; 530/350; 530/827; 435/23; 435/24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 264 OF 391 USPATFULL ON STN
ΑN
        2002:174955 USPATFULL
TI
        Methods of screening for agents that inhibit aggregation of polypeptides
TN
       Housman, David E., Newton, MA, United States
       Preisinger, Elizabeth A., Roslindale, MA, United States
Kazantsev, Aleksey G., Boston, MA, United States
       Massachusetts Institute of Technology, Boston, MA, United States (U.S.
PA
        corporation)
PΙ
       US 6420122
                            в1
                                 20020716
       US 1999-405048
ΑT
                                 19990927 (9)
DT
       Utility
FS
        GRANTED
LN.CNT
       1135
INCL
        INCLM: 435/007.100
       INCLS: 435/004.000; 436/501.000; 530/300.000; 530/350.000
NCL
               435/007.100
       NCLM:
       NCLS:
               435/004.000; 436/501.000; 530/300.000; 530/350.000
IC
        [7]
       ICM: G01N033-53
EXF
       436/86; 436/501; 536/23.4; 530/300; 530/350; 435/7.1; 435/4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 265 OF 391 USPATFULL ON STN
       2002:172315
AN
                    USPATFULL
TI
       Endothelin converting enzymes and the amyloid beta peptide
ΙN
       Eckman, Christopher B., Ponte Vedra Beach, FL, UNITED STATES
       Eckman, Elizabeth A., Ponte Vedra Beach, FL, UNITED STATES
PΙ
       US 2002091072
                                 20020711
                           Α1
ΑI
       US 2001-824924
                           Α1
                                 20010403 (9)
PRAI
       US 2000-233012P
                            20000915 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1315
INCL
       INCLM: 514/001.000
       INCLS: 435/006.000; 435/007.210
NCL
               514/001.000
       NCLM:
       NCLS:
              435/006.000; 435/007.210
       [7]
IC
       ICM: A61K031-00
       ICS: C12Q001-68; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 266 OF 391 USPATFULL on STN
AN
       2002:164826
                    USPATFULL
TI
       PURIFIED 20 KDA PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF
       SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2
IN
       TANZI, RUDOLPH E., HULL, MA, UNITED STATES
       KIM, TAE-WAN, WALTHAM, MA, UNITED STATES
ΡI
       US 2002086444
                                 20020704
                           Α1
ΑI
       US 1998-65902
                           Α1
                                 19980424 (9)
PRAI
       US 1997-44262P
                            19970424 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT
       2012
INCL
       INCLM: 436/536.000
       INCLS: 530/388.100; 530/388.850; 436/548.000
NCL
               436/536.000
       NCLM:
       NCLS:
              530/388.100; 530/388.850; 436/548.000
IC
       [7]
       ICM: G01N033-53
       ICS: C07K016-00; C12P021-08; G01N033-536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 267 OF 391 USPATFULL on STN
L4
AN
       2002:164825
                    USPATFULL
TI
       Magnetic in situ dilution
       Bamdad, Cynthia C., Newton, MA, UNITED STATES
ΙN
PΙ
       US 2002086443
                                 20020704
                           A1
       us 2001-971099
AΤ
                           Α1
                                 20011003 (9)
PRAI
       US 2000-237427P
                            20001003 (60)
```

US 2001-272727P

20010301 (60)

```
FS
        APPLICATION
LN.CNT 1494
INCL
       INCLM: 436/526.000
NCL
       NCLM: 436/526.000
IC
        [7]
        ICM: G01N033-553
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 268 OF 391 USPATFULL ON STN
        2002:157080 USPATFULL
ΑN
TI
       NARC8 programmed cell-death-associated molecules and uses thereof
ΙN
       Chiang, Lillian Wei-Ming, Cambridge, MA, UNITED STATES
       Millennium Pharmaceuticals, Inc. (U.S. corporation)
PA
PΙ
       US 2002081679
                                 20020627
                           Α1
       us 2001-775009
                                 20010201 (9)
ΑI
                           Α1
       Continuation-in-part of Ser. No. US 2000-692785, filed on 20 Oct 2000,
RLI
       PENDING
PRAI
       US 1999-161188P
                            19991022 (60)
       Utility
DT
       APPLICATION
FS
LN.CNT 4095
       INCLM: 435/183.000
INCL
       INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000
NCL
       NCLM:
               435/183.000
              435/320.100; 435/325.000; 435/069.100; 536/023.200; 435/226.000
       NCLS:
IC
        [7]
       ICM: C12N009-00
       ICS: C12N009-64; C07H021-04; C12N005-06; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 269 OF 391 USPATFULL ON STN
       2002:157035
                    USPATFULL
ΑN
       Alzheimer's disease secretase, APP substrates therefor, and uses
TI
       therefor
ΙN
       Gurney, Mark E., Reykjavik, ICELAND
       Bienkowski, Michael J., Portage, MI, UNITED STATES
       Heinrikson, Robert L., Plainwell, MI, UNITED STATES
       Parodi, Luis A., Stockholm, SWEDEN
       Yan, Riqiang, Kalamazoo, MI, UNITED STATES
ΡI
       US 2002081634
                           Α1
                                 20020627
       US 2001-681442
                                 20010405 (9)
ΑI
                           Α1
       Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
RLI
       Continuation-in-part of Ser. No. US 1999-404133, filed on 23 Sep 1999,
       PENDING Continuation-in-part of Ser. No. WO 1999-US20881, filed on 23
       Sep 1999, UNKNOWN
       US 1999-155493P
PRAI
                             19990923 (60)
       US 1998-101594P
                            19980924 (60)
       US 1998-101594P
                            19980924 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 5573
       INCLM: 435/007.210
INCL
       INCLS: 435/006.000; 435/226.000
NCL
       NCLM:
              435/007.210
       NCLS: 435/006.000; 435/226.000
IC
       [7]
       ICM: G01N033-567
       ICS: C12Q001-68; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 270 OF 391 USPATFULL ON STN 2002:149132 USPATFULL
L4
ΑN
TI
       Synthetic immunogenic but non-amyloidogenic peptides homologous to
       amyloid beta for induction of an immune response to amyloid beta and
       amyloid deposits
IN
       Frangione, Blas, New York, NY, UNITED STATES
       Wisniewski, Thomas, Staten Island, NY, UNITED STATES
       Sigurdsson, Einar M., New York, NY, UNITED STATES
New York University, New York, NY (U.S. corporation)
PA
       US 2002077288
                                 20020620
PΙ
                           Α1
       us 2001-861847
ΑI
                                 20010522 (9)
                           Α1
       US 1996-16233P
                            19960426 (60)
PRAI
       Utility
DT
       APPLICATION
FS
```

LN.CNT 1875

```
INCLS: 514/013.000; 514/014.000; 530/324.000; 530/326.000; 530/327.000
NCL
               514/012.000
       NCLS:
               514/013.000; 514/014.000; 530/324.000; 530/326.000; 530/327.000
IC
        [7]
       ICM: A61K038-16
       ICS: C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 271 OF 391 USPATFULL ON STN
ΑN
       2002:149131 USPATFULL
TI
             ***human***
                            secreted proteins
IN
       Ruben, Steven M., Olney, MD, UNITED STATES
       Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Li, Yi, Sunnyvale, CA, UNITED STATES
       Zeng, Zhizhen, Lansdale, PA, UNITED STATES
       Kyaw, Hla, Frederick, MD, UNITED STATES
       Fischer, Carrie L., Burke, VA, UNITED STATES
       Li, Haodong, Gaithersburg, MD, UNITED STATES
       Soppet, Daniel R., Centreville, VA, UNITED STATES Gentz, Reiner L., Rockville, MD, UNITED STATES
       Wei, Ying-Fei, Berkeley, CA, UNITED STATES
       Moore, Paul A., Germantown, MD, UNITED STATES
       Young, Paul E., Gaithersburg, MD, UNITED STATES
       Greene, John M., Gaithersburg, MD, UNITED STATES
Ferrie, Ann M., Tewksbury, MA, UNITED STATES
                                 20020620
PΙ
       US 2002077287
                            Α1
ΑI
       US 2001-852659
                                 20010511 (9)
                            Α1
RLI
       Continuation-in-part of Ser. No. US 1998-152060, filed on 11 Sep 1998,
       UNKNOWN
       Utility
DT
       APPLICATION
LN.CNT 17779
INCL
       INCLM: 514/012.000
       INCLS: 435/325.000; 435/320.100; 435/069.100; 435/183.000; 530/350.000;
               536/023.200
NCL
       NCLM:
               514/012.000
       NCLS:
               435/325.000; 435/320.100; 435/069.100; 435/183.000; 530/350.000;
               536/023.200
       [7]
IC
       ICM: A61K038-17
       ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 272 OF 391 USPATFULL ON STN
ΑN
       2002:148656 USPATFULL
       Compositions and methods for modulating TGF-beta signaling
TI
       Wang, Tongwen, Seattle, WA, UNITED STATES US 2002076799 A1 20020620
ΙN
PΙ
       US 2001-927738
ΑI
                            A1
                                 20010810 (9)
       Continuation-in-part of Ser. No. WO 2000-US3561, filed on 11 Feb 2000,
RLI
       UNKNOWN
       US 1999-119786P
PRAI
                             19990211 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 5961
INCL
       INCLM: 435/226.000
       INCLS: 435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260;
               536/023.200
NCL
       NCLM:
               435/226.000
       NCLS:
               435/069.100; 435/325.000; 435/320.100; 435/183.000; 530/388.260;
               536/023.200
       [7]
IC
       ICM: C12N009-64
       ICS: C12N009-00; C07H021-04; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 273 OF 391 USPATFULL ON STN
ΑN
       2002:148614 USPATFULL
             ***human***
TI
                            secreted proteins
IN
       Ruben, Steven M., Olney, MD, UNITED STATES
       Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Li, Yi, Sunnyvale, CA, UNITED STATES
       Zeng, ZhiZhen, Lansdale, PA, UNITED STATES
       Kyaw, Hla, Frederick, MD, UNITED STATES
```

Fischer, Carrie L., Burke, VA, UNITED STATES

```
Soppet, Daniel R., Centreville, VA, UNITED STATES
         Gentz, Reiner L., Rockville, MD, UNITED STATES
         Wei, Ying-Fei, Berkeley, CA, UNITED STATES
         Moore, Paul A., Germantown, MD, UNITED STATES
         Young, Paul E., Gaithersburg, MD, UNITED STATES
         Greene, John M., Gaithersburg, MD, UNITED STATES
         Ferrie, Ann M., Painted Post, NY, UNITED STATES US 2002076756 A1 20020620
PΙ
         US 2001-853161
ΑI
                                         20010511 (9)
                                  Α1
PRAI
         US 2001-265583P
                                   20010202 (60)
DT
         Utility
FS
         APPLICATION
LN.CNT 17788
INCL
         INCLM: 435/069.100
         INCLS: 435/325.000; 435/320.100; 530/350.000; 536/023.500
NCL
         NCLM:
                  435/069.100
         NCLS:
                  435/325.000; 435/320.100; 530/350.000; 536/023.500
IC
          [7]
         ICM: C12P021-02
         ICS: C12N005-06; C07H021-04; C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 274 OF 391 USPATFULL ON STN
ΑN
         2002:129982 USPATFULL
TI
         N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
         comprising same, and methods for inhibiting alpha- amyloid peptide
         release and/or its synthesis by use of such compounds
         Audia, James E., Indianapolis, IN, United States
Folmer, Beverly K., Newark, DE, United States
John, Varghese, San Francisco, CA, United States
Latimer, Lee H., Oakland, CA, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett Eugene D. Moss Reach CA United States
IN
         Thorsett, Eugene D., Moss Beach, CA, United States
         Whitesitt, Celia A., Greenwood, IN, United States
PA
         Athena Neurosciences, Inc., San Francisco, CA, United States (U.S.
         corporation)
         Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PΙ
         US 6399628
                                  в1
                                         20020604
         US 1999-266908
                                         19990312
ΑI
RLI
         Continuation of Ser. No. US 1997-975977, filed on 21 Nov 1997, now
         patented, Pat. No. US 5965614
PRAI
         US 1996-104593P
                                   19961122 (60)
DT
         Utility
FS
         GRANTED
LN.CNT 2944
INCL
         INCLM: 514/311.000
                  514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000; 514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000; 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000; 548/540.000; 549/439.000; 549/451.000; 549/496.000; 569/463.000; 549/451.000; 549/496.000;
                   560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
NCL
         NCLM:
                  514/311.000
                  514/367.000; 514/415.000; 514/423.000; 514/452.000; 514/465.000;
         NCLS:
                  514/467.000; 514/471.000; 514/529.000; 514/533.000; 514/538.000; 514/550.000; 514/567.000; 546/171.000; 548/161.000; 548/496.000; 548/540.000; 549/366.000; 549/439.000; 549/451.000; 549/496.000; 560/043.000; 560/045.000; 560/161.000; 562/433.000; 562/457.000
IC
         [7]
         ICM: C07D215-38
         ICS: C07D277-82; C07D209-20; C07D319-14; C07D317-44; C07D307-02;
         C07C229-28
EXF
         514/311; 514/367; 514/413; 514/423; 514/452; 514/465; 514/467; 514/471;
         514/529; 514/533; 514/538; 514/550; 514/567; 546/171; 548/161; 548/496;
         548/540; 549/366; 549/439; 549/451; 549/496; 560/43; 560/45; 560/161;
         562/433; 562/457
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 275 OF 391 USPATFULL on STN
         2002:129731 USPATFULL
AN
         Methods of detection of amyloidogenic proteins
TI
         Krishnamurthy, Girija, Chestnut Ridge, NY, United States
IN
PA
         American Cyanamid Company, Madison, NY, United States (U.S. corporation)
                                        20020604
PΙ
         us 6399314
                                  B1
```

19991229 (9)

us 1999-474970

ΑI

```
FS
         GRANTED
LN.CNT 1359
INCL
         INCLM: 435/007.100
         INCLS: 514/001.000; 514/002.000; 530/387.100
NCL
                  435/007.100
         NCLS:
                  514/001.000; 514/002.000; 530/387.100
         [7]
IC
         ICM: G01N033-53
         ICS: A01N061-00; A61K031-00; C07K016-00 514/1; 514/2; 435/7.1; 530/387.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
       ANSWER 276 OF 391 USPATFULL ON STN
AN
         2002:126307 USPATFULL
TI
         Alzheimer's disease secretase, APP substrates therefor, and uses
         therefor
IN
         Gurney, Mark E., Grand Rapids, MI, UNITED STATES
         Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
         Parodi, Luis A., Stockholm, SWEDEN
Yan, Riqiang, Kalamazoo, MI, UNITED STATES
Pharmacia & Upjohn Company (U.S. corporation)
PA
         US 2002064819
PΙ
                                  Α1
                                        20020530
ΑI
         US 2001-794925
                                  A1
                                        20010227 (9)
         Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING
RLI
         Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
         Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
         US 1999-155493P
US 1998-101594P
PRAI
                                   19990923 (60)
                                   19980924 (60)
         Utility
DT
         APPLICATION
LN.CNT 5465
INCL
         INCLM: 435/069.100
         INCLS: 435/325.000; 435/320.100; 536/023.200
         NCLM: 435/069.100
NCL
         NCLS:
                 435/325.000; 435/320.100; 536/023.200
IC
         [7]
         ICM: C07H021-04
         ICS: C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 277 OF 391 USPATFULL on STN
ΑN
         2002:122820 USPATFULL
                                             ***human***
TI
         Transgenic mice expressing
                                                                presenilin proteins
IN
         St. George-Hyslop, Peter H., Toronto, CANADA
         Rommens, Johanna M., Toronto, CANADA
         Fraser, Paul E., Toronto, CANADA
The Hospital for sick Children, Toronto, CANADA (non-U.S. corporation)
PA
         HSC Research and Development Limited Partnership, Toronto, CANADA
         (non-U.S. corporation)
         The Geverning Council of the University of Toronto, Toronto, CANADA
         (non-U.S. corporation)
PΙ
         us 6395960
                                        20020528
ΑI
         US 1998-124523
                                        19980729 (9)
         Division of Ser. No. US 1997-967101, filed on 10 Nov 1997, now patented, Pat. No. US 5840540 Division of Ser. No. US 1996-592541, filed on 26 Jan 1996, now patented, Pat. No. US 5986054 Continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995, now abandoned Continuation-in-part of Ser. No. US 1995-496841, filed on 28 Jun 1995, now patented, Pat. No. US 1995-496841, filed on 28 Jun 1995, now patented, Pat. No.
RLI
         US 6210919 Continuation-in-part of Ser. No. US 1995-431048, filed on 28
         Apr 1995
DT
         Utility
         GRANTED
FS
LN.CNT 4103
INCL
         INCLM: 800/018.000
         INCLS: 800/012.000; 800/013.000; 800/014.000; 800/017.000
NCL
         NCLM:
                  800/018.000
                  800/012.000; 800/013.000; 800/014.000; 800/017.000
         NCLS:
         [7]
IC
         ICM: A01K067-00
         ICS: A01K067-027; A01K067-033
EXF
         800/8; 800/12; 800/13; 800/14; 800/17; 800/18
L4
      ANSWER 278 OF 391 USPATFULL ON STN
         2002:119886 USPATFULL
AN
```

```
Yang, Michael G., Wilmington, DE, UNITED STATES
IN
       Liu, Hong, Glen Mills, PA, UNITED STATES
PΙ
       US 2002061874
                            A1
                                  20020523
ΑI
       US 2001-824945
                                  20010403 (9)
                            Α1
PRAI
       US 2000-194302P
                             20000403 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 4518
INCL
       INCLM: 514/212.040
       INCLS: 514/212.070; 514/212.080; 514/221.000; 540/504.000; 540/522.000; 540/523.000; 540/524.000
NCL
       NCLM:
               514/212.040
       NCLS:
               514/212.070; 514/212.080; 514/221.000; 540/504.000; 540/522.000;
               540/523.000: 540/524.000
       [7]
IC
       ICM: A61K031-5513
       ICS: A61K031-55; C07D243-24; C07D223-16; C07D223-18
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 279 OF 391 USPATFULL ON STN 2002:112541 USPATFULL
L4
ΑN
       Proteins related to schizophrenia and uses thereof
TI
       St. George-Hyslop, Peter H., Toronto, CANADA
IN
       Fraser, Paul E., Toronto, CANADA
       The Governing Council of the University of Toronto (non-U.S.
PA
       corporation)
                                  20020516
PΙ
       us 2002058276
                            Α1
                                  20010831 (9)
       US 2001-945258
                            Α1
ΑI
       US 2000-229889P
                             20000901 (60)
PRAI
DT
       Utility
       APPLICATION
FS
LN.CNT 2909
INCL
       INCLM: 435/006.000
       INCLS: 424/009.200; 800/003.000
              435/006.000
NCL
       NCLM:
               424/009.200; 800/003.000
       NCLS:
IC
       [7]
       ICM: C12Q001-68
       ICS: A61K049-00; A01K067-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 280 OF 391 USPATFULL ON STN
L4
       2002:106320 USPATFULL
ΑN
TI
       Method for treating alzheimer's disease
       Bisgaier, Charles Larry, Ann Arbor, MI, UNITED STATES Emmerling, Mark Richard, Chelsea, MI, UNITED STATES
IN
       Roher, Alex Eugene, Carefree, AZ, UNITED STATES US 2002055529 Al 20020509
PΙ
       US 2001-888592
                            Α1
                                  20010626 (9)
ΑI
       Division of Ser. No. US 2000-554994, filed on 23 May 2000, PENDING
RLI
       WO 1998-US25495
                             19981202
PRAI
DT
       Utility
FS
       APPLICATION
LN.CNT 819
TNCL
       INCLM: 514/369.000
       INCLS: 514/381.000; 514/356.000; 514/559.000; 514/560.000; 514/557.000
NCL
               514/369.000
       NCLM:
               514/381.000; 514/356.000; 514/559.000; 514/560.000; 514/557.000
       NCLS:
       [7]
IC
       ICM: A61K031-455
       ICS: A61K031-426; A61K031-41; A61K031-202; A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 281 OF 391 USPATFULL on STN
       2002:106292 USPATFULL
AN
TI
       Succinoylamino carbocycles and heterocycles as inhibitors of a-beta
       protein production
       Olson, Richard E., Wilmington, DE, UNITED STATES
IN
       Maduskuie, Thomas P., Wilmington, DE, UNITED STATES
       Thompson, Lorin A., Wilmington, DE, UNITED STATES
       Tebben, Andrew J., Wallingford, PA, UNITED STATES
       Wang, Nenghui, Newark, DE, UNITED STATES
       Deng, Wei, Wilmington, DE, UNITED STATES
       Liu, Hong, Newark, DE, UNITED STATES US 2002055501 A1 20020509
```

PΙ

HC 6

```
AΤ
       US 2001-788227
                            A1
                                 20010216 (9)
       US 2000-183186P
PRAI
                             20000217 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 7229
INCL
       INCLM: 514/212.050
       INCLS: 514/221.000; 540/500.000; 540/523.000
NCL
       NCLM:
               514/220.000
       NCLS:
               540/496.000
       [7]
IC
       ICM: A61K031~551
       ICS: A61K031-55; C07D498-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 282 OF 391 USPATFULL ON STN
       2002:102272 USPATFULL
ΑN
ΤI
       Alzheimer's related proteins and methods of use
       St. George-Hyslop, Peter H., Toronto, CANADA
IN
       Fraser, Paul E., Toronto, CANADA
The Governing Council of the University of Toronto, Toronto, CANADA
PA
       (non-U.S. corporation)
       US 6383758
PT
                                 20020507
                           В1
ΑI
       us 1999-227725
                                 19990108 (9)
PRAI
       US 1998-70948P
                            19980109 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 1420
INCL
       INCLM: 435/007.100
       INCLS: 530/350.000
               435/007.100
NCL
       NCLM:
       NCLS: 530/350.000
IC
       [7]
       ICM: G01M033-53
       ICS: C07K014-00
       435/7.1; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 283 OF 391 USPATFULL ON STN 2002:99459 USPATFULL
ΑN
       Hydroxyalkanoylaminolactams and related structures as inhibitors of a
TI
       beta protein production
       Olson, Richard E., Wilmington, DE, UNITED STATES
IN
       Liu, Hong, Glen Mills, PA, UNITED STATES
       Thompson III, Lorin A., Wilmington, DE, UNITED STATES
       US 2002052360
                                 20020502
PΙ
                            Α1
       us 6503902
                            В2
                                 20030107
ΑI
       US 2001-805645
                            Α1
                                 20010314 (9)
       Continuation-in-part of Ser. No. US 2000-661008, filed on 13 Sep 2000,
RLI
       PENDING
PRAI
       US 1999-153511P
                             19990913 (60)
       US 2000-224388P
                             20000809 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 6949
INCL
       INCLM: 514/212.040
       INCLS: 514/218.000; 514/220.000; 540/522.000; 540/523.000; 540/504.000
NCL
       NCLM:
               514/221.000
       NCLS:
              540/509.000
IC
       [7]
       ICM: A61K031-55
       ICS: A61K031-5513; A61K031-551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 284 OF 391 USPATFULL on STN
AN
       2002:99421 USPATFULL
       Methods and compounds for inhibiting
TI
                                                 ***beta*** - ***amvloid***
       peptide release and/or its synthesis
       Audia, James E., Indianapolis, IN, UNITED STATES Britton, Thomas C., Carmel, IN, UNITED STATES
IN
       Droste, James J., Indianapolis, IN, UNITED STATES
       Folmer, Beverly K., Newark, DE, UNITED STATES
       Huffman, George W., Carmel, IN, UNITED STATES
       Varghese, John, San Francisco, CA, UNITED STATES
       Latimer, Lee H., Oakland, CA, UNITED STATES
```

Mabry, Thomas E., Indianapolis, IN, UNITED STATES

```
Porter, Warren J., Indianapolis, IN, UNITED STATES
       Reel, Jon K., Carmel, IN, UNITED STATES
       Thorsett, Eugene D., Moss Beach, CA, UNITED STATES
       Tung, Jay S., Belmont, CA, UNITED STATES Wu, Jing, San Mateo, CA, UNITED STATES
       Eid, Clark Norman, Cheshire, CT, UNITED STATES
       Scott, William Leonard, Indianapolis, IN, UNITED STATES
ΡI
       US 2002052322
                                 20020502
                           A1
ΑI
       US 2001-789487
                           Α1
                                 20010220 (9)
       Continuation of Ser. No. US 1997-976289, filed on 21 Nov 1997, GRANTED,
RLI
       Pat. No. US 6191166
       US 1996-108166P
                             19961122 (60)
PRAI
       US 1997-108161P
                             19970228 (60)
       US 1997-98558P
                             19970228 (60)
       US 1997-64859P
                             19970228 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 14911
INCL
       INCLM: 514/018.000
               514/019.000; 514/400.000; 514/563.000; 514/419.000
       INCLS:
NCL
       NCLM:
               514/018.000
       NCLS:
               514/019.000; 514/400.000; 514/563.000; 514/419.000
IC
        [7]
       ICM: A61K038-06
       ICS: A61K031-05; A61K031-4172; A61K031-405; A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 285 OF 391 USPATFULL on STN
       2002:92777 USPATFULL
AN
       Catalytically active recombinant memapsin and methods of use thereof
TI
       Tang, Jordan J. N., Edmond, OK, UNITED STATES
Lin, Xinli, Edmond, OK, UNITED STATES
IN
       Koelsch, Gerald, Oklahoma City, OK, UNITED STATES
       Hong, Lin, Oklahoma City, OK, UNITED STATES
       us 2002049303
                                 20020425
PΙ
                           Α1
       us 2001-796264
ΑI
                           A1.
                                 20010228 (9)
       Division of Ser. No. US 2000-604608, filed on 27 Jun 2000, PENDING
RLI
PRAI
       US 1999-141363P
                             19990628 (60)
          1999-168060P
                             19991130 (60)
       US 2000-177836P
                             20000125 (60)
                             20000127 (60)
       US 2000-178368P
       Utility
DT
       APPLICATION
FS
LN.CNT 2441
       INCLM: 530/350.000
INCL
       INCLS: 435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200;
               514/002.000; 530/387.900
NCL
       NCLM:
               530/350.000
               435/069.100; 435/252.300; 435/320.100; 435/006.000; 435/069.200;
       NCLS:
               514/002.000: 530/387.900
IC
        [7]
       ICM: C12N015-09
       ICS: C12N009-64; C12N015-74
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 286 OF 391 USPATFULL on STN
       2002:91754 USPATFULL
AN
       Methods and composition for restoring conformational stability of a
ΤI
       protein of the p53 family
       Rastinejad, Farzan, Old Saybrook, CT, UNITED STATES
IN
       Foster, Barbara A., Mystic, CT, UNITED STATES
       Coffey, Heather A., Groton, CT, UNITED STATES
       Connell, Richard D., East Lyme, CT, UNITED STATES
PΙ
       us 2002048271
                                 20020425
                           A1
ΑI
       us 2001-863976
                           Α1
                                 20010523 (9)
       Continuation of Ser. No. US 1999-443542, filed on 19 Nov 1999, PENDING
RLI
PRAI
       US 1998-110542P
                             19981202 (60)
       Utility
DT
       APPLICATION
LN.CNT 2082
INCL
       INCLM: 370/395.000
       INCLS: 514/228.200; 514/232.800; 514/234.500; 514/252.170; 514/259.000;
               514/253.020; 514/253.030; 514/284.000; 514/290.000
               370/395.000
NCL
       NCLM:
```

514/228.200; 514/232.800; 514/234.500; 514/252.170; 514/259.000;

NCLS:

```
IC
        [7]
        ICM: A61K031-5415
        ICS: A61K031-5377; A61K031-496; A61K031-517; A61K031-473; H04L012-28;
        H04L012-56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 287 OF 391 USPATFULL ON STN
        2002:88227 USPATFULL
ΑN
        Screening methods for agents that modulate or inhibit tau association
TI
        with tau or map2
        Wischik, Claude Michel, Cambridge, UNITED KINGDOM
Edwards, Patricia Carol, Cambridge, UNITED KINGDOM
IN
        Harrington, Charles Robert, Cambridge, UNITED KINGDOM
        Roth, Martin, Cambridge, UNITED KINGDOM
        Klug, Aaron, Cambridge, UNITED KINGDOM
        University Court of the University of Aberdeen, Aberdeen, UNITED KINGDOM
PA
        (non-U.S. corporation)
                                   20020423
PΙ
        US 6376205
                              в1
                     19961003
        WO 9630766
        US 1997-913915
                                    19971212 (8)
ΑI
        WO 1996-EP1307
                                   19960325
                                    19971212 PCT 371 date
PRAI
        GB 1995-6197
                               19950327
DT
        Utility
        GRANTED
FS
LN.CNT 1856
INCL
        INCLM: 435/007.800
        INCLS: 435/007.100; 435/007.920; 436/501.000; 436/503.000; 436/504.000
NCL
                435/007.800
                435/007.100; 435/007.920; 436/501.000; 436/503.000; 436/504.000
        NCLS:
        [7]
TC
        ICM: G01N033-53
        435/701; 435/7.8; 435/7.92; 436/501; 436/503; 436/504
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 288 OF 391 USPATFULL on STN
        2002:85579 USPATFULL
AN
TI
        Method and composition for modulating amyloidosis
IN
        Reiner, Peter B., Vancouver, CANADA
        Connop, Bruce P., Vancouver, CANADA
The University of British Columbia (non-U.S. corporation)
PA
        us 2002045621
                             Α1
                                   20020418
PΙ
        us 6472145
                              В2
                                   20021029
AΙ
        us 2001-874968
                             Α1
                                   20010605 (9)
       Continuation of Ser. No. US 2000-660599, filed on 13 Sep 2000, ABANDONED Continuation of Ser. No. US 1999-383317, filed on 25 Aug 1999, PATENTED Continuation of Ser. No. US 1998-80141, filed on 15 May 1998, PATENTED
RLI
DT
        Utility
FS
        APPLICATION
LN.CNT 1150
INCL
        INCLM: 514/237.800
        INCLS: 514/247.000; 514/255.060; 514/255.010; 514/256.000; 514/317.000;
                514/370.000; 514/377.000; 514/430.000; 514/415.000; 514/426.000;
                514/459.000; 514/646.000
NCL
                435/004.000
        NCLM:
        NCLS:
                435/029.000
        [7]
IC
        ICM: A61K031-535
        ICS: A61K031-50; A61K031-495; A61K031-135; A61K031-40; A61K031-405
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 289 OF 391 USPATFULL on STN
        2002:78763 USPATFULL
ΑN
          ***Beta*** - ***amyloid***
TT
                                              inhibitors, processes for preparing
        them, and their use in pharmaceutical compositions
        Briem, Hans, Bremen, GERMANY, FEDERAL REPUBLIC OF Mendla, Klaus, Ingelheim, GERMANY, FEDERAL REPUBLIC OF
IN
        Romig, Helmut Michael, Gau-Alegsheim, GERMANY, FEDERAL REPUBLIC OF
        Fechteler, Katja, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF
        Fuchs, Klaus, Gau-Algesheim, GERMANY, FEDERAL REPUBLIC OF
        US 2002042420
ΡI
                             ΑÌ
                                   20020411
        us 6514969
                             В2
                                   20030204
        us 2001-911825
                                   20010724 (9)
AΙ
                             Α1
        DE 2000-10040016
                               20000816
PRAI
```

US 2000-227039P

20000823 (60)

```
APPLICATION
LN.CNT 1132
INCL
        INCLM: 514/253.040
                514/300.000; 546/113.000; 514/233.200; 544/128.000; 544/362.000
        INCLS:
NCL
        NCLM:
                514/233.200
                514/253.090; 514/322.000; 544/129.000; 544/364.000; 546/199.000
        NCLS:
        [7]
IC
        ICM: C07D471-02
        ICS: A61K031-5377; A61K031-4745; A61K031-496
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 290 OF 391 USPATFULL ON STN
ΑN
        2002:67190 USPATFULL
        METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS
TI
        REINER, PETER B., VANCOUVER, CANADA
IN
        LAM, FRED CHIU-LAI, VANCOUVER, CANADA
        US 2002037843
                             A1
                                    20020328
PΙ
        US 6514686
                              В2
                                    20030204
        US 1998-177413
                                    19981023 (9)
ΑI
                              Α1
        Continuation-in-part of Ser. No. US 1998-67523, filed on 28 Apr 1998,
RLI
        ABANDONED Continuation-in-part of Ser. No. US 1997-847616, filed on 28
        Apr 1997, ABANDONED Utility
DT
FS
        APPLICATION
LN.CNT 2452
INCL
        INCLM: 514/011.000
        INCLS: 530/317.000; 435/004.000; 435/007.100; 436/086.000; 530/324.000;
                435/183.000
NCL
        NCLM:
                435/004.000
                435/007.400; 436/086.000; 530/324.000
        NCLS:
        [7]
IC
        ICM: C120001-00
        ICS: G01N033-53; A61K038-00; G01N033-00; C12N009-00; C07K005-00;
        C07K007-00; C07K016-00; C07K017-00; A61K038-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 291 OF 391 USPATFULL on STN
        2002:66664 USPATFULL
ΑN
        Alzheimer's disease secretase, APP substrates therefor, and uses
TI
        therefor
IN
        Gurney, Mark E., Grand Rapids, MI, UNITED STATES
        Bienkowski, Michael J., Portage, MI, UNITED STATES
Heinrikson, Robert L., Plainwell, MI, UNITED STATES
Parodi, Luis A., Stockholm, SWEDEN
        Yan, Riqiang, Kalamazoo, MI, UNITED STATES
        Pharmacia & Upjohn Company (U.S. corporation)
PA
                                    20020328
PΙ
        us 2002037315
                              Α1
                                    20010227 (9)
        US 2001-794748
ΑI
                              Α1
        Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING
RLI
        Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN US 1999-155493P 19990923 (60) US 1998-101594P 19980924 (60)
PRAI
        US 1998-101594P
DT
        Utility
        APPLICATION
LN.CNT 5440
INCL
        INCLM: 424/450.000
        INCLS: 424/093.210; 514/044.000
        NCLM:
NCL
               424/450.000
        NCLS:
                424/093.210: 514/044.000
IC
        [7]
        ICM: A61K048-00
        ICS: A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 292 OF 391 USPATFULL on STN
        2002:60975 USPATFULL
ΑN
        Avian and reptile derived polynucleotide encoding a polypeptide having
TI
        heparanase activity
IN
        Goldshmidt, Orit, Jerusalem, ISRAEL
        Pecker, Iris, Rishon LeZion, ISRAEL
        Vlodavsky, Israel, Mevaseret Zion, ISRAEL
        Michal, İsrael, Ashkelon, ISRAEL
Zcharia, Eyal, Jerusalem, ISRAEL
```

Insight Strategy And Marketing Ltd. (non-U.S. corporation)

PA

```
ΑI
       US 2001-930218
                           Α1
                                 20010816 (9)
RLI
       Continuation-in-part of Ser. No. US 2000-666390, filed on 20 Sep 2000,
       PENDING
DT
       Utility
       APPLICATION
FS
LN.CNT 2355
INCL
       INCLM: 435/200.000
       INCLS: 435/069.100; 435/325.000; 435/320.100; 424/094.610; 536/023.200
NCL
              435/200.000
       NCLM:
               435/069.100; 435/325.000; 435/320.100; 424/094.610; 536/023.200
       NCLS:
IC
       [7]
       ICM: C12N009-24
       ICS: C07H021-04; A61K038-47; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 293 OF 391 USPATFULL on STN
       2002:43588 USPATFULL
ΑN
TI
       Substituted lactams as inhibitors of A beta protein production
       Han, Qi, Hockessin, DE, UNITED STATES
IN
       Liu, Hong, Glen Mills, PA, UNITED STATES
       Olson, Richard E., Wilmington, DE, UNITED STATES
       Yang, Michael G., Wilmington, DE, UNITED STATES
PΙ
       us 2002025955
                                 20020228
                           Α1
       US 6632812
                            B2
                                 20031014
       US 2001-832455
                                 20010411 (9)
ΑI
                           Α1
                            20000411 (60)
PRAI
       US 2000-196549P
DT
       Utility
       APPLICATION
FS
LN.CNT 5194
INCL
       INCLM: 514/212.040
               514/212.070; 514/212.080; 514/221.000; 540/500.000; 540/522.000;
               540/523.000; 540/524.000
NCL
       NCLM:
               514/221.000
       NCLS:
               540/509.000
       [7]
IC
       ICM: A61K031-55
       ICS: A61K031-5513; C07D243-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 294 OF 391 USPATFULL ON STN
       2002:32581 USPATFULL
ΑN
       Methods to treat alzheimer's disease
TI
       Hom, Roy, San Francisco, CA, UNITED STATES
IN
       Mamo, Shumeye S., Oakland, CA, UNITED STATES
       Tung, Jay, Belmont, CA, UNITED STATES
       Gailunas, Andrea, San Francisco, CA, UNITED STATES
       John, Varghese, San Francisco, CA, UNITED STATES Fang, Lawrence Y., Foster City, CA, UNITED STATES
       US 2002019403
US 2001-816876
                                 20020214
PΙ
                           Α1
ΑI
                            Α1
                                 20010323 (9)
       US 2000-191528P
PRAI
                            20000323 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 8655
       INCLM: 514/256.000
INCL
       INCLS: 514/519.000; 514/520.000; 514/534.000
       NCLM:
               514/256.000
NCL
       NCLS:
               514/519.000; 514/520.000; 514/534.000
       [7]
IC
       ICM: A61K031-505
       ICS: A61K031-275; A61K031-277; A61K031-24
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 295 OF 391 USPATFULL on STN
L4
       2002:28127 USPATFULL
ΑN
TI
       TRANSGENIC ANIMAL EXPRESSING NON-NATIVE WILD-TYPE AND FAMILIAL
       ALZHEIMER'S DISEASE MUTANT PRESENILIN 1 PROTEIN ON NATIVE PRESENILIN 1
       NULL BACKGROUND
IN
       ZHENG, HUI, EDISON, NJ, UNITED STATES
       JIANG, PING, PLAINSBORO, NJ, UNITED STATES
       QIAN, SU, SAYREVILLE, NJ, UNITED STATES VAN DER PLOEG, LEONARDUS H. T., SCOTCH PLAINS, NJ, UNITED STATES
       WONG, PHILIP CHUN-YING, TIMONIUM, MD, UNITED STATES
       SISODIA, SANGRAM S., CHICAGO, IL, UNITED STATES
PΙ
       us 2002016978
                                 20020207
                         A1
```

```
AΙ
       US 1998-78871
                                 19980514 (9)
                            Α1
PRAI
       US 1998-78465P
                             19980318 (60)
       US 1997-46488P
                             19970514 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1262
INCL
       INCLM: 800/009.000
       INCLS: 800/012.000; 800/014.000; 800/018.000; 800/025.000; 800/003.000
NCL
       NCLM:
               800/012.000
               435/029.000; 435/354.000; 800/003.000; 800/018.000; 800/022.000;
       NCLS:
               800/025.000
IC
        [7]
       ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 296 OF 391 USPATFULL on STN
AN
       2002:17292
                   USPATFULL
TI
       Lactams as inhibitors of A-beta protein production
       Thompson, Lorin A., Wilmington, DE, UNITED STATES
TN
PΙ
       US 2002010172
                            Α1
                                 20020124
       us 6495540
                            В2
                                 20021217
       US 2001-817957
                                 20010327 (9)
ΑI
                            Α1
       US 2000-192527P
                             20000328 (60)
PRAI
       Utility
DT
       APPLICATION
FS
LN.CNT 1265
INCL
       INCLM: 514/212.030
       INCLS: 540/527.000
NCL
       NCLM:
               514/212.030
       NCLS:
               514/212.080; 540/524.000; 540/525.000; 540/527.000
        [7]
IC
       ICM: A61K031-55
       ICS: C07D223-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 297 OF 391 USPATFULL on STN
       2002:16894 USPATFULL
ΑN
       18036,a novel calpain-like protease and uses thereof
TI
       Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES Millennium Pharmaceuticals, Inc. (U.S. corporation) US 2002009774 A1 20020124
IN
PA
PΙ
       us 6620592
                                 20030916
                            В2
ΑI
       us 2001-794960
                                 20010226 (9)
                            Α1
PRAI
       US 2000-185333P
                             20000228 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 3989
INCL
       INCLM: 435/069.100
       INCLS: 435/325.000; 435/183.000; 435/320.100; 536/023.100
               435/023.000
NCL
       NCLM:
       NCLS:
               435/219.000; 435/069.100; 435/325.000; 435/320.100; 435/252.300;
               536/023.200
IC
        [7]
       ICM: C12P021-02
       ICS: C12N005-06; C07H021-04; C12N005-00; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 298 OF 391 USPATFULL ON STN
       2002:16893 USPATFULL
ΑN
TI
       DEATH DOMAIN CONTAINING RECEPTORS
       YU, GUO-LIANG, DARNESTOWN, MD, UNITED STATES
IN
       NI, JIAN, ROCKVILLE, MD, UNITED STATES
       GENTZ, REINER L., SILVER SPRING, MD, UNITED STATES
       DILLON, PATRICK J., GAITHERSBURG, MD, UNITED STATES
PΑ
       Human Genome Sciences, Inc. (U.S. corporation)
       us 2002009773
PΙ
                                 20020124
                            Α1
ΑI
       us 1999-333966
                           Α1
                                 19990616 (9)
RLI
       Division of Ser. No. US 1997-815469, filed on 11 Mar 1997, GRANTED, Pat.
       No. US 6153402
       US 1996-13285P
PRAI
                             19960312 (60)
       US 1996-28711P
                             19961017 (60)
       US 1997-37341P
                             19970206 (60)
DT
       Utility
FS
       APPLICATION
```

LN.CNT 3011

43E /000 100

```
INCLS: 536/023.500; 435/320.100; 530/325.000; 435/325.000; 530/324.000; 530/387.900; 514/002.000
NCL
                 435/069.100
         NCLM:
                 536/023.500; 435/320.100; 530/325.000; 435/325.000; 530/324.000; 530/387.900; 514/002.000
         NCLS:
IC
         [7]
         ICM: A01N037-18
         ICS: A61K038-00; C07H021-04; C12P021-06; C12N015-00; C12N015-09;
C12N015-63; C12N015-70; C12N015-74; C07K005-00; C07K007-00; C07K016-00; C07K017-00; C12N005-00; C12N005-02; C07K001-00; C07K014-00; C12P021-08 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 299 OF 391 USPATFULL on STN
         2002:16872 USPATFULL
AN
TI
         Compounds that selectively bind to expanded polyglutamine repeat domains
         and methods of use thereof
         Burke, James R., Chapel Hill, NC, UNITED STATES
IN
         Strittmatter, Warren J., Durham, NC, UNITED STATES
        Nagai, Yoshitaka, Osaka, JAPAN
        us 2002009752
                                      20020124
PΙ
                                Α1
        us 6632616
                                      20031014
                                B2
        US 2001-780070
US 2000-189781P
ΑI
                                Α1
                                      20010209 (9)
PRAI
                                 20000316 (60)
DT
        Utility
FS
         APPLICATION
LN.CNT 1749
        INCLM: 435/007.100
INCL
         INCLS: 530/324.000; 435/325.000
NCL
                 435/007.100
         NCLS:
                 435/006.000; 435/004.000; 530/350.000
IC
         [7]
        ĬCM: G01N033-53
         ICS: C12N005-06; C07K007-00; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 300 OF 391 USPATFULL on STN
        2002:1251 USPATFULL
ΑN
         Lactacystin analogs
TI
        Fenteany, Gabriel, Cambridge, MA, United States
IN
         Jamison, Timothy F., Cambridge, MA, United States
        Schreiber, Stuart L., Boston, MA, United States
        Standaert, Robert F., Arlington, MA, United States
President and Fellows of Harvard College, Cambridge, MA, United States
PA
         (U.S. corporation)
        ùs 6335358
ΡI
                                в1
                                      20020101
        us 1995-421583
ΑI
                                      19950412 (8)
DT
        Utility
        GRANTED
FS
LN.CNT 2285
INCL
        INCLM: 514/412.000
        INCLS: 514/210.000; 514/414.000; 514/422.000; 514/424.000; 514/428.000; 514/439.000; 514/441.000; 514/443.000; 514/444.000; 514/465.000; 514/465.000; 514/466.000
NCL
        NCLM:
                 514/412.000
                 514/192.000; 514/210.050; 514/210.060; 514/414.000; 514/422.000; 514/424.000; 514/428.000; 514/439.000; 514/441.000; 514/443.000; 514/444.000; 514/465.000; 514/466.000
        NCLS:
         [7]
IC
         ICM: A61K031-36
         ICS: A61K031-385; A61K031-38; A61K031-40
        514/210; 514/412; 514/414; 514/422; 514/424; 514/428; 514/439; 514/441; 514/443; 514/444; 514/465; 514/466
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 301 OF 391 USPATFULL on STN 2001:235274 USPATFULL
AN
        N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
TI
        comprising same, and methods for inhibiting . ***beta*** .-
           ***amyloid***
                              peptide release and/or its synthesis by use of such
        compounds
        Wu, Jing, San Mateo, CA, United States
IN
        Thorsett, Eugene D., Moss Beach, CA, United States
        Nissen, Jeffrey S., Indianapolis, IN, United States
        Mabry, Thomas E., Indianapolis, IN, United States
```

Latimer, Lee H., Oakland, CA, United States

```
Fang, Lawrence Y., Foster City, CA, United States Audia, James E., Indianapolis, IN, United States
PΑ
        Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
        corporation)
        Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PΙ
       US 6333351
                           В1
                                 20011225
       US 1999-303655
ΑI
                                 19990503 (9)
RLI
        Continuation of Ser. No. US 1997-976179, filed on 21 Nov 1997, now
        patented, Pat. No. US 6117901
PRAI
       US 1996-98551P
                             19961122 (60)
       US 1996-19790P
                             19960614 (60)
DT
       Utility
        GRANTED
FS
LN.CNT 3252
INCL
        INCLM: 514/538.000
               560/037.000; 514/432.000; 514/452.000; 549/023.000; 549/362.000
       INCLS:
NCL
       NCLM:
               514/538.000
               514/432.000; 514/452.000; 549/023.000; 549/362.000; 560/037.000
       NCLS:
IC
        [7]
        ICM: C07C229-06
       ICS: A61K031-24; A61K031-38; A61K031-335
EXF
        560/37; 514/538; 514/432; 514/452; 549/23; 549/362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 302 OF 391 USPATFULL ON STN
                    USPATFULL
       2001:231155
ΑN
       Use of small molecule radioligands to discover inhibitors of
TI
       amyloid-beta peptide production
IN
       Zaczek, Robert, 18 Roosevelt Way, Avondale, PA, United States
       Olson, Richard E., 7 Pelham Rd., Wilmington, DE, United States
       Seiffert, Dietmar A., 3719 Highland Dr., Boothwyn, PA, United States
       19061
       Thompson, Lorin Andrew, 600 Silverside Rd., Wilmington, DE, United
                19809
       States
PΙ
       US 6331408
                            в1
                                 20011218
       US 1999-438901
ΑI
                                 19991112 (9)
                             19990427 (60)
PRAI
       US 1999-131284P
       US 1998-108147P
                             19981112 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 3570
       INCLM: 435/023.000
INCL
       INCLS: 435/024.000; 435/004.000; 435/968.000
              435/023.000
NCL
       NCLM:
       NCLS:
              435/004.000; 435/024.000; 435/968.000
        [7]
IC
       ICM: C12Q001-37
       ICS: c12Q001-00; G01N033-53
       435/23; 435/24; 435/4; 435/968
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 303 OF 391 USPATFULL ON STN
       2001:229689 USPATFULL
AN
TI
       Method for treating Alzheimer's disease
       Ahn, Kyunghye, Ann Arbor, MI, United States
Emmerling, Mark Richard, Chelsea, MI, United States
IN
       Haske, Taraneh, Ann Arbor, MI, United States
       Hupe, Donald J., Ann Arbor, MI, United States
       Sebolt-Leopold, Judith, Ann Arbor, MI, United States
       LeVine, Harry, III, Ann Arbor, MI, United States
       Scholten, Jeffrey David, Pinckney, MI, United States
PΙ
                                 20011213
       US 2001051642
                           Α1
ΑI
       us 2001-771529
                                 20010129 (9)
                            Α1
PRAI
       US 2000-197484P
                             20000417 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT
       729
INCL
       INCLM: 514/341.000
       INCLS: 514/314.000; 514/400.000
NCL
               514/341.000
       NCLM:
       NCLS:
              514/314.000; 514/400.000
IC
       [7]
       ICM: A61K031-4164
       ICS: A61K031-4439; A61K031-4709
```

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L4
      ANSWER 304 OF 391 USPATFULL ON STN 2001:211963 USPATFULL
ΑN
TI
         Smilagenin and its use
IN
         Xia, Žongqin, Shanghai, China
         Rubin, Ian, Leicester, Great Britain
         Whittle, Brian, Hornsea, Great Britain
         Gunning, Philip, Saffron Walden, Great Britain
         Hu, Yaer, Shanghai, China
Brostoff, Jonathan, London, Great Britain
         Wang, Weijun, Huntingdon, Great Britain
US 2001043955 A1 20011122
PΙ
         US 2001-866234
ΑI
                                 Α1
                                        20010525 (9)
         Division of Ser. No. US 1999-362328, filed on 28 Jul 1999, GRANTED, Pat.
RLI
         No. US 6258386
         GB 1999-5275
PRAI
                                   19990308
DT
         Utility
FS
         APPLICATION
LN.CNT 682
INCL
         INCLM: 424/725.000
         INCLS: 424/769.000; 514/025.000
NCL
         NCLM:
                 424/725.000
         NCLS:
                  424/769.000; 514/025.000
         [7]
IC
         ĪCM: A61K035-78
         ICS: A61K031-70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 305 OF 391 USPATFULL on STN
AN
         2001:208478 USPATFULL
TI
         Modulators of amyloid aggregation
         Findeis, Mark A., Cambridge, MA, United States
Benjamin, Howard, Lexington, MA, United States
Garnick, Marc B., Brookline, MA, United States
Gefter, Malcolm L., Lincoln, MA, United States
Hundal, Arvind, Brighton, MA, United States
IN
         Kasman, Laura, Athens, GA, United States
         Musso, Gary, Hopkinton, MA, United States
         Signer, Ethan R., Cambridge, MA, United States
         Wakefield, James, Brookline, MA, United States
         Reed, Michael J., Marietta, GA, United States
PA
         Praecis Pharmaceuticals Incorporated, Cambridge, MA, United States (U.S.
         corporation)
PI
         us 6319498
                                        20011120
                                 В1
         us 1996-617267
                                        19960314 (8)
ΑI
RLI
         Continuation-in-part of Ser. No. US 1995-548998, filed on 27 Oct 1995,
         now abandoned Continuation-in-part of Ser. No. US 1995-475579, filed on
         7 Jun 1995, now patented, Pat. No. US 5854215 Continuation-in-part of
         Ser. No. US 1995-404831, filed on 14 Mar 1995, now patented, Pat. No. US
         5817626
DT
         Utility
FS
         GRANTED
LN.CNT 4293
INCL
         INCLM: 424/094.300
         INCLS: 424/094.610; 435/188.000; 435/206.000; 514/007.000; 514/012.000; 514/021.000; 530/307.000; 530/324.000; 530/345.000; 530/359.000; 530/382.000; 530/394.000; 530/402.000; 530/410.000
NCL
         NCLM:
                  424/094.300
         NCLS:
                  424/094.610; 435/188.000; 435/206.000; 514/007.000; 514/012.000;
                  514/021.000; 530/307.000; 530/324.000; 530/345.000; 530/350.000; 530/359.000; 530/382.000; 530/394.000; 530/402.000; 530/410.000
IC
         [7]
         ICM: A61K038-02
         ICS: A61K038-17; C07K001-113; C07K014-47
514/7; 514/12; 514/21; 435/188; 435/206; 424/94.3; 424/94.61; 530/307;
530/324; 530/325; 530/326; 530/345; 530/350; 530/359; 530/382; 530/394;
530/402; 530/410
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 306 OF 391 USPATFULL ON STN
L4
         2001:197049 USPATFULL
AN
         N(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
TI
         comprising same, and methods for inhibiting . ***beta***
           ***amyloid***
                                peptide release and/or its synthesis by use of such
         compounds
```

IN

Wu, Jing, San Mateo, CA, United States

```
Nissen, Jeffrey S., Indianapolis, IN, United States
       Mabry, Thomas E., Indianapolis, IN, United States
       Latimer, Lee H., Oakland, CA, United States
John, Varghese, San Francisco, CA, United States
       Fang, Lawrence Y., Foster City, CA, United States
Audia, James E., Indianapolis, IN, United States
       Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
PΙ
       US 6313152
                                  20011106
                            В1
ΑI
       US 1999-390692
                                  19990907 (9)
       Division of Ser. No. US 1997-976179, filed on 21 Nov 1997, now patented,
RLI
       Pat. No. US 6117901
       US 1996-98551P
                             19961122 (60)
PRAI
       US 1996-19790P
                             19960614 (60)
       Utility
DT
       GRANTED
FS
LN.CNT 3130
       INCLM: 514/357.000
INCL
       INCLS: 514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000;
               514/469.000
NCL
       NCLM:
               514/357.000
               514/375.000; 514/379.000; 514/438.000; 514/439.000; 514/461.000;
       NCLS:
               514/469.000
       [7]
IC
       ICM: A61K031-44
       ICS: A61K031-425
       514/357; 514/375; 514/379; 514/438; 514/439; 514/461; 514/469
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 307 OF 391 USPATFULL on STN
L4
ΑN
       2001:185101 USPATFULL
ΤI
       Controlling protein levels in eucaryotic organisms
       Kenten, John H., Boyds, MD, United States
IN
       Roberts, Steven F., Bethesda, MD, United States
       Proteinex, Inc., Gaithersburg, MD, United States (U.S. corporation)
PA
                                  20011023
PΙ
       us 6306663
                            В1
       US 1999-406781
                                  19990928 (9)
ΑI
PRAI
       US 1999-119851P
                             19990202 (60)
DT
       Utility
FS
       GRANTED
LN.CNT 2668
       INCLM: 436/501.000
INCL
       INCLS: 424/094.100; 435/004.000; 435/007.720; 435/041.000; 435/106.000;
               514/002.000; 530/300.000; 530/350.000; 930/020.000
NCL
       NCLM:
               436/501.000
               424/094.100; 435/004.000; 435/007.720; 435/041.000; 435/106.000;
       NCLS:
               514/002.000; 530/300.000; 530/350.000; 930/020.000
       [7]
IC
       ICM: G01N033-566
       435/41; 435/106; 435/4; 435/7.72; 436/501; 514/2; 530/300; 530/350; 930/20; 424/94.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 308 OF 391 USPATFULL on STN
ΑN
       2001:173781 USPATFULL
ΤI
       Transgenic mouse expressing an APP-FAD DNA sequence
       Hardy, John Anthony, Tampa, FL, United States
IN
       Chartier-Harlin, Marie-Christine, Villeneuve d'Ascq, France
       Goate, Alison Mary, St. Louis, MO, United States
Owen, Michael John, South Glamorgan, United Kingdom
       Mullan, Michael John, Tampa, FL, United States
       Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PA
       corporation)
       us 6300540
                                  20011009
PΙ
                            В1
       us 1995-464250
                                  19950605 (8)
ΑI
RIT
       Continuation of Ser. No. US 104165, now patented, Pat. No. US 5877015
                             19910121
PRAI
       GB 1991-1307
       GB 1991-18445
                             19910828
DT
       Utility
FS
       GRANTED
LN.CNT 1358
INCL
       INCLM: 800/018.000
```

INCLS: 800/003.000; 800/012.000

```
NCLS: 800/003.000; 800/012.000
IC
         [7]
        ICM: A01K067-027
        ICS: A01K067-033; G01N033-00
800/2; 800/DIG.1; 800/3; 800/12; 800/18; 536/23.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 309 OF 391 USPATFULL ON STN
        2001:163000 USPATFULL
ΑN
TI
        Protein fragment complementation assays for the detection of biological
        or drug interactions
        Michnick, Stephen William Watson, Westmount, Canada
ΙN
        Remy, Ingrid, Montreal, Canada
Odyssey Pharmaceuticals Inc., San Ramon, CA, United States (U.S.
PA
        corporation)
PΙ
        US 6294330
                                     20010925
                               В1
        US 1998-124850
                                     19980730 (9)
ΑI
        Continuation-in-part of Ser. No. US 1998-17412, filed on 2 Feb 1998
RLI
PRAI
        CA 1997-2196496
                                19970131
DT
        Utility
FS
        GRANTED
        3238
LN.CNT
        INCLM: 435/006.000
INCL
        INCLS: 435/069.700; 435/325.000; 435/252.300; 435/254.110; 435/440.000; 435/455.000; 435/468.000; 435/320.100; 536/023.400; 536/023.500
                 435/006.000
NCL
        NCLS:
                435/069.700; 435/252.300; 435/254.110; 435/320.100; 435/325.000;
                435/440.000; 435/455.000; 435/468.000; 536/023.400; 536/023.500
        [7]
IC
        ICM: C12Q001-68
        ICS: C12N005-10; C12N001-21; C12N015-11; C12N015-63
435/6; 435/69.7; 435/320.1; 435/325; 435/252.3; 435/254.11; 435/440;
435/455; 435/468; 536/23.4; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 310 OF 391 USPATFULL on STN
ΑN
        2001:158079 USPATFULL
        Methods of screening for factors that disrupt neurotrophin conformation
TI
        and reduce neurotrophin biological activity
IN
        Riopelle, Richard J., Kingston, Canada
        Ross, Gregory M., Kingston, Canada
        Dory, Magdalena I., Rhisnes, Belgium
        Weaver, Donald F., Kingston, Canada
Shamovsky, Igor L., Kingston, Canada
Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)
PA
        us 6291247
PΙ
                                     20010918
                              в1
ΑI
        US 1997-853910
                                     19970509 (8)
        Continuation-in-part of Ser. No. US 1994-241462, filed on 11 May 1994,
RLI
        now abandoned Continuation-in-part of Ser. No. US 1996-745608, filed on
        8 Nov 1996, now abandoned
PRAI
        CA 1996-2190296
                                19961112
DT
        Utility
FS
        GRANTED
LN.CNT 2529
INCL
        INCLM: 436/002.000
        INCLS: 435/007.200; 436/173.000; 436/164.000; 436/161.000; 436/183.000;
                530/402.000; 530/412.000
NCL
        NCLM:
                436/002.000
                435/007.200; 436/161.000; 436/164.000; 436/173.000; 436/183.000; 530/402.000; 530/412.000
        NCLS:
IC
        [7]
        ICM: G01N030-00
        ICS: G01N024-00; G01N033-00; G01N021-00
        436/501; 436/164; 436/173; 436/183; 436/161; 436/2; 530/412; 530/402;
EXF
        435/7.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 311 OF 391 USPATFULL ON STN
L4
AN
        2001:155460 USPATFULL
TI
        Alzheimer's disease secretase, APP substrates therefor, and uses
        therefor
IN
        Gurney, Mark E., Grand Rapids, MI, United States
        Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
```

Parodi, Luis A., Stockholm, sweden

```
PA
         Pharmacia & Upjohn Company (U.S. corporation)
PΙ
         US 2001021391
                                        20010913
                                 Α1
ΑI
         US 2001-794743
                                 Α1
                                        20010227 (9)
         Continuation of Ser. No. US 1999-416901, filed on 13 oct 1999, PENDING Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
RLI
                                   19990923 (60)
PRAI
         US 1999-155493P
         US 1998-101594P
                                   19980924 (60)
         Utility
DT
         APPLICATION
FS
LN.CNT 2962
         INCLM: 424/450.000
INCL
         INCLS: 435/226.000
NCL
         NCLM:
                 424/450.000
         NCLS: 435/226.000
IC
         [7]
         ICM: C12N009-64
         ICS: A61K009-127
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 312 OF 391 USPATFULL ON STN
AN
         2001:150648 USPATFULL
         N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS
TI
         COMPRISING SAME, AND METHODS FOR INHIBITING ***BETA***
            ***AMYLOID***
                                PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH
         COMPOUNDS
         AUDIA, JAMES E., INDIANAPOLIS, IN, United States FOLMER, BEVERLY K., NEWARK, DE, United States
ΙN
         JOHN, VARGHESE, SAN FRANCISCO, CA, United States
         LATIMER, LEE H., OAKLAND, CA, United States
         NISSEN, JEFFREY S., INDIANAPOLIS, IN, United States
         PORTER, WARREN J., INDIANAPOLIS, IN, United States
         THORSETT, EUGENE D., MOSS BEACH, CA, United States
         WU, JING, SAN MATEO, CA, United States US 2001020097 A1 20010906
ΡI
         us 6495693
                                        20021217
                                 В2
         US 1999-280966
                                        19990330 (9)
ΑI
                                 Α1
         Continuation of Ser. No. US 1997-976191, filed on 21 Nov 1997, GRANTED.
RI T
         Pat. No. US 6096782
DT
         Utility
FS
         APPLICATION
LN.CNT 3729
INCL
         INCLM: 546/162.000
         INCLS: 514/313.000; 514/367.000; 514/400.000; 514/419.000; 514/616.000; 514/620.000; 514/506.000; 514/399.000; 560/039.000; 560/043.000; 560/041.000; 564/156.000; 564/157.000; 564/163.000; 564/168.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000; 546/163.000
NCL
         NCLM:
                  546/162.000
         NCLS:
                  546/163.000; 548/161.000; 548/178.000; 548/338.100; 548/495.000;
                  560/039.000; 560/041.000; 560/043.000; 564/156.000; 564/157.000;
                  564/163.000: 564/168.000
IC
         [7]
         ICM: C07D277-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 313 OF 391 USPATFULL ON STN
ΑN
         2001:145073 USPATFULL
TI
         Alzheimer's disease secretase, APP substrates therefor, and uses
TN
         Gurney, Mark E., Grand Rapids, MI, United States
         Bienkowski, Michael J., Portage, MI, United States
         Heinrikson, Robert L., Plainwell, MI, United States
         Parodi, Luis A., Stockholm, Sweden
         Yan, Riqiang, Kalamazoo, MI, United States
PA
         Pharmacia & Upjohn Company (U.S. corporation)
PΙ
         US 2001018208
                                 Α1
                                        20010830
         us 2001-795847
ΑI
                                        20010228 (9)
                                 Α1
        Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
RLI
                                  19990923 (60)
PRAI
         US 1999-155493P
         US 1998-101594P
                                  19980924 (60)
DT
         Utility
```

APPLICATION

FS

LN.CNT 2995

```
INCLS: 435/320.100; 536/023.200
NCL
        NCLM: 435/325.000
        NCLS: 435/320.100; 536/023.200
IC
        [7]
        ICM: C07H021-04
        ICS: C12N005-10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 314 OF 391 USPATFULL ON STN 2001:139291 USPATFULL
ΑN
TI
        Novel protein and monoclonal
                                           ***antibody***
                                                             specific thereto
IN
        Seiki, Motoharu, Shinagawa, Japan
        Sato, Hiroshi, Kanazawa, Japan
        Shinagawa, Akira, Takaoka, Japan
        US 2001016333
                                    20010823
PΙ
                              Α1
ΑI
        US 2000-734002
                              Α1
                                    20001212 (9)
        Division of Ser. No. US 1998-41, filed on 20 Feb 1998, GRANTED, Pat. No.
RLI
        US 6191255 A 371 of International Ser. No. WO 1996-JP1956, filed on 12
        Jul 1996, UNKNOWN
        JP 1995-200319
                               19950714
PRAI
        JP 1995-200320
                               19950714
        Utility
DT
        APPLICATION
LN.CNT 2744
        INCLM: 435/069.100
INCL
        INCLS: 530/324.000; 435/070.100; 435/320.100; 536/023.500
NCL
        NCLM: 435/069.100
               530/324.000; 435/070.100; 435/320.100; 536/023.500
        NCLS:
        [7]
IC
        ICM: C12P021-02
        ICS: C12P021-08; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 315 OF 391 USPATFULL ON STN
        2001:139289 USPATFULL
AN
        Serine protease specific monoclonal
                                                    ***antibodies***
                                                                         and their use
TI
IN
        Kominami, Katsuya, Osaka, Japan
        Okui, Akira, Yamatokoriyama-shi, Japan
        Mitsui, Shinichi, Kyoto-shi, Japan
Yamaguchi, Nozomi, Kyoto-shi, Japan
        us 2001016331
PΙ
                              Αĺ
                                   20010823
ΑI
        us 2000-741171
                             Α1
                                   20001221 (9)
        Continuation-in-part of Ser. No. WO 1999-JP3578, filed on 2 Jul 1999,
RLI
        UNKNOWN
PRAI
        JP 1998-187506
                               19980702
DT
        Utility
FS
        APPLICATION
LN.CNT 1613
        INCLM: 435/007.950
INCL
        NCLM: 435/007.950
NCL
        [7]
IC
        ICM: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 316 OF 391 USPATFULL ON STN
L4
        2001:139282 USPATFULL
AN
        Alzheimer's disease secretase, APP substrates therefor, and uses
TI
        therefor
        Gurney, Mark E., Grand Rapids, MI, United States
IN
        Bienkowski, Michael J., Portage, MI, United States
Heinrikson, Robert L., Plainwell, MI, United States
        Parodi, Luis A., Stockholm, Sweden
        Yan, Riqiang, Kalamazoo, MI, United States
PA
        Pharmacia & Upjohn Company (U.S. corporation)
ΡI
                                   20010823
        US 2001016324
                              A1
ΑI
        us 2001-794927
                                    20010227 (9)
                              Α1
        Continuation of Ser. No. US 1999-416901, filed on 13 Oct 1999, PENDING Continuation of Ser. No. US 1999-404133, filed on 23 Sep 1999, PENDING Continuation of Ser. No. WO 1999-US20881, filed on 23 Sep 1999, UNKNOWN
RLI
        US 1999-155493P
                               19990923 (60)
PRAI
        US 1998-101594P
                               19980924 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 5574
```

INCL INCLM: 435/007.100

```
NCL
       NCLM:
               435/007.100
       NCLS:
               435/006.000
IC
        [7]
       ICM: C12Q001-68
       ICS: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 317 OF 391 USPATFULL ON STN 2001:134006 USPATFULL
L4
ΑN
       Assay for disease related conformation of a protein and isolating same
TI
       Prusiner, Stanley B., San Francisco, CA, United States
IN
       Safar, Jiri G., Concord, CA, United States
                                  20010816
PΙ
       US 2001014455
                            A1
       US 6406864
                                  20020618
                            В2
       us 2001-754443
                            Α1
                                 20010103 (9)
AΙ
       Continuation of Ser. No. US 1998-169574, filed on 9 Oct 1998, GRANTED,
RLI
       Pat. No. US 6214565
       Utility
DT
       APPLICATION
FS
LN.CNT 1618
INCL
       INCLM: 435/007.100
       INCLS: 435/068.100
NCL
       NCLM:
               435/007.100
               424/009.100; 424/130.100; 424/147.100; 435/070.100; 435/071.100;
       NCLS:
               436/503.000; 436/518.000; 436/547.000; 530/387.100
IC
        ICM: G01N033-573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 318 OF 391 USPATFULL ON STN
ΑN
       2001:128901 USPATFULL
             ***human***
TI
                            secreted proteins
       LaFleur, David W., Washington, DC, United States
IN
       Soppet, Daniel R., Centreville, VA, United States
       Olsen, Henrik, Gaithersburg, MD, United States
       Ruben, Steven M., Olney, MD, United States
Ni, Jian, Rockville, MD, United States
       Rosen, Craig A., Laytonsville, MD, United States
       Brewer, Laurie A., St. Paul, MN, United States
       Duan, Roxanne, Bethesda, MD, United States
       Ebner, Reinhard, Gaithersburg, MD, United States
PΙ
       US 2001012889
                            A1
                                 20010809
       us 2000-739907
                                 20001220 (9)
ΑI
                            A1
       Continuation of Ser. No. US 1999-348457, filed on 7 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US108, filed on 6 Jan 1999,
RLI
       UNKNOWN
       US 1998-70704P
                             19980107 (60)
PRAI
                             19980107 (60)
       US 1998-70658P
       US 1998-70692P
                             19980107 (60)
       US 1998-70657P
                             19980107 (60)
DΤ
       Utility
FS
       APPLICATION
LN.CNT 10341
INCL
       INCLM: 536/023.100
       INCLS: 530/300.000; 530/387.100; 435/006.000; 435/007.100; 435/325.000;
               435/069.100
NCL
       NCLM:
               536/023.100
       NCLS:
               530/300.000; 530/387.100; 435/006.000; 435/007.100; 435/325.000;
               435/069.100
        [7]
IC
       ICM: C07H021-00
       ICS: A61K038-00; C07K016-00; C12Q001-68; G01N033-53; C12P021-06;
       C12N005-00; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 319 OF 391 USPATFULL on STN
       2001:125737 USPATFULL
ΑN
TI
       Protein fragment complementation assays for the detection of biological
       or drug interactions
IN
       Michnick, Stephen William Watson, Westmount, Canada
       Pelletier, Joelle Nina, Westmount, Canada
       Remy, Ingrid, Montreal, Canada
PA
       Odyssey Pharmaceuticals Inc., San Ramon, CA, United States (U.S.
       corporation)
```

PΙ

us 6270964

В1

20010807

```
PRAI
        CA 1997-2196496
                               19970131
DT
        Utility
FS
        GRANTED
LN.CNT 2701
INCL
        INCLM: 435/006.000
        INCLS: 435/069.700; 435/410.000; 435/243.000; 435/325.000; 530/350.000; 536/023.100; 536/023.400
NCL
        NCLM:
                435/006.000
        NCLS:
                435/069.700; 435/243.000; 435/325.000; 435/410.000; 530/350.000;
                536/023.100; 536/023.400
        [7]
IC
        ICM: C12Q001-68
        ICS: C12P021-02; C12N015-52
        435/6; 435/4; 435/69.7; 435/410; 435/243; 435/325; 530/350; 536/23.4; 536/23.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 320 OF 391 USPATFULL ON STN
ΑN
        2001:117037 USPATFULL
TI
        Flourine-substituted biphenyl butyric acids and their derivatives as
        inhibitors of matrix metalloproteinases
        Purchase, Jr., Claude Forsey, Ann Arbor, MI, United States
IN
        Roth, Bruce David, Plymouth, MI, United States
        Schielke, Gerald Paul, Ann Arbor, MI, United States Walker, Lary Craswell, Ann Arbor, MI, United States
        White, Andrew David, Pinckney, MI, United States
Warner-Lambert, Morris Plains, NJ, United States (U.S. corporation)
PA
PΙ
        US 6265432
                                    20010724
                              В1
        us 2000-503235
                                    20000211 (9)
ΑI
        Division of Ser. No. US 1999-256714, filed on 24 Feb 1999, now patented,
RLI
        Pat. No. US 6169103
        US 1998-76633P
PRAT
                               19980303 (60)
        Utility
DT
FS
        GRANTED
LN.CNT 2226
        INCLM: 514/417.000
INCL
        INCLS: 514/532.000; 514/522.000; 514/553.000; 514/561.000; 548/477.000;
                560/027.000; 560/035.000; 562/026.000; 562/426.000; 562/440.000
NCL
        NCLM:
                514/417.000
                514/522.000; 514/532.000; 514/553.000; 514/561.000; 548/477.000;
        NCLS:
                560/027.000; 560/035.000; 562/026.000; 562/426.000; 562/440.000
IC
        [7]
        ICM: A61K031-40
        ICS: A61K031-275; C07D209-48; C07C229-08; C07C249-10 548/477; 514/389; 514/522; 514/561; 514/553; 514/532; 514/417; 562/435;
EXF
        558/414
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 321 OF 391 USPATFULL ON STN
ΑN
        2001:112566 USPATFULL
        N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical compositions comprising same, and methods for inhibiting . ***beta***
.- ***amyloid*** peptide release and/or its synthesis by use of suc
TI
                               peptide release and/or its synthesis by use of such
        compounds
IN
        Wu, Jing, San Mateo, CA, United States
        Tung, Jay S., Belmont, CA, United States
        Nissen, Jeffrey S., Indianapolis, IN, United States
        Mabry, Thomas E., Indianapolis, IN, United States
        Latimer, Lee H., Oakland, CA, United States
        Eid, Clark N., Cheshire, CT, United States
        Audia, James É., Indianapolis, IN, United States
Elan Pharmaceuticals, Inc., S. San Francisco, CA, United States (U.S.
PA
        corporation)
        Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
                              B1
PΙ
        US 6262302
                                    20010717
        US 1999-398211
                                    19990917 (9)
ΑI
        Continuation of Ser. No. US 1997-976295, filed on 21 Nov 1997, now
RLI
        patented, Pat. No. US 6153652
        US 1996-98551P
PRAI
                               19961122 (60)
        US 1997-113671P
                               19970228 (60)
        Utility
DT
        GRANTED
FS
LN.CNT 4050
        INCLM: 564/152.000
INCL
```

INCLS: 564/155.000; 564/158.000; 564/168.000; 560/039.000; 560/041.000

```
548/475.000; 546/309.000; 514/349.000; 514/352.000; 514/357.000;
                  514/417.000; 514/470.000; 514/535.000; 514/539.000; 514/619.000
NCL
         NCLM:
                  564/152.000
                  546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/155.000; 564/158.000
         NCLS:
IC
         [7]
         ICM: C07C229-38
         ICS: C07C233-64; C07D307-00; C07D211-00; C07D213-00
560/43; 560/45; 560/47; 560/39; 560/41; 560/42; 514/349; 514/352;
514/357; 514/417; 514/470; 514/535; 514/539; 514/619; 564/152; 564/168;
564/155; 564/158; 549/303; 549/304; 548/471; 548/475; 546/309
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 322 OF 391 USPATFULL on STN 2001:107472 USPATFULL
L4
ΑN
ΤI
         Smilagenin and its use
ΙN
         Xia, Zongqin, Shanghai, China
         Rubin, Ian, Castle Donington, United Kingdom
         Whittle, Brian, Hornsea, United Kingdom
         Gunning, Philip, Saffron Walden, United Kingdom
         Hu, Yaer, Shanghai, China
         Brostoff, Jonathan, London, United Kingdom Wang, Weijun, Huntingdon, United Kingdom
PA
         Phytopharm PLC, Cambridgeshire, United Kingdom (non-U.S. corporation)
PΙ
                                       20010710
         US 6258386
                                в1
                                       19990728 (9)
         US 1999-362328
ΑI
         GB 1999-5275
PRAI
                                  19990308
DT
         Utility
FS
         GRANTED
LN.CNT 550
INCL
         INCLM: 424/725.000
         NCLM: 424/725.000
NCL
IC
         [7]
         ICM: A61K035-78
         424/195.1; 424/725
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 323 OF 391 USPATFULL on STN
L4
ΑN
         2001:86665 USPATFULL
TI
         Transgenic rodent comprising APP-Swedish
        McLonlogue, Lisa C., San Francisco, CA, United States
Zhao, Jun, La Jolla, CA, United States
IN
         Sinha, Sukanto, San Francisco, CA, United States
         Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PA
         corporation)
PΙ
         US 6245964
                                       20010612
        us 1998-209647
ΑI
                                       19981210 (9)
         Continuation of Ser. No. US 1997-785943, filed on 22 Jan 1997, now
RLI
         patented, Pat. No. US 5850003 Continuation of Ser. No. US 1993-148211,
         filed on 1 Nov 1993, now patented, Pat. No. US 5612486
         Continuation-in-part of Ser. No. US 1993-143697, filed on 27 Oct 1993,
        now patented, Pat. No. US 5604102 Utility
DT
FS
         GRANTED
LN.CNT 2117
INCL
         INCLM: 800/012.000
         INCLS: 800/003.000; 800/014.000; 800/018.000; 800/022.000
NCL
        NCLM:
                 800/012.000
        NCLS:
                 800/003.000; 800/014.000; 800/018.000; 800/022.000
IC
         [7]
         ICM: A01K067-00
         ICS: A01K067-027; G01N033-00; C12N015-00
         800/3; 800/12; 800/14; 800/18; 800/22; 424/9.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 324 OF 391 USPATFULL on STN
         2001:71330 USPATFULL
ΑN
TI
        Recombinant helix modification recognition proteins and uses thereof
        Kmiec, Eric B., Malvern, PA, United States
Holloman, William K., Yorktown Heights, NY, United States
Gerhold, David, Lansdale, PA, United States
Thomas Jefferson University, Philadelphia, PA, United States (U.S.
IN
PA
        corporation)
```

20010515

В1

us 6232095

PΙ

```
DT
         Utility
FS
         Granted
LN.CNT 1621
INCL
         INCLM: 435/069.100
         INCLS: 435/320.100; 435/325.000; 435/069.700; 435/252.300; 536/023.400; 536/023.740; 530/350.000; 530/371.000
NCL
                  435/069.100
         NCLS:
                  435/069.700; 435/252.300; 435/320.100; 435/325.000; 530/350.000;
                  530/371.000; 536/023.400; 536/023.740
IC
         [7]
         ICM: C12N015-00
         ICS: C12N015-63; C12N001-20; C12N015-85; C07H021-04; C07K014-00 435/6; 435/252.3; 435/69.1; 435/69.7; 435/325; 435/320.1; 530/350;
EXF
         530/371; 530/387.1; 536/23.1; 536/23.4; 536/23.74; 424/130.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
      ANSWER 325 OF 391 USPATFULL on STN
ΑN
         2001:59689 USPATFULL
TI
         Method and composition for modulating amyloidosis
IN
         Reiner, Peter B., Vancouver, Canada
         Connop, Bruce P., Vancouver, Canada
The University of British Columbia, Vancouver, British Columbia, United
PA
         States (non-U.S. corporation)
         US 6221667
US 1999-383317
PΙ
                                       20010424
                                 в1
ΑI
                                       19990825 (9)
         Continuation of Ser. No. US 1998-80141, filed on 15 May 1998, now
RLI
         patented, Pat. No. US 5981168
DT
         Utility
FS
         Granted
LN.CNT 982
INCL
         INCLM: 435/975.000
         INCLS: 435/004.000; 514/741.000
NCL
         NCLM:
                 514/248.000
                 435/004.000; 514/231.500; 514/255.010; 514/255.060; 514/313.000; 514/352.000; 514/370.000; 514/383.000; 514/415.000; 514/447.000;
         NCLS:
                  514/741.000
IC
         [7]
         ICM: G01N033-53
         ICS: C12Q001-00
EXF
         435/975; 435/4; 514/741
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 326 OF 391 USPATFULL on STN 2001:56082 USPATFULL
L4
ΑN
TI
         Amyloid .beta. protein (globular assembly and uses thereof)
         Krafft, Grant A., Glenview, IL, United States
IN
         Klein, William L., Winnetka, IL, United States
         Chromy, Brett A., Evanston, IL, United States
         Lambert, Mary P., Glenview, IL, United States Finch, Caleb E., Altadena, CA, United States
         Morgan, Todd, Manhattan Beach, CA, United States
         Wals, Pat, Los Angeles, CA, United States
        Rozovsky, Irina, Pasadena, CA, United States
Barlow, Ann, Evanston, IL, United States
Northwestern University, Evanston, IL, United States (U.S. corporation)
University of Southern California, Los Angeles, CA, United States (U.S.
PA
         corporation)
PΙ
         us 6218506
                                в1
                                       20010417
         US 1997-796089
ΑI
                                       19970205 (8)
         Utility
DT
FS
         Granted
LN.CNT 941
         INCLM: 530/324.000
INCL
         INCLS: 530/350.000; 514/012.000; 436/086.000
                 530/324.000
NCL
         NCLM:
         NCLS:
                 436/086.000: 530/350.000
IC
         [7]
         ICM: A61K038-16
         ICS: C07K014-435
EXF
         530/324; 530/350; 514/12; 436/86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 327 OF 391 USPATFULL on STN
AN
         2001:52086 USPATFULL
```

TI

Lactacystin analogs

```
Jamison, Timothy F., Cambridge, MA, United States
         Schreiber, Stuart L., Boston, MA, United States
Standaert, Robert F., Arlington, MA, United States
President and Fellows of Harvard College, Cambridge, MA, United States
PΑ
          (U.S. corporation)
PΙ
         US 6214862
                                   81
                                          20010410
         US 1997-937228
ΑI
                                          19970911 (8)
RLI
         Continuation of Ser. No. US 1995-421583, filed on 12 Apr 1995
         Utility
DT
         Granted
FS
LN.CNT 2249
INCL
          INCLM: 514/423.000
         INCLS: 514/369.000; 514/370.000; 514/371.000; 514/376.000; 514/377.000; 514/365.000; 514/445.000; 514/446.000; 514/448.000; 514/439.000; 514/441.000; 514/440.000; 514/473.000; 514/452.000
                   514/423.000
         NCLM:
NCL
         NCLS:
                   514/365.000; 514/369.000; 514/370.000; 514/371.000; 514/376.000;
                   514/377.000; 514/439.000; 514/440.000; 514/441.000; 514/445.000; 514/446.000; 514/448.000; 514/452.000; 514/473.000
IC
          [7]
         ICM: A01N043-36
         ICS: A01N043-78; A01N043-76; A01N043-06
514/423; 514/369; 514/370; 514/371; 514/376; 514/377; 514/365; 514/445;
514/446; 514/448; 514/439; 514/441; 514/440; 514/473; 514/452
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 328 OF 391 USPATFULL ON STN
ΑN
         2001:51789 USPATFULL
TI
         Assay for disease related conformation of a protein and isolating same
IN
         Prusiner, Stanley B., San Francisco, CA, United States
         Safar, Jiri G., Concord, CA, United States
The Regents of the University of California, Oakland, CA, United States
PA
         (U.S. corporation)
US 6214565
PΙ
                                   в1
                                          20010410
         US 1998-169574
ΑI
                                          19981009 (9)
         Utility
DT
FS
         Granted
LN.CNT 1675
INCL
         INCLM: 435/007.100
         INCLS: 435/070.100; 435/071.100; 424/009.100; 424/130.100; 424/147.100;
                   436/503.000; 436/518.000; 436/547.000; 530/387.100
NCL
         NCLM:
                   435/007.100
                   424/009.100; 424/130.100; 424/147.100; 435/070.100; 435/071.100; 436/503.000; 436/518.000; 436/547.000; 530/387.100
         NCLS:
         [7]
IC
         ICM: G01N033-53
         ICS: G01N033-567; C12P021-04; A61K049-00; C07K016-00
         424/9.1; 424/130.1; 424/147.1; 435/7.1; 435/70.1; 435/71.1; 530/387.1;
EXF
         436/518; 436/503; 436/547
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 329 OF 391 USPATFULL on STN
         2001:48108 USPATFULL Compounds for inhibiting .
AN
                                              ***beta*** .- ***amyloid***
TI
                                                                                           peptide
         release and/or its synthesis
         Wu, Jing, San Mateo, CA, United States
Tung, Jay S., Belmont, CA, United States
ΙN
         Thorsett, Eugene D., Moss Beach, CA, United States Reel, Jon K., Carmel, IN, United States
         Porter, Warren J., Indianapolis, IN, United States
         Nissen, Jeffrey S., Indianapolis, IN, United States
         Mabry, Thomas E., Indianapolis, IN, United States
         Latimer, Lee H., Oakland, CA, United States
         John, Varghese, San Francisco, CA, United States
         Folmer, Beverly K., Newark, DE, United States
Droste, James J., Indianapolis, IN, United States
Britton, Thomas C., Carmel, IN, United States
Audia, James E., Indianapolis, IN, United States
Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
PΑ
         corporation)
         Eli Lilly & Company, Indianapolis, IL, United States (U.S. corporation)
PΙ
         US 6211235
                                  В1
                                          20010403
ΑI
         US 1998-164448
                                          19980930 (9)
RLI
         Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
```

PRAI

US 1996-108166P 19961122 (60)

```
US 1997-98558P
                             19970228 (60)
        Utility
DT
FS
        Granted
LN.CNT 14056
INCL
        INCLM:
               514/534.000
        INCLS:
               574/619.000; 560/041.000; 560/040.000; 564/163.000
               514/534.000
NCL
        NCLM:
               514/019.000; 514/619.000; 544/162.000; 546/233.000; 546/336.000;
        NCLS:
               548/479.000: 548/496.000: 560/040.000: 560/041.000: 564/163.000
        [7]
IC
        ICM: A01N037-12
        ICS: C07C229-00; C07C233-00
514/534; 514/619; 564/163; 560/40; 560/41
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 330 OF 391 USPATFULL on STN
        2001:47793 USPATFULL
AN
ΤI
        Genetic sequences and proteins related to alzheimer's disease
IN
        St. George-Hyslop, Peter H., Toronto, Canada
        Rommens, Johanna M., Toronto, Canada
        Fraser, Paul E., Toronto, Canada
PA
       HSC Research and Development Limited Partnership, Toronto, Canada
        (non-U.S. corporation)
ΡI
        us 6210919
                                  20010403
       US 1995-496841
ΑI
                                  19950628 (8)
       Continuation-in-part of Ser. No. US 1995-431048, filed on 28 Apr 1995
RLI
DT
       Utility
FS
        Granted
LN.CNT 2533
INCL
        INCLM: 435/069.100
       INCLS: 536/023.500; 536/023.100; 435/320.100; 435/325.000; 435/455.000;
               530/350.000
       NCLM:
NCL
               435/069.100
               435/320.100; 435/325.000; 435/455.000; 530/350.000; 536/023.100;
       NCLS:
               536/023.500
        [7]
IC
        ICM: C12N015-63
        ICS: C07H021-04; C07K014-47
        536/23.5; 435/6; 435/69.1; 435/172.1; 435/172.3; 435/325; 435/375;
EXF
        435/320.1; 435/455; 800/2; 800/DIG.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 331 OF 391 USPATFULL ON STN
        2001:44268 USPATFULL
AN
        Compounds for inhibiting .
                                      ***beta*** .- ***amyloid***
TI
                                                                         peptide
        release and/or its synthesis
       Audia, James E., Indianapolis, IN, United States
IN
       Britton, Thomas C., Carmel, IN, United States
       Droste, James J., Indianapolis, IN, United States
       Folmer, Beverly K., Newark, DE, United States
       Huffman, George W., Carmel, IN, United States
        John, Varghese, San Francisco, CA, United States
        Latimer, Lee H., Oakland, CA, United States
       Mabry, Thomas E., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
       Thorsett, Eugene D., Moss Beach, CA, United States
       Tung, Jay S., Belmont, CA, United States
       Wu, Jing, San Mateo, CA, United States
PA
       Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
       corporation)
        Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PΙ
       us 6207710
                            B1
                                  20010327
ΑI
       us 1998-164385
                                  19980930 (9)
       Continuation-in-part of Ser. No. US 1997-976289, filed on 21 Nov 1997
RLI
                             19961122 (60)
       US 1996-108166P
PRAI
                             19970228 (60)
       US 1997-64859P
       us 1997-108161P
                             19970228 (60)
       US 1997-98558P
                             19970228 (60)
DT
       Utility
FS

    Granted

LN.CNT 12026
       INCLM: 514/551.000
INCL
```

INCLS: 514/534.000; 514/563.000; 560/037.000; 560/038.000; 560/040.000;

```
NCL
       NCLM:
               514/551.000
               514/534.000; 514/563.000; 530/331.000; 560/037.000; 560/038.000; 560/040.000; 560/041.000; 564/123.000; 564/155.000
       NCLS:
       [7]
IC
       ICM: A01N037-12
       ICS: C07C229-00; C07C233-00
       514/551; 514/534; 514/563; 560/37; 560/38; 560/40; 560/41; 564/123;
EXF
       564/155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 332 OF 391 USPATFULL ON STN
14
ΑN
       2001:29306 USPATFULL
       Methods for determining risk of developing alzheimer's disease by
TT
       detecting mutations in the presentlin 1 (PS-1) gene
       St. George-Hyslop, Peter H., Toronto, Canada
ΙN
       Rommens, Johanna M., Toronto, Canada
       Fraser, Paul E., Toronto, Canada
       The Hospital for Sick Children, HSC Research and Development Limited
PΑ
       Partnership, Canada (non-U.S. corporation)
       The Governing Council of the University of Toronto, Canada (non-U.S.
       corporation)
PΙ
       us 6194153
                           в1
                                 20010227
       US 1998-127480
                                 19980731 (9)
ΑI
       Division of Ser. No. US 1996-592541, filed on 26 Jan 1996, now patented,
RLI
       Pat. No. US 5986054 Continuation-in-part of Ser. No. US 1995-509359,
       filed on 31 Jul 1995 Continuation-in-part of Ser. No. US 1995-496841
       filed on 28 Jun 1995 Continuation-in-part of Ser. No. US 1995-431048,
       filed on 28 Apr 1995
DT
       Utility
FS
       Granted
LN.CNT 4255
INCL
       INCLM: 435/006.000
       INCLS: 435/007.100; 435/091.200; 536/023.500; 536/024.310; 536/024.330
NCL
       NCLM:
              435/006.000
               435/007.100; 435/091.200; 536/023.500; 536/024.310; 536/024.330
       NCLS:
       [7]
IC
       ICM: C12Q001-68
       ICS: C12P019-34; C07H021-04
EXF
       435/6; 435/91.2; 435/7.1; 536/21.31; 536/24.33; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 333 OF 391 USPATFULL ON STN
       2001:26018 USPATFULL
AN
       Protein and monoclonal
                                  ***antibody***
                                                    specific thereto
ΤI
       Seiki, Motoharu, Shinagawa, Japan
ΙN
       Sato, Hiroshi, Kanazawa, Japan
       Shinagawa, Akira, Takaoka, Japan
       Fuji Yakuhin Kogyo Kabushiki Kaisha, Toyama, Japan (non-U.S.
PA
       corporation)
       US 6191255
                                 20010220
PΤ
                           В1
       wo 9704080
                   19970206
ΑI
       US 1998-41
                                 19980220 (9)
       WO 1996-JP1956
                                 19960712
                                           PCT 371 date
                                 19980220
                                 19980220
                                           PCT 102(e) date
                            19950714
PRAI
       JP 1995-200319
       JP 1995-200320
                            19950714
DT
       Utility
FS
       Granted
LN.CNT 2653
INCL
       INCLM: 530/324.000
       INCLS: 530/400.000; 536/023.200; 536/023.500; 536/024.310; 435/069.100; 435/320.100; 435/325.000
NCL
       NCLM:
               530/324.000
       NCLS:
               435/069.100; 435/320.100; 435/325.000; 530/400.000; 536/023.200;
               536/023.500; 536/024.310
       [71
IC
       ICM: A61K038-43
       ICS: C07K001-00; C07H021-04
       530/324; 530/400; 536/23.5; 536/23.2; 536/24.31; 435/69.1; 435/320.1;
EXF
       435/325
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 334 OF 391 USPATFULL on STN
```

2001:25931 USPATFULL

AN

```
peptide release and/or its_synthesis
IN
        Audia, James E., Indianapolis, IN, United States
        Britton, Thomas C., Carmel, IN, United States
        Droste, James J., Indianapolis, IN, United States Folmer, Beverly K., Newark, DE, United States
        Huffman, George W., Carmel, IN, United States
        Varghese, John, San Francisco, CA, United States
        Latimer, Lee H., Oakland, CA, United States
        Mabry, Thomas E., Indianapolis, IN, United States
        Nissen, Jeffrey S., Indianapolis, IN, United States
Porter, Warren J., Indianapolis, IN, United States
Reel, Jon K., Carmel, IN, United States
Thorsett, Eugene D., Moss Beach, CA, United States
        Tung, Jay S., Belmont, CA, United States
        Wu, Jing, San Mateo, CA, United States
        Eid, Clark Norman, Cheshire, CT, United States
        Scott, William Leonard, Indianapolis, IN, United States
PΑ
        Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
        corporation)
        Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PΙ
        US 6191166
                              В1
                                    20010220
        US 1997-976289
ΑI
                                     19971121 (8)
        US 1996-108166P
                                19961122 (60)
PRAI
                                19970228 (60)
        US 1997-64859P
        US 1997-108161P
                                19970228 (60)
        US 1997-698556P
                                19970228 (60)
DT
        Utility
        Granted
FS
LN.CNT 12827
INCL
        INCLM: 514/534.000
        INCLS: 514/535.000; 514/616.000; 514/619.000
                 514/534.000
NCL
        NCLM:
        NCLS:
                514/535.000; 514/616.000; 514/619.000
        [7]
TC
        ICM: A01N037-12
EXF
        574/534; 574/535; 574/616; 574/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 335 OF 391 USPATFULL ON STN
AN
        2001:14622 USPATFULL
TI
        Peptide nucleic acid conjugates
        Wickstrom, Eric, Philadelphia, PA, United States
Basu, Soumitra, New Haven, CT, United States
ΙN
        Thomas Jefferson University, Philadelphia, PA, United States (U.S.
PA
        corporation)
PΙ
        us 6180767
                                    20010130
        us 1997-779072
                                    19970107 (8)
ΑI
                                19960111 (60)
PRAI
        US 1996-9747P
DT
        Utility
FS
        Granted
LN.CNT 1510
INCL
        INCLM: 536/022.100
        INCLS: 435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;
                 536/025.330; 536/025.340
NCL
        NCLM:
                536/022.100
        NCLS:
                435/006.000; 536/023.100; 536/025.300; 536/025.310; 536/025.320;
                536/025.330; 536/025.340
IC
        [7]
        ICM: C07H019-00
        ICS: C07H021-02; C07H021-00; C07H021-04
536/22.1; 536/23.1; 536/25.3; 536/25.31; 536/25.32; 536/25.33;
536/25.34; 435/6
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 336 OF 391 USPATFULL ON STN
L4
        2001:14261 USPATFULL
ΑN
TI
        Antisense inhibition of tumor necrosis factor alpha converting enzyme
        (TACE) expression
        Flournoy, Shin Cheng, San Diego, CA, United States
Bennett, C. Frank, Carlsbad, CA, United States
ΙN
        Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S.
PA
        corporation)
        us 6180403
                                    20010130
PΙ
                              В1
        US 1999-429093
                                    19991028 (9)
ΑI
```

DT

Utility

```
LN.CNT 1609
INCL
        INCLM: 435/375.000
        INCLS: 435/366.000; 435/006.000; 435/091.100; 435/325.000; 536/023.100;
                 536/024.310; 536/024.330; 536/024.500
NCL
        NCLM:
                435/375.000
        NCLS:
                435/006.000; 435/091.100; 435/325.000; 435/366.000; 536/023.100; 536/024.310; 536/024.330; 536/024.500
IC
        ICM: C07H021-04
        ICS: C12N015-00; C12Q001-68
        435/6; 435/91.1; 435/91.3; 435/375; 435/325; 536/23.1; 536/23.2;
        536/24.5; 536/24.3; 536/24.33; 536/24.31; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 337 OF 391 USPATFULL on STN
ΑN
        2001:8029 USPATFULL
TI
        Neurotrophic peptides of activity dependent neurotrophic factor
IN
        Brenneman, Douglas E., Damascus, MD, United States
        Ramot University Authority for Applied Research and Industrial Development, Ltd., Tel Aviv, Israel (non-U.S. corporation)
The United States of America as represented by the Department of Health
PA
        and Human Services, Washington, DC, United States (U.S. government)
PI
        US 6174862
                              в1
                                    20010116
ΑI
        US 1994-324297
                                    19941017 (8)
RLI
        Continuation-in-part of Ser. No. US 1992-871973, filed on 22 Apr 1992,
        now patented, Pat. No. US 5767240 Continuation-in-part of Ser. No. US
        1991-688087, filed on 22 Apr 1991, now abandoned
        Utility
DT
FS
        Granted
LN.CNT 1591
        INCLM: 514/015.000
INCL
        INCLS: 514/012.000; 514/013.000; 514/014.000; 530/326.000; 530/327.000;
                530/328.000; 530/324.000
NCL
        NCLM:
                514/015.000
                514/012.000; 514/013.000; 514/014.000; 530/324.000; 530/326.000; 530/327.000; 530/328.000
        NCLS:
        [7]
IC
        ICM: A61K038-08
ICS: A61K038-10; A61K038-17
EXF 514/12-15; 530/324; 530/326-328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 338 OF 391 USPATFULL on STN
L4
ΑN
        2001:4717 USPATFULL
        Treatments for neurotoxicity in Alzheimer's disease caused by .
ΤI
          ***beta***
                             ***amyloid***
                                               peptides
        Ingram, Vernon M., Cambridge, MA, United States
IN
        Blanchard, Barbara J., Cambridge, MA, United States
        Massachusetts Institute of Technology, Cambridge, MA, United States
PA
        (U.S. corporation) US 6172043
PΙ
                              в1
                                    20010109
        us 1998-5215
ΑI
                                    19980109 (9)
RLI
        Continuation-in-part of Ser. No. US 1997-960188, filed on 29 Oct 1997.
        now abandoned
PRAI
        US 1997-35847P
                               19970110 (60)
DT
        Patent
FS
        Granted
LN.CNT 1822
INCL
        INCLM: 514/017.000
        INCLS: 514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
        NCLM:
                514/017.000
NCL
        NCLS:
                514/013.000; 514/014.000; 514/015.000; 514/016.000; 530/325.000;
                530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/330.000
        [7]
IC
        ICM: A61K038-04
        ICS: C07K007-00
        530/325-330; 514/13-17
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 339 OF 391 USPATFULL ON STN
L4
        2001:1790 USPATFULL
ΑN
        Fluorine-substituted biphenyl butyric acids and their derivatives as
ΤI
        inhibitors of matrix metalloproteinases
```

Purchase, Jr., Claude Forsey, Ann Arbor, MI, United States

TN

```
Schielke, Gerald Paul, Ann Arbor, MI, United States Walker, Lary Craswell, Ann Arbor, MI, United States
         White, Andrew David, Pinckney, MÍ, United States
Warner-Lambert, Morris Plains, NJ, United States (U.S. corporation)
PA
PΙ
          US 6169103
                                          20010102
                                   В1
ΑI
          US 1999-256714
                                          19990224 (9)
          US 1998-76633P
PRAI
                                     19980303 (60)
          Utility
DT
          Granted
FS
LN.CNT 2031
          INCLM: 514/389.000
INCL
                   514/389.000; 514/522.000; 514/419.000; 514/567.000; 558/414.000; 548/494.000; 548/319.500; 548/477.000; 560/035.000; 562/492.000
          INCLS:
NCL
          NCLM:
                   514/389.000
          NCLS:
                   514/419.000; 514/522.000; 514/567.000; 548/319.500; 548/477.000;
                   548/494.000; 558/414.000; 560/035.000; 562/492.000
IC
          [7]
          ICM: A61K031-40
          ICS: A61K031-275; C07D209-48
          558/414; 548/319.5; 548/494; 548/477; 548/479; 562/440; 560/35; 514/425;
EXF
          514/522; 514/555; 514/389; 514/419; 514/417; 514/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
       ANSWER 340 OF 391 USPATFULL on STN
         2000:161048 USPATFULL
ΑN
         N-(aryl/heteroaryl/alkylacetyl) amino acid amides, pharmaceutical
TI
         compositions comprising same, and methods for inhibiting . ***beta***
               ***amyloid***
                                    peptide release and/or its synthesis by use of such
         compounds
IN
         Wu, Jing, San Mateo, CA, United States
         Tung, Jay S., Belmont, CA, United States
         Nissen, Jeffrey S., Indianapolis, IN, United States Mabry, Thomas E., Indianapolis, IN, United States Latimer, Lee H., Oakland, CA, United States Eid, Clark N., Cheshire, CT, United States Audia, James E., Indianapolis, IN, United States
PA
         Elan Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S.
         corporation)
         Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
PΙ
         US 6153652
                                          20001128
         US 1997-976295
ΑI
                                          19971121 (8)
         US 1996-1551P
US 1997-113671P
                                     19961122 (60)
PRAI
                                    19970228 (60)
DT
         Utility
FS
         Granted
LN.CNT 3652
INCL
         INCLM: 514/619.000
         INCLS: 514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000;
                   514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
NCL
         NCLM:
                   514/619.000
                   514/349.000; 514/352.000; 514/357.000; 514/417.000; 514/470.000; 514/535.000; 514/539.000; 546/309.000; 548/471.000; 548/475.000; 549/303.000; 549/304.000; 560/039.000; 560/041.000; 560/042.000; 560/043.000; 564/152.000; 564/155.000; 564/158.000; 564/168.000
         NCLS:
         [7]
IC
         ICM: A01N037-18
         ICS: A01N037-12; A01N037-44; A61K031-165 564/155; 564/158; 564/152; 564/168; 546/309; 548/471; 548/475; 549/303;
EXF
         549/304; 560/39; 560/41; 560/42; 560/43; 514/349; 514/352; 514/357;
         514/417; 514/470; 514/535; 514/539; 514/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 341 OF 391 USPATFULL ON STN 2000:160799 USPATFULL
ΑN
         Death domain containing receptors
TI
         Yu, Guo-Liang, Darnestown, MD, United States
IN
         Ni, Jian, Rockville, MD, United States
         Gentz, Reiner L., Silver Spring, MD, United States
         Dillon, Patrick J., Gaithersburg, MD, United States
PA
         Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
         corporation)
ΡI
         us 6153402
                                          20001128
```

19970311 (8)

us 1997-815469

AΙ

```
US 1996-28711P
                             19961017 (60)
       US 1997-37341P
                             19970206 (60)
DT
       Utility
FS
        Granted
LN.CNT 3364
INCL
       INCLM: 435/069.100
        INCLS: 435/252.300; 435/320.100; 536/023.500
NCL
              435/069.100
       NCLS:
              435/252.300; 435/320.100; 536/023.500
        [7]
IC
       ICM: C12N015-12
EXF
       435/69.1; 435/325; 435/252.3; 536/23.5; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 342 OF 391 USPATFULL on STN
       2000:153855 USPATFULL
ΑN
TI
       Lactacystin analogs
       Fenteany, Gabriel, Cambridge, MA, United States
IN
       Jamison, Timothy F., Cambridge, MA, United States
       Schreiber, Stuart L., Boston, MA, United States
       Standaert, Robert F., Arlington, MA, United States
       President and Fellows of Harvard College, Cambridge, MA, United States
PA
        (U.S. corporation)
ΡI
       US 6147223
                                 20001114
ΑI
       US 1995-468408
                                 19950606 (8)
RLI
       Division of Ser. No. US 1995-421583, filed on 12 Apr 1995
DT
       Utility
FS
       Granted
LN.CNT 2354
       INCLM: 548/453.000
INCL
NCL
       NCLM: 548/453.000
        [7]
IC
       ICM: C07D491-044
EXF 548/453; 540/203
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 343 OF 391 USPATFULL on STN
AN
       2000:121621 USPATFULL
       Presenilin-2 and mutations thereof
TI
IN
       St. George-Hyslop, Peter H., Toronto, Canada
       Rommens, Johanna M., Toronto, Canada
       Fraser, Paul E., Toronto, Canada
The Governing Council of the University of Toronto, Toronto, Canada
PA
       (non-U.S. corporation)
       HSC Research and Development Limited Partnership, Toronto, Canada
       (non-U.S. corporation)
PΙ
       us 6117978
                                 20000912
                                 19980729 (9)
       us 1998-124698
ΑI
RLI
       Division of Ser. No. US 1997-967101, filed on 10 Nov 1997, now patented,
       Pat. No. US 5840540 which is a division of Ser. No. US 1996-592541,
       filed on 26 Jan 1996, now patented, Pat. No. US 5986054 which is a
       continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995
       which is a continuation-in-part of Ser. No. US 1995-496841, filed on 28
       Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
       filed on 28 Apr 1995
DT
       Utility
       Granted
FS
LN.CNT 7847
INCL
       INCLM: 530/350.000
       NCLM: 530/350.000
NCL
IC
       [7]
       ICM: C07K014-00
       530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 344 OF 391 USPATFULL on STN 2000:121544 USPATFULL
L4
AN
TI
       N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions
       comprising same, and methods for use
IN
       Wu, Jing, San Mateo, CA, United States
       Thorsett, Eugene D., Moss Beach, CA, United States
       Nissen, Jeffrey S., Indianapolis, IN, United States
       Mabry, Thomas E., Indianapolis, IN, United States
       Latimer, Lee H., Oakland, CA, United States
```

John, Varghese, San Francisco, CA, United States

```
Audia, James E., Indianapolis, IN, United States
PA
       Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
       corporation)
       Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
ΡI
       US 6117901
                                20000912
ΑI
       US 1997-976179
                                19971121 (8)
PRAI
       US 1996-98551P
                            19961122 (60)
       US 1996-19790P
                            19960614 (60)
DT
       Utility
FS
       Granted
LN.CNT 3321
INCL
       INCLM: 514/513.000
NCL
       NCLM: 514/513.000
       [7]
       ICM: A61K031-16
       514/513
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 345 OF 391 USPATFULL ON STN
AN
       2000:98466 USPATFULL
TI
       N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions
       comprising same and methods for inhibiting . ***beta***
         ***amyloid***
                         peptide release and/or its synthesis by use of such
       compounds
IN
       Audia, James E., Indianapolis, IN, United States Folmer, Beverly K., Newark, DE, United States
       John, Varghese, San Francisco, CA, United States
       Latimer, Lee H., Oakland, CA, United States
       Nissen, Jeffrey S., Indianapolis, IN, United States
       Porter, Warren J., Indianapolis, IN, United States
       Thorsett, Eugene D., Moss Beach, CA, United States
       Wu, Jing, San Mateo, CA, United States
PΑ
       Athena Neurosciences, Inc., South San Francisco, CA, United States (U.S.
       corporation)
       Eli Lilly & Company, Indianapolis, IN, United States (U.S. corporation)
ΡI
       us 6096782
                                20000801
       US 1997-976191
                                19971121 (8)
ΑI
PRAI
       US 1996-77175P
                            19961122 (60)
       Utility
DT
FS
       Granted
LN.CNT 3343
       INCLM: 514/506.000
INCL
       INCLS: 514/399.000; 548/335.500; 560/041.000
NCL
       NCLM:
              514/506.000
       NCLS:
              514/399.000; 548/335.500; 560/041.000
       [7]
IC
       ICM: A01N037-20
       ICS: A01N043-50; C07C229-24; C07D233-61
EXF
       560/41: 514/506: 514/399: 548/335.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 346 OF 391 USPATFULL on STN
AN
       2000:94696 USPATFULL
       Amyloid precursor protein protease
TI
IN
       Dixon, Eric P, Apex, NC, United_States
       Johnstone, Edward M., Indianapolis, IN, United States
       Little, Sheila P., Indianapolis, IN, United States
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
PA
       corporation)
       us 6093397
                                20000725
PT
       wo 9631122
                   19961010
ΑI
       US 1997-930188
                                19971002 (8)
       wo 1996-US4294
                                19960402
                                19971002
                                          PCT 371 date
                                          PCT 102(e) date
                                19971002
       Continuation of Ser. No. US 1995-416257, filed on 4 Apr 1995, now
RLI
       abandoned
       Utility
DT
       Granted
FS
LN.CNT 1530
INCL
       INCLM: 424/094.640
       INCLS: 424/078.020; 424/094.620; 435/069.100; 435/212.000; 435/213.000;
              435/219.000; 435/226.000; 435/252.300; 435/320.100
              424/094.640
NCL
       NCLM:
```

424/078.020; 424/094.620; 435/069.100; 435/212.000; 435/213.000;

NCLS:

```
IC
         ICM: A61K038-48
         ICS: C12N009-48; C12N001-20; C07H021-04
EXF 435/212; 435/213; 435/226; 435/219; 435/69.1; 435/252.3; 435/320.1; 435/252.33; 536/23.2; 536/23.5; 424/78.02; 424/94.62; 424/94.64; 935/14; 935/29; 935/32; 935/70; 935/73
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 347 OF 391 USPATFULL ON STN
L4
         2000:91941 USPATFULL
AN
         Serine proteases, their activity and their synthetic inhibitors
TI
        Augustyns, Koen Jan Ludovicus, Minderhout, Belgium
IN
        Vanhoof, Greta Constantia, Mortsel, Belgium
        Borloo, Marianne Jean Frieda, Deurne, Belgium
De Meester, Ingrid Anna Jozef, Wilrijk, Belgium
Goossens, Filip Jozef Anny, Lokeren, Belgium
Haemers, Achiel Jean-Marie, Gent, Belgium
Hendriks, Dirk Frans, Aartselaar, Belgium
Lambeir, Anne-Marie Virginie Renee, Heverlee, Belgium
         Scharpe, Simon Lodewijk, Wieze, Belgium
PΑ
        FondaTech Benelux N.V., Belgium (non-U.S. corporation)
        US 6090786
                                       20000718
PΙ
        wo 9534538
                      19951221
        us 1997-750484
                                       19970219 (8)
ΑI
        WO 1995-EP2255
                                       19950609
                                       19970219
                                                   PCT 371 date
                                                   PCT 102(e) date
                                       19970219
        EP 1994-201668
                                  19940610
PRAI
        EP 1994-203707
                                  19941220
        Utility
DT
FS
         Granted
LN.CNT 1511
        INCLM: 514/019.000
INCL
        INCLS: 514/020.000; 514/002.000; 530/330.000; 540/130.000
NCL
        NCLM:
                 514/019.000
                 514/002.000; 514/020.000; 530/330.000; 540/130.000
         [7]
IC
         ICM: A61K038-05
        ICS: C07K005-078
EXF
         514/19; 514/20; 514/2; 530/330; 540/130
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 348 OF 391 USPATFULL ON STN
        2000:84054 USPATFULL
AN
        Cloning and expression of .beta.APP-C100 receptor (C100-R)
TI
IN
        Manly, Susan P., Wallingford, CT, United States
        Kozlowski, Michael R., Palo Alto, CA, United States
        Neve, Rachael L., Belmont, MA, United States
        Bristol-Myers Squibb Company, New York, NY, United States (U.S.
PA
        corporation)
        McLean Hospital Corporation, Belmont, MA, United States (U.S.
        corporation)
PΙ
        us 6083713
                                       20000704
                                       19951115 (8)
ΑI
        us 1995-559397
        Continuation-in-part of Ser. No. US 1993-114555, filed on 30 Aug 1993, now patented, Pat. No. US 5854392 And a continuation-in-part of Ser. No.
RLI
        US 1992-938184, filed on 31 Aug 1992, now abandoned
        Utility
DT
FS
        Granted
IN.CNT 3220
INCL
         INCLM: 435/069.100
        INCLS: 435/069.700; 435/325.000; 435/252.300; 435/320.100; 536/023.100;
                 536/023.400; 536/023.500
                 435/069.100
NCL
        NCLM:
                 435/069.700; 435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/023.400; 536/023.500
        NCLS:
         [7]
IC
         ICM: C12N015-12
        ICS: C12N015-70; C12N015-85
        536/23.1; 536/23.4; 536/23.5; 435/69.1; 435/320.1; 435/325; 435/252.3;
EXF
        435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 349 OF 391 USPATFULL on STN
L4
```

AN

2000:77202 USPATFULL

```
ΙN
        Der, Channing, Chapel Hill, NC, United States
        O'Bryan, John, Chapel Hill, NC, United States
        Pawson, Anthony, Toronto, Canada
PA
       Mount Sinai Hospital Corporation, Toronto, Canada (non-U.S. corporat University of North Carolina at Chapel Hill, NC, United States (U.S.
                                                      Canada (non-U.S. corporation)
        corporation)
PΙ
        US 6077686
                                  20000620
ΑI
       US 1997-807342
                                  19970228 (8)
DT
       Utility
FS
        Granted
LN.CNT 2849
INCL
        INCLM: 435/069.100
        INCLS: 435/325.000; 435/320.100; 435/252.100
NCLM: 435/069.100
NCL
        NCLS: 435/252.100; 435/320.100; 435/325.000
        [7]
TC
        ICM: C12P021-06
        ICS: C12N001-12; C12N015-00; C12N005-00
EXF
        435/69.1; 435/252.3; 435/320.1; 435/325; 435/252.1; 530/350; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 350 OF 391 USPATFULL on STN
L4
       2000:37839 USPATFULL
ΑN
ΤI
        Tyramine compounds and their neuronal effects
       Giulian, Dana J., Houston, TX, United States
Baylor College of Medicine, Houston, TX, United States (U.S.
IN
PA
       corporation)
PΙ
       US 6043283
                                  20000328
       US 1997-870967
ΑI
                                  19970606 (8)
RLI
       Continuation-in-part of Ser. No. US 1996-717551, filed on 20 Sep 1996
DT
       Utility
FS
        Granted
LN.CNT 3153
INCL
        INCLM: 514/617.000
       NCLM: 514/617.000
NCL
IC
        [7]
        ICM: A61K031-165
        514/152; 514/617
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 351 OF 391 USPATFULL ON STN
L4
       2000:31594 USPATFULL
AN
       Transgenic mouse expressing an . ***beta*** .- ***Amyloid***
TI
        transgene
IN
       Sato, Masahiro, Kawagoe, Japan
       Kobayashi, Takashi, Fukuoka, Japan
       Tada, Norihiro, Kawagoe, Japan
       Shoji, Mikio, Gunma-gun, Japan
       Kawarabayashi, Takeshi, Maebashi, Japan
PA
       Hoechst Japan Limited, Tokyo, Japan (non-U.S. corporation)
       US 6037521
PΙ
                                  20000314
       US 1994-339708
JP 1993-306026
ΑI
                                  19941114 (8)
PRAI
                             19931112
       Utility
DT
FS
       Granted
LN.CNT 1316
INCL
       INCLM: 800/018.000
       INCLS: 800/009.000; 800/012.000; 800/003.000; 424/009.100; 424/009.200
NCL
       NCLM:
               800/018.000
       NCLS:
               424/009.100; 424/009.200; 800/003.000; 800/009.000; 800/012.000
IC
        [7]
       ICM: A01K067-00
        ICS: A01K067-027
EXF
       800/2; 435/172.3; 424/9; 424/9.1; 424/9.2
L4
     ANSWER 352 OF 391 USPATFULL ON STN
       2000:28107 USPATFULL
AN
TI
        .beta.-sheet nucleating peptidomimetics
IN
       Kelly, Jeffery W., 213 Chimney Hill Cir., College Station, TX, United
       States
                77840
PΤ
       us 6034211
                                  20000307
       US 1996-664379
US 1996-18925P
                                  19960614 (8)
ΑI
PRAI
                             19960603 (60)
       Utility
DT
```

FS

Granted

```
INCL
        INCLM: 530/317.000
       INCLS: 546/101.000
               530/317.000
NCL
       NCLM:
               546/101.000
       NCLS:
IC
        [7]
       ICM: C07K005-00
EXF
        548/427; 546/101; 514/323-328; 530/317
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 353 OF 391 USPATFULL on STN
AN
       2000:12606
                   USPATFULL
       Method for identifying substances that affect the interaction of a
TI
       presentlin-1-interacting protein with a mammalian presentlin-1 protein
IN
       St. George-Hyslop, Peter H., Toronto, Canada
       Rommens, Johanna M., Toronto, Canada
       Fraser, Paul E., Toronto, Canada
PA
       Research and Development Limited Partnership, Toronto, Canada (non-U.S.
       corporation)
PΙ
       US 6020143
                                20000201
                                19970703 (8)
       US 1997-888077
AΙ
RLI
       Continuation-in-part of Ser. No. US 1996-592541, filed on 26 Jan 1996
                            19960705 (60)
PRAI
       US 1996-21673P
       US 1996-21700P
                            19960712 (60)
       US 1996-29895P
                            19961108 (60)
       US 1997-34590P
                            19970102 (60)
DT
       Utility
FS
       Granted
LN.CNT 7847
       INCLM: 435/007.100
INCL
       INCLS: 530/350.000
NCL
       NCLM:
              435/007.100
              530/350.000
       NCLS:
IC
       [6]
       ICM: C12Q001-00
       ICS: C07K014-00
       435/7.1; 530/350
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 354 OF 391 USPATFULL ON STN
ΑN
       2000:12437 USPATFULL
TI
       SPE-4 peptides
       L'Hernault, Steven W., Atlanta, GA, United States
IN
PA
       Emory University, Atlanta, GA, United States (U.S. corporation)
PΙ
       us 6019974
                                20000201
       US 1997-788231
ΑI
                                19970124 (8)
       US 1996-10672P
PRAI
                            19960126 (60)
DT
       Utility
FS
       Granted
LN.CNT 1297
INCL
       INCLM: 424/191.100
       INCLS: 424/185.100; 424/184.100; 424/192.100; 424/193.100; 424/194.100;
               530/300.000; 530/350.000; 530/326.000; 530/327.000; 530/387.100
NCL
       NCLM:
              424/191.100
       NCLS:
              424/184.100; 424/185.100; 424/192.100; 424/193.100; 424/194.100;
              530/300.000; 530/326.000; 530/327.000; 530/350.000; 530/387.100
IC
       [6]
       ĪCM: C07K007-00
       ICS: A61K039-00
       530/300; 530/350; 530/326; 530/327; 530/387.1; 424/184.1; 424/185.1;
FXF
       424/192.1; 424/193.1; 424/194.1; 424/191.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 355 OF 391 USPATFULL ON STN 1999:146753 USPATFULL
L4
ΑN
TI
       Genetic sequences and proteins related to alzheimer's disease
       St. George-Hyslop, Peter H., Toronto, Canada
IN
       Rommens, Johanna M., Toronto, Canada
       Fraser, Paul E., Toronto, Canada
       The Hospital for Sick Children, HSC Research and Development Limited
PΑ
       Partnership, Canada (non-U.S. corporation)
       The Governing Council of the University of Toronto, Canada (non-U.S.
       corporation)
                                19991116
       us 5986054
PT
       us 1996-592541
ΑI
                                19960126 (8)
```

Continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995

RLI

```
Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
        filed on 28 Apr 1995
DT
        Utility
FS
        Granted
LN.CNT 7292
INCL
        INCLM: 530/350.000
        INCLS: 435/069.100
                530/350.000
NCL
        NCLM:
        NCLS: 435/069.100
IC
        [6]
        ICM: C07K014-00
        ICS: C12P021-06
        530/350; 435/69.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 356 OF 391 USPATFULL ON STN
        1999:141615 USPATFULL
ΑN
TT
        Diagnostic assay for Alzheimer's disease based on the proteolysis of the
        amyloid precursor protein
        Tamburini, Paul P., Kensington, CT, United States
Dreyer, Robert N., Wallingford, CT, United States
Bausch, Kathryn M., West Haven, CT, United States
Bayer Corporation, West Haven, CT, United States (U.S. corporation)
ΙN
PA
        US 5981208
                                   19991109
PΙ
        us 1994-319339
ΑI
                                   19941006 (8)
RLI
        Continuation of Ser. No. US 1993-156516, filed on 23 Nov 1993, now
        abandoned which is a continuation of Ser. No. US 1992-865167, filed on 9
        Apr 1992, now abandoned
DT
        Utility
FS
        Granted
LN.CNT 901
INCL
        INCLM: 435/023.000
        INCLS: 435/007.100; 436/518.000; 436/811.000
                435/023.000
NCL
        NCLM:
        NCLS:
                435/007.100; 436/518.000; 436/811.000
IC
        [6]
        ICM: G01N033-53
        435/7.1; 435/7.9; 435/7.92; 435/7.93; 435/7.94; 435/7.95; 435/23;
EXF
        435/24;
                435/975; 435/4; 436/501; 436/518; 436/528; 436/531; 436/811;
        530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 357 OF 391 USPATFULL on STN 1999:141575 USPATFULL
L4
AN
TI
        Method and composition for modulating amyloidosis
        Reiner, Peter B., Vancouver, Canada
IN
        Connop, Bruce P., Vancouver, Canada
        The University of British Columbia, Vancouver, Canada (non-U.S.
PA
        corporation)
PI
        US 5981168
                                   19991109
        US 1998-80141
                                   19980515 (9)
ΑI
DT
        Utility
FS
        Granted
LN.CNT 1184
INCL
        INCLM: 435/004.000
        INCLS: 435/029.000; 514/639.000; 514/638.000; 514/600.000; 514/601.000;
                514/395.000; 514/310.000; 514/255.000
NCL
        NCLM:
                435/004.000
                435/029.000; 514/255.060; 514/310.000; 514/395.000; 514/600.000; 514/601.000; 514/638.000; 514/639.000
        NCLS:
IC
        [6]
        ICM: C12Q001-00
        435/4; 435/29; 514/639; 514/638; 514/600; 514/601; 514/395; 514/310;
EXF
        514/255
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 358 OF 391 USPATFULL on STN
AN
        1999:132768 USPATFULL
TI
        Method for the treatment of neurodegenerative diseases by administering
        VIP, an analogue, fragment or a conjugate thereof
IN
        Gozes, Illana, Ramat Hasharon, Israel
        Fridkin, Matityahu, Rehovot, Israel
PA
        Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S.
        corporation)
        Ramot University Authority for Applied Research and Industrial
```

```
PΙ
                                  19991026
        US 5972883
        US 1995-413708
ΑI
                                  19950330 (8)
RLI
        Continuation-in-part of Ser. No. US 1994-207671, filed on 9 Mar 1994,
        now abandoned
        IL 1993-105061
PRAI
                              19930316
DT
        Utility
FS
        Granted
LN.CNT 1190
INCL
        INCLM: 514/012.000
        INCLS: 530/324.000
NCL
        NCLM:
               514/012.000
        NCLS:
               530/324.000
IC
        [6]
        ĪCM: A61K038-00
FXF
        514/12; 514/879; 530/324; 530/327; 530/328
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 359 OF 391 USPATFULL on STN
        1999:132524 USPATFULL
ΑN
        Diagnostic assay for Alzheimer's disease: assessment of A.beta.
TI
        abnormalities
        Tanzi, Rudolph E., Canton, MA, United States
IN
       Bush, Ashley I., Somerville, MA, United States
Moir, Robert D., Boston, MA, United States
PΑ
        The General Hospital Corporation, Boston, MA, United States (U.S.
        corporation)
PΙ
        us 5972634
                                  19991026
                     19960502
        wo 9612544
        US 1997~817423
                                  19970804 (8)
ΑI
        wo 1994-US11895
                                  19941019
                                  19970804
                                             PCT 371 date
                                  19970804 PCT 102(e) date
DT
        Utility
FS
        Granted
LN.CNT 2476
INCL
        INCLM: 435/007.940
        INCLS: 435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000;
               436/525.000; 436/164.000; 436/172.000
        NCLM:
               435/007.940
NCL
               435/007.100; 435/007.900; 435/007.920; 435/007.950; 435/975.000; 436/164.000; 436/172.000; 436/525.000
        NCLS:
        [6]
IC
        ICM: G01N033-53
        435/7.1; 435/7.92; 435/7.94; 435/7.95; 435/975; 435/7.9; 436/525;
EXF
        436/164; 436/172; 436/63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 360 OF 391 USPATFULL ON STN
        1999:124950 USPATFULL
ΑN
        N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
TI
       comprising same, and methods for inhibiting . ***beta***
***amyloid*** peptide release and/or its synthesis by
                           peptide release and/or its synthesis by use of such
        compounds
       Audia, James E., Indianapolis, IN, United States Folmer, Beverly K., Newark, DE, United States
IN
        John, Varghese, San Francisco, CA, United States
        Latimer, Lee H., Oakland, CA, United States
        Nissen, Jeffrey S., Indianapolis, IN, United States
        Reel, Jon K., Carmel, IN, United States
        Thorsett, Eugene D., Moss Beach, CA, United States
        Whitesitt, Celia A., Greenwood, IN, United States
PA
        Athena Neurosciences, Inc., United States (U.S. corporation)
                                  19991012
        us 5965614
ΡI
       US 1997-975977
                                   19971121 (8)
ΑI
       US 1996-104593P
PRAI
                              19961122 (60)
        Utility
DT
        Granted
FS
       2939
LN.CNT
        INCLM: 514/538.000
INCL
        INCLS: 514/508.000; 560/043.000; 560/035.000
                514/538.000
NCL
        NCLM:
        NCLS:
               514/508.000; 560/035.000; 560/043.000
        [6]
IC
        ICM: A01N037-12
```

ICS: A01N037-52; C07C229-28

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 361 OF 391 USPATFULL ON STN 1999:113631 USPATFULL
ΑN
TI
       Stable macroscopic membranes formed by self-assembly of amphiphilic
       peptides and uses therefor
TN
       Holmes, Todd, Somerville, MA, United States
       Zhang, Shuguang, Cambridge, MA, United States
       Rich, Alexander, Cambridge, MA, United States
       DiPersio, C. Michael, Norton, MA, United States
       Lockshin, Curtis, Lexington, MA, United States
PA
       Massachusetts Institute of Technology, Cambridge, MA, United States
       (U.S. corporation) US 5955343
PΙ
                                 19990921
       US 1994-293284
                                 19940822 (8)
ΑI
       Continuation-in-part of Ser. No. US 1992-973326, filed on 28 Dec 1992,
RLI
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2516
INCL
       INCLM: 435/240.100
       INCLS: 435/240.200; 435/240.230; 435/240.241
       NCLM: 435/325.000
NCL.
       NCLS:
              435/378.000; 435/395.000; 435/401.000
IC
       [6]
       ĪCM: C12N005-02
       435/240.1; 435/240.2; 435/240.23; 435/240.241
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 362 OF 391 USPATFULL on STN
       1999:106439 USPATFULL
ΑN
TI
       Peptides and pharmaceutical compositions thereof for treatment of
       disorders or diseases associated with abnormal protein folding into
       amyloid or amyloid-like deposits
IN
       Soto-Jara, Claudio, New York, NY, United States
       Baumann, Marc H., Helsinski, Finland
       Frangione, Blas, New York, NY, United States
PA
       New York University, New York, NY, United States (U.S. corporation)
       us 5948763
PΙ
                                 19990907
ΑI
       US 1996-630645
                                 19960410 (8)
RLI
       Continuation-in-part of Ser. No. US 1995-478326, filed on 6 Jun 1995
DT
       Utility
       Granted
LN.CNT 1306
       INCLM: 514/014.000
INCL
       INCLS: 514/015.000; 514/016.000; 514/017.000; 514/018.000
NCL
       NCLM:
               514/014.000
       NCLS:
               514/015.000; 514/016.000; 514/017.000; 514/018.000
IC
       [6]
       ICM: A61K038-00
       514/2; 514/14; 514/15; 514/16; 514/17; 514/18; 530/300; 530/326; 530/327; 530/328; 530/329; 530/330; 530/331
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 363 OF 391 USPATFULL on STN
       1999:85236 USPATFULL
ΑN
TI
       Kit for detecting Alzheimer's disease
IN
       Nixon, Ralph A., Arlington, MA, United States
       Saito, Ken-Ichi, Yokahama, Japan
       The McLean Hospital Corporation, Belmont, MA, United States (U.S.
PA
       corporation)
       us 5928885
us 1996-681375
PΙ
                                 19990727
ΑI
                                 19960723 (8)
RLI
       Continuation of Ser. No. US 1994-184603, filed on 24 Jan 1994, now
       patented, Pat. No. US 5624807 which is a continuation of Ser. No. US
       1993-95319, filed on 22 Jul 1993, now abandoned which is a
       continuation-in-part of Ser. No. US 1992-925594, filed on 22 Jul 1992,
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 1112
INCL
       INCLM: 435/007.400
       INCLS: 435/967.000; 435/975.000; 436/518.000; 530/387.100; 530/388.100;
               530/388.260
```

435/007.400

NCL

NCLM:

```
530/388.260
IC
        [6]
        ICM: G01N033-573
       ICS: C07K016-00; C12P021-08
       435/975; 435/7.1; 435/7.4; 435/7.92; 435/7.93; 435/7.94; 435/7.95; 435/967; 436/518; 436/524; 436/528; 436/530; 436/531; 530/357.1;
EXF
       530/388.1; 530/388.26
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 364 OF 391 USPATFULL ON STN
       1999:67429 USPATFULL
AN
       Transgenic non- ***human***
                                        mice displaying the amyloid-forming
ΤI
       pathology of alzheimer's disease
IN
       Cordell, Barbara, Palo Alto, CA, United States
       Scios Inc., Mountain View, CA, United States (U.S. corporation)
PΔ
       us 5912410 us 1995-422333
                                  19990615
PΙ
       US 1995-422333 19950413 (8)
Continuation of Ser. No. US 1994-327381, filed on 21 Oct 1994, now
ΑI
RLI
       abandoned which is a continuation-in-part of Ser. No. US 1991-716725,
       filed on 17 Jun 1991, now patented, Pat. No. US 5387742 which is a
       continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990,
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2702
INCL
       INCLM: 800/002.000
       INCLS: 800/DIG.001; 424/009.200; 935/062.000
               800/012.000
NCL
       NCLM:
       NCLS: 424/009.200
       [6]
IC
       ICM: C12N015-00
       ICS: C12N005-00; A61K049-00
EXF
       800/2; 800/DIG.1; 935/62; 424/9.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 365 OF 391 USPATFULL on STN
       1999:27476 USPATFULL
ΑN
       APP770 mutant in alzheimer's disease
ΤI
       Hardy, John Anthony, Tampa, FL, United States
Chartier-Harlin, Marie-Christine, Villeneuve d'Ascq, France
ΙN
       Goate, Alison Mary, Michael, MO, United States
       Owen, Michael John, South Glamorgan, Scotland
       Mullan, Michael John, Tampa, FL, United States
PA
       Imperial College of Science, Technology of Medicine, London, England
        (non-U.S. corporation)
       us 5877015
PΙ
                                 19990302
       WO 9213069
                   19920806
                                 19920121 (8)
ΑI
       US 1992-104165
       WO 1992-GB123
                                 19920121
                                 19940121
                                            PCT 371 date
                                  19940121 PCT 102(e) date
                             19910121
PRAI
       GB 1991-1307
       GB 1991-18445
                             19910828
DT
       Utility
FS
       Granted
LN.CNT 1734
       INCLM: 435/325.000
INCL
       INCLS: 435/252.300; 536/023.500
NCL
       NCLM:
              435/325.000
       NCLS:
               435/252.300; 536/023.500
IC
        [6]
        ICM: C12N005-10
       ICS: C12N001-21; C07H021-04
       435/29; 435/240.1; 435/252.3; 435/6; 435/325; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 366 OF 391 USPATFULL on STN
AN
       1998:162469 USPATFULL
       A.beta. peptides that modulate . ***beta*** .- ***amyloid***
TI
       aggregation
       Finders, Mark A., Cambridge, MA, United States
IN
       Benjamin, Howard, Lexington, MA, United States
       Garnick, Marc B., Brookline, MA, United States
       Gefter, Malcolm L., Lincoln, MA, United States
```

Hundal, Arvind, Brighton, MA, United States

```
Musso, Gary, Hopkinton, MA, United States
        Signer, Ethan R., Cambridge, MA, United States Wakefield, James, Brookline, MA, United States Reed, Michael, Marietta, GA, United States Molineaux, Susan, Brookline, MA, United States
         Kubasek, William, Belmont, MA, United States
         Chin, Joseph, Salem, MA, United States
         Lee, Jung-Ja, Wayland, MA, United States
         Kelley, Michael, Arlington, MA, United States
PΑ
         Praecis Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
         corporation)
PΙ
         us 5854204
                                      19981229
        US 1996-612785
ΑI
                                      19960314 (8)
        Continuation-in-part of Ser. No. US 1995-404831, filed on 14 Mar 1995 And a continuation-in-part of Ser. No. US 1995-475579, filed on 7 Jun
RLI
         1995 And a continuation-in-part of Ser. No. US 1995-548998, filed on 27
        Oct 1995
DT
        Utility
FS
        Granted
LN.CNT 4304
INCL
         INCLM: 514/002.000
         INCLS: 514/012.000; 514/014.000; 530/324.000; 530/326.000
NCL
        NCLM:
                 514/002.000
                 514/012.000; 514/014.000; 530/324.000; 530/326.000
        NCLS:
TC
         [6]
         ICM: C07K014-435
         ICS: C07K007-08
EXF
         514/14; 514/12; 514/2; 530/300; 530/324; 530/326; 930/10
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 367 OF 391 USPATFULL on STN
AN
         1998:157207
                       USPATFULL
         Diagnostic assays for Alzheimer's disease
TI
        Nixon, Ralph, Arlington, MA, United States
Honda, Toshiyuki, Yokohama, Japan
IN
PA
        The McLean Hospital Corporation, Belmont, MA, United States (U.S.
        corporation)
PΙ
        US 5849600
                                     19981215
ΑI
        US 1993-149975
                                     19931110 (8)
        Utility
DT
FS
        Granted
LN.CNT 960
        INCLM: 436/518.000
INCL
         INCLS: 436/528.000; 436/529.000; 436/530.000; 436/161.000; 436/811.000
                 436/518.000
NCL
        NCLM:
        NCLS:
                 436/161.000; 436/528.000; 436/529.000; 436/530.000; 436/811.000
IC
         [6]
        ICM: G01N033-544
        435/7.1; 435/975; 436/518; 436/530; 436/547; 436/524; 436/528; 436/529; 436/811; 436/161; 530/350; 530/387.1; 530/387.9; 530/389.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 368 OF 391 USPATFULL ON STN
ΑN
        1998:147262
                        USPATFULL
TI
        Nucleic acids encoding presentlin II
        St. George-Hyslop, Peter H., Toronto, Canada
IN
        Rommens, Johanna M., Toronto, Canada
        Fraser, Paul E., Toronto, Canada
The Hospital for Sick Children, Canada (non-U.S. corporation)
PA
        HSC Research and Development Limited Partnership, Canada (non-U.S.
        corporation)
        US 5840540
US 1997-967101
                                      19981124
PΙ
ΑI
                                     19971110 (8)
        Division of Ser. No. US 1996-592541, filed on 26 Jan 1996 which is a continuation-in-part of Ser. No. US 1995-509359, filed on 31 Jul 1995
RLI
        which is a continuation-in-part of Ser. No. US 1995-496841, filed on 28
        Jun 1995 which is a continuation-in-part of Ser. No. US 1995-431048,
        filed on 28 Apr 1995
DT
        Utility
        Granted
FS
LN.CNT 6709
INCL
        INCLM: 435/069.100
        INCLS: 435/320.100; 435/252.300; 435/325.000; 536/023.100; 536/024.300;
                 530/350.000
```

NCL

NCLM:

435/069.100

```
536/024.300
IC
         [6]
         ICM: C12P021-06
         ICS: C07H017-00; C07K014-00
EXF
         435/69.1; 435/320.1; 435/252.3; 435/325; 536/23.1; 536/24.3; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
      ANSWER 369 OF 391 USPATFULL on STN
         1998:143904 USPATFULL
ΑN
         Directed evolution of novel binding proteins
TI
        Ladner, Robert Charles, Ijamsville, MD, United States
Gutterman, Sonia Kosow, Belmont, MA, United States
Roberts, Bruce Lindsay, Milford, MA, United States
Markland, William, Milford, MA, United States
IN
         Ley, Arthur Charles, Newton, MA, United States
         Kent, Rachel Baribault, Boxborough, MA, United States
PΑ
         Dyax, Corp., Cambridge, MA, United States (U.S. corporation)
         us 5837500
ΡI
                                     19981117
         US 1995-415922
ΑI
                                     19950403 (8)
RLI
         Continuation of Ser. No. US 1993-9319, filed on 26 Jan 1993, now
         patented, Pat. No. US 5403484 which is a division of Ser. No. US
        1991-664989, filed on 1 Mar 1991, now patented, Pat. No. US 5223409 which is a continuation-in-part of Ser. No. US 1990-487063, filed on 2
         Mar 1990, now abandoned which is a continuation-in-part of Ser. No. US
         1988-240160, filed on 2 Sep 1988, now abandoned
DT
         Utility
FS
         Granted
LN.CNT 15973
         INCLM: 435/069.700
INCL
         INCLS: 435/172.300; 530/350.000; 530/412.000; 536/023.400
NCL
         NCLM:
                 435/069.700
         NCLS:
                 435/091.100; 435/091.200; 435/471.000; 530/350.000; 530/412.000;
                 536/023.400
         [6]
IC
         ICM: C12N015-62
         ICS: C07K019-00
EXF
         435/69.7; 435/172.3; 530/350; 530/412; 536/23.4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 370 OF 391 USPATFULL on STN
L4
ΑN
         1998:139024 USPATFULL
TI
         Soluble form of PrP.sup.SC which is insoluble in native form
IN
        Prusiner, Stanley B., San Francisco, CA, United States
        Cohen, Fred E., San Francisco, CA, United States
Muramoto, Tamaki, San Francisco, CA, United States
The Regents of the University of California, Oakland, CA, United States
PA
         (U.S. corporation)
PΙ
        US 5834593
                                     19981110
ΑI
        us 1996-740947
                                     19961105 (8)
DT
        Utility
FS
        Granted
LN.CNT 1331
INCL
         INCLM: 530/350.000
        INCLS: 530/356.000; 435/006.000; 435/007.100; 435/002.300; 435/072.300;
                 435/236.000
                 530/350.000
NCL
        NCLM:
        NCLS:
                435/006.000; 435/007.100; 435/023.000; 435/236.000; 530/356.000
         [6]
IC
         ICM: C07K001-00
        ICS: C07K014-00; C07K016-00; C07K017-00
        530/350; 530/356; 435/236; 435/23; 435/6; 435/7.1; 435/172.3
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 371 OF 391 USPATFULL ON STN 1998:98980 USPATFULL
L4
AN
        Amyloid precursor protein in alzheimer's disease
TI
        Mullan, Michael John, Tampa, FL, United States
IN
        Alzheimer's Institute of America, Prairie Village, KS, United States
PΑ
         (U.S. corporation)
PΙ
        us 5795963
                                     19980818
ΑI
        us 1997-815637
                                     19970313 (8)
        Continuation of Ser. No. US 1995-487118, filed on 7 Jun 1995, now
RLI
        abandoned which is a division of Ser. No. US 1993-94547, filed on 19 Feb 1993, now abandoned which is a continuation of Ser. No. US 1992-894211,
```

filed on 4 Jun 1992, now patented, Pat. No. US 5455169, issued on 3 oct

```
DT
       Utility
FS
       Granted
LN.CNT
       1053
INCL
       INCLM: 530/350.000
NCL
       NCLM:
              530/350.000
IC
       [6]
       ICM: C07K001-00
EXF
       530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 372 OF 391 USPATFULL ON STN
ΑN
       1998:88671
                    USPATFULL
                     ***antibody***
ΤI
       Monoclonal
                                       369.2B specific for .beta. A4 peptide
       Konig, Gerhard, Branford, CT, United States
ΙN
       Graham, Paul, New Haven, CT, United States
       Bayer Corporation, Pittsburgh, PA, United States (U.S. corporation)
PA
PΙ
       us 5786180
                                19980728
ΑI
       US 1995-388463
                                19950214 (8)
       Utility
DT
       Granted
FS
LN.CNT 926
       INCLM: 435/070.210
INCL
       INCLS: 435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900; 530/388.100; 530/389.100
       NCLM:
              435/070.210
NCL
       NCLS:
              435/331.000; 436/547.000; 436/548.000; 530/327.000; 530/387.900;
               530/388.100; 530/389.100
IC
       [6]
       ICM: A61K039-395
       435/70.21; 435/240.27; 435/70.2; 435/326; 435/331; 530/388.1; 530/388.2;
FXF
       530/327; 530/387.9; 530/389.1; 436/548; 436/547; 424/184.1; 424/185.1;
       424/193.1; 424/194.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 373 OF 391 USPATFULL ON STN
       1998:58182 USPATFULL
AN
TI
       Lactacystin analogs
IN
       Fenteany, Gabriel, Cambridge, MA, United States
       Jamison, Timothy F., Cambridge, MA, United States
       Schreiber, Stuart L., Boston, MA, United States
       Standaert, Robert F., Arlington, MA, United States
       President and Fellows of Harvard College, Cambridge, MA, United States
PA
       (U.S. corporation) US 5756764
ΡI
                                19980526
       us 1995-466468
                                19950606 (8)
ΑI
       Division of Ser. No. US 1995-421583, filed on 12 Apr 1995
RLI
DT
       Utility
FS
       Granted
LN.CNT 2392
       INCLM: 548/541.000
INCL
       INCLS: 548/512.000; 548/543.000; 548/557.000
NCL
       NCLM:
               548/541.000
              548/512.000; 548/543.000; 548/557.000
       NCLS:
       [6]
IC
       ICM: C07D207-12
       ICS: C07D207-10; C07D207-08
       548/543; 548/512; 548/557; 548/541
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 374 OF 391 USPATFULL on STN
L4
ΑN
       1998:30992 USPATFULL
TI
       Method for treating Alzheimer's disease using glial line-derived
       neurotrophic factor (GDNF) protein product
IN
       Williams, Lawrence R., Thousand Oaks, CA, United States
       Amgen Inc., Thousand Oaks, CA, United States (U.S. corporation)
PA
                                19980324
PΙ
       US 5731284
       us 1995-535682
ΑI
                                19950928 (8)
DT
       Utility
FS
       Granted
LN.CNT 1677
INCL
       INCLM: 514/008.000
       INCLS: 514/021.000
NCL
       NCLM:
               514/008.000
       NCLS:
              514/021.000
```

TC

[6]

```
ICS: A61K047-00; A61K031-685; A61K038-00
       514/8; 514/21
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 375 OF 391 USPATFULL ON STN
       1998:28190 USPATFULL
ΑN
         ***Antibodies***
ΤI
                             directed against elk ligand
       Lyman, Stewart, Seattle, WA, United States
ΙN
       Beckmann, M. Patricia, Poulsbo, WA, United States
       Baum, Peter R., Seattle, WA, United States
PA
       Immunex Corporation, Seattle, WA, United States (U.S. corporation)
       US 5728813
US 1996-747240
PΙ
                                19980317
ΑI
                                19961112 (8)
       Division of Ser. No. US 1995-460741, filed on 2 Jun 1995, now patented,
RLI
       Pat. No. US 5670625 which is a division of Ser. No. US 1994-213403,
       filed on 15 Mar 1994, now patented, Pat. No. US 5512457 which is a
       continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
       now abandoned
DT
       Utility
       Granted
FS
LN.CNT 1717
INCL
       INCLM: 530/387.900
       INCLS: 530/388.230; 424/139.100
NCLM: 530/387.900
NCL
       NCLS:
              424/139.100; 530/388.230
IC
       [6]
       ICM: C07K016-24
       530/387.9; 530/388.23; 530/350; 435/69.1; 435/325; 435/331; 435/335;
EXF
       424/139.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 376 OF 391 USPATFULL ON STN
       1998:19582 USPATFULL
ΑN
       In Vitro method for screening . ***beta*** .- ***amyloid***
TI
       deposition
IN
       Maggio, John E., Brookline, MA, United States
       Mantyh, Patrick W., Edina, MN, United States
       Regents of the University of Minnesota, Minneapolis, MN, United States
PA
       (U.S. corporation)
       President and Fellows of Harvard College, Boston, MA, United States
       (U.S. corporation)
       us 5721106
PΙ
                                19980224
       us 1994-304585
                                19940912 (8)
ΑI
       Continuation-in-part of Ser. No. US 1991-744767, filed on 13 Aug 1991,
RLI
       now patented, Pat. No. US 5434050
DT
       Utility
FS
       Granted
       1977
LN.CNT
INCL
       INCLM: 435/007.800
       INCLS: 435/007.100; 435/007.900; 436/501.000; 436/504.000
NCL
       NCLM:
              435/007.800
       NCLS:
              435/007.100; 435/007.900; 436/501.000; 436/504.000
IC
       [6]
       ICM: G01N033-53
       435/4; 435/7.1; 435/7.21; 435/7.8; 435/7.9; 436/501; 436/86; 436/504
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 377 OF 391 USPATFULL ON STN
ΑN
       97:123343 USPATFULL
       Amyloid precursor proteins and method of using same to assess agents
ΤI
       which down-regulate formation of . ***beta***
                                                        .- ***amyloid***
       peptide
       Vitek, Michael Peter, East Norwich, NY, United States
ΙN
       Jacobsen, Jack Steven, Ramsey, NJ, United States
PA
       American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
       US 5703209
                                19971230
PΙ
ΑI
       US 1995-464248
                                19950605 (8)
RLI
       Division of Ser. No. US 1993-123659, filed on 20 Sep 1993 which is a
       continuation-in-part of Ser. No. US 1992-877675, filed on 1 May 1992,
       now abandoned
       Utility
DT
FS
       Granted
LN.CNT 1937
       INCLM: 530/350.000
INCLS: 530/539.000; 514/012.000; 435/069.100; 435/172.300
INCL
```

```
NCLS: 435/069.100; 530/839.000
IC
        [6]
        ICM: C07K014-435
        ICS: C07K014-47; C12N015-12
EXF
        435/69.1; 435/172.3; 514/2; 514/12; 530/350; 530/839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
14
     ANSWER 378 OF 391 USPATFULL ON STN
        97:112579 USPATFULL
ΑN
       Method of isolating .beta.A4 peptide species ending at carboxy-terminals
TI
                                       ***antibody***
        residue 42 using monoclonal
                                                           369.2B
        Konig, Gerhard, Branford, CT, United States
IN
        Graham, Paul, New Haven, CT, United States
PA
        Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PΙ
        us 5693753
                                  19971202
        US 1995-472627
ΑI
                                  19950607 (8)
RLI
        Division of Ser. No. US 1995-388463, filed on 14 Feb 1995
       Utility
DT
FS
        Granted
LN.CNT
       924
INCL
        INCLM: 530/344.000
        INCLS: 530/412.000; 530/413.000
NCL
               530/344.000
        NCLM:
       NCLS:
               530/412.000; 530/413.000
        [6]
IC
        ICM: C07K001-22
        530/387.9; 530/388.1; 530/389.1; 530/391.1; 530/391.3; 530/391.5;
EXF
        530/391.9; 530/344; 530/412; 530/413
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 379 OF 391 USPATFULL ON STN
ΑN
        97:96730 USPATFULL
       Methods of detecting .beta.A4 peptide species ending at carboxy-terminus
TI
       residue 42 using monoclonal
                                        ***antibody***
                                                           369.2B
        Konig, Gerhard, Branford, CT, United States
TN
        Graham, Paul, New Haven, CT, United States
PA
       Bayer Corporation, West Haven, CT, United States (U.S. corporation)
PΙ
       US 5679531
                                  19971021
ΑI
       US 1995-484969
                                  19950607 (8)
RLI
       Division of Ser. No. US 1995-388463, filed on 14 Feb 1995
DT
       Utility
FS
        Granted
LN.CNT 932
       INCLM: 435/007.100
INCL
       INCLS: 435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900;
               530/388.100
NCL
               435/007.100
       NCLS:
               435/007.920; 435/007.950; 435/040.500; 435/040.520; 530/387.900;
               530/388.100
IC
        [6]
       ICM: G01N033-53
       ICS: C07K016-18
435/70.21; 435/240.27; 435/387.9; 435/7.1; 435/7.21; 435/7.9; 435/40.52;
435/40.5; 435/7.92; 435/7.95; 530/388.1; 530/358.2; 530/327; 436/548;
424/184.1; 424/185.1; 424/193.1; 424/194.1
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 380 OF 391 USPATFULL on STN
ΑN
       97:86731 USPATFULL
TI
       Elk ligand fusion proteins
       Lyman, Stewart, Seattle, WA, United States
IN
       Beckmann, M. Patricia, Poulsbo, WA, United States
       Baum, Peter R., Seattle, WA, United States
PΑ
       Immunex Corporation, Seattle, WA, United States (U.S. corporation)
ΡI
       us 5670625
                                  19970923
       us 1995-460741
AΙ
                                 19950602 (8)
       Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented,
RLI
       Pat. No. US 5512457, issued on 30 Apr 1996 which is a
       continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 1742
       INCLM: 530/387.300
INCL
```

INCLS: 435/069.700; 435/172.300; 424/085.100; 424/192.100; 536/023.400;

```
NCL
        NCLM:
               530/387.300
        NCLS:
               424/085.100; 424/192.100; 435/069.700; 530/351.000; 536/023.400;
               930/140.000
IC
        [6]
        ICM: C07K014-52
        ICS: C07K019-00
EXF
        530/387.3; 530/351; 435/69.7; 435/172.3; 435/69.1; 435/320.1; 424/85.1; 424/192.1; 536/23.4; 536/23.5; 935/10; 930/140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 381 OF 391 USPATFULL on STN
        97:86591 USPATFULL
ΑN
TI
        Stable macroscopic membranes formed by self-assembly of amphiphilic
        peptides and uses therefor
IN
        Zhang, Shuguang, Cambridge, MA, United States
        Lockshin, Curtis, Lexington, MA, United States
        Rich, Alexander, Cambridge, MA, United States
       Holmes, Todd, Cambridge, MA, United States
Massachusetts Insititute of Technology, Cambridge, MA, United States
PA
        (U.S. corporation)
        US 5670483
PΙ
                                  19970923
       US 1994-346849
ΑI
                                  19941130 (8)
       Continuation of Ser. No. US 1992-973326, filed on 28 Dec 1992, now
RLI
        abandoned
DT
        Utility
FS
        Granted
LN.CNT 2210
INCL
        INCLM: 514/014.000
       INCLS: 514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000;
               530/326.000; 530/327.000; 530/350.000
NCL
       NCLM:
               514/014.000
               514/012.000; 514/013.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000; 530/327.000; 530/350.000
       NCLS:
        [6]
IC
        ICM: A61K007-08
        ICS: A61K014-00; C07K038-10; C07K038-16
        530/300; 530/350; 514/12; 514/13; 514/14
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 382 OF 391 USPATFULL ON STN
L4
AN
       97:70918 USPATFULL
       Amyloid precursor proteins and method of using same to assess agents
TI
       which down-regulate formation of . ***beta**** .- ***amyloid***
       peptide
IN
       Vitek, Michael Peter, East Norwich, NY, United States
        Jacobsen, Jack Steven, Ramsey, NJ, United States
PA
       American Cyanamid Company, Madison, NJ, United States (U.S. corporation)
                                  19970812
PΙ
       us 5656477
                                  19930920 (8)
       US 1993-123659
ΑI
       Continuation-in-part of Ser. No. US 1992-877675, filed on 1 May 1992,
RLI
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2040
INCL
       INCLM: 435/325.000
       INCLS: 435/252.300; 435/254.110; 435/348.000; 435/358.000; 435/365.000;
               435/365.100; 435/366.000; 536/023.500; 530/839.000
               435/325.000
NCL
       NCLM:
               435/252.300; 435/254.110; 435/348.000; 435/358.000; 435/365.000; 435/365.100; 435/366.000; 530/839.000; 536/023.500
       NCLS:
IC
        [6]
        ICM: C12N001-15
       ICS: C12N001-21; C12N005-10; C12N015-12
       435/172.3; 435/240.2; 435/252.3; 435/254.11; 435/320.1; 536/23.5;
EXF
       935/79; 530/350; 530/839
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 383 OF 391 USPATFULL on STN
L4
       97:49530 USPATFULL
ΑN
       Method of modulating DNA binding activity of recombinant .alpha.-1
TT
       antichymotrypsin and other serine protease inhibitors
       Rubin, Harvey, Philadelphia, PA, United States
IN
       Cooperman, Barry, Penn Valley, PA, United States
The Trustees of the University of Pennsylvania, Philadelphia, PA, United
PA
```

States (U.S. corporation)

```
US 1995-435480 19950505 (8)
Continuation-in-part of Ser. No. US 1994-276936, filed on 19 Jul 1994,
ΑI
RLI
        now patented, Pat. No. US 5612194 which is a continuation-in-part of
        Ser. No. US 1994-229286, filed on 18 Apr 1994, now abandoned which is a
        continuation-in-part of Ser. No. US 1994-221078, filed on 31 Mar 1994
        Ser. No. Ser. No. US 1994-221171, filed on 31 Mar 1994 And Ser. No. US
        1993-5908, filed on 15 Jan 1993, now patented, Pat. No. US 5367064 which
        is a division of Ser. No. US 1991-735335, filed on 24 Jul 1991, now
        patented, Pat. No. US 5252725 which is a division of Ser. No. US 1989-370704, filed on 23 Jun 1989, now patented, Pat. No. US 5079336 ,
                             -221078 which is a continuation-in-part of Ser. No.
        said Ser. No. US
        US
              -5908
        Utility
DT
FS
        Granted
LN.CNT 702
        INCLM: 435/069.200
INCL
        INCLS: 435/172.300; 530/350.000; 530/395.000; 536/023.500
NCL
        NCLM:
               435/069.200
        NCLS:
               530/350.000; 530/395.000; 536/023.500
IC
        [6]
        ICM: C07K014-435
        ICS: C07K014-81; C12N015-15
435/69.2; 435/172.3; 530/350; 530/395; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 384 OF 391 USPATFULL ON STN
14
        97:38610 USPATFULL
ΑN
ΤI
        Cytokine designated elk ligand
ΙN
        Lyman, Stewart, Seattle, WA, United States
        Beckmann, M. Patricia, Poulsbo, WA, United States
Baum, Peter R., Seattle, WA, United States
Immunex Corporation, Seattle, WA, United States (U.S. corporation)
US 5627267 19970506
PA
PΙ
       US 1995-458077
                                   19950601 (8)
ΑI
        Division of Ser. No. US 1994-213403, filed on 15 Mar 1994, now patented,
RLI
        Pat. No. US 5512457 which is a continuation-in-part of Ser. No. US
        1992-977693. filed on 13 Nov 1992. now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1743
INCL
        INCLM: 530/351.000
        INCLS: 424/085.100; 435/069.500; 536/023.500; 935/009.000; 930/140.000
NCL
        NCLM:
                530/351.000
                424/085.100; 435/069.500; 536/023.500; 930/140.000
        NCLS:
        [6]
IC
        ICM: C07K014-52
        530/351; 424/85.1; 514/12; 435/69.5; 536/23.5; 935/9; 930/140
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 385 OF 391 USPATFULL on STN
AN
        97:36068 USPATFULL
TI
        Methods for detecting Alzheimer's disease by measuring ratios of
        calcium-activated neutral protease isoforms
        Nixon, Ralph A., Arlington, MA, United States
Saito, Ken-Ichi, Yokohama, Japan
IN
        The McLean Hospital Corporation, Belmont, MA, United States (U.S.
PA
        corporation)
PΙ
        US 5624807
                                   19970429
        US 1994-184603
                                   19940124 (8)
ΑI
        Continuation of Ser. No. US 1993-95319, filed on 22 Jul 1993, now
RLI
        abandoned which is a continuation-in-part of Ser. No. US 1992-925594, filed on 22 Jul 1992, now abandoned
DT
        Utility
        Granted
FS
LN.CNT 1268
        INCLM: 435/007.400
INCL
        INCLS: 435/007.900; 435/007.920; 436/063.000; 436/518.000; 436/547.000;
                436/548.000; 436/811.000
                435/007.400
NCL
        NCLM:
        NCLS:
                435/007.900; 435/007.920; 436/063.000; 436/518.000; 436/547.000;
                436/548.000; 436/811.000
IC
        [6]
        ICM: G01N033-573
        ICS: G01N033-53; G01N033-48
```

435/7.4; 435/7.9; 435/7.92; 435/7.95; 435/975; 435/973; 435/967;

EXF

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 386 OF 391 USPATFULL ON STN
ΑN
        96:101466 USPATFULL
TI
        Directed evolution of novel binding proteins
IN
        Ladner, Robert C., Ijamsville, MD, United States
        Guterman, Sonia K., Belmont, MA, United States
       Roberts, Bruce L., Milford, MA, United States
Markland, William, Milford, MA, United States
Ley, Arthur C., Newton, MA, United States
        Kent, Rachel B., Boxborough, MA, United States
Protein Engineering Corporation, Cambridge, MA, United States (U.S.
PA
        corporation)
PΙ
        us 5571698
                                  19961105
        us 1993-57667
                                  19930618 (8)
ΑI
        Continuation of Ser. No. US 1991-664989, filed on 1 Mar 1991, now
RLI
        patented, Pat. No. US 5223409 which is a continuation-in-part of Ser.
        No. US 1990-487063, filed on 2 Mar 1990, now abandoned which is a
        continuation-in-part of Ser. No. US 1988-240160, filed on 2 Sep 1988,
        now_abandoned
        Utility
DΤ
        Granted
FS
LN.CNT 15323
INCL
        INCLM: 435/069.700
        INCLS: 435/006.000; 435/064.100; 435/172.300; 435/252.300; 435/320.100
               435/069.700
NCL
        NCLM:
        NCLS:
               435/006.000; 435/069.100; 435/252.300; 435/320.100; 435/477.000
        [6]
IC
        ICM: C12N025-62
EXF
        435/6; 435/64.1; 435/64.7; 435/172.3; 435/252.3; 435/320.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 387 OF 391 USPATFULL on STN
        96:36458 USPATFULL
ΑN
ΤI
        Cytokine designated elk ligand
        Lyman, Stewart, Seattle, WA, United States
IN
        Beckmann, M. Patricia, Poulsbo, WA, United States
        Baum, Peter R., Seattle, WA, United States
        Carpenter, Melissa K., Issaquah, WA, United States
PA
        Immunex Corporation, Seattle, WA, United States (U.S. corporation)
       US 5512457
US 1994-213403
                                  19960430
PΙ
       US 1994-213403 19940315 (8)
Continuation-in-part of Ser. No. US 1992-977693, filed on 13 Nov 1992,
ΑI
RLI
        now abandoned
DT
        Utility
        Granted
FS
LN.CNT
       1746
INCL
        INCLM: 435/069.500
        INCLS: 435/172.100; 435/320.100; 424/085.100; 536/023.500; 536/024.310;
               935/009.000; 530/351.000; 930/140.000
NCL
        NCLM:
               435/069.500
        NCLS:
               424/085.100; 435/320.100; 530/351.000; 536/023.500; 536/024.310;
               930/140.000
        [6]
IC
        ICM: C07H021-04
        ICS: C12P021-02; C12N015-19; C07K014-52
        536/23.5; 536/24.5; 536/24.31; 530/350; 530/351; 435/69.1; 435/320.1;
EXF
        435/172.1; 935/9; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 388 OF 391 USPATFULL on STN
14
       95:88386 USPATFULL
AN
TI
       Nucleic acids for diagnosing and modeling Alzheimer's disease
       Mullan, Michael J., Tampa, FL, United States
IN
PA
       Alzheimer's Institute of America, Inc., Prairie Village, KS, United
       States (U.S. corporation)
PI
       us 5455169
                                  19951003
ΑI
       US 1992-894211
                                  19920604 (7)
DT
       Utility
FS
       Granted
LN.CNT 1040
INCL
       INCLM: 435/240.200
       INCLS: 435/320.100; 536/023.100; 536/023.500; 536/024.310; 536/024.330
NCL
       NCLM:
               435/325.000
```

435/320.100; 536/023.100; 536/023.500; 536/024.310; 536/024.330

NCLS:

```
ICM: C12N005-10
       ICS: C12N015-12; C12N015-85
       435/240.2; 435/320.1; 435/172.3; 435/6; 536/23.1; 536/23.5; 536/24.31;
EXF
       536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 389 OF 391 USPATFULL ON STN
L4
       95:11757 USPATFULL
ΑN
       Transgenic mice displaying the amyloid-forming pathology of alzheimer's
ΤI
       disease
       Cordell, Barbara, Palo Alto, CA, United States
IN
PΑ
       Scios Nova Inc., Mountain View, CA, United States (U.S. corporation)
                                19950207
       US 5387742
PΙ
       US 1991-716725
                                19910617 (7)
ΑI
       Continuation-in-part of Ser. No. US 1990-538857, filed on 15 Jun 1990.
RLI
       now abandoned
DT
       Utility
FS
       Granted
LN.CNT 2014
       INCLM: 800/002.000
INCL
       INCLS: 424/009.000; 435/142.300; 536/023.500
NCL
       NCLM:
              800/012.000
              536/023.500; 800/018.000
       NCLS:
TC
       [6]
       ICM: A61K049-00
       ICS: C12N015-00; C07H015-12
EXF
       800/2; 435/6; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 390 OF 391 USPATFULL on STN
ΑN
       93:52487 USPATFULL
       Directed evolution of novel binding proteins
ΤI
       Ladner, Robert C., Ijamsville, MD, United States
ΙN
       Guterman, Sonia K., Belmont, MA, United States
       Roberts, Bruce L., Milford, MA, United States
       Markland, William, Milford, MA, United States
       Ley, Arthur C., Newton, MA, United States
       Kent, Rachel B., Boxborough, MA, United States
PA
       Protein Engineering Corp., Cambridge, MA, United States (U.S.
       corporation)
       us 5223409
us 1991-664989
PΙ
                                19930629
                                19910301 (7)
ΑI
       Continuation-in-part of Ser. No. US 1990-487063, filed on 2 Mar 1990,
RLI
       now abandoned And a continuation-in-part of Ser. No. US 1988-240160,
       filed on 2 Sep 1988, now abandoned
DT
       Utility
       Granted
FS
LN.CNT 15410
INCL
       INCLM: 435/069.700
       INCLS: 435/069.100; 435/172.300; 435/252.300; 435/320.100; 530/380.300;
               530/387.500
              435/069.700
NCL
       NCLM:
       NCLS:
              435/005.000; 435/069.100; 435/252.300; 435/320.100; 435/472.000;
              530/387.300; 530/387.500
IC
       [5]
       ICM: C12N015-09
       ICS: C12N015-62; C12N015-63
EXF
       435/69.1; 435/172.3; 435/252.3; 435/320.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L4
     ANSWER 391 OF 391 USPATFULL on STN
       92:61895 USPATFULL
AN
       Nerve growth factor peptides
TI
       Mobley, William C., Moraga, CA, United States
IN
       Longo, Frank M., San Francisco, CA, United States
       Kauer, James C., Kennett Square, PA, United States
       Regents of the University of California, Berkeley, CA, United States
PA
       (U.S. corporation)
US 5134121
                                19920728
PΙ
                                19910114 (7)
ΑI
       us 1991-640577
       Continuation of Ser. No. US 1989-299698, filed on 23 Jan 1989, now
RLI
       abandoned which is a continuation-in-part of Ser. No. US 1988-173975,
       filed on 28 Mar 1988, now abandoned
DT
       utility
```

FS

Granted